



DEVELOPMENT	  OF	  MICRO	  FLUIDIC	  BASED	  DEVICES	  FOR	  STUDYING	  
TUMOUR	  BIOLOGY	  AND	  EVALUATING	  TREATMENT	  RESPONSE	  IN	  HEAD	  




being	  a	  Thesis	  submitted	  for	  the	  Degree	  of	  Doctorate	  of	  Medicine	  
	  







Deborah	  Claire	  Sylvester	  	  
	  
Bsc	  (Hons)	  University	  of	  Leeds,	  MBChB	  (Hons)	  University	  of	  Leeds,	  	  
MRCS	  Royal	  College	  of	  Surgeons	  of	  England	  
	  
October	  2011	  




Firstly	  to	  my	  supervisors:	  Professor	  Greenman,	  whose	  enthusiasm	  was	  
endless,	  knowledge	  limitless,	  patience	  tireless	  and	  supply	  of	  green	  ink	  seemingly	  
bottomless.	  To	  Professor	  Stafford	  who	  guided	  me	  through	  applying	  for	  funding,	  
tissue	  collection	  and	  general	  diplomacy,	  and	  whose	  ever	  open	  door	  provided	  clinical	  
and	  pastoral	  support.	  	  
	   Without	  the	  support	  of	  my	  sponsors,	  the	  Royal	  College	  of	  Surgeons	  of	  
England,	  this	  work	  would	  certainly	  not	  be	  possible.	  	  Their	  generosity,	  not	  only	  
financial	  but	  also	  extending	  to	  research	  courses,	  library	  facilities	  and	  continuing	  
support	  was	  remarkable	  and	  I	  am	  forever	  indebted.	  	  I	  also	  thank	  the	  Henry	  
Chatterton	  fund	  whose	  contribution	  to	  consumables	  was	  gratefully	  received.	  
	   To	  the	  other	  members	  of	  the	  Head	  and	  Neck	  research	  team	  and	  University	  of	  
Hull:	  to	  Ann	  Lowry	  for	  her	  expert	  teaching	  on	  tissue	  sectioning,	  to	  Vicky	  and	  Anna,	  
for	  your	  teaching	  and	  patience,	  and	  to	  Sam	  D	  for	  your	  company	  and	  forever	  advising	  
me	  how	  to	  get	  out	  of	  whatever	  pickle	  I	  had	  managed	  to	  get	  myself	  into.	  	  A	  special	  
thank	  you	  to	  Sam	  H,	  ‘the	  guru	  of	  micro	  fluidics’	  whose	  perseverance	  and	  attention	  
to	  detail	  will	  forever	  astound	  me,	  and	  without	  whom	  I	  would	  have	  fallen	  at	  the	  first	  
hurdle.	  
My	  friends	  and	  family	  for	  all	  of	  their	  support,	  and	  putting	  up	  with	  me	  
through	  times	  of	  stress	  yet	  again,	  I	  promise	  this	  will	  be	  it	  now	  (well	  until	  the	  next	  
time).	  	  Finally	  to	  my	  Mum,	  my	  inspiration	  behind	  everything,	  sadly	  missed.	  
iii	  	  
Thesis	  Associated	  Publications	  
	  
Development	  of	  micro	  fluidic-­‐based	  analytical	  methodology	  for	  studying	  the	  
effects	  of	  chemotherapy	  agents	  on	  cancer	  tissue	  
Sylvester	  DC,	  Hattersley	  SM,	  Stafford	  ND,	  Haswell	  SJ,	  Greenman	  J	  
Submitted	  to	  Current	  Analytical	  Chemistry	  
	  
An	  innovative	  explant	  tissue	  model	  using	  micro	  fluidics	  for	  the	  comparison	  of	  
tumour	  tissue	  responses	  to	  chemotherapy	  regimens	  
Hattersley	  SM,	  Sylvester	  DC,	  Dyer	  CE,	  Stafford	  ND,	  Haswell	  SJ,	  Greenman	  J	  
Submitted	  to	  Annals	  of	  Biomedical	  Engineering	  
	  
Micro	  fluidic	  devices	  for	  evaluating	  HNSCC	  tumor	  biology	  	  
Sylvester	  DC,	  M	  Hattersley	  SM,	  Dyer	  CE,	  Stafford	  ND,	  Haswell	  SJ,	  Greenman	  J	  
Otolaryngology	  -­‐	  Head	  and	  Neck	  Surgery	  	  
August	  2010	  Vol.	  143,	  Issue	  2,	  Supplement	  2,	  Page	  P166	  
Thesis	  Associated	  Presentations	  
	  
Development	  of	  micro	  fluidic	  based	  devices	  for	  studying	  tumour	  biology	  and	  
evaluating	  treatment	  response	  in	  head	  and	  neck	  cancer	  biopsies	  (Poster)	  	  
Sylvester	  DC,	  M	  Hattersley	  SM,	  Dyer	  CE,	  Stafford	  ND,	  Haswell	  SJ,	  Greenman	  J	  	  	  
The	  14th	  International	  Conference	  on	  Miniaturized	  Systems	  for	  Chemistry	  and	  Life	  
Sciences,	  µTAS	  2010	  Conference,	  Groningen,	  The	  Netherlands,	  2010	  
	  
Micro	  fluidic	  devices	  for	  evaluating	  head	  and	  neck	  tumour	  biology	  (Poster)	  
Sylvester	  DC,	  M	  Hattersley	  SM,	  Stafford	  ND,	  Haswell	  SJ,	  Greenman	  J	  
American	  Academy	  of	  Otolaryngology	  —	  Head	  and	  Neck	  Surgery	  Foundation's	  
Annual	  Meeting,	  Boston,	  US,	  2010	  
	  
iv	  	  
Microfluidic	  based	  devices	  for	  the	  evaluation	  of	  chemotherapy	  response	  in	  head	  
and	  neck	  cancer	  biopsies	  (Poster)	  
Sylvester	  DC,	  M	  Hattersley	  SM,	  Stafford	  ND,	  Haswell	  SJ,	  Greenman	  J	  
Otorhinolaryngology	  Research	  Society,	  Coventry,	  UK,	  2010	  	  




Figure	  1.1	  	   Anatomical	  divisions	  of	  the	  head	  and	  neck	   4	  
Figure	  1.2	  	   The	  lymph	  nodes	  of	  the	  neck	   6	  
Figure	  1.3	   The	  anatomy	  of	  the	  larynx;	  supraglottis,	  glottis	  and	  subglottis	   7	  
Figure	  1.4	  	   Image	  of	  “classic"	  or	  non-­‐keratinizing	  dysplasia	  of	  the	  larynx	   12	  
Figure	  1.5	  	   The	  stepped	  progression	  model	  for	  HNSCC	   12	  
Figure	  1.6	  	   Image	  of	  invasive	  squamous	  cell	  carcinoma	  of	  the	  UADT	   13	  
Figure	  1.7	  	   Age-­‐standardised	  incidence	  rates,	  by	  sex,	  oral	  cancer,	  UK,	  1975-­‐
2007	  
15	  
Figure	  1.8	  	   The	  incidence	  of	  laryngeal	  UK	  by	  country	  and	  region,	  1991-­‐1999	   16	  
Figure	  1.9	  	   Cell	  cycle	  regulation	  by	  Rb	  and	  p53	  tumour	  suppressor	  proteins	   21	  
Figure	  1.10	  	   Activation	  and	  inhibition	  mechanisms	  of	  CDK4	   22	  
Figure	  1.11	  	   General	  schema	  for	  the	  management	  of	  HNSCC	   27	  
Figure	  1.12	  	   Treatment	  schema	  for	  loco-­‐regionally	  advanced	  HNSCC	  showing	  
possible	  timings	  of	  chemotherapy	  
36	  
Figure	  1.13	  	  	   Structure	  of	  cisplatin	   40	  
Figure	  1.14	  	  	   The	  platinum	  atom	  of	  cisplatin	  binding	  covalently	  to	  the	  N7	  
position	  of	  purines	  	  
41	  
Figure	  1.15	  	  	   Structure	  of	  5-­‐fluorouracil	   42	  
Figure	  1.16	  	   Structure	  of	  docetaxel	   44	  
Figure	  1.17	  	   EGFR	  signalling	  pathway	   45	  
Figure	  1.18	  	   Tissue	  culture	  methods	  	   51	  
Figure	  1.19	  	  	   The	  origin	  of	  cell	  lines	   52	  
Figure	  1.20	   A	  combination	  of	  analytical	  images	  of	  spheroid	  median	  sections	  
studied	  with	  different	  technologies	  
61	  
Figure	  1.21	  	   Schematic	  demonstrating	  how	  laminar	  flow	  allows	  streams	  to	  
flow	  side-­‐by-­‐side	  and	  mix	  only	  by	  diffusion	  in	  microchannels	  
67	  




Figure	  2.2	   	  Schematic	  diagram	  of	  the	  base	  glass	  plate	  with	  a	  channel	  width	  
of	  190	  µm	  depth	  of	  70	  µm.	  
88	  
Figure	  2.3	  	   Representation	  of	  the	  micro	  fluidic	  device	  	   89	  
Figure	  2.4	  	   Micro	  fluidic	  devices	   90	  
Figure	  2.5	   Micro	  fluidic	  system	   92	  
Figure	  2.6	  	   LDH	  release	  assay	   94	  
Figure	  2.7	  	   Conversion	  of	  the	  tetrazolium	  salt,	  WST-­‐1,	  to	  formazan	  	   96	  
Figure	  3.1	  	  	   Stability	  of	  LDH	  activity	  within	  tumour	  effluent	  over	  8	  days	   102	  
Figure	  3.2	  	  	   Pattern	  of	  LDH	  release	  per	  µg	  of	  tissue	  over	  74	  h	  incubation	  of	  
fresh	  tumour	  biopsies	  	  
103	  
Figure	  3.3	  	  	   Pattern	  of	  LDH	  release	  per	  µg	  of	  tissue	  over	  74	  h	  incubation	  of	  
fresh	  tumour	  biopsies	  	  
104	  
Figure	  3.4	  	   Pattern	  of	  WST-­‐1	  detection	  per	  µg	  of	  tissue	  over	  74	  h	  incubation	  
of	  fresh	  tumour	  biopsies	  	  
105	  
Figure	  3.5	   Pattern	  LDH	  release	  per	  µg	  of	  tissue	  over	  74	  h	  incubation	  of	  
fresh	  and	  frozen	  tumour	  biopsies	  	  
112	  
Figure	  3.6	  	   Pattern	  of	  WST-­‐1	  metabolism	  per	  µg	  of	  tissue	  after	  addition	  at	  
18	  h	  incubation	  over	  74	  h	  incubation	  of	  fresh	  and	  frozen	  tumour	  
biopsies	  	  
113	  
Figure	  3.7	  	   Tumour/node	  at	  0	  h,	  centre	  at	  a)	  x5,	  b)	  x20,	  c)	  x40	  magnification	   118	  
Figure	  3.8	  	   Tumour/node	  at	  48	  h,	  centre	  at	  a)	  x5,	  b)	  x20,	  c)	  x40	  
magnification	  
119	  
Figure	  3.9	   Tumour/node	  at	  96	  h,	  centre	  at	  a)	  x5,	  b)	  x20,	  c)	  x40	  
magnification	  
120	  
Figure	  3.10	  	   Tumour	  microenvironent	  gradients	   127	  
Figure	  3.11	  	   LDH	  release	  per	  µg	  of	  tissue	  per	  single	  micro	  fluidic	  device	  after	  
addition	  and	  continued	  perfusion	  with	  differing	  concentrations	  
of	  cisplatin	  
130	  
Figure	  3.12	  	   LDH	  release	  per	  µg	  of	  tissue	  in	  a	  single	  micro	  fluidic	  device	  after	  




Figure	  3.13	  	   LDH	  release	  per	  µg	  of	  tissue	  in	  a	  single	  micro	  fluidic	  device	  after	  
addition	  and	  continued	  perfusion	  with	  differing	  concentrations	  
of	  docetaxel	  
132	  
Figure	  3.14	  	   Pattern	  of	  LDH	  release	  per	  µg	  of	  tissue	  of	  control	  and	  after	  
addition	  and	  continued	  perfusion	  with	  cisplatin,	  5FU,	  docetaxel,	  
cisplatin	  plus	  docetaxel	  and	  all	  3	  agents	  	  
135	  
Figure	  3.15	  	   Pattern	  of	  LDH	  release	  per	  µg	  of	  tissue	  of	  control	  and	  after	  
addition	  and	  continued	  perfusion	  with	  cisplatin,	  5FU,	  docetaxel,	  






Table	  1.1	  	   The	  number	  of	  new	  cases	  of	  HNSCC	  in	  the	  UK	  in	  2007	   15	  
Table	  1.2	  	  	   Summary	  of	  publications	  demonstrating	  relative	  risk	  of	  laryngeal	  
cancer	  attributed	  to	  tobacco	  consumption	  
17	  
Table	  1.3	  	   Summary	  of	  TNM	  staging	  	   24	  
Table	  1.4	   Classification	  of	  nodal	  metastasis	  in	  HNSCC	   25	  
Table	  1.5	  	  	   HNSCC	  Stages	  I-­‐IV	  based	  on	  the	  TNM	  Classification	   26	  
Table	  1.6	  	   Summary	  of	  research	  involving	  tumour	  spheroids	   60	  
Table	  1.7	   Published	  literature	  on	  the	  use	  of	  micro	  fluidics	  for	  whole	  tissue	  
culture,	  to	  January	  2011	  	  
80	  
Table	  2.7	   Example	  of	  calculations	  of	  LDH	  activity	  for	  individual	  aliquots	   95	  
Table	  3.1	  	   Summary	  of	  number	  of	  experiments,	  tumour	  sub-­‐sites	  and	  
successful	  chips	  run	  for	  optimisation	  studies	  
101	  
Table	  3.2	  	   Summary	  of	  number	  of	  experiments,	  tumour	  sub-­‐sites	  and	  
successful	  chips	  run	  for	  fresh	  versus	  frozen	  studies	  
111	  
Table	  3.3	  	   Summary	  of	  number	  of	  experiments,	  tumour	  sub-­‐sites	  number	  of	  
pieces	  of	  tissue	  frozen	  at	  each	  time	  point	  for	  histo-­‐architectural	  
interpretation	  
116	  
Table	  3.4	  	  	   Summary	  of	  number	  of	  experiments,	  tumour	  sub-­‐sites	  and	  
successful	  chips	  for	  short	  term	  chemotherapy	  studies.	  
135	  
Table	  3.5	  	  	   Summary	  of	  number	  of	  experiments,	  tumour	  sub-­‐sites	  and	  






5FU	  	   5-­‐fluorouracil	  	  
7-­‐EC	  	   7-­‐ethoxycoumarin	  	  
AJCC	  	   The	  American	  Joint	  Committee	  on	  Cancer	  	  
ATP	   Adenosine	  Triphosphate	  
AUC	  	   Area	  Under	  the	  Curve	  	  
BCNU	   1,3-­‐bis(2-­‐chloroethyl)-­‐l-­‐nitrosourea	  	  
CAD	  	   Computer	  Assisted	  Design	  	  
CDCA	  	   Chenodeoxycholic	  Acid	  	  
CDK	   Cyclin	  Dependent	  Kinase	  	  
CEA	  	   Carcinoembryonic	  Antigen	  	  
Cmax	  	   Mean	  Observed	  Peak	  Concentration	  
CTC	  	   Circulating	  Tumour	  Cell	  	  
CTL/LAK	   Cytotoxic	  T	  lymphocyte/human	  Lymphokine	  Activated	  Killer	  cells	  	  
DC	   Dendritic	  Cells	  	  
DNA	   Deoxyribonucleic	  Acid	  
EBV	   Epstein-­‐Barr	  Virus	  	  
EC	   Electron	  Coupling	  Reagent	  
ECM	  	   Extracellular	  Matrix	  	  
EGF	   Epidermal	  Growth	  Factor	  
EGFR	  	   Epidermal	  Growth	  Factor	  Receptor	  	  
ELISA	  	   Enzyme-­‐linked	  Immunosorbent	  Assay	  	  
EMD	  72000	   Humanised	  anti-­‐EGFR	  Monoclonal	  Antibody	  Matuzumab	  	  
EORTC	  	   European	  Organisation	  for	  Research	  and	  Treatment	  of	  Cancer	  	  
FAK	   Focal	  Adhesion	  Kinase	  
FdUMP	  	   Fluorodeoxyuridine	  Monophosphate	  	  
FGF	   Fibroblast	  Growth	  factor	  	  
GFP	   Green	  Fluorescent	  Protein	  
H&E	  	   Haematoxylin	  and	  Eosin	  	  
x	  	  
HER	   Human	  Epidermal	  Growth	  Factor	  Receptor	  
HIV	   Human	  Immunodeficiency	  Virus	  
HMG	   High	  Mobility	  Group	  family	  proteins	  
HNSCC	  	   Head	  and	  Neck	  Squamous	  Cell	  Carcinoma	  	  
HPV	   Human	  Papilloma	  Virus	  	  
HUVEC	   Human	  Umbilical	  Vein	  Endothelial	  Cells	  
IC	   Intracellular	  
IHC	  	   Immunohistochemistry	  	  
IMRT	   Intensity	  Modulated	  Radio	  Therapy	  	  
IUCC	  	   The	  Union	  for	  International	  Cancer	  Control	  	  
LDH	  	   Lactate	  Dehydrogenase	  	  
LIF	   Leukaemia	  Inhibitory	  Factor	  	  
LMP	  	   Latent	  Membrane	  Protein	  
MAPK	  	   Mitogen	  Activated	  Protein	  Kinase	  	  
MIBG	   Meta-­‐iodobenzylguanidine	  	  	  
MIF-­‐1α	  	   Macrophage	  Migration	  Inhibitory	  Factor	  1-­‐alpha	  	  
MMP-­‐8	   Matrix	  Metalloproteinase-­‐8	  	  
mRNA	   messenger	  Deoxyribonucleic	  Acid	  
MTS	  	   Multicellular	  Tumour	  Spheroids	  	  
MTT	  	   3-­‐(4,5-­‐Dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyltetrazolium	  bromide	  
NAD+/NADH	  	   Nicotinamide	  Adenine	  Dinucleotide	  
NPC	   Nasopharyngeal	  Carcinoma	  	  
P-­‐gp	  	   Permeability	  glycoprotein	  	  
PBMC	   Peripheral	  Blood	  Mononuclear	  Cell	  
PCNA	   Proliferating	  Cell	  Nuclear	  Antigen	  
PCR	   Polymerase	  Chain	  Reaction	  
PD	  	   Pharmacodynamics	  	  
PDGF	   Platelet	  Derived	  Growth	  Factor	  
PDMS	  	   Poly(dimethylsiloxane)	  	  
PI3K	  	   Phosphatidylinositol	  3-­‐kinase	  	  
PK	  	   Pharmacokinetics	  	  	  
xi	  	  
	  
POCT	  	   Point	  of	  Care	  testing	  
pRb	  	   Retinoblastoma	  protein	  
RDTs	  	   Rapid	  Diagnostic	  Tests	  	  
RR	  	   Relative	  Risk	  
RS	   Mitochondrial	  Succinate-­‐tetrazolium-­‐reductase	  System	  
SAV	  	   Surface	  Area	  to	  Volume	  ratios	  	  
SCC	  	   Squamous	  Cell	  Carcinoma	  	  
STAT	  	   Signal	  Transducers	  and	  Activators	  of	  Transcription	  	  
TAA	   Tumour-­‐associated	  Antigen	  
SAV	   Surface	  Area	  to	  Volume	  Ratio	  
TANIS	  	   The	  Tumour	  and	  Node	  Interger	  Score	  System	  	  
TGF-­‐α/β	   Transforming	  Growth	  Factor	  α/β	  
TNM	   Tumour	  Node	  Metastases	  
TPF	  	   Taxotere,	  Cisplatin	  and	  5FU	  
UADT	  	   Upper	  Aero	  Digestive	  Tract	  	  
VEGF	   Vascular	  Endothelial	  Growth	  Factor	  	  
WHO	   World	  Health	  Organisation	  	  
WST-­‐1	   Water	  Soluble	  Tetrazolium,	  4-­‐[3-­‐[4	  -­‐	  lodophenyl]	  -­‐	  2	  -­‐	  4	  (4	  
nitrophenyl)-­‐	  2H-­‐	  5-­‐tetrazolio-­‐1,	  3-­‐benzene	  disulfonate	  	  
XTT	  	   2,3-­‐bis-­‐(2-­‐methoxy-­‐4-­‐nitro-­‐5-­‐sulfophenyl)-­‐2H-­‐tetrazolium-­‐5-­‐
carboxanilide	  	  
µCCA	   Microscale	  Cell	  Culture	  Analogue	  	  
	   	  xii	  
Table	  of	  Contents	  
ABSTRACT…………………………………………………..……………………………………………………….	  1	  
1	  	  INTRODUCTION	  ..................................................................................................	  2	  
1.1	  	  Anatomy	  and	  Histology	  of	  HNSCC	  ....................................................................	  4	  
1.1.1	  	  The	  Lymph	  Nodes	  of	  the	  Neck	  .......................................................................	  5	  
1.1.2	  	  The	  Larynx	  ......................................................................................................	  6	  
1.1.3	  	  The	  Oropharynx	  .............................................................................................	  8	  
1.1.4	  	  The	  Nasopharynx	  ...........................................................................................	  9	  
1.1.5	  	  The	  Hypopharynx	  ...........................................................................................	  9	  
1.1.6	  	  Histology	  of	  HNSCC	  ......................................................................................	  10	  
1.1.6.1	  	  Leukoplakia	  ...........................................................................................	  10	  
1.1.6.2	  	  Erythroplakia	  .........................................................................................	  11	  
1.1.6.3	  	  Dysplasia	  ...............................................................................................	  11	  
1.1.6.4	  	  Squamous	  Cell	  Carcinoma	  .....................................................................	  12	  
1.2	  	  Epidemiology	  of	  HNSCC	  .................................................................................	  14	  
1.3	  	  Aetiology	  of	  HNSCC	  .......................................................................................	  17	  
1.3.1	  	  Tobacco	  ........................................................................................................	  17	  
1.3.2	  	  Alcohol	  .........................................................................................................	  18	  
1.3.3	  	  Human	  Papilloma	  Virus	  (HPV)	  ......................................................................	  19	  
1.3.4	  	  Epstein-­‐Barr	  Virus	  (EBV)	  ...............................................................................	  20	  
1.3.5	  	  Genetic	  Alterations	  in	  HNSCC	  .......................................................................	  20	  
1.3.5.1	  	  p53	  ........................................................................................................	  20	  
1.3.5.2	  	  Cyclins	  ...................................................................................................	  22	  
1.3.5.3	  	  EGFR	  ......................................................................................................	  23	  
1.3.6	  	  Summary	  ......................................................................................................	  23	  
1.4	  	  Staging	  of	  HNSCC	  ...........................................................................................	  24	  
	  	  
	  
	   	  xiii	  
1.5	  	  Management	  of	  HNSCC	  .................................................................................	  27	  
1.5.1	  	  Management	  of	  Cervical	  Metastases	  ...........................................................	  27	  
1.5.2	  	  Laryngeal	  Carcinoma	  ....................................................................................	  29	  
1.5.3	  	  Oropharyngeal	  Carcinoma	  ...........................................................................	  30	  
1.5.4	  	  Nasopharyngeal	  Carcinoma	  .........................................................................	  31	  
1.5.5	  	  Hypopharyngeal	  Carcinoma	  .........................................................................	  32	  
1.5.6	  	  Summary	  ......................................................................................................	  33	  
1.6	  	  Radiotherapy	  .................................................................................................	  34	  
1.7	  	  Chemotherapy………………………………………..…………………………………..………….……34	  
1.7.1	  	  Cisplatin	  ........................................................................................................	  40	  
1.7.2	  	  5-­‐Fluorouracil	  ...............................................................................................	  42	  
1.7.3	  	  Docetaxel	  .....................................................................................................	  44	  
1.7.4	  	  Cetuximab	  ....................................................................................................	  45	  
1.7.5	  	  Predicting	  Chemotherapy	  Response	  ............................................................	  46	  
1.8	  	  HNSCC	  Culture	  Techniques	  ............................................................................	  50	  
1.8.1	  	  Cell	  culture	  ...................................................................................................	  51	  
1.8.2	  	  Organ	  Culture	  ...............................................................................................	  55	  
1.8.3	  	  Histotypic	  Culture	  .........................................................................................	  56	  
1.8.4	  	  Organotypic	  Culture	  .....................................................................................	  62	  
1.9	  	  Micro	  fluidics	  .................................................................................................	  64	  
1.9.1	  	  Properties	  of	  Micro	  Fluidics	  .........................................................................	  65	  
1.9.1.1	  	  Fluid	  Properties	  .....................................................................................	  65	  
1.9.1.2	  	  Transport	  Properties	  .............................................................................	  67	  
1.9.1.3	  	  Shear	  Effects	  ..........................................................................................	  68	  
1.9.1.4	  	  Surface	  of	  Microchannels	  ......................................................................	  69	  
1.9.1.5	  	  Device	  Fabrication	  .................................................................................	  69	  
1.9.2	  	  Biomedical	  Applications	  of	  Micro	  Fluidics	  ....................................................	  70	  
1.9.2.1	  	  Cell	  Culture	  ............................................................................................	  70	  
1.9.2.2	  	  Clinical	  Diagnostics	  ................................................................................	  71	  
	   	  xiv	  
1.9.2.3	  	  Point	  of	  Care	  Testing	  .............................................................................	  72	  
1.9.2.4	  	  Pharmacological	  Studies	  .......................................................................	  74	  
1.9.2.5	  	  Tumour	  Spheroids	  in	  Micro	  Fluidic	  Chambers	  ......................................	  76	  
1.9.2.6	  	  Whole	  Tissue	  Culture	  ............................................................................	  78	  
1.10	  	  Study	  Aims	  ..................................................................................................	  83	  
2	  	  MATERIALS	  AND	  METHODS	  ..............................................................................	  84	  
2.1	  	  Obtaining	  Tissue	  for	  Use	  in	  Micro	  Fluidic	  Devices	  ..........................................	  84	  
2.1.1	  	  Ethical	  Approval	  ...........................................................................................	  84	  
2.1.2	  	  Patient	  Selection	  ..........................................................................................	  84	  
2.1.3	  	  Tissue	  Sampling	  ............................................................................................	  85	  
2.2	  	  Device	  Fabrication	  .........................................................................................	  86	  
2.3	  The	  Micro	  Fluidic	  System	  ................................................................................	  90	  
2.3.1	  	  System	  Components	  ....................................................................................	  90	  
2.3.2	  	  Device	  Assembly	  and	  Priming	  ......................................................................	  91	  
2.3.3	  	  Effluent	  Collection	  ........................................................................................	  93	  
2.4	  Materials	  ........................................................................................................	  93	  
2.4.1	  	  Chemotherapy	  Agents	  ..................................................................................	  93	  
2.4.1.1	  	  Cisplatin	  .................................................................................................	  93	  
2.4.1.2	  	  5-­‐Fluorouracil	  ........................................................................................	  93	  
2.4.1.3	  	  Docetaxel	  ..............................................................................................	  93	  
2.4.2	  	  Cell	  Death	  Analysis	  .......................................................................................	  94	  
2.4.3	  	  Cell	  Viability	  Analysis	  ....................................................................................	  95	  
2.4.4	  	  Histo-­‐architectural	  Analysis	  .........................................................................	  97	  
3.0	  	  RESULTS	  ........................................................................................................	  98	  
3.1	  	  Optimisation	  Studies	  .....................................................................................	  98	  
3.1.1	  	  Aims	  ..............................................................................................................	  98	  
3.1.2	  	  Introduction	  .................................................................................................	  98	  
	   	  xv	  
3.1.3	  	  Materials	  and	  Methods	  ..............................................................................	  100	  
3.1.4	  	  Results	  ........................................................................................................	  100	  
3.1.4.1	  	  Stability	  of	  LDH	  ....................................................................................	  102	  
3.1.4.2	  	  Cell	  Death	  Analysis	  ..............................................................................	  102	  
3.1.4.3	  	  Cell	  Viability	  Analysis	  ...........................................................................	  104	  
3.1.4.4	  	  Assessment	  of	  Bacterial	  Contamination	  .............................................	  105	  
3.1.5	  	  Discussion	  ...................................................................................................	  105	  
3.2	  	  Comparative	  Studies	  on	  Fresh	  and	  Frozen	  Tissue	  .........................................	  109	  
3.2.1	  	  Aims	  ............................................................................................................	  109	  
3.2.2	  	  Introduction	  ...............................................................................................	  109	  
3.2.3	  	  Materials	  and	  Methods	  ..............................................................................	  109	  
3.2.4	  	  Results	  ........................................................................................................	  110	  
3.2.4.1	  	  Cell	  Death	  Analysis	  ..............................................................................	  110	  
3.2.4.2	  	  Cell	  Viability	  Analysis	  ...........................................................................	  112	  
3.2.5	  	  Discussion	  ...................................................................................................	  113	  
3.3	  	  Histo-­‐architectural	  Studies………………………………………………….……………….…….111	  
3.3.1	  	  Aims	  ............................................................................................................	  115	  
3.3.2	  	  Introduction	  ...............................................................................................	  115	  
3.3.3	  	  Materials	  and	  Methods	  ..............................................................................	  115	  
3.3.4	  	  Results	  ........................................................................................................	  116	  
3.3.5	  	  Discussion	  ...................................................................................................	  121	  
3.4	  	  Chemotherapy	  Studies	  ................................................................................	  124	  
3.4.1	  	  Aims	  ............................................................................................................	  124	  
3.4.2	  	  Introduction	  ...............................................................................................	  124	  
3.4.3	  	  Materials	  and	  Methods	  ..............................................................................	  128	  
3.4.4	  	  Results	  ........................................................................................................	  129	  
3.4.4.1	  	  Dose	  response	  .....................................................................................	  129	  
3.4.4.2	  	  Short	  Term	  Chemotherapy	  ..................................................................	  146	  
3.4.4.3	  	  Longer	  Term	  Chemotherapy	  ...............................................................	  136	  
3.4.5	  	  Discussion	  ...................................................................................................	  139	  
	   	  xvi	  
4.0	  THESIS	  SUMMARY	  ........................................................................................	  142	  
REFERENCES	  	  
APPENDIX	  	  
	  	  	  	  	  	  	  	  	  	  I	  	  Staging	  of	  Head	  and	  Neck	  Sub	  Sites	  
	  	  	  	  	  	  	  	  	  	  II	  	  Information	  Sheets	  and	  Consent	  Form	  
	  	  	  	  	  	  	  	  	  	  III	  	  Additional	  Histology	  Figures	  
	  Abstract	  
Head	  and	  Neck	  Squamous	  Cell	  Carcinoma	  (HNSCC)	  presents	  particular	  
challenges	  to	  both	  the	  researcher	  and	  the	  clinician.	  	  Encompassing	  a	  group	  of	  
tumours	  with	  distinct	  epidemiological	  and	  oncological	  behaviour,	  each	  sub	  site	  
differs	  greatly	  in	  its	  management	  and	  prognosis.	  	  However,	  due	  to	  insufficient	  tissue	  
quantities	  and	  culture	  techniques,	  research	  studies	  commonly	  group	  together	  
different	  sub	  sites,	  limiting	  our	  understanding	  of	  the	  biological	  behaviour	  and	  
treatment	  response	  of	  tumours	  from	  distinct	  sites.	  
Micro	  fluidics	  relates	  to	  the	  science	  of	  systems	  that	  process	  or	  manipulate	  
small	  amounts	  of	  fluids	  within	  micro	  channels.	  	  When	  applied	  in	  biology,	  the	  
technology	  enables	  the	  production	  of	  simple,	  robust	  and	  highly	  versatile	  systems	  for	  
studying	  cells	  and	  tissues.	  	  The	  aim	  of	  the	  work	  in	  this	  thesis	  was	  to	  maintain	  small	  
biopsies	  of	  tumour	  in	  a	  physiological	  state,	  more	  comparable	  to	  the	  in	  vivo	  
environment	  than	  traditional	  tissue	  culture	  techniques,	  for	  up	  to	  9	  days.	  	  This	  
recreation	  of	  the	  ‘tumour	  microenvironment’	  in	  vitro	  provided	  a	  platform	  for	  the	  
testing	  of	  chemotherapy	  agents	  and	  analysing	  individual	  tumour	  behaviour.	  	  
Initial	  optimisation	  studies	  were	  performed	  to	  demonstrate	  tissue	  viability	  
within	  this	  novel	  culture	  method.	  	  Based	  on	  LDH	  excretion	  as	  a	  marker	  of	  cell	  death	  
and	  WST-­‐1	  metabolism	  as	  a	  marker	  of	  viability,	  tumour	  and	  nodal	  biopsies	  from	  a	  
variety	  of	  sub	  sites	  remained	  viable	  within	  the	  device	  until	  the	  addition	  of	  cell	  lysis	  
buffer	  at	  68	  h.	  	  Histo-­‐architectural	  examination	  of	  tissue	  incubated	  within	  the	  device	  
for	  96	  h	  demonstrated	  that	  original	  tissue	  structure	  is	  largely	  maintained.	  In	  
addition,	  comparison	  of	  viability	  between	  fresh	  and	  frozen	  tissues	  showed	  little	  
difference,	  thus	  the	  clinical	  applicability	  of	  the	  technique	  was	  significantly	  enhanced,	  
as	  biopsies	  could	  be	  collected	  and	  stored	  prior	  to	  use	  at	  a	  later	  date.	  	  	  
Using	  clinically	  relevant	  combinations	  of	  chemotherapy	  drugs,	  nodal	  biopsies	  
(n=50	  micro	  chips	  from	  n=2	  tumours	  with	  all	  experiments	  duplicated)	  were	  
interrogated	  with	  cisplatin,	  5-­‐Fluorouracil	  and	  docetaxel	  within	  the	  micro	  device	  for	  
up	  to	  9	  days.	  	  The	  addition	  of	  each	  chemotherapeutic	  agent	  resulted	  in	  increased	  
cell	  death	  compared	  to	  control,	  with	  a	  synergistic	  effect	  seen	  when	  agents	  were	  
given	  in	  combination;	  results	  in	  agreement	  with	  clinical	  trial	  data.	  
This	  study	  demonstrates	  a	  robust	  and	  reproducible	  system	  for	  the	  
maintenance	  and	  ‘interrogation’	  of	  individual	  tumour	  biopsies.	  	  The	  innovative	  
model	  provides	  a	  new	  platform	  for	  testing	  individual	  patient	  responses	  to	  
chemotherapy,	  paving	  the	  way	  for	  ‘personalised’	  treatment	  regimens.	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1	  	  Introduction	  	  
Head	  and	  Neck	  Squamous	  Cell	  Carcinoma	  (HNSCC)	  accounted	  for	  around	  3%	  
of	  all	  cancers	  in	  the	  UK	  in	  2007	  (http://info.cancerresearchuk.org/cancerstats/)	  but	  
represents	  the	  sixth	  most	  common	  cancer	  worldwide	  (Ferlay	  et	  al.,	  2010).	  The	  
condition	  encompasses	  malignancies	  of	  the	  oral	  cavity,	  nasopharynx,	  oropharynx,	  
hypopharynx,	  and	  larynx.	  HNSCC	  is	  a	  solid	  tumour	  with	  remarkable	  ability	  to	  evade	  
normal	  immune	  surveillance	  and	  suppress	  any	  elicited	  immune	  response.	  Such	  
tumours	  often	  cause	  high	  morbidity	  due	  to	  their	  location,	  both	  through	  loss	  of	  
function	  and	  disfigurement.	  Current	  treatments	  commonly	  contribute	  to	  morbidity;	  
extensive	  surgical	  resection	  can	  adversely	  affect	  speech	  and	  swallowing	  even	  when	  
local	  cure	  is	  achieved,	  and	  the	  complications	  of	  radiotherapy	  such	  as	  xerostomia	  are	  
often	  life-­‐long	  (Gleeson	  and	  Scott-­‐Brown,	  2008).	  
Treatment	  planning	  options	  for	  optimal	  outcome	  are	  becoming	  increasingly	  
challenging	  as	  more	  and	  more	  single	  and	  multiple	  treatment	  modality	  regimes	  
become	  available.	  	  New	  concepts	  such	  as	  induction	  chemotherapy,	  integration	  of	  
targeted	  therapies,	  concurrent	  and	  sequential	  chemo-­‐radiation	  strategies	  offer	  an	  
alternative	  to	  the	  traditional	  definitive	  surgical	  procedures	  (Choong	  and	  Vokes,	  
2008).	  	  Predicting	  outcome	  is	  particularly	  difficult	  in	  HNSCC;	  heterogeneity	  of	  tumour	  
response,	  impaired	  late	  functional	  outcome	  and	  increased	  late	  toxicity	  of	  
chemotherapy	  regimens	  (especially	  if	  simultaneously	  applied	  with	  radiation)	  all	  
influence	  treatment	  response.	  Retrospectively	  looking	  at	  ‘non-­‐responders’	  to	  chemo-­‐
radiotherapy	  highlights	  those	  for	  whom	  primary	  surgery	  is	  likely	  to	  have	  achieved	  
better	  results.	  The	  inability	  to	  predict	  this	  information	  beforehand,	  however,	  means	  
that	  some	  patients	  will	  unnecessarily	  suffer	  the	  side	  effects	  of	  chemo-­‐radiotherapy	  
and	  in	  addition,	  this	  time	  delay	  means	  that	  the	  tumour	  is	  more	  advanced	  when	  
surgery	  is	  performed.	  	  Having	  a	  platform	  to	  test	  therapies	  on	  an	  individual	  tumour,	  
before	  they	  are	  given	  to	  the	  patient,	  would	  mean	  that	  the	  most	  appropriate	  modality	  
or	  chemotherapy	  regimen	  is	  given	  as	  first	  choice.	  
Micro	  fluidics	  relates	  to	  the	  science	  of	  systems	  that	  process	  or	  manipulate	  
small	  amounts	  of	  fluids	  within	  micro	  channels,	  enabling	  the	  production	  of	  simple,	  
	   	  3	  
reproducible	  and	  highly	  versatile	  biological	  tissue	  systems.	  The	  application	  of	  micro	  
fluidic	  devices	  to	  the	  study	  of	  tumour	  biology	  and	  treatment	  response	  has	  the	  
potential	  to	  revolutionise	  the	  way	  we	  study	  not	  just	  HNSCC	  but	  all	  solid	  tumour	  
types.	  	  
How	  well	  traditional	  cell	  based	  tumour	  cultures	  represent	  the	  in	  vivo	  
behaviour	  of	  a	  tumour	  has	  long	  been	  questioned.	  Tumours	  exist	  not	  just	  as	  groups	  
of	  identical	  cells,	  but	  as	  part	  of	  a	  complex	  cellular	  body,	  dependant	  on	  interactions	  
with	  normal	  cells	  and	  supporting	  proteins.	  Not	  only	  is	  the	  validity	  of	  in	  vitro	  studies	  
questionable,	  the	  length	  of	  time	  taken	  to	  culture	  cells	  and	  investigate	  treatment	  
response	  means	  that	  a	  real	  time	  personalised	  treatment	  model	  is	  unobtainable.	  	  The	  
application	  of	  micro	  fluidic	  technology	  serves	  to	  mimic	  in	  vivo	  tumour	  conditions	  
whilst	  providing	  a	  practical	  analytical	  model	  for	  assessing	  individual	  tumour	  
response	  to	  treatment.	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1.1	  	  Anatomy	  and	  Histology	  of	  HNSCC	  
Head	  and	  Neck	  cancer	  encompasses	  a	  wide	  range	  of	  tumours	  of	  anatomical	  
and	  histological	  distinction.	  	  Although	  90%	  of	  tumours	  are	  of	  the	  squamous	  cell	  type	  
(Curado	  and	  Hashibe,	  2009),	  being	  derived	  from	  the	  upper-­‐aero	  digestive	  tract	  
(UADT),	  other	  tumour	  types	  derived	  from	  skin,	  salivary	  glands	  and	  the	  thyroid	  gland,	  
are,	  less	  commonly	  found.	  	  The	  current	  work	  has	  focused	  on	  tumours	  of	  squamous	  
cell	  type,	  predominantly	  collected	  from	  the	  larynx,	  oropharynx,	  nasopharynx	  and	  
hypopharynx	  and	  associated	  lymph	  nodes,	  reflecting	  their	  clinical	  prevalence	  and	  
therefore	  these	  sites	  will	  be	  briefly	  described	  in	  turn.	  
The	  head	  and	  neck	  can	  be	  divided	  into	  anatomically	  defined	  regions,	  namely	  
the	  nasal	  cavity	  and	  paranasal	  sinuses,	  oral	  cavity,	  pharynx	  (further	  divided	  into	  
nasopharynx,	  oropharynx	  and	  hypopharynx)	  and	  larynx	  (Figure	  1.1).	  	  Approximately	  
60-­‐70%	  of	  head	  and	  neck	  tumours	  are	  found	  within	  the	  oral	  cavity	  and	  larynx	  with	  
tumours	  of	  the	  nasal	  cavity	  and	  paranasal	  sinuses	  (3%)	  being	  relatively	  rare	  (Gleeson	  
and	  Scott-­‐Brown,	  2008).	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1.1	  Anatomical	  divisions	  of	  the	  head	  and	  neck	  (Gleeson	  and	  Scott-­‐Brown,	  
2008).	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1.1.1	  	  The	  Lymph	  Nodes	  of	  the	  Neck	  
For	  HNSCC,	  lymphatic	  spread	  is	  a	  key	  feature	  with	  approximately	  40%	  of	  patients	  
demonstrating	  evidence	  of	  nodal	  involvement	  at	  presentation	  as	  detected	  clinically	  
or	  radiologically	  (Genden	  et	  al.,	  2003).	  	  Up	  to	  a	  further	  20%	  of	  patients	  presumed	  
‘node-­‐negative’	  have	  evidence	  of	  micro-­‐metastasis	  after	  histopathological	  evaluation	  
(Ferlito	  et	  al.,	  2001).	  	  Given	  that	  the	  presence	  of	  lymph	  node	  metastasis	  is	  associated	  
with	  a	  50%	  reduction	  in	  survival	  rates	  on	  average	  (Wenzel	  et	  al.,	  2004),	  predicting	  
lymphatic	  spread	  is	  important	  in	  clinical	  treatment	  planning.	  	  The	  likely	  sites	  of	  lymph	  
node	  metastasis	  for	  each	  anatomical	  site	  of	  the	  head	  and	  neck	  were	  mapped	  by	  a	  
key	  study	  by	  Lindberg	  et	  al.	  (1972)	  and	  based	  on	  these	  findings,	  the	  descriptive	  neck	  
levels	  above	  (originally	  five,	  with	  a	  further	  two	  levels	  being	  added	  since	  (Robbins	  et	  
al.,	  2008)	  were	  described	  by	  surgeons	  at	  the	  Memorial	  Sloan-­‐Kettering	  Cancer	  Centre	  
in	  1981,	  thus	  standardising	  nomenclature	  in	  neck	  dissection	  operations.	  
The	  lymph	  node	  levels,	  described	  by	  their	  groupings	  and	  anatomical	  locations	  are	  
summarised	  as	  follows	  (Robbins	  et	  al.,	  2008)	  and	  depicted	  in	  Figure	  1.2:	  	  	  
• Level	  I,	  submental	  and	  submandibular	  lymph	  nodes	  
• Level	  II,	  cervical	  jugular	  chain	  nodes	  above	  the	  level	  of	  the	  hyoid.	  Further	  
divided	  into	  IIa	  and	  IIb	  by	  their	  relationship	  to	  the	  accessory	  nerve	  	  
• Level	  III,	  cervical	  jugular	  chain	  nodes	  from	  the	  level	  of	  the	  hyoid	  to	  the	  level	  of	  
the	  cricoid	  
• Level	  IV,	  cervical	  jugular	  chain	  nodes	  from	  the	  level	  of	  the	  cricoid	  to	  the	  
suprasternal	  notch	  
• Level	  V,	  posterior	  triangle	  lymph	  nodes.	  Can	  be	  further	  divided	  into	  Va	  and	  Vb	  
as	  to	  whether	  they	  are	  above	  or	  below	  the	  omohyoid	  muscle	  
• Level	  VI,	  central	  compartment	  nodes	  
• Level	  VII,	  superior	  mediastinal	  nodes	  
Between	  100	  and	  200	  lymph	  nodes	  are	  located	  within	  each	  side	  of	  the	  neck,	  
joined	  together	  by	  a	  complex	  communication	  system	  broadly	  divided	  into	  a	  
superficial	  and	  deep	  network,	  with	  lymph	  draining	  first	  into	  the	  superficial	  network	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Figure	  1.2	  The	  lymph	  nodes	  of	  the	  neck,	  a)	  the	  anatomical	  distribution	  of	  the	  lymph	  
nodes	  of	  the	  neck,	  b)	  the	  Memorial	  Sloane-­‐Kettering	  levels	  I-­‐V	  as	  described	  in	  1981,	  
c),	  d)	  the	  more	  recently	  added	  divisions	  and	  levels	  I-­‐VII	  (Gleeson	  and	  Scott-­‐Brown,	  
2008)	  Adapted	  from	  (Bailey,	  2001).	  
1.1.2	  	  The	  Larynx	  
The	  larynx	  serves	  to	  provide	  voice	  and	  divide	  the	  respiratory	  tract	  from	  the	  
digestive	  tract.	  	  It	  consists	  of	  a	  cartilaginous	  framework	  connected	  by	  ligaments,	  
membranes	  and	  muscles	  covered	  by	  respiratory	  and	  stratified	  mucosal	  epithelium.	  	  
Arterial	  blood	  supply	  is	  from	  the	  external	  carotid	  artery	  and	  the	  thyrocervical	  trunk	  
via	  the	  superior	  and	  inferior	  thyroid	  arteries.	  	  Venous	  drainage	  is	  to	  the	  internal	  
jugular	  vein	  via	  the	  superior	  and	  inferior	  thyroid	  veins.	  	  Innervation	  of	  the	  muscles	  of	  
the	  larynx	  is	  from	  the	  recurrent	  laryngeal	  branch	  of	  the	  vagus	  nerve	  except	  for	  
cricothyroid	  which	  is	  innervated	  by	  the	  external	  laryngeal	  nerve	  (Last	  and	  
Sinnatamby,	  1999).	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The	  larynx	  can	  be	  divided	  into	  three	  parts:	  the	  supraglottis	  (tip	  of	  the	  epiglottis	  
superiorly	  to	  the	  under	  surface	  of	  the	  false	  cords	  inferiorly),	  glottis	  (from	  the	  
ventricle	  between	  the	  true	  and	  false	  cords	  to	  0.5cm	  below	  the	  free	  edge	  of	  the	  true	  
cords)	  and	  subglottis	  (the	  inferior	  extent	  of	  the	  glottis	  to	  the	  inferior	  border	  of	  the	  
cricoid	  cartilage)	  as	  shown	  in	  figure	  1.3.	  	  	  
The	  supraglottis	  and	  glottis	  are	  composed	  of	  the	  following:	  
• Supraglottis	  -­‐	  suprahyoid	  epiglottis	  (tip,	  lingual	  and	  laryngeal	  surfaces),	  
aryepiglottic	  fold,	  arytenoid,	  infrahyoid	  epiglottis,	  false	  cords	  
• Glottis	  –	  vocal	  cords,	  anterior	  commissure,	  posterior	  commisure	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1.3	  The	  anatomy	  of	  the	  larynx;	  supraglottis,	  glottis	  and	  subglottis	  (Gleeson	  
and	  Scott-­‐Brown,	  2008)	  Adapted	  from	  (Bailey,	  2001).	  
Between	  30	  and	  40%	  of	  laryngeal	  cancers	  arise	  from	  the	  supraglottic	  area,	  
the	  most	  common	  site	  being	  the	  infrahyoid	  epiglottis.	  	  The	  glottis	  is	  the	  most	  
common	  site	  for	  laryngeal	  cancer	  with	  50-­‐70%	  of	  tumours	  located	  in	  this	  area.	  	  
Tumours	  in	  this	  area	  can	  spread	  superficially	  across	  the	  anterior	  commisure	  (the	  
anterior	  apex	  of	  the	  vocal	  cords)	  onto	  the	  opposite	  cord	  or	  into	  adjacent	  sub	  sites.	  	  
True	  subglottic	  cancers	  are	  rare,	  accounting	  for	  only	  5%	  of	  laryngeal	  cancers.	  	  The	  
majority	  of	  tumour	  found	  in	  this	  area	  is	  a	  direct	  extension	  of	  glottic	  carcinoma	  rather	  
than	  of	  true	  subglottic	  origin.	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The	  differing	  embryological	  origins	  of	  each	  sub	  site	  can	  explain,	  in	  part,	  the	  
variation	  in	  clinical	  behaviour	  of	  cancers	  from	  each	  site.	  	  The	  supraglottis,	  derived	  
from	  the	  midline	  buccopharyngeal	  primordium	  and	  branchial	  arches	  3	  and	  4,	  rich	  in	  
lymphatics	  has	  a	  tendency	  for	  early	  bilateral	  regional	  lymphatic	  spread	  with	  
approximately	  50%	  of	  patients	  having	  nodal	  involvement	  at	  presentation.	  	  In	  
contrast,	  the	  glottis,	  formed	  by	  the	  fusion	  of	  the	  lateral	  structures	  derived	  from	  the	  
tracheobronchial	  primordium	  and	  arches	  4	  and	  5	  with	  a	  paucity	  of	  lymphatics,	  rarely	  
spreads	  to	  regional	  lymphatics	  and	  tends	  to	  remain	  confined	  to	  the	  larynx	  (Lalwani,	  
2008).	  	  The	  Lymphatic	  drainage	  of	  all	  areas	  of	  the	  larynx	  and	  hence	  the	  sites	  of	  nodal	  
metastasis	  is	  to	  levels	  II,	  III,	  IV	  and	  sometimes	  VI	  (see	  Figure	  1.2).	  Fibroblastic	  
membranes	  and	  ligaments	  further	  divide	  the	  larynx	  into	  the	  pre-­‐epiglottic	  and	  para-­‐
epiglottic	  space	  and	  also	  acts	  as	  physical	  barriers,	  helping	  to	  prevent	  extra-­‐laryngeal	  
tumour	  spread	  (Lalwani,	  2008).	  	  
1.1.3	  	  The	  Oropharynx	  
The	  oropharynx	  is	  the	  area	  posterior	  to	  the	  oral	  cavity	  and	  extends	  from	  the	  
plane	  of	  the	  superior	  surface	  of	  the	  soft	  palate	  above	  to	  the	  surface	  of	  the	  hyoid	  
bone	  or	  floor	  of	  the	  valecullae	  below.	  	  It	  contains:	  
• Anterior	  sub	  sites	  (lymphatic	  drainage	  to	  level	  II	  nodes)	  –	  posterior	  one	  third	  
of	  tongue	  and	  vallecula	  
• Lateral	  sub	  sites	  (lymphatic	  drainage	  to	  retropharyngeal	  nodes)	  –	  lateral	  wall,	  
tonsil,	  tonsillar	  fossa	  and	  pillar	  
• Superior	  sub	  sites	  (lymphatic	  drainage	  to	  retropharyngeal	  and	  level	  II	  and	  III	  
nodes)	  –	  inferior	  surface	  of	  soft	  palate,	  uvula	  
The	  oropharynx	  receives	  a	  sensory	  and	  motor	  nerve	  supply	  from	  the	  
glossopharyngeal	  and	  vagal	  nerves.	  	  The	  hypoglossal	  nerve	  supplies	  motor	  
innervation	  to	  the	  base	  of	  the	  tongue	  and	  the	  trigeminal	  nerve	  (V2,	  V3)	  supplies	  the	  
motor	  and	  sensory	  innervation	  to	  the	  soft	  palate	  (Lalwani,	  2008).	  	  Arterial	  blood	  
supply	  is	  from	  branches	  of	  the	  external	  carotid	  artery.	  It	  is	  lined	  by	  smooth	  stratified	  
squamous	  epithelium	  and	  has	  a	  rich	  lymphatic	  drainage	  system.	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In	  the	  UK,	  the	  commonest	  site	  of	  oropharyngeal	  SCC	  is	  the	  lateral	  wall,	  
incorporating	  the	  lateral	  sub	  sites	  above	  and	  accounting	  for	  50%	  of	  tumours	  in	  this	  
area.	  	  Between	  65%	  and	  77%	  of	  oropharyngeal	  tumours	  are	  complicated	  by	  nodal	  
disease	  at	  presentation	  (with	  20%	  of	  presentations	  having	  bilateral	  nodal	  disease)	  
especially	  when	  the	  primary	  tumour	  is	  located	  in	  the	  posterior	  third	  of	  the	  tongue	  
(Mukherji	  et	  al.,	  2001).	  The	  UK	  incidence	  in	  oropharyngeal	  SCC	  is	  rising;	  association	  
with	  human	  papilloma	  virus	  (HPV)	  implicated.	  
1.1.4	  	  The	  Nasopharynx	  
The	  nasopharynx	  is	  a	  cuboidal	  shaped	  muscular	  tube	  lined	  by	  pseudostratified	  
columnar	  epithelium.	  	  It	  extends	  from	  the	  posterior	  choana	  anteriorly	  to	  the	  level	  of	  
the	  free	  border	  of	  the	  soft	  palate	  along	  the	  plane	  of	  the	  airway.	  Lymphatic	  drainage	  
is	  to	  the	  posterior	  cervical	  and	  jugulodiagastric	  nodes.	  	  Squamous	  cell	  carcinoma	  of	  
the	  nasopharynx	  is	  rare	  in	  Western	  countries,	  with	  patients	  often	  presenting	  with	  
late	  stage	  disease	  and	  associated	  lymphadenopathy	  as	  early	  disease	  is	  largely	  
symptomless	  (Gleeson	  and	  Scott-­‐Brown,	  2008).	  	  
1.1.5	  	  The	  Hypopharynx	  
This	  area	  extends	  from	  the	  plane	  of	  the	  superior	  border	  of	  the	  hyoid	  bone	  (or	  
floor	  of	  the	  vallecula)	  to	  the	  plane	  corresponding	  to	  the	  lower	  border	  of	  the	  cricoid	  
cartilage.	  The	  hypopharynx	  is	  lined	  by	  stratified	  squamous	  epithelium	  and	  has	  a	  rich	  
lymphatic	  supply,	  draining	  to	  the	  deep	  cervical	  and	  paratracheal	  nodes	  (levels	  III-­‐VI).	  	  
It	  is	  sub-­‐divided	  into	  the	  following	  areas:	  
• Postcricoid	  –	  from	  the	  level	  of	  the	  arytenoid	  cartilages	  to	  the	  inferior	  border	  
of	  the	  cricoid	  cartilage	  	  
• Pyriform	  sinus	  –	  from	  the	  pharyngoepiglottic	  fold	  to	  the	  upper	  end	  of	  the	  
oesophagus	  
• Posterior	  pharyngeal	  wall	  –	  from	  the	  superior	  border	  of	  hyoid	  to	  the	  inferior	  
border	  of	  the	  cricoid	  cartilage	  and	  from	  the	  apex	  of	  one	  piriform	  fossa	  to	  the	  
other	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HNSCC	  in	  this	  region	  is	  relatively	  rare	  with	  only	  10%	  of	  cases	  originating	  from	  this	  
area	  (Stell	  et	  al.,	  2010).	  	  Presentation	  is	  often	  late	  with	  significant	  dysphagia	  and/or	  
referred	  pain	  due	  to	  involvement	  of	  the	  glossopharyngeal	  and	  vagal	  nerves.	  	  The	  
commonest	  sub	  site	  is	  the	  pyriform	  fossa	  with	  65-­‐85%	  of	  tumours	  found	  here	  
(Lalwani,	  2008).	  These	  tumours	  often	  extend	  medially	  through	  the	  aryepiglottic	  fold	  
to	  invade	  the	  paraglottic	  space,	  anteriorly	  into	  the	  pre-­‐epiglottic	  space,	  inferiorly	  to	  
the	  post-­‐cricoid	  region	  and	  often	  present	  with	  lymph	  node	  metastasis	  (67-­‐75%;	  
Lalwani,	  2008).	  	  Post-­‐cricoid	  tumours,	  although	  often	  extending	  inferiorly	  to	  the	  
cervical	  oesophagus	  and	  laterally	  in	  the	  tracheo-­‐oesophageal	  groove,	  are	  often	  less	  
aggressive	  and	  present	  with	  nodal	  disease	  less	  often	  (20-­‐30%;	  Lalwani,	  2008),	  
reflecting	  the	  differing	  lymphatic	  drainage	  between	  sites.	  
1.1.6	  	  Histology	  of	  HNSCC	  
As	  described	  above,	  the	  majority	  of	  the	  UADT	  is	  lined	  by	  stratified	  squamous	  
epithelium	  with	  malignant	  transformation	  resulting	  in	  squamous	  cell	  carcinoma	  
(SCC)	  and	  accounting	  for	  90%	  of	  tumours	  of	  the	  head	  and	  neck	  (Curado	  and	  Hashibe,	  
2009).	  	  Although	  other	  tumours	  such	  as	  salivary	  gland,	  thyroid,	  malignant	  melanoma	  
and	  lymphoma	  can	  be	  found	  in	  this	  area,	  only	  SCC	  and	  its	  possible	  pre-­‐malignant	  
precursors	  will	  be	  discussed	  because	  of	  their	  prevalence.	  
1.1.6.1	  	  Leukoplakia	  
Leukoplakia	  is	  a	  descriptive	  term	  relating	  to	  a	  ‘white	  plaque’	  that	  cannot	  be	  
characterised	  clinically	  or	  pathologically	  as	  any	  other	  disease.	  	  It	  is	  most	  likely	  found	  
in	  the	  oral	  cavity,	  thought	  to	  arise	  from	  chronic	  irritation	  of	  the	  mucosa,	  e.g.	  
pressure	  from	  an	  adjacent	  sharp	  tooth.	  	  Its	  pathological	  hallmarks	  include;	  
hyperkeratosis	  (increased	  numbers	  of	  nucleated	  cells	  near	  the	  surface),	  acanthosis	  
(elongation	  of	  rete	  pegs	  into	  the	  submucosa),	  abnormal	  orientation	  of	  cells,	  nuclear	  
hyperchromatism,	  increased	  number	  of	  mitotic	  figures	  and	  an	  altered	  nuclear	  to	  
cytoplasmic	  ratio.	  	  The	  frequency	  of	  dysplastic	  or	  malignant	  cell	  alterations	  within	  
the	  lesion	  ranges	  from	  16-­‐39%	  (Neville	  and	  Day,	  2002),	  however	  the	  consensus	  for	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1.1.6.2	  	  Erythroplakia	  
Erythroplakia	  is	  defined	  as	  a	  red	  mucosal	  plaque,	  usually	  found	  on	  the	  soft	  
palate	  and	  tonsillar	  pillars.	  	  Although	  less	  common	  then	  leukoplakia,	  it	  has	  a	  higher	  
incidence	  of	  dysplasia,	  which	  is	  noted	  on	  histological	  evaluation	  of	  most	  cases.	  	  The	  
risk	  of	  malignant	  transformation	  is	  as	  much	  as	  seventeen	  times	  higher	  than	  in	  
leukoplakia	  (Scully	  et	  al.,	  2003).	  
1.1.6.3	  	  Dysplasia	  
Dysplasia	  is	  a	  histological	  diagnosis	  characterised	  by:	  
• Cellular	  atypia	  –	  increased	  nuclear	  to	  cytoplasmic	  ratio,	  cellular	  
pleomorphism	  
• Loss	  of	  cellular	  maturity	  –	  increased	  mitotic	  figures,	  and	  
• Loss	  of	  stratification	  –	  abnormal	  progression	  from	  the	  basal	  to	  the	  more	  
superficial	  layers	  
The	  World	  Health	  Organisation	  classified	  dysplasia	  into	  three	  groups	  (Pindborg	  
et	  al.,	  1997)	  (Figure	  1.4):	  
1) Mild	  –	  changes	  are	  limited	  to	  the	  lower	  third	  of	  the	  epithelial	  thickness.	  
2) Moderate	  –	  changes	  are	  limited	  to	  the	  lower	  two	  thirds	  of	  the	  epithelial	  
thickness	  
3) Severe	  –	  in	  which	  the	  changes	  involve	  more	  than	  the	  lower	  two	  thirds	  of	  the	  
epithelial	  thickness.	  	  Full	  thickness	  changes	  can	  also	  be	  described	  as	  
carcinoma-­‐in-­‐situ	  with	  evidence	  of	  an	  intact	  basal	  membrane.	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1.1.6.4	  	  Squamous	  Cell	  Carcinoma	  
The	  progression	  of	  SCC	  from	  pre-­‐cancerous	  lesions	  is	  summarised	  by	  a	  step-­‐
wise	  progression	  model	  (Figure	  1.5).	  	  As	  with	  dysplasia,	  it	  is	  categorised	  into	  well,	  
moderately	  and	  poorly	  differentiated	  lesions	  based	  on	  the	  degree	  of	  differentiation,	  
cellular	  pleomorphism	  and	  mitotic	  activity.	  	  Invasion	  through	  the	  basement	  
membrane	  (Figure	  1.6)	  is	  the	  salient	  feature,	  distinguishing	  the	  development	  of	  
frankly	  invasive	  disease	  from	  a	  carcinoma-­‐in-­‐situ.	  	  
Figure	  1.5	  Diagram	  demonstrating	  the	  stepped	  progression	  model	  for	  HNSCC.	  
Figure	  1.4	  "Classic"	  or	  non-­‐keratinizing	  dysplasia	  
of	  the	  larynx.	  	  Stained	  with	  haemotoxylin	  and	  
eosin,	  x	  100	  magnification.	  A,	  Mild	  dysplasia.	  B,	  
Moderate	  dysplasia.	  C,	  Severe	  dysplasia	  with	  full-­‐
thickness	  replacement	  of	  the	  squamous	  
epithelium	  by	  atypical,	  small,	  immature	  basaloid	  
cells	  (Wenig,	  2002).	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The	  clinical	  appearance	  of	  invasive	  SCC	  is	  quite	  variable	  and	  includes	  
ulcerated,	  flat,	  exophytic,	  verrucoid,	  or	  papillary	  growths.	  Invasion	  can	  be	  as	  large	  
cords	  or	  cohesive	  aggregates	  or	  can	  appear	  as	  single	  cells	  of	  small	  irregular	  
aggregates.	  	  A	  desmoplastic	  stromal	  response	  (Figure	  1.6),	  is	  a	  hallmark	  feature	  of	  
invasive	  cancer,	  as	  is	  a	  foreign	  body	  reaction	  to	  keratin	  in	  the	  stroma	  (Wenig,	  2002).	  
	  
Figure	  1.6	  Image	  of	  invasive	  squamous	  cell	  
carcinoma	  of	  the	  UADT.	  Stained	  with	  
haemotoxylin	  and	  eosin,	  x	  100	  
magnification.	  A,	  cohesive	  or	  nested	  growth	  
pattern.	  B,	  	  dyscohesive	  growth	  pattern.	  In	  
both	  illustrations,	  there	  is	  desmoplastic	  
stromal	  response	  to	  the	  presence	  of	  invasive	  
carcinoma	  (Wenig,	  2002).	  
	   	  14	  
1.2	  	  Epidemiology	  of	  HNSCC	  	  
The	  incidence	  of	  HNSCC	  varies	  significantly	  according	  to	  geographical	  
location,	  sex	  and	  site,	  however,	  in	  general,	  the	  incidence	  of	  HNSCC	  has	  been	  in	  
decline	  over	  the	  last	  decade	  in	  the	  Indian	  Subcontinent,	  East	  Asia,	  Western	  Europe	  
and	  the	  United	  States	  in	  men	  and	  levels	  have	  generally	  stabilised	  in	  women	  (Parkin	  
et	  al.,	  2005).	  North	  and	  Eastern	  Europe	  has	  seen	  an	  increase	  in	  oral	  cavity,	  tongue	  
and	  pharyngeal	  cancer	  in	  both	  men	  and	  women	  (Curado	  and	  Hashibe,	  2009).	  
Oral	  cavity	  SCC	  is	  the	  most	  common	  form	  of	  HNSCC	  worldwide,	  accounting	  
for	  274,000	  cases	  in	  2002,	  with	  almost	  two-­‐thirds	  of	  cases	  in	  men	  (Parkin	  et	  al.,	  
2005).	  	  Areas	  of	  high	  incidence	  include	  Melanesia	  (31.5	  per	  100,000	  in	  men	  and	  20.2	  
per	  100,000	  in	  women),	  Western	  Europe	  (11.3	  per	  100,000	  in	  men),	  and	  south	  Asia	  
(12.7	  per	  100,000	  in	  men)	  with	  patterns	  of	  incidence	  reflecting	  risk	  factors,	  such	  as	  
tobacco/alcohol	  use	  in	  Western	  Europe,	  and	  the	  chewing	  of	  betel	  nut	  in	  South-­‐
central	  Asia	  and	  Melanesia.	  	  
There	  were	  159,000	  new	  cases	  and	  90,000	  deaths	  due	  to	  laryngeal	  carcinoma	  
worldwide	  in	  2002	  (Parkin	  et	  al.,	  2005).	  It	  is	  less	  common	  in	  women	  (M:F	  sex	  ratio,	  
7:1).	  Areas	  of	  high	  incidence	  include	  Southern	  Europe	  (France,	  Italy,	  Spain),	  Eastern	  
Europe	  (Russia,	  Ukraine),	  South	  America	  (Uruguay,	  Argentina)	  and	  Western	  Asia	  
(Turkey,	  Iraq)	  where	  it	  accounts	  for	  4.7%	  of	  cancers	  in	  men	  compared	  with	  2.4%	  
worldwide	  (Parkin	  et	  al.,	  2005).	  	  
Globally,	  oropharyngeal	  cancer	  accounted	  for	  174,200	  cases	  in	  2002,	  again	  
almost	  two	  thirds	  occurring	  in	  men	  (Parkin	  et	  al.,	  2005).	  Nasopharyngeal	  cancer	  
accounts	  for	  very	  few	  cases	  of	  HNSCC	  worldwide	  with	  incidence	  rate	  less	  than	  1	  in	  
100000	  for	  the	  most	  part.	  	  It	  is	  however	  common	  in	  some	  ethnic	  groups	  (as	  further	  
explained	  in	  section	  1.3.5)	  with	  the	  highest	  rate	  found	  among	  the	  Chinese,	  
particularly	  in	  Hong	  Kong	  and	  Singapore	  (Goldsmith	  et	  al.,	  2002).	  Males	  are	  more	  
often	  affected	  than	  females	  (M:F	  sex	  ratio,	  2.3:1),	  and	  in	  most	  populations	  risk	  
increases	  with	  age	  (Parkin	  et	  al.,	  2005).	  	  	  
In	  the	  UK,	  HNSCC	  represents	  3%	  of	  all	  diagnosed	  cancers.	  	  The	  2007	  incidence	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disproportionately	  in	  comparison	  with	  other	  sites	  of	  HNSCC	  (Figure	  1.7).	  	  This	  is	  
thought	  to	  be	  partly	  due	  to	  previous	  increased	  use	  of	  tobacco	  and	  alcohol	  within	  the	  
population	  as	  this	  tumour	  is	  highly	  associated	  with	  smoking	  and	  drinking.	  	  The	  
increased	  incidence	  of	  oropharyngeal	  SCC	  is	  also	  likely	  to	  be	  responsible	  as	  
oropharyngeal	  SCC	  is	  often	  wrongly	  included	  within	  the	  oral	  cavity	  group	  when	  cases	  
are	  reported.	  
Cancer	  Site	   Male	   Female	   Total	  (%)	  
















Larynx	   1,844	   361	   2,205	  (28)	  
Oropharynx	   812	   272	   1,084	  (14)	  
Nasopharynx	   167	   74	   241	  (3)	  
Table	  1.1	  The	  number	  of	  new	  cases	  of	  HNSCC	  in	  the	  UK	  in	  2007.	  Adapted	  from	  
figures	  by	  Cancer	  Research	  UK	  (http://info.cancerresearchuk.org/cancerstats/)	  
	  
Figure	  1.7	  Graph	  of	  age-­‐standardised	  incidence	  rates,	  by	  sex,	  oral	  cancer,	  UK,	  1975-­‐
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Regional	  variations	  in	  incidence	  are	  seen	  throughout	  the	  UK	  and	  statistics	  for	  
laryngeal	  cancer,	  demonstrating	  highest	  rates	  in	  Scotland,	  are	  given	  below	  (Figure	  
1.8).	  One	  reason	  for	  this	  is	  variations	  in	  socio-­‐economic	  status,	  Thorne	  et	  al.	  (1997)	  
found	  that	  the	  incidence	  of	  oral	  cancer	  in	  men	  was	  significantly	  higher	  in	  the	  most	  
economically	  deprived	  group.	  	  
	  
	  
Figure	  1.8	  Graph	  showing	  the	  incidence	  of	  laryngeal	  UK	  by	  country	  and	  region,	  1991-­‐
1999	  (Cancer	  Atlas	  of	  the	  UK	  and	  Ireland,	  1991-­‐2001)	  http://www.statistics.gov.uk).	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1.3 	  	  Aetiology	  of	  HNSCC	  
1.3.1	  	  Tobacco	  	  
Tobacco	  use	  is	  known	  to	  be	  the	  main	  causative	  factor	  in	  laryngeal	  cancer,	  
with	  98%	  of	  patients	  being	  smokers	  (Tuyns	  et	  al.,	  1988).	  Likewise,	  oral	  cavity	  and	  
oropharyngeal	  cancer	  are	  most	  strongly	  associated	  with	  tobacco	  and	  alcohol	  
consumption	  (although	  the	  recently	  described	  association	  of	  oropharyngeal	  SCC	  with	  
HPV	  may	  be	  more	  important	  in	  some	  patients).	  	  In	  both	  of	  these	  cancers,	  higher	  
tobacco	  consumption	  and	  increased	  length	  of	  exposure	  confer	  an	  increased	  risk	  of	  
malignancy	  with	  the	  added	  effects	  of	  alcohol	  seemingly	  synergistic	  (Kabat	  et	  al.,	  
1994).	  Epidemiological	  studies	  citing	  figures	  for	  relative	  risks	  (RR)	  are	  summarised	  in	  
Table	  1.2:	  
Author,	  year	  of	  publication	   SCC	  sub	  site	   Findings	  
Wynder	  et	  al.	  (1976)	   Laryngeal	  	   RR	  4.4	  <10	  cigs/day	  
RR	  34.4	  >40	  cigs/day	  
Falk	  et	  al.	  (1989)	   Laryngeal	  	   RR	  4.4	  >20	  cigs/day	  
RR	  10.4	  >40	  cigs/day	  	  
Merletti	  et	  al.	  (1989)	   Oral/oropharyngeal	   RR	  4-­‐6	  medium	  to	  high	  consumption	  of	  
tobacco	  
Maier	  et	  al.	  (1992)	   UADT	   RR	  23.4	  >60	  pack	  years	  
Macfarlane	  et	  al.	  (1996)	   UADT	  	   RR	  2.4	  7	  cigs/day	  
RR16.4	  >25	  cigs/day	  











Table	  1.2	  Summary	  of	  publications	  demonstrating	  relative	  risk	  of	  laryngeal	  cancer	  
attributed	  to	  tobacco	  consumption.	  
The	  method	  of	  tobacco	  use	  often	  reflects	  incidence	  of	  specific	  sub	  sites	  of	  
HNSCC;	  areas	  where	  chewing	  tobacco	  is	  prevalent	  (e.g.	  India)	  have	  high	  rates	  of	  oral	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cavity	  and	  hypopharyngeal	  cancer	  (Sapkota	  et	  al.,	  2007),	  whereas	  where	  reverse	  
smoking	  is	  common-­‐place,	  palatal	  SCC	  predominates	  (Squier,	  1984).	  	  	  
Tobacco	  is	  known	  to	  contain	  a	  variety	  of	  carcinogenic	  compounds,	  with	  over	  
60	  compounds	  identified	  (Kuper	  et	  al.,	  2002).	  Potent	  carcinogens	  include	  polycyclic	  
hydrocarbons	  such	  as	  benzo-­‐pyrene,	  nitrosamines	  and	  aromatic	  amines	  (Zaridze	  and	  
Peto,	  1986).	  
1.3.2	  	  Alcohol	  
Alcohol	  is	  thought	  to	  potentiate	  tobacco	  related	  carcinogenesis	  rather	  than	  
act	  as	  a	  carcinogen	  per	  se.	  The	  mechanisms	  for	  this	  are	  not	  fully	  understood.	  It	  was	  
thought	  that	  ethanol	  may	  enhance	  the	  contact	  of	  the	  tobacco	  carcinogens	  to	  the	  
mucosal	  lining	  of	  the	  upper	  aero	  digestive	  tract	  (Blot	  et	  al.,	  1988).	  This	  does	  not	  
however	  fully	  explain	  the	  persistence	  of	  elevated	  risk	  after	  cessation	  of	  drinking.	  
Other	  studies	  have	  suggested	  a	  direct	  chromosomal	  effect	  with	  altered	  alkylated	  
DNA	  repair	  (Garro	  et	  al.,	  1986,	  Mufti	  et	  al.,	  1988).	  More	  recently,	  several	  groups	  have	  
suggested	  that	  the	  acetaldehyde	  component	  is	  a	  major	  factor,	  causing	  DNA	  damage	  
by	  the	  formation	  of	  DNA	  adducts	  (Brooks	  and	  Theruvathu,	  2005,	  Boffetta	  and	  
Hashibe,	  2006).	  
The	  type	  of	  alcohol	  is	  also	  important;	  a	  Danish	  population	  study	  (Gronbaek	  et	  
al.,	  1998)	  of	  28,180	  found	  that	  people	  who	  only	  drank	  beers	  and/or	  spirits	  had	  a	  
higher	  RR	  of	  developing	  HNSCC	  in	  comparison	  to	  those	  who	  included	  wine	  in	  their	  
alcohol	  intake.	  More	  recently,	  pooled	  data	  from	  15	  case	  controlled	  studies	  on	  HNSCC	  
(Purdue	  et	  al.,	  2009)	  including	  9,107	  cases	  and	  14,219	  controls	  found	  a	  similar	  RR	  in	  
liquor-­‐only	  and	  beer-­‐only	  drinkers	  for	  ethanol-­‐standardised	  consumption	  frequency	  
of	  >30	  drinks	  per	  week.	  Among	  wine-­‐only	  drinkers,	  the	  odds	  ratios	  for	  moderate	  
levels	  of	  consumption	  frequency	  approached	  the	  null,	  whereas	  those	  for	  higher	  
consumption	  levels	  were	  comparable	  to	  those	  of	  drinkers	  of	  other	  beverage	  types.	  
Thus,	  whilst	  there	  is	  a	  strong	  association	  between	  beer	  and	  spirit	  consumption	  and	  
HNSCC,	  those	  drinking	  a	  similar	  quantity	  of	  wine	  are	  at	  a	  lower	  risk,	  with	  moderate	  
consumption	  possibly	  offering	  a	  degree	  of	  protection.	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1.3.3	  	  Human	  Papilloma	  Virus	  (HPV)	  
Known	  to	  be	  an	  important	  risk	  factor	  in	  SCC	  of	  the	  cervix,	  HPV	  has	  now	  been	  
implicated	  in	  HNSCC.	  DNA	  from	  HPV	  subtypes	  16	  and	  18	  is	  frequently	  detected	  in	  
HNSCC.	  A	  recent	  meta-­‐analysis	  of	  62	  studies	  examining	  paraffin-­‐embedded	  biopsies	  
of	  HNSCC	  found	  the	  pooled	  prevalence	  of	  HPV	  DNA	  by	  either	  PCR-­‐detection	  or	  in-­‐situ	  
hybridisation	  to	  be	  34.5%	  (excluding	  oral),	  with	  a	  higher	  rate	  of	  38.1%	  in	  oral	  SCC	  
(Termine	  et	  al.,	  2008).	  	  	  
The	  molecular	  and	  histopathological	  characteristics	  of	  HPV	  associated	  HNSCC	  
are	  not	  yet	  fully	  understood,	  but	  current	  evidence	  suggests	  that	  tumours	  with	  
detectable	  HPV	  express	  E6/E7	  mRNA,	  which	  is	  known	  to	  inactivate	  the	  tumour	  
suppressor	  gene	  products	  p53	  and	  pRb	  (Retinoblastoma	  protein)	  products,	  
potentiating	  cell	  immortalisation	  (Rampias	  et	  al.,	  2009).	  	  	  
Although	  numerous	  studies	  have	  detected	  the	  presence	  of	  HPV,	  controversy	  
still	  remains	  as	  to	  whether	  it	  is	  an	  incidental	  finding	  or	  plays	  an	  important	  role	  in	  the	  
initiation	  and	  promotion	  of	  SCC.	  	  Emerging	  evidence,	  particularly	  regarding	  the	  
association	  of	  HPV	  with	  oropharyngeal	  SCC	  suggests	  that	  HPV	  positive	  patients	  have	  
a	  better	  outcome	  than	  HPV-­‐negative	  ones	  despite	  presenting	  at	  a	  more	  advanced	  
stage	  (Schlecht,	  2005,	  Ang	  et	  al.,	  2010).	  In	  a	  recent	  study	  by	  Ang	  et	  al.	  (2010)	  the	  
63.8%	  of	  patients	  with	  HPV-­‐positive	  oropharyngeal	  cancer	  (206	  of	  323)	  had	  improved	  
3-­‐year	  rates	  of	  overall	  survival	  (82.4%	  vs.	  57.1%)	  among	  patients	  with	  HPV-­‐negative	  
tumours.	  In	  addition,	  after	  adjustment	  for	  age,	  race,	  tumour	  and	  nodal	  stage,	  
tobacco	  exposure,	  and	  treatment	  assignment,	  HPV-­‐positive	  patients	  had	  a	  58%	  
reduction	  in	  the	  risk	  of	  death,	  leading	  the	  authors	  to	  conclude	  that	  tumour	  HPV	  
status	  is	  a	  strong	  and	  independent	  prognostic	  factor	  for	  survival	  among	  patients	  with	  
oropharyngeal	  cancer.	  	  
The	  evidence	  of	  increased	  incidence	  of	  HPV	  in	  oropharyngeal	  SCC,	  reduced	  
age	  of	  incidence	  and	  altered	  prognosis,	  all	  support	  the	  opinion	  that	  tumourigenesis	  
in	  HPV	  positive	  oropharyngeal	  positive	  SCC	  may	  be	  due	  to	  an	  alternative,	  though	  
overlapping,	  mechanism	  separate	  to	  the	  ‘classic’	  HNSCC	  carcinogenesis	  per	  se	  (Li	  and	  
Sturgis,	  2006).	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1.3.4	  	  Epstein-­‐Barr	  Virus	  (EBV)	  
There	  is	  strong	  evidence	  for	  the	  role	  of	  EBV	  in	  the	  development	  of	  
nasopharyngeal	  carcinoma	  (NPC),	  however	  the	  pandemic	  nature	  of	  this	  infection	  and	  
the	  distinct	  geographical	  variations	  of	  NPC	  worldwide	  mean	  that	  this	  is	  not	  the	  only	  
causative	  factor.	  The	  virus,	  not	  normally	  found	  in	  epithelial	  cells	  of	  the	  nasopharynx,	  
is	  often	  present	  in	  NPC	  tumour	  cells	  as	  well	  as	  dysplastic	  and	  carcinoma	  in	  situ	  
lesions	  (Pathmanathan	  et	  al.,	  1995).	  The	  virus	  alone	  cannot	  drive	  normal	  cells	  
towards	  carcinoma	  development;	  it	  is	  thought	  that	  loss	  of	  heterozygosity,	  possibly	  as	  
a	  result	  of	  inherited	  traits	  (Chinese	  ethnicity)	  (Goldsmith	  et	  al.,	  2002),	  exposure	  to	  
dietary	  factors	  (salted	  fish)	  (Morton	  and	  Benjamin,	  1989)	  and	  other	  environmental	  
cofactors,	  is	  an	  early	  occurrence	  in	  NPC.	  It	  is	  within	  these	  low-­‐grade,	  pre-­‐invasive	  
lesions,	  subsequent	  to	  further	  genetic	  and	  epigenetic	  alterations,	  where	  EBV	  
infection	  occurs.	  The	  expression	  of	  EBV	  latent	  genes	  (encoding	  latent	  membrane	  
proteins	  LMP1,	  LMP2A	  and	  LMP2B)	  provides	  growth	  and	  survival	  advantages	  to	  
these	  infected	  cells,	  ultimately	  leading	  to	  the	  development	  of	  NPC	  (Shah	  and	  Young,	  
2009).	  The	  role	  of	  EBV	  in	  tumour	  formation,	  although	  unique	  to	  NPC,	  clearly	  
demonstrates	  the	  role	  of	  viral	  aetiology	  in	  cancer	  
1.3.5	  	  Genetic	  Alterations	  in	  HNSCC	  
The	  development	  of	  HNSCC	  is	  a	  multistep	  carcinogenesis	  process	  involving	  
the	  progressive	  loss	  of	  homeostatic	  control	  of	  cell	  growth	  and	  death	  (Califano	  et	  al.,	  
1996).	  	  Alterations	  in	  the	  expression	  of	  cell	  cycle	  regulatory	  proteins	  involved	  in	  DNA	  
repair,	  proliferation,	  apoptosis,	  invasion	  and	  angiogenesis	  result	  from	  the	  activation	  
of	  proto-­‐oncogenes	  and	  the	  inactivation	  of	  tumour	  suppression	  genes.	  This	  
ultimately	  leads	  to	  an	  unbalanced	  mitogenic	  signal	  and	  consequent	  aberrant	  cell	  
proliferation.	  	  Key	  events	  in	  this	  process	  include	  inactivation	  of	  the	  p53	  tumour	  
suppressor	  gene,	  inactivation	  of	  the	  cyclin-­‐dependent	  kinase	  (CDK)	  inhibitor	  p16	  and	  
over-­‐expression	  of	  epidermal	  growth	  factor	  receptor	  (EGFR)(Hardisson,	  2003).	  	  
1.3.5.1	  	  p53	  
The	  p53	  gene	  encodes	  a	  tumour	  suppressor	  protein	  with	  the	  ability	  to	  
activate	  DNA	  repair	  proteins	  after	  damage,	  induce	  growth	  arrest	  by	  holding	  the	  cell	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cycle	  at	  the	  G1/S	  regulation	  point	  on	  DNA	  damage	  recognition	  and	  initiate	  apoptosis	  
if	  the	  DNA	  damage	  proves	  to	  be	  irreparable	  (Hollstein	  et	  al.,	  1991).	  A	  diagrammatic	  
representation	  of	  the	  activation/inactivation	  of	  p53	  is	  shown	  in	  Figure	  1.9.	  Studies	  
have	  shown	  a	  presence	  of	  the	  mutated	  form	  in	  25-­‐80%	  of	  cases	  of	  HNSCC	  (Fan,	  
2001).	  Mutations	  are	  more	  common	  in	  patients	  with	  a	  history	  of	  alcohol	  and	  tobacco	  
use;	  the	  type,	  frequency	  and	  location	  of	  p53	  mutations	  have	  been	  associated	  with	  
specific	  carcinogenic	  agents.	  Base	  transitions,	  typically	  G	  →T	  substitutions	  and	  
transversions,	  for	  example	  are	  thought	  to	  be	  related	  to	  exposure	  to	  exogenous	  
exposures	  such	  as	  tobacco	  smoke	  (Pfeifer	  et	  al.,	  2002)	  and	  are	  more	  likely	  to	  be	  
found	  in	  HNSCC	  compared	  to	  other	  sites,	  e.g.	  colon	  (Olshan	  et	  al.,	  1997).	  	  
	  	  	  	  	  	  	  	  	   	  	  	  	  	  
Figure	  1.9	  Diagram	  demonstrating	  cell	  cycle	  regulation	  by	  Rb	  and	  p53	  tumour	  
suppressor	  proteins.	  Adapted	  from	  (Yip	  et	  al.,	  2006).	  Inactivation	  of	  Rb	  and	  p53	  
proteins	  occurs	  by	  phosphorylation,	  enabling	  the	  cell	  cycle	  to	  progress	  from	  the	  G1	  
to	  the	  S	  phase.	  Kinase	  function	  of	  CDK4	  is	  activated	  by	  cyclin	  D1	  and	  inactivated	  by	  
p16	  proteins.	  	  Cyclin	  E	  and	  p21	  control	  the	  activation	  and	  inactivation	  of	  CDK2,	  
respectively.	  Ubiquitination	  of	  p53	  takes	  place	  by	  complexing	  with	  MDM2	  that	  is	  
blocked	  by	  p14ARF.	  	  
The	  presence	  of	  a	  p53	  mutation	  is	  likely	  to	  be	  of	  prognostic	  significance.	  
Poeta	  et	  al.	  (2007)	  correlated	  the	  presence	  of	  any	  p53	  mutation,	  as	  found	  in	  224	  of	  
their	  440	  HNSCC	  tumours,	  with	  decreased	  overall	  survival.	  	  In	  addition,	  a	  stronger	  
association	  was	  seen	  with	  disruptive	  mutations	  leading	  the	  authors	  to	  conclude	  that	  
the	  site	  of	  the	  p53	  mutation	  is	  crucial,	  with	  mutations	  in	  the	  DNA-­‐binding	  domain	  of	  
Cell	  Cycle	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most	  prognostic	  importance.	  In	  agreement,	  p53	  mutations	  in	  direct	  DNA	  contact	  
areas	  resulted	  in	  accelerated	  tumour	  progression	  and	  reduced	  therapeutic	  
responsiveness	  in	  HNSCC	  (Erber	  et	  al.,	  1998,	  Temam	  et	  al.,	  2000).	  
1.3.5.2	  	  Cyclins	  
Cyclins,	  part	  of	  the	  cell	  cycle	  regulation	  process,	  are	  often	  altered	  in	  
malignancies.	  Cyclin	  D1	  activates	  cyclin-­‐dependent	  kinase	  4	  (CDK4),	  allowing	  the	  cell	  
to	  proceed	  through	  a	  checkpoint	  in	  the	  cell	  cycle,	  whereas	  p16	  inhibits	  CDK4,	  acting	  
as	  a	  tumour	  suppressor	  as	  shown	  in	  Figure	  1.10.	  	  In	  a	  population-­‐based	  case-­‐control	  
study	  of	  698	  cases	  and	  777	  controls,	  immunohistochemical	  staining	  of	  variant	  cyclin	  
D1	  protein	  overexpression	  resulted	  in	  an	  increased	  protein	  half-­‐life	  and	  was	  
associated	  with	  an	  increased	  risk	  of	  HNSCC	  in	  addition	  to	  poorer	  survival	  outcomes	  
(Marsit	  et	  al.,	  2008).	  	  Furthermore,	  amplification	  of	  cyclin	  D1	  or	  deletion	  of	  p16	  in	  
tumours	  was	  associated	  with	  recurrence,	  distant	  metastasis,	  and	  reduced	  survival	  at	  
36	  months	  in	  a	  study	  of	  103	  HNSCC	  tumours	  by	  Namazie	  et	  al.	  (2002).	  	  The	  finding	  of	  
alterations	  in	  cyclin	  D1	  and	  p16	  in	  biopsies	  of	  mild	  and	  moderate	  dysplasia	  is	  
evidence	  for	  their	  involvement	  in	  the	  early	  stages	  of	  carcinogenesis	  
(Papadimitrakopoulou	  et	  al.,	  2001).	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  1.10	  Diagram	  demonstrating	  the	  activation	  and	  inhibition	  mechanisms	  of	  
CDK4.	  	  Activation	  and	  inactivation	  of	  p16	  by	  deletion,	  methylation,	  or	  mutation	  
and/or	  by	  amplified	  expression	  of	  cyclin	  D1	  leads	  to	  increased	  phosphorylation	  of	  Rb.	  
However,	  increased	  expression	  of	  p16	  and	  reduced	  expression	  of	  cyclin	  D1	  results	  in	  
hypophosphorylated	  Rb	  binding	  to	  E2F	  transcription	  factor	  leading	  to	  the	  inactivation	  
of	  transcription.	  	  Adapted	  from	  Yip	  et	  al.,	  2006.	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1.3.5.3	  	  EGFR	  
	  EGFR	  (or	  erbB1)	  is	  a	  membrane	  receptor	  and	  a	  member	  of	  the	  tyrosine	  kinase	  
family	  (HER	  RTKs).	  Binding	  of	  the	  ligands	  (EGF	  and	  transforming	  growth	  factor-­‐β,	  
TGFβ)	  to	  the	  receptor's	  extracellular	  domain	  induces	  EGFR	  dimerization,	  resulting	  in	  
the	  activation	  of	  receptor	  tyrosine	  kinase	  activity	  and	  EGFR	  autophosphorylation	  on	  
specific	  tyrosine	  residues	  (Schlessinger,	  2000).	  Various	  intracellular	  signalling	  
pathways	  such	  as	  Ras/Raf/MEK/MAPS	  that	  control	  cellular	  proliferation,	  migration	  
and	  differentiation	  can	  then	  be	  initiated	  (Schlessinger,	  2000,	  Hubbard	  and	  Miller,	  
2007).	  
Alterations	  in	  the	  EGFR	  signalling	  pathway	  can	  cause	  malignant	  transformation	  
through	  various	  mechanisms,	  including	  receptor	  over-­‐expression,	  alteration	  in	  
dimerization	  and	  deficiency	  of	  specific	  phosphatases	  (Grunwald	  and	  Hidalgo,	  2003).	  
The	  over-­‐expression	  of	  EGFR	  has	  been	  reported	  in	  73–92%	  of	  HNSCC	  (Hiraishi	  et	  al.,	  
2006,	  Laimer	  et	  al.,	  2007,	  Sarkis	  et	  al.,	  2010).	  	  EGFR	  over-­‐expression	  has	  been	  found	  
to	  correlate	  with	  more	  aggressive	  disease,	  resistance	  to	  both	  chemotherapy	  and	  
radiotherapy	  and	  poor	  prognosis	  (Ang	  et	  al.,	  2002,	  Kong	  et	  al.,	  2006).	  
1.3.6	  	  Summary	  
After	  considering	  the	  various	  aetiological	  factors	  and	  the	  genetic	  pathways	  
implicated	  in	  the	  development	  of	  HNSCC,	  it	  is	  obvious	  that	  numerous	  factors	  are	  
involved.	  	  Also	  highlighted,	  is	  the	  difference	  in	  protein	  expression,	  not	  just	  between	  
tumour	  sub	  sites	  but	  also	  within	  tumours	  of	  the	  same	  location.	  	  An	  appreciation	  of	  
this,	  combined	  with	  other	  patient	  related	  factors	  such	  as	  the	  immune	  response	  and	  
co-­‐existing	  morbidities,	  perhaps	  goes	  someway	  into	  explaining,	  or	  more	  importantly	  
appreciating,	  the	  heterogeneity	  of	  tumour	  response	  to	  standard	  treatment.
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1.4	  	  Staging	  of	  HNSCC	  
The	  staging	  of	  HNSCC	  is	  a	  system	  designed	  to	  convey	  the	  disease	  extent	  or	  
relative	  severity.	  	  It	  can	  give	  an	  indication	  of	  prognosis,	  aid	  the	  clinician	  in	  planning	  
treatment,	  assist	  in	  evaluation	  of	  treatment	  results	  and	  facilitate	  exchange	  of	  
information	  between	  centres.	  Staging	  is	  determined	  by	  clinical	  and	  histopathological	  
means,	  dependent	  on	  extent	  of	  primary	  tumour	  (T),	  absence	  or	  presence	  and	  extent	  
of	  regional	  lymph	  node	  metastases	  (N)	  and	  absence	  or	  presence	  of	  distant	  
metastases	  (M).	  	  	  This	  system	  was	  first	  described	  by	  Pierre	  Denoix	  in	  1944	  (Denoix,	  
1952)	  and	  later	  modified	  by	  the	  World	  Health	  Organisation	  (WHO)	  and	  the	  Union	  for	  
International	  Cancer	  Control	  (UICC).	  The	  American	  Joint	  Committee	  on	  Cancer	  (AJCC)	  
also	  developed	  a	  staging	  system,	  however,	  the	  TNM	  system	  has	  now	  been	  adopted	  
by	  all,	  with	  both	  the	  current	  (sixth)	  edition	  of	  the	  AJCC	  cancer	  manual	  and	  the	  
current	  sixth	  edition	  of	  the	  UICC	  (Sobin	  et	  al.,	  2002),	  both	  published	  in	  2002,	  
containing	  identical	  classifications.	  The	  TNM	  system	  is	  further	  adapted	  for	  each	  
tumour	  sub	  site	  of	  the	  head	  and	  neck	  (see	  Appendix	  1)	  but	  can	  be	  generalised	  for	  all	  
tumour	  types	  as	  shown	  below	  (Sobin	  et	  al.,	  2002).	  
T/N/M	   Definition	  
TX	   Primary	  tumour	  cannot	  be	  assessed	  
T0	   No	  evidence	  of	  primary	  tumour	  
Tis	   Carcinoma	  in	  situ	  
T1,T2,T3,T4	   Increasing	  size	  and	  /or	  local	  extent	  of	  tumour	  
NX	   Regional	  lymph	  nodes	  cannot	  be	  assessed	  
N0	   No	  evidence	  of	  regional	  lymph	  node	  metastasis	  
N1,N2,N3	   Increasing	  involvement	  of	  regional	  lymph	  nodes	  
MX	   Distant	  metastasis	  cannot	  be	  assessed	  
M0	   No	  distant	  metastasis	  
M1	   Distant	  metastasis	  
Table	  1.3	  Summary	  of	  TNM	  staging	  (Sobin	  et	  al.,	  2002).	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   The	  status	  of	  regional	  lymph	  node	  metastasis	  in	  HNSCC	  is	  of	  great	  importance	  
and	  irrespective	  of	  sub	  site,	  is	  as	  follows:	  
N	   Definition	  
N1	   Metastasis	  in	  a	  single	  ipsilateral	  node,	  ≥3cm	  	  
N2a	   Metastasis	  in	  a	  single	  ipsilateral	  lymph	  node	  >3cm	  but	  ≤6cm	  
N2b	   Metastasis	  in	  multiple	  ipsilateral	  lymph	  nodes	  ≤6cm	  
N2c	   Metastasis	  in	  bilateral	  or	  contra	  lateral	  lymph	  nodes	  ≤6cm	  
N3	   Metastasis	  in	  a	  lymph	  node	  >6cm	  
Table	  1.4	  Classification	  of	  nodal	  metastasis	  in	  HNSCC	  (Sobin	  et	  al.,	  2002)	  
Although	  the	  TNM	  is	  a	  global,	  standardised,	  system	  applicable	  to	  all	  HNSCC,	  
there	  are	  limitations.	  	  Only	  the	  anatomical	  extent	  of	  the	  tumour	  is	  taken	  into	  
account;	  other	  factors	  known	  to	  influence	  outcome	  and	  disease	  progression	  are	  not	  
taken	  into	  account	  (e.g.	  extra-­‐capsular	  spread	  of	  nodal	  disease).	  	  Other	  staging	  
systems	  are	  more	  specific	  e.g.	  the	  tumour	  and	  node	  interger	  score	  system,	  TANIS	  
(Carinci	  et	  al.,	  1999)	  and	  the	  Halls	  system	  (Lydiatt	  et	  al.,	  2001),	  however	  are	  more	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The	  TNM	  stages	  are	  further	  grouped	  into	  stages	  (Sobin	  et	  al.,	  2002),	  reflecting	  
survival	  rates.	  	  
Stage	   T	   N	   M	  
0	   Tis	   N0	   M0	  
I	   T1	   N0	   M0	  
II	   T2	   N0	   M0	  


















IVc	   Any	  T	   Any	  N	   M1	  
Table	  1.5	  HNSCC	  Stages	  I-­‐IV	  based	  on	  the	  TNM	  Classification	  (Sobin	  et	  al.,	  2002)	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1.5	  	  Management	  of	  HNSCC	  
When	  considering	  the	  primary	  tumour,	  early	  stage	  squamous	  carcinoma	  (T1	  and	  
T2)	  at	  most	  sites	  is	  treated	  by	  a	  single	  modality,	  either	  surgery,	  or	  radiotherapy	  (see	  
figure	  1.11).	  	  More	  advanced	  tumours	  (T3	  and	  T4)	  are	  commonly	  managed	  by	  a	  
combination	  of	  surgery	  and	  postoperative	  radiotherapy	  or	  chemo-­‐radiotherapy	  with	  
or	  without	  induction	  chemotherapy	  (Choong	  and	  Vokes,	  2008).	  	  
	  
Figure	  1.11	  General	  schema	  for	  the	  management	  of	  HNSCC,	  adapted	  from	  (Choong	  
and	  Vokes,	  2008).	  
The	  current	  ‘standard’	  treatments	  based	  on	  tumour	  site	  and	  stage	  are	  
summarised	  below	  
1.5.1	  	  Management	  of	  Cervical	  Metastases	  
Elective	  treatment	  of	  the	  N0	  neck	  depends	  on	  the	  site	  and	  histology	  of	  the	  
primary	  tumour	  and	  in	  general	  consists	  of	  a	  selective	  neck	  dissection	  or	  radiotherapy	  
in	  those	  tumours	  with	  an	  incidence	  of	  micro-­‐metastases	  of	  more	  than	  20%	  (Weiss	  et	  
al.,	  1994).	  	  In	  the	  presence	  of	  cervical	  metastases,	  neck	  dissection	  is	  recommended.	  	  
The	  exception	  however	  is	  in	  small	  volume	  nodal	  disease	  (<2	  cm),	  when	  it	  can	  be	  
successfully	  encompassed	  in	  a	  radiation	  field.	  	  For	  example	  in	  N1	  necks	  in	  tonsillar	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carcinoma,	  surgical	  and	  radiotherapy	  results	  are	  comparable	  (Robson,	  2001).	  	  In	  
some	  advanced	  cases,	  metastases	  may	  be	  considered	  unresectable	  for	  technical	  
reasons,	  e.g.	  infiltration	  of	  prevertebral	  musculature,	  brachial	  plexus	  etc.	  	  In	  some	  
patients,	  although	  it	  may	  be	  possible	  to	  resect	  the	  nodal	  disease,	  it	  is	  considered	  to	  
be	  too	  functionally	  disabling,	  or	  the	  patient	  co-­‐morbidity	  considered	  too	  risky	  to	  
attempt	  to	  do	  so.	  A	  patient	  may	  choose	  not	  to	  undergo	  surgical	  treatment.	  	  In	  such	  
circumstances	  radiotherapy	  or,	  in	  fit	  patients,	  chemo-­‐radiotherapy,	  may	  then	  be	  
offered	  as	  primary	  treatment.	  	  
The	  type	  of	  neck	  dissection	  performed	  is	  classified	  in	  accordance	  with	  the	  
consensus	  statement	  on	  the	  classification	  and	  terminology	  of	  neck	  dissection	  
(Robbins	  et	  al.,	  2008).	  A	  radical	  neck	  dissection	  describes	  the	  removal	  of	  lymph	  node	  
levels	  I-­‐V,	  the	  sternocleidomastoid	  muscle,	  internal	  jugular	  vein	  and	  accessory	  nerve.	  
This	  technique,	  originally	  described	  by	  Crile	  in	  1906	  (Rinaldo	  et	  al.,	  2008)	  is	  the	  gold	  
standard	  of	  neck	  dissection,	  but	  due	  to	  its	  inevitable	  morbidity	  is	  now	  reserved	  for	  
advanced	  nodal	  disease.	  	  If	  possible,	  a	  modified	  neck	  dissection	  is	  now	  performed,	  
with	  the	  aim	  of	  preserving	  one	  or	  more	  of	  the	  non-­‐lymphatic	  structures	  above.	  	  	  
An	  appreciation	  of	  the	  patterns	  of	  nodal	  metastatic	  spread	  from	  individual	  
tumour	  sites	  within	  the	  head	  and	  neck,	  based	  on	  the	  clinical	  studies	  of	  Lindberg	  
(1972),	  has	  led	  to	  the	  increased	  use	  of	  the	  selective	  neck	  dissection,	  allowing	  for	  the	  
preservation	  one	  or	  more	  lymph	  node	  groups	  thus	  limiting	  morbidity.	  An	  extended	  
neck	  dissection	  describes	  the	  additional	  removal	  of	  other	  lymph	  node	  groups	  
(parapharyngeal,	  paratracheal,	  superior	  mediastinal),	  or	  other	  non-­‐lymphatic	  
structures	  (carotid	  artery,	  vagus	  nerve,	  hypoglossal	  nerve,	  prevertebral	  muscle).	  
In	  addition	  to	  surgery,	  post-­‐operative	  radiotherapy	  is	  given	  when	  there	  are	  
more	  than	  two	  nodes	  pathologically	  involved,	  when	  the	  nodal	  disease	  is	  found	  in	  
more	  than	  one	  surgical	  level,	  if	  there	  are	  any	  nodes	  more	  than	  3cm	  in	  size	  and	  /	  or	  if	  
there	  is	  extra-­‐capsular	  rupture	  (Gleeson	  and	  Scott-­‐Brown,	  2008).	  	  The	  timing	  of	  post-­‐
operative	  radiotherapy	  is	  of	  importance,	  within	  6	  weeks	  of	  surgery	  being	  optimal	  as	  
delay	  of	  >6	  weeks	  decreases	  the	  likelihood	  of	  cure	  (Vikram,	  1979,	  Schiff	  et	  al.,	  1990).	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1.5.2	  	  Laryngeal	  Carcinoma	  
Treatment	  selection	  varies	  based	  on	  precise	  anatomical	  location	  with	  glottic	  
and	  supraglottic	  tumours	  differing.	  	  In	  general	  radiotherapy	  and	  conservation	  surgery	  
alone	  are	  options	  for	  T1-­‐2,	  N0	  lesions	  whereas	  combined	  surgery	  and	  radiotherapy	  is	  
used	  for	  advanced	  (high	  volume	  T3	  and	  T4)	  and	  nodal	  disease.	  	  
Regarding	  glottic	  tumours,	  for	  T1-­‐2,	  N0,	  single	  modality	  treatment	  is	  
recommended;	  traditionally	  radical	  radiotherapy,	  however	  recent	  interest	  in	  
endoscopic	  laser	  techniques	  has	  led	  to	  their	  increased	  use.	  A	  Cochrane	  review	  
published	  in	  2002	  (Dey	  et	  al.,	  2002),	  comparing	  radiotherapy,	  open	  surgery	  and	  
endolaryngeal	  excision	  (with	  or	  without	  laser)	  for	  early	  (T1,	  T2)	  glottic	  tumours	  
suggests	  they	  confer	  similar	  survival	  advantages.	  	  This	  was	  echoed	  by	  a	  meta-­‐analysis	  
by	  Higgins	  et	  al.	  (2009)	  comparing	  the	  survival	  outcomes	  for	  laser	  resection	  and	  
radiotherapy	  for	  early	  stage	  glottic	  cancer;	  although	  it	  was	  suggested	  there	  was	  an	  
improved	  voice	  quality	  following	  radiotherapy.	  
In	  stage	  3	  disease	  (T3	  or	  T1-­‐3,	  N1),	  tumours	  can	  vary	  in	  their	  bulk,	  but	  most	  
are	  managed	  with	  the	  aim	  of	  laryngeal	  preservation.	  The	  current	  trend	  is	  towards	  
treatment	  with	  neoadjuvant	  and/or	  concomitant	  chemotherapy	  with	  radiotherapy,	  
with	  surgery	  reserved	  as	  salvage	  for	  residual	  disease	  as	  assessed	  approximately	  3-­‐4	  
months	  after	  treatment.	  In	  certain	  limited	  tumours	  partial	  open	  surgery	  or	  laser	  
resection	  can	  be	  attempted.	  	  
In	  T4	  tumours,	  surgery	  (usually	  total	  laryngectomy)	  with	  selective	  (in	  the	  N0	  
neck)	  or	  modified	  radical	  (in	  the	  N+	  neck)	  neck	  dissection	  with	  or	  without	  post-­‐
operative	  radiotherapy	  is	  the	  treatment	  of	  choice.	  	  To	  date,	  there	  are	  no	  randomised	  
controlled	  trials	  comparing	  different	  surgical	  treatments	  for	  advanced	  laryngeal	  
cancer,	  but	  the	  Veterans	  Administration	  trial	  (The	  Department	  of	  Veterans	  Affairs	  
Cooperative	  Studies	  Program,	  1991)	  (see	  section	  1.7)	  recommends	  total	  
laryngectomy	  and	  voice	  rehabilitation	  in	  T4	  tumours	  and	  is	  unequivocal	  towards	  
radiotherapy	  or	  surgery	  for	  T3	  tumours.	  	  In	  tumours	  of	  relatively	  low	  bulk	  and	  limited	  
invasion	  of	  laryngeal	  framework	  and	  low	  bulk	  lymph	  nodes,	  neoadjuvant	  and/or	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concomitant	  chemotherapy	  with	  radiotherapy	  is	  an	  option,	  however	  salvage	  
laryngectomy	  is	  likely	  in	  approximately	  50%	  of	  all	  cases.	  	  
Supraglottic	  tumours	  have	  a	  high	  incidence	  of	  overt	  and	  occult	  nodal	  
metastatic	  disease	  and	  this	  is	  reflected	  in	  their	  treatment.	  As	  with	  glottic	  tumours,	  
early	  stage	  tumours	  are	  usually	  treated	  with	  a	  single	  modality	  and	  advanced	  tumours	  
with	  combined	  surgery	  and	  radiotherapy.	  In	  T1-­‐2,	  N0	  stage	  tumours,	  conservation	  
surgery	  or	  radiotherapy	  can	  achieve	  similar	  cure	  rates	  (Spriano	  et	  al.,	  1997),	  the	  
choice	  depending	  on	  the	  tumour	  distribution	  and	  the	  patient’s	  co-­‐morbidities.	  For	  
T3-­‐4,	  N0-­‐3	  tumours	  the	  treatment	  of	  choice	  is	  surgery,	  i.e.	  subtotal	  or	  total	  
laryngectomy	  with	  neck	  dissection	  plus	  radiotherapy	  if	  indicated.	  	  
For	  the	  less	  common	  subglottic	  laryngeal	  tumours,	  radiotherapy	  is	  indicated	  
in	  early	  (T1,	  T2	  stages)	  whereas	  T3	  and	  T4	  tumours	  are	  generally	  managed	  by	  
laryngectomy.	  	  
For	  early	  stage	  laryngeal	  tumours,	  the	  survival	  benefits	  associated	  with	  
different	  treatment	  modalities	  is	  negligible,	  for	  advanced	  staged	  tumours	  however,	  
much	  debate	  still	  exists	  and	  of	  current	  interest	  is	  the	  role	  of	  chemotherapy	  in	  its	  
adjuvant,	  neoadjuvant	  and	  synchronous	  settings	  as	  will	  be	  discussed	  further	  in	  
section	  1.7.	  
1.5.3	  	  Oropharyngeal	  Carcinoma	  
Surgery	  and	  radiotherapy	  give	  comparable	  results	  in	  T1	  and	  T2,	  N0	  disease;	  
data	  from	  the	  Scottish	  Head	  &	  Neck	  Cancer	  audit	  (1999–2001)	  demonstrated	  no	  
significant	  difference	  in	  disease-­‐specific	  survival	  between	  early	  stage	  disease	  treated	  
with	  primary	  surgery	  (42	  patients)	  or	  non-­‐surgical	  treatment	  (30	  patients).	  	  The	  
choice	  therefore	  depends	  on	  the	  site	  of	  the	  lesion	  and	  the	  patient’s	  medical	  
condition	  and	  preferences	  and	  based	  on	  primarily	  the	  above	  evidence,	  a	  recent	  
consensus	  statement	  (Robson	  and	  Paleri,	  2010)	  recommended	  that	  early	  stage	  
disease	  can	  be	  treated	  by	  surgical	  or	  non-­‐surgical	  methods.	  	  
For	  stage	  3	  disease	  (T1/2	  N1,	  T3N0)	  there	  are	  various	  treatment	  options:	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1)	  	  Neoadjuvant	  chemotherapy	  with	  cisplatin	  and	  5-­‐fluorouracil	  (5FU),	  
particularly	  if	  there	  is	  bulky	  nodal	  disease	  or	  TPF	  (Taxotere,	  Cisplatin	  and	  5FU)	  for	  
medically	  fit,	  unresectable	  T4	  N3	  patients	  followed	  by	  radical	  radiotherapy	  with	  
concurrent	  cisplatin.	  	  	  
2)	  Surgery	  and	  post-­‐operative	  radiotherapy.	  	  
3)	  Surgery	  and	  post-­‐operative	  chemoradiotherapy	  if	  high	  risk	  i.e.	  positive	  
margins	  or	  extra	  nodal	  spread.	  
4)	  Radiotherapy	  +/-­‐	  chemotherapy	  with	  brachytherapy	  boost	  for	  base	  of	  
tongue	  cancers.	  	  
	  	   Stage	  4	  tumours	  tend	  to	  be	  inoperable	  or	  have	  functionally	  poor	  operative	  
results.	  	  Patients	  may	  be	  treated	  with	  aggressive	  chemoradiotherapy,	  a	  split	  course	  
or	  short	  course	  radiotherapy	  or	  palliative	  chemotherapy.	  	  
There	  is	  inadequate	  evidence	  to	  support	  either	  surgical	  or	  non-­‐surgical	  
treatment	  for	  advanced	  disease	  (Robson	  and	  Paleri,	  2010)	  and	  to	  date	  no	  
randomised	  data	  are	  available	  comparing	  surgery	  and	  radiation	  +/−	  chemotherapy	  in	  
oropharyngeal	  cancer.	  The	  role	  of	  surgery	  versus	  chemoradiotherapy	  remains	  
controversial,	  with	  some	  groups	  finding	  that	  patients	  treated	  with	  non-­‐surgical	  
modalities	  have	  better	  functional	  outcomes	  (Parsons	  et	  al.,	  2002)	  and	  others	  (Kim	  et	  
al.,	  2010)	  finding	  better	  quality	  of	  life	  outcomes	  in	  those	  managed	  with	  surgery.	  
As	  described	  in	  section	  1.3.4,	  recent	  evidence	  from	  Ang	  et	  al.	  (2010),	  
concurring	  with	  evidence	  from	  a	  previous	  meta-­‐analysis	  (Ragin	  and	  Taioli,	  2007),	  has	  
demonstrated	  a	  better	  prognosis	  for	  HPV	  positive	  than	  negative	  tumours	  in	  
oropharyngeal	  cancer.	  There	  is	  emerging	  evidence	  that	  patients	  with	  HPV	  positive	  
oropharyngeal	  cancer	  should	  be	  offered	  less	  aggressive	  treatment	  than	  HPV	  negative	  
cancers	  because	  of	  the	  more	  favourable	  prognosis	  (Robson	  and	  Paleri,	  2010),	  
however	  these	  findings	  require	  further	  validation.	  
1.5.4	  	  Nasopharyngeal	  Carcinoma	  
NPC	  is	  extremely	  radiosensitive	  and	  the	  mainstay	  of	  treatment	  for	  primary	  
local	  and	  regional	  disease	  is	  invariably	  radiotherapy,	  almost	  irrespective	  of	  the	  stage	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of	  the	  disease	  (Gleeson	  and	  Scott-­‐Brown,	  2008).	  	  For	  patients	  with	  advanced	  disease,	  
chemotherapy	  appears	  to	  enhance	  the	  overall	  treatment	  results.	  With	  the	  addition	  
of	  concurrent	  (cisplatin)	  based	  chemoradiation,	  a	  significant	  short-­‐term	  progression-­‐
free	  survival	  benefit,	  up	  to	  a	  mean	  disease	  free	  survival	  of	  three	  years	  was	  shown	  by	  
two	  independent	  phase	  III	  studies	  (Al-­‐Sarraf	  et	  al.,	  1998,	  Chan	  et	  al.,	  2002)	  and	  by	  
meta-­‐analysis	  (Huncharek	  and	  Kupelnick,	  2002).	  	  	  
1.5.5	  	  Hypopharyngeal	  Carcinoma	  
Hypopharyngeal	  cancer	  has	  a	  poor	  prognosis	  due	  to	  its	  relatively	  late	  
presentation.	  Local	  control	  is	  best	  achieved	  in	  advanced	  and	  node	  positive	  disease	  by	  
combined	  surgery	  and	  radiotherapy.	  Conservative	  surgery	  (including	  larynx	  
preservation)	  followed	  by	  radiotherapy	  or	  the	  option	  of	  radiotherapy	  with	  
neoadjuvant	  and/or	  concomitant	  chemotherapy	  is	  commonly	  used	  for	  earlier	  stage	  
disease.	  Evidence	  suggests	  that	  there	  is	  little	  difference	  between	  radiotherapy	  and	  
surgery	  for	  T1-­‐3	  pyriform	  fossa	  tumours	  (Jones	  et	  al.,	  1994)	  and	  node	  negative	  post-­‐
cricoid	  tumours	  (Dische	  et	  al.,	  1997).	  	  Results	  from	  the	  European	  Organisation	  for	  
Research	  and	  Treatment	  of	  Cancer	  (EORTC)	  (Lefebvre	  et	  al.,	  1996)	  suggest	  that	  
laryngeal	  preservation	  is	  possible	  in	  advanced	  pyriform	  fossa	  disease	  by	  using	  
induction	  cisplatin	  and	  5FU	  and	  adapting	  treatment,	  i.e.	  further	  chemotherapy	  and	  
radical	  radiation	  or	  surgery	  following	  irradiation	  depending	  on	  initial	  chemotherapy	  
response.	  There	  is	  also	  evidence	  for	  the	  addition	  of	  adjuvant	  chemotherapy	  to	  
existing	  surgical	  and	  radiotherapy	  regimens	  in	  some	  circumstances	  (see	  section	  1.7)	  
If	  conservative	  surgery	  is	  not	  possible	  then	  a	  laryngectomy	  and	  partial	  
pharyngectomy	  (+/-­‐	  flap)	  or	  total	  pharyngo-­‐laryngectomy	  (plus	  stomach	  
transposition	  or	  jejunal	  graft	  transfer)	  and	  neck	  dissection	  is	  necessary	  depending	  on	  
the	  exact	  site.	  	  In	  addition,	  a	  selective	  neck	  dissection	  (levels	  II,	  III,	  IV	  +/-­‐	  VI)	  is	  
performed	  in	  the	  N0	  and	  sometimes	  the	  N1	  neck.	  Radical	  or	  modified	  radical	  
dissection	  is	  performed	  for	  N2-­‐3.	  Bilateral	  dissection	  is	  required	  for	  mid-­‐line	  tumours	  
due	  to	  the	  frequency	  of	  bilateral	  neck	  node	  metastasis.	  
	   	  33	  
1.5.6	  	  Summary	  
The	  management	  of	  HNSCC	  varies	  for	  each	  sub	  site	  and	  whilst	  in	  some	  cases	  
optimal	  regimens	  are	  potentially	  understood	  (e.g.	  nasopharyngeal)	  the	  role	  of	  
chemotherapy	  in	  other	  tumours	  is	  still	  questioned.	  	  Using	  the	  incorrect	  treatment	  
modality	  may	  be	  of	  serious	  consequence	  to	  the	  patient,	  either	  in	  terms	  of	  under-­‐	  or	  
overtreatment	  leading	  to	  death	  or	  an	  intolerable	  quality	  of	  life.	  	  This	  highlights	  the	  
need	  for	  tools	  for	  predicting	  treatment	  response.	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1.6	  	  Radiotherapy	  
Radiotherapy	  induces	  cell	  death	  largely	  by	  damage	  to	  nuclear	  DNA,	  with	  
breakage	  leading	  to	  irreversible	  loss	  of	  the	  reproductive	  integrity	  of	  the	  cell	  and	  
eventual	  cell	  death	  (Rosen	  et	  al.,	  2000).	  	  Damage	  can	  be	  caused	  directly	  by	  the	  
radiotherapy	  beam	  ionizing	  the	  atoms	  which	  make	  up	  the	  DNA	  chain,	  or	  indirectly,	  as	  
a	  result	  of	  the	  ionization	  of	  water,	  forming	  free	  radicals,	  notably	  hydroxyl	  radicals,	  
which	  then	  damage	  the	  DNA.	  	  The	  therapeutic	  mechanism	  for	  radiation	  is	  based	  on	  
the	  intrinsic	  ability	  of	  normal	  cells	  to	  repair	  damage,	  whilst	  tumour	  cells,	  particularly	  
radiosensitive	  ones,	  possess	  inappropriate	  mechanisms	  of	  damage	  detection	  and	  
repair	  leading	  to	  the	  activation	  of	  apoptotic	  pathways	  and	  ultimately	  programmed	  
cell	  death	  (Rosen	  et	  al.,	  2000).	  Radiotherapy	  is	  indicated	  as	  a	  primary	  treatment	  as	  
described	  above	  and	  as	  a	  post-­‐operative	  addition	  in	  the	  case	  of	  positive	  resection	  
margins,	  extracapsular	  lymph	  node	  spread,	  two	  or	  more	  histological	  positive	  nodes	  
or	  multiple	  nodes	  at	  multiple	  levels,	  in	  most	  tumour	  sub-­‐sites	  (Gleeson	  and	  Scott-­‐
Brown,	  2008).	  	  
Conventional	  radical,	  fractionated,	  treatment	  dosage	  is	  usually	  1.8-­‐2	  Gy	  per	  day,	  
administered	  5	  days	  a	  week	  for	  5-­‐7	  weeks	  to	  a	  total	  of	  66	  to	  70	  Gy,	  depending	  on	  
the	  particular	  clinical	  situation	  (Gleeson	  and	  Scott-­‐Brown,	  2008).	  	  The	  exception	  is	  
small	  volume	  (e.g.	  T1	  glottic	  tumours)	  disease	  when	  55Gy	  in	  20	  fractions	  over	  4	  
weeks	  is	  given.	  For	  adjuvant	  (post-­‐operative)	  radiotherapy,	  60Gy	  in	  30	  daily	  fractions	  
(or	  if	  high	  risk	  /	  macroscopic	  residual	  66Gy	  in	  33	  fractions)	  is	  given.	  
Efforts	  to	  improve	  the	  loco-­‐regional	  control	  by	  altering	  the	  fractionation	  have	  
had	  some	  successful.	  	  Hyperfractionation	  (Fu	  et	  al.,	  2000,	  Horiot	  et	  al.,	  1992)	  (e.g.	  
multiple	  smaller	  fragments	  of	  1.2Gy	  twice	  a	  day	  over	  the	  same	  time	  period)	  and	  
accelerated	  hyperfractionation	  (Fu	  et	  al.,	  2000,	  Overgaard	  et	  al.,	  2003)	  (delivery	  of	  
the	  total	  dose	  over	  a	  shorter	  time	  period)	  have	  been	  compared	  with	  conventional	  
fractionation.	  	  Altered	  regimens	  have	  led	  to	  a	  10	  to	  20%	  improvement	  in	  local	  
control	  rates,	  but	  with	  less	  clear	  effects	  on	  survival	  and	  increased	  acute	  toxicity	  (Fu	  
et	  al.,	  2000).	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More	  recently,	  Intensity	  Modulated	  Radio	  Therapy	  (IMRT)	  is	  being	  used	  for	  a	  
number	  of	  head	  and	  neck	  sites.	  	  Multiple	  beams	  of	  varying	  intensities	  are	  used	  to	  
create	  irregular	  shapes,	  if	  necessary,	  with	  concave	  contours.	  This	  technique	  allows	  
for	  the	  more	  precise	  delivery	  of	  radiation	  and	  optimization	  of	  the	  dose	  intensity	  to	  
specific	  volumes,	  while	  sparing	  the	  dose	  to	  critical	  normal	  structures	  such	  as	  the	  
parotid	  glands	  (Caglar	  and	  Allen,	  2007)	  .	  IMRT	  has	  been	  shown	  in	  a	  number	  of	  
clinical	  sites	  to	  improve	  local	  control	  and	  decrease	  side	  effects	  (Dawson	  et	  al.,	  2000,	  
Kwong	  et	  al.,	  2004)	  and	  improve	  quality	  of	  life	  when	  compared	  to	  conventional	  
radiotherapy	  (Graff	  et	  al.,	  2007).	  Most	  recently,	  principally	  from	  a	  UK	  randomised	  
trial	  of	  88	  patients,	  IMRT	  reduced	  radiation	  induced	  xerostomia	  (the	  main	  long	  term	  
side	  effect	  of	  standard	  radiotherapy)	  from	  75%	  to	  39%	  at	  12	  months	  after	  treatment	  
(Nutting	  et	  al.,	  2009).
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1.7	  	  Chemotherapy	  
	   In	  HNSCC,	  chemotherapy	  is	  employed	  either	  as	  a	  palliative	  therapy	  for	  
patients	  with	  metastatic	  disease	  or	  administered	  simultaneously/	  prior	  to	  
radiotherapy	  in	  order	  to	  induce	  radio-­‐sensitization	  of	  the	  tumour.	  The	  combination	  
of	  chemotherapy	  and	  radiotherapy	  in	  head	  and	  neck	  cancer	  has	  been	  the	  subject	  of	  
many	  studies	  in	  recent	  years,	  the	  rationale	  founded	  upon	  high	  response	  rates	  of	  
HNSCC	  to	  a	  variety	  of	  chemotherapy	  agents	  including	  methotrexate,	  vinblastine,	  
bleomycin,	  5FU,	  cisplatin,	  carboplatin	  and	  the	  taxanes,	  either	  alone	  or	  in	  
combination	  (Stupp	  et	  al.,	  1994).	  	  
Chemotherapy	  may	  be	  administered	  before	  definitive	  treatment	  (induction	  or	  
neo-­‐adjuvant),	  simultaneously	  with	  radiotherapy	  (concomitant	  or	  concurrent),	  or	  
after	  surgery	  (adjuvant)	  in	  loco-­‐regionally	  advanced	  (i.e.	  T3/T4)	  HNSCC	  (Figure	  1.12).	  	  
	  
	  
Fig	  1.12	  Treatment	  schema	  for	  loco-­‐regionally	  advanced	  HNSCC	  showing	  possible	  
timings	  of	  chemotherapy,	  adapted	  from	  (Choong	  and	  Vokes,	  2008).	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Historically,	  the	  most	  appropriate	  primary	  treatment	  modality	  for	  locally	  
advanced	  or	  T3/4	  HNSCC	  was	  largely	  determined	  by	  the	  tumour	  resectability.	  
Although	  this	  varied	  between	  disease	  site	  and	  extent,	  surgeons	  and	  institutions,	  in	  
most	  cases	  surgery	  was	  deemed	  the	  optimal	  modality.	  	  However,	  the	  growing	  
amount	  of	  information	  derived	  from	  phase	  III	  clinical	  trials	  on	  the	  use	  of	  
multimodality	  treatment,	  has	  lead	  to	  the	  questioning	  of	  the	  traditional	  surgery	  
model.	  	  
The	  Department	  of	  Veterans	  Affairs	  Cooperative	  Studies	  Program	  (1991)	  
began	  in	  1984	  and	  randomised	  332	  patients	  with	  resectable	  laryngeal	  SCC	  to	  receive	  
either	  standard	  surgery	  followed	  by	  radiation	  therapy	  or	  neo-­‐adjuvant	  therapy	  
(cisplatin	  and	  5FU)	  followed	  by	  radiotherapy	  for	  those	  achieving	  a	  greater	  than	  50%	  
response	  to	  the	  chemotherapy.	  	  Although	  there	  were	  fewer	  local	  recurrences	  and	  
distant	  metastases	  in	  the	  chemotherapy	  arm,	  estimated	  two-­‐year	  survival	  was	  very	  
similar	  (68%)	  for	  both	  groups.	  	  Importantly,	  only	  36%	  of	  patients	  in	  the	  
chemotherapy	  arm	  required	  total	  laryngectomy	  (primary	  or	  salvage)	  within	  two	  
years.	  	  These	  results	  were	  interpreted	  as	  suggesting	  that	  chemotherapy	  could	  be	  
effective	  in	  avoiding	  laryngectomy	  in	  a	  large	  proportion	  of	  patients	  with	  advanced	  
laryngeal	  cancer.	  	  However,	  follow-­‐up	  time	  was	  relatively	  short	  (median	  33	  months)	  
and	  there	  was	  no	  arm	  for	  radiotherapy	  alone,	  the	  effects	  of	  which	  may	  have	  been	  
responsible	  for	  the	  laryngeal	  preservation.	  	  	  
A	  study	  by	  the	  Radiation	  Oncology	  Group	  and	  Head	  and	  Neck	  Intergroup	  
(Forastiere	  et	  al.,	  2003)	  compared	  radiation	  alone	  with	  induction	  and	  synchronous	  
chemotherapy	  in	  the	  treatment	  of	  stage	  III	  and	  IV	  laryngeal	  cancer.	  	  Median	  follow-­‐
up	  of	  3.8	  years	  demonstrated	  no	  obvious	  differences	  with	  regards	  to	  laryngeal	  
preservation	  at	  this	  stage,	  but	  there	  was	  significantly	  better	  loco-­‐regional	  control	  and	  
laryngeal	  preservation	  with	  synchronous	  chemoradiation	  (cisplatin	  and	  5FU).	  
In	  the	  year	  2000,	  10,741	  patients	  from	  63	  high	  quality	  trials	  had	  become	  
available	  and	  formed	  the	  basis	  for	  a	  large	  meta-­‐analysis	  based	  upon	  individual	  
patient	  data	  (Pignon	  et	  al.,	  2000).	  This	  study	  reported	  a	  4%	  survival	  benefit	  at	  five	  
years	  for	  chemotherapy	  overall:	  neo-­‐adjuvant	  and	  adjuvant	  chemotherapy	  conferred	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small,	  non-­‐significant	  advantages,	  whilst	  a	  gain	  of	  8%	  was	  achieved	  using	  
‘concurrent’	  combinations.	  However,	  the	  authors	  affirmed	  that	  clear	  conclusions	  
could	  not	  be	  drawn	  because	  of	  heterogeneity	  of	  the	  results.	  An	  update	  of	  these	  data	  
in	  2009	  (Pignon	  et	  al.,	  2009),	  analysed	  87	  randomized	  trials	  including	  16,485	  patients	  
with	  a	  median	  follow-­‐up	  of	  5.5	  years	  and	  comprising	  50	  concomitant,	  32	  induction	  
and	  9	  adjuvant	  chemotherapy	  trials.	  The	  absolute	  survival	  benefit	  for	  chemotherapy	  
overall	  was	  4.5%	  at	  five	  years	  and	  as	  previously	  reported	  by	  the	  group,	  the	  best	  
results	  were	  with	  concomitant	  therapy,	  offering	  an	  6.5%	  gain;	  however	  these	  latter	  
results	  are	  free	  from	  significant	  heterogeneity.	  	  The	  least	  benefit	  was	  noted	  for	  
adjuvant	  chemotherapy.	  	  
An	  early	  meta-­‐analysis	  of	  the	  use	  of	  adjuvant	  chemotherapy	  in	  HNSCC	  
demonstrated	  unfavourable	  results,	  with	  a	  survival	  advantage	  of	  6%	  but	  a	  death	  rate	  
from	  complications	  of	  7%	  (Stell	  and	  Rawson,	  1990).	  	  However,	  this	  study	  did	  not	  
segregate	  tumours	  by	  staging	  and	  included	  studies	  of	  adjuvant,	  synchronous	  and	  
neo-­‐adjuvant	  settings.	  	  	  
Although	  the	  benefits	  of	  adjuvant	  chemotherapy	  are	  not	  immediately	  evident	  
from	  the	  above	  meta-­‐analyses,	  two	  randomised	  controlled	  trials	  have	  shown	  that	  
concomitant	  use	  of	  cisplatin	  and	  radiotherapy	  after	  surgery	  increases	  tumour	  control	  
and	  overall	  survival	  in	  high	  risk	  patients	  with	  positive	  resection	  margins	  or	  extra-­‐
capsular	  lymph	  node	  spread	  (Bernier	  et	  al.,	  2004,	  Cooper	  et	  al.,	  2004).	  	  
The	  role	  of	  induction	  chemotherapy,	  as	  highlighted	  above	  is	  controversial.	  
Two	  recent	  randomised	  trials	  (Posner	  et	  al.,	  2007,	  Vermorken	  et	  al.,	  2007)	  suggested	  
that	  the	  addition	  of	  docetaxel	  to	  cisplatin	  and	  5FU	  given	  before	  definitive	  
radiotherapy,	  improved	  survival.	  However,	  the	  use	  of	  non-­‐standard	  radiotherapy	  and	  
chemoradiation	  schedules	  in	  these	  trials	  has	  led	  to	  uncertainty	  about	  the	  benefits	  of	  
this	  approach	  when	  standard	  chemoradiotherapy	  is	  prescribed,	  so	  further	  work	  is	  
required.	  
A	  recently	  published	  Cochrane	  review	  (Furness	  et	  al.,	  2010)	  evaluated	  
chemotherapy	  for	  the	  treatment	  of	  oral	  cavity	  and	  oropharyngeal	  cancer.	  The	  review	  
included	  twenty-­‐five	  randomised	  controlled	  trials	  where	  more	  than	  50	  percent	  of	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participants	  had	  primary	  tumours	  in	  the	  oral	  cavity	  or	  oropharynx.	  	  The	  trials,	  which	  
compared	  the	  addition	  of	  chemotherapy	  to	  other	  treatments	  such	  as	  radiotherapy	  
and/or	  surgery,	  or	  compared	  two	  or	  more	  chemotherapy	  regimens	  or	  modes	  of	  
administration,	  were	  included.	  	  The	  study	  concluded	  that	  chemotherapy,	  in	  addition	  
to	  radiotherapy	  and	  surgery,	  was	  associated	  with	  improved	  overall	  survival	  in	  
patients	  with	  oral	  cavity	  and	  oropharyngeal	  cancers;	  induction	  chemotherapy	  was	  
associated	  with	  a	  9%	  increase	  in	  survival	  and	  adjuvant	  concomitant	  
chemoradiotherapy	  was	  associated	  with	  a	  16%	  increase	  in	  overall	  survival	  following	  
surgery.	  In	  patients	  with	  unresectable	  tumours,	  concomitant	  chemoradiotherapy	  
showed	  a	  22%	  benefit	  in	  overall	  survival	  compared	  with	  radiotherapy	  alone,	  
however,	  the	  additional	  toxicity	  attributable	  to	  chemotherapy	  in	  the	  combined	  
regimens	  remained	  unquantified.	  
In	  addition	  to	  traditional	  chemotherapy	  agents,	  biologically	  targeted	  
treatment	  in	  the	  form	  of	  cetuximab,	  an	  anti-­‐epidermal	  growth	  factor	  receptor	  
antibody	  has	  been	  shown	  to	  be	  effective	  in	  HNSCC.	  The	  concurrent	  administration	  of	  
cetuximab,	  with	  radiotherapy,	  was	  shown	  to	  increase	  overall	  survival	  (median	  
survival	  49	  months	  versus	  29.3	  months)	  and	  loco-­‐regional	  control	  in	  patients	  with	  
HNSCC	  of	  the	  head	  and	  neck	  in	  a	  multi-­‐centred	  randomised	  controlled	  trial	  including	  
a	  total	  of	  424	  patients	  (Bonner	  et	  al.,	  2006).	  
In	  summary,	  the	  evidence	  for	  the	  use	  of	  chemotherapy	  in	  HNSCC	  is	  most	  
favourable	  for	  the	  use	  of	  concurrent	  regimes.	  	  The	  role	  of	  induction	  and	  adjuvant	  
therapies	  are	  less	  clearly	  understood,	  however	  it	  seems	  evident	  that	  some	  drug	  
combinations	  for	  certain	  tumours/stage	  may	  confer	  a	  survival	  advantage.	  	  Clinical	  
trials	  and	  meta-­‐analyses	  largely	  group	  together	  tumours	  of	  several	  sub	  sites	  and	  of	  
differing	  stages	  due	  to	  the	  relative	  rarity	  of	  some	  tumour	  sites.	  	  This	  highlights	  the	  
potential	  role	  for	  methods	  to	  evaluate	  ‘personalised’	  predictors	  of	  chemotherapy	  
response.	  
The	  most	  commonly	  used	  drugs	  in	  clinical	  practice	  are	  cisplatin,	  5FU,	  
docetaxel	  and	  cetuximab,	  the	  mechanisms	  of	  which	  are	  discussed	  below.	  The	  local	  
treatment	  guidelines	  in	  relation	  to	  dosage	  and	  timings	  are	  discussed	  in	  section	  3.4.2.	  
	   	  40	  
1.7.1	  	  Cisplatin	   	  
	  
Figure	  1.13	  Structure	  of	  cisplatin	  (Rang,	  2003)	  
	  
Cisplatin	  is	  a	  water	  soluble	  square	  planar	  co-­‐ordination	  complex	  containing	  a	  
central	  platinum	  atom	  surrounded	  by	  two	  chlorine	  atoms	  and	  two	  ammonia	  groups	  
(Figure	  1.13).	  Neutrality	  of	  charge	  and	  the	  cis	  configuration	  are	  necessary	  for	  the	  
cisplatin	  complex	  to	  exert	  anti-­‐neoplastic	  activity.	  In	  the	  relatively	  high	  chloride	  
concentration	  of	  plasma,	  the	  cisplatin	  complex	  is	  un-­‐ionized,	  allowing	  passage	  of	  the	  
drug	  through	  cell	  membranes.	  Intracellularly,	  in	  the	  presence	  of	  a	  low	  chloride	  
concentration,	  the	  chloride	  ligands	  of	  the	  complex	  are	  displaced	  by	  water	  (aquation),	  
resulting	  in	  formation	  of	  positively	  charged	  platinum	  complexes	  [Pt(NH3)2Cl(OH2)]+	  
and	  [Pt(NH3)2(OH2)2]2+	  (Wang	  and	  Lippard,	  2005).	  
The	  platinum	  complexes	  can	  react	  with	  DNA,	  forming	  both	  intrastrand	  and	  
interstrand	  cross-­‐links.	  The	  N7	  of	  guanine	  is	  a	  particularly	  reactive	  site,	  leading	  to	  
platinum	  cross-­‐links	  between	  adjacent	  guanines	  on	  the	  same	  DNA	  strand	  (Figure	  
1.14).	  DNA	  adducts	  formed	  by	  cisplatin	  inhibit	  DNA	  replication	  and	  transcription	  and	  
lead	  to	  breaks	  and	  miscoding.	  	  This	  damage	  activates	  several	  signal	  transduction	  
pathways,	  including	  those	  involving	  ATR,	  p53,	  p73,	  and	  MAPK,	  and	  culminate	  in	  the	  
activation	  of	  apoptosis	  (Siddiq,	  2003).	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Figure	  1.14	  Diagram	  depicting	  the	  platinum	  atom	  of	  cisplatin	  binding	  covalently	  to	  
the	  N7	  position	  of	  purines	  to	  form	  1,2-­‐	  or	  1,3-­‐intrastrand	  crosslinks,	  and	  interstrand	  
crosslinks	  to	  bring	  about	  various	  cellular	  responses	  (Wang	  and	  Lippard,	  2005).	  	  
Cisplatin	  resistance	  is	  a	  common	  problem	  in	  clinical	  practice	  with	  several	  
potential	  mechanisms	  implicated.	  	  These	  include	  reduced	  drug	  accumulation	  due	  to	  
cell	  membrane	  barriers	  (Timmer-­‐Bosscha	  et	  al.,	  1992),	  enhanced	  repair	  of	  cisplatin	  
DNA	  adducts	  or	  enhanced	  capacity	  to	  tolerate	  cisplatin-­‐induced	  damage	  due	  to	  
alterations	  in	  proteins	  that	  recognise	  cisplatin-­‐DNA	  damage	  (mismatch	  repair	  and	  
high-­‐mobility	  group	  (HMG)	  family	  proteins	  (Perez,	  1998)).	  	  	  
The	  altered	  expression	  of	  oncogenes	  and	  tumour	  suppressor	  genes	  are	  also	  
important	  contributors	  to	  cisplatin	  resistance.	  	  Considerable	  evidence	  indicates	  that	  
mutated	  p53	  plays	  a	  significant	  role	  in	  the	  development	  of	  cisplatin	  resistance	  since	  
several	  genes	  implicated	  in	  drug	  resistance	  and	  apoptosis	  (e.g.	  mismatch	  repair,	  bcl-­‐
2,	  HMGs,	  DNA	  polymerases	  alpha	  and	  beta,	  PCNA,	  and	  insulin-­‐like	  growth	  factor)	  are	  
known	  to	  be	  regulated	  by	  the	  p53	  oncoprotein	  (Dempke	  et	  al.,	  2000).	  By	  using	  p53	  
genetic	  suppressor	  elements	  to	  decrease	  protein	  levels,	  Gallagher	  et	  al.	  (1997)	  saw	  
an	  8-­‐fold	  increase	  in	  cisplatin	  resistance	  in	  ovarian	  cancer	  cells.	  	  Within	  HNSCC	  cell	  
lines,	  wild-­‐type	  p53	  tends	  to	  confer	  cisplatin	  resistance.	  Bradford	  et	  al.	  (2003)	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identified	  mutations	  of	  the	  p53	  gene	  in	  13	  of	  23	  HNSCC	  cell	  lines	  tested.	  The	  average	  
drug	  dose	  required	  to	  inhibit	  50%	  of	  cell	  growth	  for	  cell	  lines	  with	  mutant	  p53	  was	  
6.8	  µmol	  compared	  with	  13.7µmol	  for	  cell	  lines	  with	  wild-­‐type	  p53.	  	  
Cisplatin	  resistance	  has	  been	  shown	  to	  correlate	  with	  c-­‐myc	  dependent	  
expression	  of	  cyclin	  D1	  (Warenius	  et	  al.,	  1996),	  with	  carcinoma	  cell	  lines	  expressing	  
higher	  levels	  of	  cyclin	  D1	  exhibiting	  higher	  resistance	  to	  cisplatin.	  The	  association	  of	  
loss	  of	  p16	  expression	  with	  poorer	  outcome	  in	  HNCSC	  patients	  as	  previously	  
described,	  in	  some	  circumstances	  may	  be	  due	  to	  the	  reduced	  cisplatin-­‐induced	  cell	  
cycle	  arrest	  through	  the	  p16/p53-­‐dependent	  pathway	  (Yip	  et	  al.,	  2006).	  In	  contrast,	  
Taguchi	  et	  al.	  (2004)	  found	  HNSCC	  cell	  lines	  with	  strong	  expression	  of	  p21,	  p27	  or	  Bax	  
showed	  significantly	  higher	  sensitivity	  to	  cisplatin	  as	  opposed	  to	  other	  commonly	  
administered	  chemotherapy	  agents	  used	  in	  the	  treatment	  of	  HNSCC.	  	  	  
The	  role	  of	  p53	  and	  p16	  in	  the	  cytotoxic	  action	  of	  cisplatin	  is	  of	  potential	  
clinical	  importance	  as	  these	  genes	  may	  have	  significance	  as	  prognostic	  markers	  to	  
predict	  a	  tumour’s	  chemosensitivity.	  	  Yip	  et	  al.	  (2006)	  demonstrated	  the	  elevated	  
expression	  of	  p16,	  p53	  and	  p21	  following	  the	  addition	  of	  cisplatin	  by	  western	  blot	  
analysis	  in	  parental	  and	  antisense	  cyclin	  D1	  cell	  lines,	  and	  suggested	  that	  the	  
evaluation	  of	  the	  expression	  status	  or	  indeed	  changes	  in	  expression	  of	  p53	  and	  p16	  
following	  chemotherapy	  treatment	  in	  vitro	  may	  be	  a	  valuable	  tool	  for	  treatment	  
planning.	  	  
1.7.2	  	  5-­‐Fluorouracil	  
	  
Figure	  1.15	  Structure	  of	  5-­‐fluorouracil	  (Rang,	  2003).	  
	  
5FU	  is	  a	  pyrimidine	  analogue	  which	  inhibits	  the	  synthesis	  of	  DNA	  via	  its	  
interference	  with	  thymidylate	  synthesis	  (Rang,	  2003).	  It	  is	  converted	  into	  a	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fraudulent	  ‘nucleotide’	  fluorodeoxyuridine	  monophosphate	  (FdUMP)	  that	  interacts	  
with	  thymidylate	  synthetase	  and	  the	  folate	  cofactors.	  	  As	  this	  cannot	  be	  converted	  
into	  thymidylate	  (as	  in	  FdUMP	  the	  fluorine	  has	  replaced	  hydrogen	  at	  C5	  where	  
methylation	  would	  take	  place),	  this	  carbon-­‐fluorine	  bond	  is	  less	  susceptible	  to	  
enzymatic	  cleavage	  than	  the	  carbon-­‐hydrogen	  bond.	  	  This	  results	  in	  inhibition	  of	  DNA	  
synthesis	  but	  not	  RNA	  and	  protein	  synthesis.	  
As	  with	  cisplatin,	  resistance	  to	  5FU	  is	  commonly	  encountered	  and	  is	  
multifactorial.	  	  Possible	  pathways	  include	  transport	  mechanisms,	  increased	  
metabolism,	  protection	  from	  apoptosis,	  and	  resistance	  via	  cell	  cycle	  kinetics	  (Mader	  
et	  al.,	  1998).	  	  
Regarding	  the	  effect	  of	  5FU	  on	  the	  cell	  cycle	  in	  HNSCC,	  Liu	  et	  al.	  (2006)	  found	  
that	  5FU	  induces	  apoptosis	  via	  a	  p53-­‐independent	  pathway;	  p53	  expression	  was	  not	  
induced	  in	  either	  of	  their	  laryngeal	  cell	  lines	  tested.	  5FU	  induced	  the	  accumulation	  of	  
Rb	  protein	  and	  a	  cyclin	  dependent	  kinase	  inhibitor,	  p21WAF1/CIP1	  and	  in	  addition,	  
G1/S	  cell	  cycle	  phase	  arrest	  was	  associated	  with	  anti-­‐proliferative	  activity	  of	  5FU	  in	  
both	  cell	  lines.	  Conversely,	  Lee	  et	  al.	  (2005)	  found	  in	  a	  panel	  of	  hypopharyngeal	  
carcinoma	  cell	  lines,	  that	  following	  exposure	  to	  5FU,	  p21WAF1/CIP1	  protein	  and	  p53	  
protein	  increased,	  and	  G1-­‐phase	  arrest	  of	  the	  cell	  cycle	  was	  observed	  whereas	  
apoptosis	  was	  not,	  suggesting	  that	  the	  mechanism	  is	  not	  fully	  understood	  or	  may	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1.7.3	  	  Docetaxel	  
	  
	  
Figure	  1.16	  Structure	  of	  docetaxel	  
	  
Docetaxel	  belongs	  to	  the	  taxane	  group	  and	  is	  a	  semi-­‐synthetic	  analogue	  of	  
paclitaxel.	  Docetaxel	  reversibly	  binds	  to	  microtubules	  with	  high	  affinity	  resulting	  in	  
stabilisation	  of	  the	  microtubules.	  The	  resultant	  reduction	  in	  the	  free	  tubulin	  needed	  
for	  microtubule	  formation	  prevents	  mitotic	  cell	  division	  between	  metaphase	  and	  
anaphase	  (Eisenhauer	  and	  Vermorken,	  1998).	  Additionally,	  because	  microtubules	  do	  
not	  disassemble	  in	  the	  presence	  of	  docetaxel,	  they	  accumulate	  inside	  the	  cell	  and	  
cause	  initiation	  of	  apoptosis.	  Apoptosis	  is	  also	  encouraged	  by	  docetaxel	  blocking	  (via	  
phosphorylation)	  the	  ‘apoptosis	  inhibiting’	  oncoprotein	  bcl-­‐2.	  	  
The	  development	  of	  acquired	  resistance	  to	  docetaxel	  often	  occurs;	  several	  
possible	  mechanisms	  have	  been	  shown,	  including	  altered	  expression	  of	  mRNA	  β-­‐
tubulin	  isotypes	  and	  modulation	  of	  β-­‐tubulin	  protein	  levels	  (Shalli	  et	  al.,	  2005)	  high	  
expression	  of	  P-­‐glycoprotein	  (Bissery	  et	  al.,	  1995),	  reduced	  expression	  of	  p27	  (Brown	  
et	  al.,	  2004)	  and	  high	  expression	  of	  thioredoxin	  (Kim	  et	  al.,	  2005).	  However,	  the	  
mechanisms	  involved	  are	  not	  yet	  completely	  understood.	  	  	  
With	  regards	  to	  predictors	  of	  sensitivity,	  Taguchi	  et	  al	  (2004)	  demonstrated	  
HNSCC	  cells	  with	  strong	  expression	  of	  Bax	  or	  weak	  expression	  of	  cyclin	  E	  showed	  
significantly	  higher	  sensitivity	  to	  paclitaxel.	  	  Furthermore	  Kawakami	  and	  colleagues	  
showed	  that	  Bax	  expression	  changed	  from	  negative	  to	  positive	  in	  one	  HNSCC	  cell	  line	  
and	  Bcl-­‐2	  expression	  decreased	  in	  another	  following	  incubation	  with	  paclitaxel,	  
leading	  the	  authors	  to	  conclude	  that	  Bcl-­‐2/Bax	  status	  was	  correlated	  with	  drug	  
sensitivity	  (Kawakami	  et	  al.,	  1999).	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1.7.4	  	  Cetuximab	  
Cetuximab	  is	  a	  chimeric	  (mouse/human)	  monoclonal	  antibody	  against	  the	  
ligand-­‐binding	  domain	  of	  the	  epidermal	  growth	  factor	  receptor	  (EGFR).	  The	  EGFR	  is	  a	  
member	  of	  the	  HER	  family	  of	  tyrosine	  kinase	  growth	  factor	  receptors,	  a	  group	  of	  
proteins	  whose	  aberrant	  activity	  plays	  a	  key	  role	  growth	  and	  metastasis	  of	  solid	  
tumours	  (Bernier,	  2006).	  Binding	  to	  EGFR	  by	  its	  endogenous	  ligands,	  e.g.	  epidermal	  
growth	  factor	  (EGF)	  or	  transforming	  growth	  factor	  (TGF-­‐α),	  results	  in	  stimulation	  of	  
downstream	  signal-­‐transduction	  pathways	  (Figure	  1.17)	  such	  as	  the	  mitogen-­‐
activated	  protein	  kinase	  (MAPK),	  phosphatidylinositol	  3-­‐kinase	  (PI3K)/AKT,	  and	  signal	  
transducers	  and	  activators	  of	  transcription	  (STAT)	  signalling	  pathways,	  ultimately	  
leading	  to	  cell	  cycle	  progression,	  reduced	  apoptotic	  capacity,	  angiogenesis,	  and	  
metastatic	  phenotypes	  (Burtness,	  2005).	  	  
	  
	  
Figure	  1.17	  Diagram	  of	  he	  EGFR	  signalling	  pathway.	  	  Adapted	  from	  (Lurje	  and	  Lenz,	  
2009).	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Cetuximab	  binds	  competitively	  to	  the	  EGFR,	  preventing	  dimerization	  and	  
activation	  of	  the	  intrinsic	  receptor	  tyrosine	  kinase	  (Goldstein	  et	  al.,	  1995).	  	  Cetuximab	  
also	  affects	  ligand-­‐independent	  EGFR	  signalling	  (Dittmann	  et	  al.,	  2005).	  In	  preclinical	  
models,	  treatment	  with	  cetuximab	  stimulated	  EGFR	  internalization/degradation	  
(Prewett	  et	  al.,	  1996),	  enhanced	  tumour-­‐cell	  apoptosis,	  and	  inhibited	  proliferation,	  
angiogenesis,	  and	  invasiveness	  (Huang	  et	  al.,	  1999,	  Saleh	  et	  al.,	  1999,	  Milas	  et	  al.,	  
2004).	  	  
EGFR	  and	  its	  ligand	  TGF-­‐α	  are	  over-­‐expressed	  in	  nearly	  all	  head	  and	  neck	  
tumours	  (	  Christensen	  et	  al.,	  1992,	  Grandis	  and	  Tweardy,	  1993)	  and	  over-­‐expression	  
is	  associated	  with	  greater	  radioresistance/chemoresistance,	  shorter	  disease-­‐free	  and	  
overall	  survival	  in	  patients	  (Grandis	  and	  Tweardy,	  1993,	  Ang	  et	  al.,	  2002,	  Liang	  et	  al.,	  
2003,	  Hitt	  et	  al.,	  2005,	  Pivot	  et	  al.,	  2005,).	  The	  EGFR	  appears	  to	  be	  specifically	  
associated	  with	  adaptive	  responses	  to	  radiation;	  after	  exposure	  to	  radiation,	  the	  
EGFR	  activation	  observed	  in	  radio-­‐resistant	  tumour	  models	  is	  greater	  than	  in	  
tumours	  that	  originally	  were	  radiosensitive	  (Milas	  et	  al.,	  2000).	  Blockage	  of	  EGFR	  has	  
been	  shown	  to	  increase	  cell	  sensitivity	  to	  radiation	  (Bonner	  et	  al.,	  1994).	  
In	  the	  clinical	  management	  of	  HNSCC,	  cetuximab	  is	  predominantly	  used	  
concomitantly	  with	  radiotherapy	  due	  to	  its	  radio-­‐sensitising	  actions,	  rather	  than	  as	  a	  
cytotoxic	  agent	  per	  se,	  as	  highlighted	  by	  the	  findings	  of	  Bonner	  et	  al	  (2006)	  described	  
in	  section	  1.7.	  	  The	  current	  National	  Institute	  of	  Clinical	  Excellence	  guidelines	  state	  
that	  cetuximab,	  in	  combination	  with	  radiotherapy,	  is	  recommended	  as	  a	  possible	  
treatment	  for	  people	  with	  locally	  advanced	  squamous	  cell	  cancer	  of	  the	  head	  and	  
neck	  only	  if	  they	  have	  a	  Karnofsky	  performance-­‐status	  score	  of	  90%	  or	  more,	  and	  all	  
forms	  of	  platinum-­‐based	  chemotherapy	  are	  considered	  inappropriate	  
(http://www.nice.org.uk/TA145).	  
1.7.5	  	  Predicting	  Chemotherapy	  Response	  
Given	  the	  increasing	  availability	  of	  new	  treatment	  strategies	  such	  as	  induction	  
chemotherapy,	  concurrent	  and	  sequential	  chemo-­‐radiation	  concepts,	  and	  
multimodality-­‐based	  organ	  preservation	  strategies	  (e.g.	  IMRT),	  treatment	  planning	  
with	  regard	  to	  optimal	  outcome	  is	  becoming	  increasingly	  challenging.	  Chemo-­‐
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radiation	  is	  not	  effective	  in	  all	  patients	  and	  when	  used	  unsuccessfully,	  patients	  suffer	  
the	  potential	  side	  effects	  and	  toxicities	  of	  chemotherapy	  (e.g.,	  swallowing	  problems,	  
hearing	  loss)	  and	  radiation	  therapy	  (e.g.,	  mucositis,	  late	  toxicity).	  	  Moreover,	  the	  
outcome	  is	  difficult	  to	  predict	  due	  to	  heterogeneity	  of	  a	  tumour’s	  response,	  impaired	  
late	  functional	  outcome	  and	  increased	  late	  toxicity	  if	  simultaneously	  applied	  to	  
radiation.	  	  The	  identification	  of	  reliable	  outcome	  predictors	  in	  this	  setting	  is	  of	  great	  
interest	  and	  of	  particular	  importance	  in	  advanced	  HNSCC	  where	  a	  range	  of	  
treatments,	  namely	  chemotherapy,	  surgery,	  post-­‐operative	  radiotherapy	  and	  
cetuximab	  with	  radiotherapy	  are	  available.	  	  
A	  consensus	  document	  by	  Lefebvre	  and	  Ang	  (2009),	  outlining	  the	  guidelines	  
for	  the	  conduct	  of	  future	  phase	  III	  clinical	  trials	  of	  larynx	  preservation	  in	  patients	  with	  
locally	  advanced	  laryngeal	  and	  hypopharyngeal	  cancer,	  emphasised	  the	  importance	  
of	  translational	  research	  in	  HNSCC.	  They	  concluded	  that	  future	  studies	  should	  include	  
a	  comprehensive	  evaluation	  of	  the	  head	  and	  neck	  cancer	  molecular	  signature	  for	  
correlation	  with	  treatment	  response,	  toxicity,	  and	  survival.	  The	  authors,	  
acknowledging	  the	  importance	  of	  predicting	  response	  to	  chemotherapy,	  suggested	  
that	  further	  work	  into	  the	  role	  of	  biomarkers	  in	  HNSCC	  was	  warranted,	  based	  on	  
early	  evidence	  with	  certain	  markers	  that	  have	  demonstrated	  prognostic	  value	  and/or	  
a	  potential	  role	  for	  guiding	  treatment	  decisions.	  Over-­‐expression	  of	  EGFR	  is	  well	  
documented	  as	  described	  in	  section	  1.7.4.	  	  Additional	  biomarkers	  of	  interest	  in	  the	  
literature	  include	  E-­‐cadherin	  and	  β-­‐	  catenin	  (markers	  for	  epithelial-­‐to-­‐mesenchymal	  
transition	  (Khambata-­‐Ford	  et	  al.,	  2007,	  Mandal	  et	  al.,	  2008),	  epiregulin	  and	  
amphiregulin	  (markers	  for	  response	  to	  EGFR	  antagonists	  in	  colorectal	  carcinoma)	  
(Khambata-­‐Ford	  et	  al.,	  2007)	  and	  p53	  mutation	  (Poeta	  et	  al.,	  2007).	  	  Furthermore,	  
chemo-­‐resistance	  of	  tumour	  cells,	  in	  general,	  is	  associated	  with	  mutations	  in	  
oncogenes	  (e.g.,	  K-­‐ras),	  loss	  of	  tumour	  suppressors	  (e.g.,	  p53,	  p16)	  or	  dysregulation	  
of	  genes	  involved	  in	  cell	  cycle	  control,	  cell	  proliferation,	  signal	  transduction,	  
angiogenesis,	  or	  apoptosis	  (Glinsky,	  2008).	  However,	  in	  HNSCC	  these	  biomarkers	  only	  
show	  weak	  correlation	  with	  improved	  outcome	  after	  chemo-­‐radiation	  (Hoffmann	  et	  
al.,	  2008)	  and	  clinical	  relevance	  is	  still	  limited	  (except	  regarding	  p16INK4a	  and	  HPV-­‐
16	  in	  oropharyngeal	  cancer	  as	  described	  in	  sections	  1.3.2.6	  and	  1.3.3).	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There	  is	  an	  increasing	  availability	  of	  literature	  centred	  on	  assay-­‐based	  chemo-­‐
response	  evaluation	  in	  individual	  tumours.	  In	  principle,	  assays	  can	  be	  divided	  into	  2	  
groups:	  clonogenic	  (first	  expanding	  tumour	  cells	  before	  treatment	  with	  cytotoxic	  
agents)	  and	  non-­‐clonogenic	  (primary	  tumour	  cells	  are	  exposed	  to	  chemotherapy	  
drugs).	  The	  read-­‐out	  of	  the	  assays	  is	  commonly	  the	  measurement	  of	  cell	  
proliferation,	  cell	  death	  or	  metabolic	  activity.	  	  Clonogenic	  assays	  have	  been	  shown	  to	  
be	  clinically	  predictive	  in	  ovarian	  cancer,	  as	  demonstrated	  by	  Gallion	  et	  al.	  (2006)	  
using	  an	  ex	  vivo	  chemo-­‐response	  assay	  (ChemoFX)	  for	  uncovering	  chemo-­‐resistance.	  
Nevertheless,	  the	  major	  clinical	  need,	  i.e.,	  the	  reliable	  determination	  of	  individual	  
chemosensitivity	  patterns	  of	  solid	  tumours	  by	  means	  of	  ex	  vivo	  assays	  is	  still	  unmet	  
(Dietz	  et	  al.,	  2010).	  
Although	  in	  vitro	  based	  assays	  represent	  an	  alternative,	  Miyamoto	  et	  al.	  
(2004)	  highlight	  the	  difficulties	  with	  using	  such	  methods.	  Such	  techniques	  fail	  to	  
provide	  a	  functional	  tumour	  microenvironment	  (i.e.,	  extracellular	  matrix,	  blood	  
vessels,	  nerves,	  and	  soluble	  factors	  produced	  by	  leukocytes	  or	  the	  tumour	  itself)	  and	  
can	  also	  result	  in	  clonal	  expansion	  of	  subpopulations	  of	  tumour	  cells	  not	  
representative	  of	  the	  tumour	  as	  a	  whole,	  in	  cell	  culture.	  	  These	  factors,	  combined	  
with	  the	  possible	  absence	  of	  immune	  cells,	  may	  influence	  the	  outcome	  and	  cause	  
differences	  to	  the	  clinical	  response	  to	  any	  given	  chemotherapy.	  
For	  individual	  chemosensitivity	  of	  solid	  tumours	  (e.g.	  HNSCC),	  assays	  have	  to	  
meet	  certain	  criteria	  to	  be	  useful	  in	  terms	  of	  clinical	  practicability	  and	  methodical	  
accuracy.	  	  The	  qualities	  of	  such	  an	  assay	  have	  been	  suggested	  by	  Dietz	  et	  al.	  (2010):	  
1)	  ability	  to	  determine	  drug	  responses	  in	  small	  amounts	  of	  
	  tumour	  tissue,	  mostly	  from	  tumour	  biopsies	  	  
2)	  robust	  standard	  operating	  procedures	  for	  harvesting,	  handling,	  and	  
processing	  tumour	  samples	  
3)	  methodical	  solutions	  to	  exclude	  reactions	  in	  non-­‐malignant	  tumour	  cells	  
(stroma)	  reliably	  
4)	  high	  feasibility	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5)	  high	  predictive	  accuracy	  
6)	  provision	  of	  results	  in	  a	  clinically	  adequate	  time	  range	  
7)	  quantatively	  reliable	  information	  on	  drug	  response	  
As	  will	  be	  discussed	  in	  greater	  detail	  below,	  micro	  fluidic	  devices	  possess	  the	  
majority	  of	  these	  characteristics,	  providing	  an	  in	  vitro	  platform	  for	  evaluating	  
chemotherapy	  response	  in	  HNSCC.	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1.8	  	  HNSCC	  Culture	  Techniques	  
The	  ability	  to	  develop	  continuous	  cell	  lines	  from	  human	  tumours	  (e.g.	  HeLa;	  
(Gey,	  1952),	  aided	  by	  the	  studies	  of	  Hayflick	  on	  the	  finite	  life	  span	  of	  cells	  in	  culture	  
(Hayflick,	  1961)	  led	  to	  the	  rapid	  expansion	  in	  the	  use	  of	  cell	  lines	  in	  the	  study	  of	  
intracellular	  activity	  and	  flux,	  environmental	  and	  cell-­‐cell	  interactions,	  genetics	  and	  
cell	  products	  and	  secretions.	  	  Following	  the	  discovery	  that	  head	  and	  neck	  cancer	  lines	  
could	  be	  successfully	  cultured	  in	  vitro	  (Easty	  et	  al.,	  1981,	  Krause	  et	  al.,	  1981,	  
Rheinwald	  and	  Beckett,	  1981),	  a	  variety	  of	  cell,	  tissue	  and	  organ	  culture	  techniques	  
have	  been	  applied	  to	  its	  study.	  	  
The	  loss	  of	  histological	  characteristics	  seen	  in	  primary	  and	  disaggregated	  cell	  
line	  models	  has	  led	  to	  the	  development	  of	  culture	  techniques	  aimed	  at	  the	  
preservation	  of	  tissue	  architecture	  and	  maintenance	  of	  cell-­‐cell	  and	  cell-­‐matrix	  
interactions.	  	  Numerous	  three-­‐dimensional	  culture	  techniques	  have	  been	  developed	  
and	  can	  be	  divided	  into,	  a)	  organ	  culture	  utilising	  the	  whole	  or	  small	  fragments	  of	  the	  
original	  tissue,	  b)	  histotypic	  culture,	  growing	  cell	  lines	  at	  high	  density	  in	  a	  three	  
dimensional	  matrix	  and	  c)	  organotypic	  cultures,	  the	  maintenance	  of	  different	  cell	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Figure	  1.18	  Diagram	  of	  different	  tissue	  culture	  methods,	  1)	  Organ	  culture	  on	  a	  filter	  
disk	  on	  a	  triangular	  stainless	  steel	  grid	  over	  a	  well	  of	  medium,	  2)	  Explant	  cultures	  in	  a	  
flask,	  3)	  Disassociated	  cell	  culture	  in	  a	  stirred	  vessel	  with	  an	  enzymatic	  disaggregation	  
generating	  a	  cell	  suspension	  seeded	  as	  a	  monolayer	  in	  the	  lower	  diagram,	  4)	  
Organotypic	  culture,	  a	  filter	  well	  showing	  an	  array	  of	  cells,	  seen	  in	  section	  in	  the	  
lower	  diagram,	  combined	  with	  matrix	  and	  stromal	  cells	  (Vunjak-­‐Novakovic	  and	  
Freshney,	  2006).	  
1.8.1	  	  Cell	  culture	  
Cells	  isolated	  from	  donor	  tissue	  may	  be	  maintained	  in	  a	  number	  of	  different	  
ways	  and	  may	  be	  categorised	  into	  either	  1)	  primary	  explant	  culture	  or	  2)	  dissociated	  
cell	  culture.	  	  The	  spontaneous	  or	  mechanical	  adherence	  of	  a	  fragment	  of	  tissue	  can	  
produce	  an	  outgrowth	  of	  cells;	  the	  primary	  explant,	  with	  the	  migrating	  cells	  termed	  
the	  outgrowth.	  	  Cells	  in	  the	  outgrowth	  are	  selected,	  firstly,	  by	  their	  ability	  to	  migrate	  
from	  the	  explant	  and	  subsequently,	  if	  sub	  cultured,	  by	  their	  ability	  to	  proliferate.	  A	  
sample	  of	  tissue	  may	  also	  be	  mechanically	  or	  enzymatically	  disaggregated;	  cells	  and	  
small	  aggregates	  capable	  of	  attachment	  to	  a	  solid	  substrate	  then	  forming	  a	  
monolayer.	  Cells	  within	  the	  monolayer	  capable	  of	  proliferation	  will	  then	  be	  selected	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at	  the	  first	  subculture	  and,	  as	  with	  the	  outgrowth	  from	  a	  primary	  explant,	  may	  give	  
rise	  to	  a	  cell	  line.	  	  By	  disaggregating	  tissue,	  larger,	  more	  rapid	  cultures	  are	  produced	  
as	  compared	  to	  explant	  culture,	  however	  explant	  culture	  may	  still	  be	  preferable	  
where	  only	  small	  fragments	  of	  tissue	  are	  available	  or	  the	  fragility	  of	  the	  cells	  
precludes	  survival	  after	  disaggregation.	  	  Generally,	  the	  differentiated	  cells	  in	  a	  tissue	  
have	  limited	  ability	  to	  proliferate	  and	  do	  not	  therefore	  contribute	  to	  the	  formation	  of	  
a	  primary	  culture,	  unless	  conditions	  are	  adapted	  to	  promote	  their	  attachment	  and	  
preserve	  their	  differentiated	  status.	  It	  is	  therefore	  the	  proliferating	  committed	  
precursor	  cells	  that	  give	  rise	  to	  the	  primary	  culture	  (Figure	  1.19).	  
	  
	  
Figure	  1.19	  Diagram	  demonstrating	  the	  origin	  of	  cell	  lines;	  progression	  from	  
totipotent	  stem	  cell,	  through	  tissue	  stem	  cell	  (single	  or	  multiple	  lineage	  committed),	  
to	  transit	  amplifying	  progenitor	  cell	  compartment.	  LIF;	  leukaemia	  inhibitory	  factor,	  
TGF-­‐β;	  transforming	  growth	  factor	  β,	  MIF-­‐1α;	  Macrophage	  migration	  inhibitory	  
factor	  1-­‐alpha,	  EGF;	  epidermal	  growth	  factor,	  FGF;	  fibroblast	  growth	  factor,	  PDGF;	  
platelet	  derived	  growth	  factor.	  Adapted	  from	  Freshney	  (2005).	  
Immortalized	  cell	  lines	  derived	  from	  HNSCC	  have	  proved	  invaluable	  as	  tools	  in	  
researching	  the	  molecular,	  biochemical,	  genetic	  and	  immunological	  properties	  of	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HNSCC.	  	  Advantages	  of	  using	  cell	  lines	  include	  ease	  of	  use,	  rapid	  growth,	  result	  
reproducibility	  (Cree	  et	  al.,	  2010),	  reduced	  cost	  and	  avoidance	  of	  legal	  and	  ethical	  
issues	  associated	  with	  animal	  experimentation	  (Lin	  et	  al.,	  2007).	  	  The	  establishment	  
of	  head	  and	  neck	  cell	  lines,	  like	  other	  solid	  tumours,	  was	  initially	  hampered	  by	  
fibroblast	  overgrowth,	  long	  quiescent	  periods	  before	  the	  cells	  can	  be	  sub	  cultured,	  
and	  the	  dependence	  on	  feeder	  layers	  in	  primary	  and	  secondary	  cultures	  (Moore	  et	  
al.,	  1955,	  Easty	  et	  al.,	  1981,	  Rheinwald	  and	  Beckett,	  1981).	  However	  with	  technical	  
improvements,	  the	  permanent	  culture	  of	  HNSCC	  cell	  lines	  has	  been	  successful,	  Lin	  et	  
al.	  (2007)	  reporting	  the	  establishment	  of	  over	  300	  cell	  lines	  in	  2007.	  	  
The	  basis	  for	  using	  a	  cell	  line	  is	  the	  belief	  that	  it	  will	  mimic	  the	  clinical	  
situation.	  	  It	  is	  known	  however	  that	  tumours	  are	  not	  composed	  of	  layers	  of	  
homogenous	  cells	  but	  rather	  areas	  of	  heterogeneity	  exist	  within	  the	  tumour	  mass,	  
containing	  differing	  genetic	  expression	  and	  biological	  properties.	  	  As	  described	  
above,	  cell	  culture	  is	  a	  selective	  process;	  cells	  must	  possess	  the	  potential	  to	  grow	  in	  
culture	  medium,	  within	  which	  they	  experience	  a	  very	  different	  environment	  to	  that	  
of	  their	  originating	  tumour.	  	  The	  cell	  culture	  environment,	  namely	  substrate,	  gas	  
composition	  and	  medium	  can	  have	  significant	  influence	  on	  the	  characteristics	  of	  cells	  
that	  propagate	  from	  clinical	  samples.	  	  Ince	  et	  al.	  (2007)	  found	  that	  by	  adapting	  
conditions	  for	  the	  culture	  of	  primary	  breast	  epithelial	  cells	  (using	  a	  novel	  serum	  free	  
media	  and	  differing	  culture	  ware)	  cell	  cultures	  formed	  were	  more	  tumourigenic,	  
formed	  xenografts	  that	  more	  closely	  represented	  breast	  ductal	  adenocarcinoma	  and	  
had	  greater	  metastatic	  potential	  when	  transplanted	  into	  animals.	  
Homogenous	  cell	  lines	  also	  lack	  the	  extra-­‐cellular	  matrix	  containing	  proteins,	  
such	  as	  collagen,	  elastin	  and	  laminin,	  that	  give	  the	  tissue	  their	  mechanical	  properties	  
and	  help	  to	  organise	  communication	  between	  cells	  embedded	  in	  the	  matrix	  e.g.	  via	  
adherence	  by	  the	  integrin	  family	  of	  cell	  receptors.	  	  Lack	  of	  cell-­‐cell	  contact,	  namely	  
the	  absence	  of	  cell-­‐mediated	  signalling,	  formation	  of	  junctional	  complexes	  and	  
reduced	  potential	  for	  exchange	  of	  homocrine	  factors	  is	  apparent	  in	  cell	  lines	  
(Freshney,	  2005).	  This	  effect	  is	  manifested	  as	  cessation	  of	  cell	  motility	  and	  withdrawl	  
from	  the	  cell	  cycle	  in	  normal	  cells	  and	  reduced	  proliferation	  and	  increased	  apoptosis	  
in	  transformed	  cells.	  The	  interaction	  of	  different	  populations	  of	  cells	  is	  also	  often	  key	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in	  maintaining	  functionality	  of	  another	  cell	  type.	  	  Alveolar	  cells	  of	  the	  lung,	  for	  
example,	  only	  produce	  and	  release	  surfactant	  in	  response	  to	  the	  hormonal	  signalling	  
from	  adjacent	  fibroblasts	  (Post	  et	  al.,	  1984).	  
Lack	  of	  heterogeneity	  also	  results	  in	  the	  absence	  of	  cells	  corresponding	  to	  
cancer	  stem	  cells.	  	  The	  theory	  of	  cancer	  stem	  cells	  states	  that	  a	  small	  subset	  of	  
cancer	  cells	  within	  the	  tumour	  mass	  has	  the	  exclusive	  capacity	  to	  both	  divide	  and	  
expand	  the	  cancer	  stem	  cell	  pool	  and	  to	  differentiate	  into	  non-­‐tumourigenic,	  more	  
differentiated	  cancer	  cell	  lineages	  (Cho	  and	  Clarke,	  2008).	  This	  concept	  was	  first	  
demonstrated	  in	  a	  study	  of	  leukaemia	  where	  only	  cells	  with	  specific	  surface	  antigen	  
profiles	  were	  able	  to	  cause	  leukaemia	  when	  engrafted	  into	  immunodeficient	  mice	  
(Lapidot	  et	  al.,	  1994).	  	  This	  theory	  has	  been	  more	  recently	  extended	  to	  solid	  tumours	  
including	  HNSCC,	  in	  which	  a	  minority	  population	  of	  CD44+	  cancer	  cells,	  which	  
typically	  comprise	  <10%	  of	  the	  cells	  in	  a	  HNSCC	  tumour,	  gave	  rise	  to	  new	  tumours	  in	  
vivo	  and	  possessed	  both	  ability	  to	  self-­‐renew	  and	  to	  differentiate	  (Prince	  et	  al.,	  
2007).	  	  Such	  cells	  in	  vivo	  are	  more	  highly	  resistant	  to	  chemotherapy	  and	  are	  
postulated	  to	  be	  responsible	  for	  the	  recurrence	  of	  cancer	  after	  treatment.	  	  
Behavioural	  heterogeneity	  of	  adherent	  cell	  lines	  derived	  from	  gliomas	  and	  capable	  of	  
initiating	  xenograft	  tumours	  suggests	  that	  the	  diversity	  of	  these	  tumours	  may	  reflect	  
differing	  stem	  cell	  phenotypes	  (Pollard	  et	  al.,	  2009).	  
Within	  tumours,	  malignant	  cells	  in	  vivo	  are	  normally	  capable	  of	  independent	  
growth	  and	  show	  reduced	  attachment	  to	  substrate	  (usually	  basement	  membrane	  
proteins).	  	  In	  contrast,	  cell	  lines	  commonly	  become	  dependant	  on	  growth	  factors	  
supplied	  as	  serum	  or	  other	  supplements	  and	  adherence	  to	  plastic.	  	  Withdrawal	  of	  
serum	  or	  use	  of	  plastics	  such	  as	  polypropylene,	  which	  do	  not	  encourage	  cell	  
adherence	  result	  in	  the	  death	  of	  many	  cell	  lines	  (Cree	  et	  al.,	  2010).	  	  This	  again	  
demonstrates	  the	  limitations	  of	  translating	  information	  derived	  from	  of	  cell	  line	  
studies	  to	  in	  vivo	  tumours.	  
	  Cell	  line	  cultures	  generally	  exhibit	  a	  much	  greater	  rate	  of	  growth	  than	  their	  
parent	  tumours.	  	  Whilst	  this	  is	  useful	  to	  the	  researcher	  in	  terms	  of	  reducing	  the	  time	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needed	  for	  establishment	  of	  cells	  for	  experimentation,	  the	  variable	  S-­‐phase	  fractions	  
and	  doubling	  times	  witnessed	  in	  vivo	  are	  not	  correctly	  represented.	  	  	  
Cell	  lines	  have	  contributed	  greatly	  to	  cancer	  research	  due	  to	  their	  ease	  of	  
availability,	  use	  and	  general	  reproducibility.	  	  However	  their	  failure	  to	  adequately	  
replicate	  in	  vivo	  characteristics	  limits	  their	  clinical	  applicability	  and	  has	  therefore	  led	  
to	  an	  interest	  in	  alternative	  culture	  techniques.	  
1.8.2	  	  Organ	  Culture	  
Organ	  culture	  allows	  for	  the	  maintenance	  of	  the	  normal,	  in	  vivo	  histo-­‐
architecture	  and	  diversity	  of	  cell	  types.	  	  However,	  the	  absence	  of	  a	  functional	  
vascular	  system	  severely	  limits	  the	  size	  of	  biopsy	  that	  can	  be	  maintained	  alive,	  by	  
diffusion,	  as	  lack	  of	  nutrient	  supply	  and	  gas	  exchange	  of	  the	  cells	  becomes	  limited,	  
ultimately	  leading	  to	  central	  necrosis	  (Freshney,	  2005).	  Retention	  of	  histological	  
structure	  and	  associated	  differentiated	  properties	  may	  be	  enhanced	  at	  the	  
air/medium	  interface,	  where	  gas	  exchange	  is	  optimized	  and	  cell	  migration	  
minimised.	  	  
In	  order	  to	  optimize	  nutrient	  and	  gaseous	  exchange,	  supporting	  materials	  are	  
used	  to	  keep	  the	  tissue	  at	  the	  gas	  interface.	  Various	  methods	  have	  been	  described,	  
including	  semi-­‐solid	  agar	  gel	  (Wolff	  and	  Haffen,	  1952),	  clotted	  plasma	  (Fell	  and	  
Robison,	  1929),	  micropore	  filter,	  lens	  paper,	  or	  strips	  of	  Perspex	  or	  Plexiglass.	  The	  
organ	  cultures	  can	  also	  be	  grown	  on	  top	  of	  a	  stainless	  steel	  grid	  (Freshney,	  1992).	  
Another	  popular	  choice	  for	  growing	  organ	  cultures	  is	  the	  filter-­‐well	  inserts.	  Filter-­‐
well	  inserts	  with	  different	  materials	  like	  ceramic,	  collagen,	  nitrocellulose	  are	  now	  
commercially	  available	  and	  have	  been	  successfully	  used	  to	  develop	  functionally	  
integrated	  thyroid	  epithelium,	  stratified	  epidermis,	  intestinal	  epithelium,	  and	  renal	  
epithelium	  (Freshney,	  2005).	  	  Although	  anchorage	  to	  a	  solid	  substrate	  can	  lead	  to	  
the	  development	  of	  an	  outgrowth	  of	  cells	  from	  the	  explant,	  this	  can	  be	  minimised	  if	  
a	  non-­‐wettable	  substrate	  is	  used	  and	  if	  the	  level	  of	  the	  gas-­‐liquid	  interface	  is	  kept	  
optimal.	  
Organ	  culture	  has	  been	  used	  with	  some	  success	  in	  HNSCC.	  	  The	  culture	  of	  
oral	  mucosa	  has	  been	  studied	  (MacCallum	  et	  al.,	  1987)	  and	  information	  regarding	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interactions	  between	  tumour	  and	  basal	  epithelial	  cells	  derived	  from	  studying	  the	  
effects	  of	  differing	  calcium	  concentrations	  on	  dissociation	  of	  upper	  layers	  of	  oral	  
mucosa	  (Sacks	  et	  al.,	  1985)	  used	  to	  propose	  models	  of	  invasion.	  Kleinsasser	  et	  al.	  
(2004)	  used	  mini-­‐organ	  cultures	  of	  human	  UADT	  epithelia	  to	  study	  the	  resultant	  
DNA	  damage	  caused	  by	  exposure	  to	  genotoxic	  compounds	  in	  vitro.	  The	  organ	  
culture	  size	  was	  however	  limited	  to	  1mm3.	  	  	  Using	  a	  similar	  technique	  (1	  mm3	  
biopsies	  in	  24-­‐well	  plates	  coated	  with	  agarose	  gel),	  Baumeister	  et	  al.	  (2009)	  studied	  
the	  impact	  of	  stimulation	  by	  TGF-­‐α	  on	  carcinogen-­‐induced	  and	  oxidative	  DNA	  
damage	  in	  mucosa	  tissue	  cultures	  of	  macroscopically	  normal	  biopsies	  from	  tumour	  
patients	  and	  controls.	  	  They	  demonstrated	  a	  DNA-­‐stabilizing	  effect	  of	  stimulation	  by	  
TGF-­‐α	  in	  mucosa	  tissue	  cultures	  of	  tumour	  patients	  suggesting	  this	  as	  a	  physiological	  
response	  to	  continued	  carcinogenic	  impact	  on	  the	  epithelium	  of	  the	  UADT.	  
Organ	  culture	  is	  an	  expensive,	  labour	  intensive	  technique	  that	  offers	  little	  
reproducibility	  and	  is	  dependant	  on	  fresh	  donor	  tissue	  as	  organ	  cultures	  are	  unable	  
to	  be	  propagated	  beyond	  a	  number	  of	  weeks	  at	  most.	  	  As	  organ	  cultures	  are	  made	  
up	  of	  mostly	  fully	  differentiated	  cells,	  cultures	  do	  not	  grow,	  only	  the	  outer	  layers	  of	  
cell,	  at	  the	  air/medium	  interface	  where	  conditions	  are	  more	  favourable	  for	  growth,	  
may	  demonstrate	  evidence	  of	  proliferation.	  	  The	  problem	  of	  heterogeneity	  between	  
cultures	  is	  also	  recognised;	  the	  heterogenous	  histo-­‐organisation	  of	  a	  tumour	  is	  well	  
known	  and	  if	  one	  considers	  the	  dissection	  of	  such	  tumours	  into	  sub	  millimetre	  sized	  
pieces,	  differences	  between	  individual	  organ	  cultures	  are	  easily	  understood	  (Sacks,	  
1996).	  
1.8.3	  	  Histotypic	  Culture	  	  
Histotypic	  cultures	  aim	  to	  recreate	  the	  density	  of	  cells	  found	  in	  the	  original	  
tissue	  and	  include	  such	  techniques	  as	  simply	  allowing	  the	  cells	  to	  multilayer	  by	  
perfusing	  a	  monolayer	  (Kruse	  et	  al.,	  1970),	  recreating	  	  a	  highly	  complex	  perfused	  
membrane	  (Klement	  et	  al.,	  1987),	  the	  creation	  of	  capillary	  beds	  (Knazek	  et	  al.,	  1972)	  
and	  the	  development	  of	  spheroids	  (Linser	  and	  Moscona,	  1979).	  
To	  address	  the	  issue	  of	  limited	  gaseous	  and	  nutrient	  transfer	  at	  high	  cell	  
densities,	  Knazek	  et	  al.	  (Knazek	  et	  al.,	  1972)	  developed	  a	  perfusion	  chamber	  from	  a	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bed	  of	  plastic	  capillary	  chambers	  that	  are	  gas	  and	  nutrient	  permeable	  whilst	  able	  to	  
support	  cell	  growth	  on	  their	  outer	  surface.	  	  There	  is	  evidence	  that	  this	  goes	  some	  
way	  to	  the	  recreation	  of	  the	  tumour	  microenvironment.	  	  For	  example	  colonic	  
carcinoma	  cells	  have	  been	  shown	  to	  produce	  elevated	  levels	  of	  carcinoembryonic	  
antigen	  when	  cultivated	  in	  hollow	  fibres	  as	  compared	  with	  a	  monolayer	  culture	  
(Rutzky	  et	  al.,	  1979,	  David	  et	  al.,	  1978)	  with	  comparable	  molecular	  properties	  to	  
those	  found	  in	  vivo.	  
Spherical	  aggregates	  of	  malignant	  cells,	  i.e.	  multicellular	  tumour	  spheroids	  
(MTS),	  have	  also	  been	  proposed	  as	  in	  vitro	  models	  of	  tumour	  microregions	  and	  of	  an	  
early,	  avascular	  stage	  of	  tumour	  growth.	  The	  growth	  of	  MTS	  can	  be	  initiated	  either	  
by	  stimulating	  single	  cells	  to	  generate	  spherical	  colonies	  directly	  through	  
proliferation,	  or	  by	  initially	  inducing	  cell	  aggregation	  with	  subsequent	  growth	  of	  the	  
aggregates	  (Mueller-­‐Klieser,	  1987).	  	  More	  recently,	  microtechnologies	  in	  the	  form	  of	  
3D	  microwells	  and	  planar	  micropatterns	  have	  been	  used	  to	  provide	  the	  same	  cell	  
aggregation	  conditions,	  but	  unlike	  the	  macroscale	  approaches	  above,	  these	  
technologies	  offer	  the	  ability	  to	  replicate	  cellular	  and	  tissue	  parameters	  precisely,	  in	  
order	  to	  mass	  produce	  uniform	  tumour	  spheroids.	  	  
Spheroids	  have	  the	  ability	  to	  mimic	  some	  in	  vivo	  tumour	  properties	  such	  as	  
volume	  growth	  kinetics,	  cellular	  heterogeneity,	  e.g.	  the	  induction	  of	  proliferation	  
gradients	  and	  quiescence,	  as	  well	  as	  differentiation	  characteristics,	  such	  as	  the	  
development	  of	  specific	  histological	  structures	  or	  the	  expression	  of	  antigens	  
(Mueller-­‐Klieser,	  1987).	  	  The	  technique	  of	  experimentally	  inducing	  aggregates	  of	  
animal	  cells	  dates	  to	  the	  studies	  on	  morphogenesis	  in	  amphibian	  embryos	  by	  
Holtfreter	  (1944)	  and	  was	  applied	  to	  the	  study	  of	  tumour	  (melanoma)	  cells	  by	  
Moscona	  (1957).	  
Cancer	  cells	  in	  spheroids	  are	  exposed	  to	  a	  tumour-­‐like	  microenvironment,	  
mainly	  influenced	  by	  the	  distance	  of	  cells	  from	  the	  spheroid	  surface.	  This	  situation	  is	  
possibly	  equivalent	  to	  that	  of	  cancer	  cells	  in	  vivo	  located	  at	  different	  distances	  from	  
a	  vessel	  supplying	  nutrients.	  The	  supply	  conditions	  for	  microregions	  within	  a	  tumour	  
may	  vary	  to	  a	  large	  extent,	  leading	  to	  pronounced	  heterogeneities	  in	  relevant	  supply	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parameters	  such	  as	  local	  oxygen	  tensions	  (pO2),	  glucose	  concentrations	  or	  pH	  
(Vaupel	  et	  al.,	  1981).	  	  These	  pathophysical	  gradients	  are	  summarised	  in	  Figure	  1.20.	  	  
Most	  notable	  is	  the	  central	  area,	  with	  reduced	  O2	  tension	  and	  lacking	  in	  aerobic	  
metabolism	  (ATP),	  and	  evidence	  of	  necrosis	  both	  histologically	  and	  by	  
immunohistochemical	  analysis.	  	  As	  with	  organ	  cultures,	  the	  growth	  of	  spheroid	  
cultures	  is	  limited	  by	  diffusion	  with	  maximal	  growth	  of	  about	  1000µm	  (Sutherland,	  
1988),	  with	  a	  typical	  secondary	  central	  necrosis	  usually	  established	  from	  500µm	  
(Hirschhaeuser	  et	  al.,	  2010).	  
	  Table	  1.6	  Table	  summarising	  research	  involving	  the	  therapeutic	  applications	  of	  tumour	  spheroids.	  HUVEC;	  human	  umbilical	  vein	  endothelial	  
cells,	  BCNU;	  1,3-­‐bis(2-­‐chloroethyl)-­‐l-­‐nitrosourea	  ,	  GFP;	  green	  fluourescent	  protein,	  MIBG;	  met-­‐aiodobenzylguanidine	  ,	  MCTS;	  multicellular	  
tumour	  spheroids,	  VEGF;	  Vascular	  endothelial	  growth	  factor,	  CTL/LAK;	  cytotoxic	  T	  lymphocyte/human	  lymphokine	  activated	  killer	  cells,	  PBMC;	  
peripheral	  blood	  mononuclear	  cell,	  EMD	  72000;	  humanised	  anti-­‐EGFR	  monoclonal	  antibody	  matuzumab,	  DC;	  dendritic	  cells,	  TAA;	  tumour-­‐
associated	  antigen.	  
3D	  Model	   Cell	  types	  	   Application/therapy	   Reference	  	  
	  
Mixed	  Spheroids	   HNSCC	  cell	  line	  +	  fibroblasts	   Anti-­‐EGFR	  monoclonal	  antibody	   Hoffmann	  et	  al.	  (2009)	  
	   Prostate	  cancer	  cell	  line	  +HUVEC+	  osteoblasts	   Micro	  fluidic	  system	  for	  growth	  analysis	   Hsiao	  et	  al.	  (2009)	  
	   Cervical	  cancer	  line	  +	  fibroblasts	  	   Survival	  after	  radiotherapy	   Djordjevic	  and	  Lange	  
(2006)	  
	   Mouse	  fibrosarcoma	  line	  (cisplatin	  sensitive	  and	  
resistant)	  
Survival	  after	  radiotherapy	   Frenzel	  et	  al.	  (1995)	  
	   Rat	  brain	  tumour	  cells	  (sensitive	  and	  resistant	  to	  
1,3-­‐bis(2-­‐chloroethyl)-­‐l-­‐nitrosourea)	  
BCNU	  treatment	   Tofilon	  et	  al.	  (1987)	  
(Transfectant)	  
Mosaic	  spheroids	  
Glioma	  cell	  line	  transfected	  with	  noradrenaline	  
transporter	  gene	  or	  GFP	  
β-­‐emitting	  radio-­‐	  pharmaceutical	  [131I]	  
MIBG	  to	  assess	  bystander	  effects	  
Boyd	  et	  al.	  (2002)	  
MCTS	  on	  
monolayer	  	  
Colon	  carcinoma	  cells	  on	  monocytes/fibroblasts	   Cathepsin	  B	  expression,	  invasiveness	   Krueger	  et	  al.	  (2005)	  
	  	   Melanoma	  cell	  lines	  on	  endothelial	  cell	  lines	   Role	  of	  T-­‐cadherin	  in	  tumour	  angiogenesis	   Ghosh	  et	  al.	  (2007)	  
MCTS+	  immune	  
cell	  suspension	  	  
Benign/malignant	  urothelial	  cell	  line	  
+monocytes/macrophages	  
Influence	  of	  cytokines	  on	  monocyte	  to	  
macrophage	  differentiation	  	  
Konur	  et	  al.	  (1998)	  
	   Breast	  cancer	  cell	  line	  +	  macrophages	   VEGF	  expression	  and	  de	  novo	  vessel	  
formation	  
Bingle	  et	  al.	  (2006)	  
	   EC	  from	  benign/malignant	  pancreatic	  tissue	  
endothelial	  +	  T	  cells/Treg	  
T	  cell/Treg	  infiltration	  studies	   Nummer	  et	  al.	  (2007)	  
	   Breast	  cancer	  cell	  line	  +	  monocytes	  	   Monocytes	  as	  vehicles	  for	  gene	  therapy	   Muthana	  et	  al.	  (2008)	  
	   Bladder/renal	  carcinoma	  cell	  line	  +	  CTL/LAK	  	   Assess	  number	  of	  T	  cells	  for	  adoptive	  
therapy	  
Kawai	  et	  al.	  (2001)	  
	   HNSCC	  cell	  line	  +PBMC	  	   Therapeutic	  antibody	  EMD	  72000	   Hoffmann	  et	  al.	  (2009)	  
	   HNSCC	  cell	  line	  +PBMC	  	   Trifunctional	  bispecific	  antibody	  
catumaxomab	  
Hirschhaeuser	  et	  al.	  
(2009)	  
	   Urothelial/prostate	  carcinoma,	  melanoma	  cell	  
lines	  +monocytes	  
Differentiation	  of	  monocytes	  to	  DC	   Hirschhaeuser	  et	  al.	  
(2009)	  
	   Diverse	  entities	  +	  CTLs	  	   Cytotoxicity	  of	  CTLs	   Fischer	  et	  al.(2007)	  
	   Melanoma	  cell	  line	  +	  CTLs	  	   TAA	  recognition	  by	  CTLs	   Feder-­‐Mengus	  et	  al.	  
(2007)	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Figure	  1.20	  Diagram	  depicting	  the	  combination	  of	  analytical	  images	  of	  spheroid	  
median	  sections	  studied	  with	  different	  technologies:	  autoradiography,	  the	  TUNEL	  
assay,	  bioluminescence	  imaging	  and	  probing	  with	  oxygen	  microelectrodes.	  Together	  
these	  measurements	  enable	  the	  concentric	  arrangement	  of	  cell	  proliferation,	  
viability	  and	  the	  micromilieu	  in	  large	  spheroids	  to	  be	  understood	  (Hirschhaeuser	  et	  
al.,	  2010).	  
	   Another	  method	  of	  creating	  a	  three-­‐dimensional	  tumour	  model	  based	  on	  
isolated	  cells	  or	  cell	  lines	  is	  by	  implanting	  cells	  in	  a	  3D	  matrix	  scaffold	  generated	  
from	  either	  purified	  molecules	  or	  synthetic	  materials,	  following	  the	  demonstration	  
that	  both	  normal	  and	  malignant	  cells	  penetrate	  cellulose	  sponge	  (Leighton	  et	  al.,	  
1968)	  facilitated	  by	  collagen	  coating.	  Cells	  can	  be	  implanted	  within	  a	  3D	  matrix	  
scaffold	  generated	  from	  either	  purified	  molecules,	  such	  as	  collagen	  type	  I,	  or	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synthetic	  materials,	  such	  as	  cross-­‐linked	  glycosaminoglycan	  composites	  (Fischbach	  
et	  al.,	  2007,	  Yamada	  and	  Cukierman,	  2007).	  Another	  class	  of	  3D	  matrices	  includes	  
those	  generated	  by	  cells	  in	  vitro,	  in	  which	  fibroblasts	  are	  stimulated	  with	  ascorbic	  
acid	  to	  increase	  their	  collagen	  production	  followed	  by	  extraction	  of	  fibroblasts	  (Bass	  
et	  al.,	  2007,	  Caswell	  et	  al.,	  2008,	  Cukierman	  et	  al.,	  2001).	  The	  advantage	  of	  these	  
‘cell-­‐derived	  matrices’	  is	  the	  use	  of	  the	  naturally	  deposited	  matrix	  as	  well	  as	  the	  
ability	  to	  visualize	  cells	  using	  live-­‐cell	  imaging.	  	  However,	  these	  matrices	  often	  have	  
lower	  amounts	  of	  collagen,	  larger	  internal	  spaces	  and	  less	  depth	  than	  mature	  tissue	  
matrices,	  making	  them	  less	  suitable	  for	  the	  study	  of	  invasion	  (Even-­‐Ram	  and	  
Yamada,	  2005,	  Yamada	  and	  Cukierman,	  2007).	  Three-­‐dimensional	  cell	  culture	  
techniques	  have	  been	  applied	  to	  HNSCC	  cells.	  In	  a	  recent	  study,	  Eke	  and	  colleagues	  
(2011)	  used	  a	  laminin-­‐rich	  extracellular	  matrix	  based	  3D	  cell	  culture	  model	  to	  study	  
the	  dual	  effects	  EGFR/FAK	  inhibition	  on	  cellular	  radiosensitivity	  of	  HNSCC	  cells.	  
Such	  techniques	  of	  tissue	  engineering	  are	  in	  addition,	  as	  with	  spheroids,	  
limited	  in	  dimensions	  by	  gaseous	  and	  nutrient	  diffusion,	  however	  these	  are	  relevant	  
for	  some	  studies.	  	  
1.8.4	  	  Organotypic	  Culture	  
	   Such	  techniques	  aim	  to	  recombine	  cell	  types	  generated	  from	  a	  variety	  of	  cell	  
lines,	  recreating	  the	  cell-­‐cell	  and/or	  cell-­‐matrix	  interactions.	  	  Organotypic	  cultures	  
were	  first	  described	  for	  human	  skin	  cancer	  (Borchers	  et	  al.,	  1997,	  Boukamp	  et	  al.,	  
1982)	  and	  have	  been	  since	  been	  used	  to	  study	  its	  invasion	  characteristics.	  Gaggiolo	  
and	  colleagues	  (2007),	  for	  example,	  through	  collective	  imaging	  of	  invading	  co-­‐
cultures	  of	  carcinoma	  cells	  and	  stromal	  fibroblasts,	  revealed	  that	  carcinoma	  cells	  
move	  within	  tracks	  in	  the	  extracellular	  matrix	  behind	  the	  leading	  fibroblasts.	  
Organotypic	  cultures	  have	  been	  applied	  to	  different	  tumour	  types,	  such	  as	  ovarian,	  
breast,	  prostate	  and	  oesophageal	  cancer,	  where	  they	  have	  provided	  important	  
insights	  into,	  for	  example,	  the	  role	  of	  frequently	  altered	  genes	  in	  the	  biological	  
behaviour	  and	  the	  mechanisms	  of	  tumour	  invasion	  (Okawa	  et	  al.,	  2007,	  Oyama	  et	  
al.,	  2007).	  	  Such	  models	  however	  vary	  in	  their	  ability	  to	  mimic	  in	  vivo	  tissue	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conditions	  and	  currently	  lack	  vasculature	  and	  normal	  transport	  of	  small	  molecules,	  
host	  immune	  responses,	  and	  other	  cell-­‐cell	  interactions.	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1.9	  	  Micro	  Fluidics	  
Having	  reviewed	  the	  vast	  array	  of	  techniques	  available	  to	  culture	  tumour	  
cells	  in	  vitro	  and	  given	  an	  increased	  understanding	  of	  the	  microenvironment	  in	  
tumour	  behaviour,	  the	  need	  for	  a	  better	  culture	  model	  becomes	  apparent.	  	  
Although	  popular	  techniques	  such	  as	  spheroids	  and	  3D	  matrixes	  attempt	  to	  recreate	  
the	  three-­‐dimensional	  in	  vivo	  characteristics	  and	  may	  incorporate	  differing	  cell	  
types,	  the	  inadequate	  diffusion	  of	  gases	  and	  nutrients	  ultimately	  limit	  their	  
application.	  	  The	  aim	  of	  these	  techniques	  is	  to	  recreate	  the	  tissue	  structure	  because,	  
as	  described	  above,	  success	  with	  culturing	  the	  original	  tissue	  in	  an	  intact	  slice	  has	  
largely	  been	  unsuccessful.	  	  The	  logical,	  and	  perhaps	  simplified	  next	  step,	  therefore,	  
would	  be	  to	  modify	  organ	  culture	  in	  order	  to	  overcome	  the	  problems	  of	  diffusion,	  
allowing	  pieces	  of	  tumour	  complete	  with	  all	  supporting	  cells	  and	  structures	  to	  be	  
successfully	  cultured.	  	  	  
The	  unique	  properties	  of	  micro	  fluidic	  devices	  allow	  this	  to	  be	  done,	  
providing	  a	  simple,	  reproducible	  and	  highly	  versatile	  biological	  tissue	  system.	  	  	  As	  
previously	  described,	  cells	  exist	  in	  vivo	  in	  carefully	  maintained	  microenvironments	  
within	  the	  three	  dimensional	  cell	  communities	  that	  form	  tissue.	  	  Within	  this	  
microenvironment,	  cells	  are	  in	  close	  contact,	  receive	  a	  constant	  supply	  of	  nutrients,	  
waste	  is	  removed,	  temperature	  is	  maintained	  and	  cell	  stress	  is	  minimal.	  For	  such	  
homeostatic	  mechanisms	  to	  be	  maintained,	  efficient	  mass	  transport	  and	  mass	  
exchange	  is	  imperative.	  	  
Micro	  fluidics	  relates	  to	  the	  “science	  and	  technology	  of	  systems	  that	  process	  
or	  manipulates	  small	  (10-­‐9	  to	  10-­‐18	  litres)	  amounts	  of	  fluids,	  using	  channels	  with	  
dimensions	  of	  tens	  to	  hundreds	  of	  micrometres”	  (Whitesides,	  2006).	  	  The	  origins	  of	  
micro	  fluidics	  lay	  in	  the	  microanalytical	  methods	  in	  capillary	  format	  (e.g.	  high	  
pressure	  chromatography,	  capillary	  electrophoresis)	  first	  described	  by	  Jorgenson	  
and	  Luckas	  (1981).	  	  Success	  in	  these	  methods	  prompted	  the	  development	  of	  more	  
advanced	  and	  compacted	  formats	  for	  applications	  in	  microscale	  dimensions	  leading	  
to	  the	  concept	  of	  the	  “miniaturized	  total	  chemical	  anaylsis	  system”	  or	  µ-­‐TAS.	  	  The	  
first	  applications	  of	  micro	  fluidic	  technologies	  were	  largely	  in	  the	  area	  of	  analytical	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chemistry	  due	  to	  its	  advantageous	  properties	  relating	  to	  the	  use	  of	  small	  quantities	  
of	  samples	  and	  reagents,	  the	  ability	  to	  carry	  out	  separations	  and	  detections	  with	  
high	  resolution	  and	  sensitivity,	  low	  cost,	  short	  times	  for	  analysis	  and	  small	  footprints	  
for	  the	  analytical	  devices	  (Manz,	  1992).	  	  
Although	  early	  research	  in	  micro	  fluidics	  was	  initially	  dominated	  by	  studies	  
within	  the	  disciplines	  of	  chemistry	  and	  physics	  at	  the	  microscale,	  the	  integration	  of	  
cell	  biology	  with	  micro	  fluidics	  has	  recently	  become	  a	  major	  focus	  within	  the	  
scientific	  community.	  	  Following	  the	  first	  cell	  culture	  within	  a	  microchannel	  
(Doroszewski	  et	  al.,	  1977),	  the	  biological	  applications	  of	  micro	  fluidics	  have	  rapidly	  
grown	  and	  now	  include	  areas	  such	  as	  cell	  and	  tissue	  culture,	  enzymatic	  analysis,	  
DNA	  analysis	  (e.g.,	  polymerase	  chain	  reaction	  and	  high-­‐throughput	  sequencing),	  
proteomics	  and	  clinical	  pathology.	  	  
1.9.1	  	  Properties	  of	  Micro	  Fluidics	  
1.9.1.1	  	  Fluid	  Properties	  
	   A	  fluid	  can	  be	  defined	  as	  a	  material	  that	  deforms	  continually	  under	  shear	  
stress,	  or	  more	  specifically	  by	  the	  application	  of	  an	  external	  force	  attempting	  to	  
displace	  part	  of	  the	  fluid	  elements	  at	  the	  surface	  layer	  (Ong	  et	  al.,	  2008).	  	  Fluid	  
characterisations	  are	  further	  determined	  by	  its	  density,	  pressure	  and	  viscosity.	  	  The	  
pressure	  of	  a	  liquid	  is	  determined	  by	  its	  depth,	  which	  within	  a	  micro	  fluidic	  device,	  
should	  be	  constant.	  	  As	  the	  micro	  fluidic	  channels	  have	  inlets	  and	  outlets,	  any	  
pressure	  difference	  induced	  externally	  at	  these	  openings	  is	  transmitted	  to	  the	  liquid,	  
thereby	  inducing	  the	  liquid	  to	  flow.	  	  The	  fluid	  flow	  through	  microchannels	  is	  
characterised	  by	  low	  Reynolds	  numbers	  (based	  on	  the	  relation	  between	  the	  
magnitudes	  of	  the	  inertial	  and	  viscous	  forces).	  From	  empirical	  studies,	  Reynolds	  
numbers	  larger	  than	  about	  2300	  correspond	  to	  turbulent	  flow;	  under	  this	  regime,	  
inertial	  forces	  are	  dominant.	  When	  the	  Reynolds	  number	  is	  below	  about	  2000,	  
laminar	  (or	  creeping)	  flow	  predominates.	  	  Laminar	  flow	  allows	  multiple	  liquid	  
streams	  to	  flow	  side	  by	  side	  without	  turbulent	  mixing,	  allowing	  a	  high	  degree	  of	  
spatial	  control.	  	  Relatively	  low	  Reynolds	  numbers	  are	  attained	  at	  lower	  velocities,	  
smaller	  dimensions,	  smaller	  densities,	  or	  higher	  viscosities.	  Therefore,	  in	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microchannels,	  laminar	  flow	  regime	  is	  dominant	  due	  to	  the	  small	  dimensions,	  where	  
the	  velocities	  of	  flow	  would	  have	  to	  exceed	  the	  speed	  of	  sound	  before	  the	  onset	  of	  
turbulence	  (Walker	  et	  al.,	  2004).	  Whilst	  laminar	  flow	  reduces	  the	  shear	  damage	  to	  
cells	  attributed	  to	  fluid	  motion,	  it	  also	  accounts	  for	  the	  favourable	  diffusion	  
properties	  of	  micro	  fluidic	  devices	  described	  below.	  
	   This	  presence	  of	  laminar	  flow	  largely	  mimics	  the	  hydrodynamic	  fluid	  
movement	  within	  the	  in	  vivo	  setting	  (Webster	  et	  al.,	  2010).	  	  In	  contrast,	  fluid	  
movement	  within	  a	  culture	  flask	  is	  normally	  static,	  or	  turbulent	  if	  roller	  bottles	  are	  
used	  to	  create	  fluid	  movement.	  	  	  
In	  addition,	  laminar	  flow	  in	  microchannels	  can	  allow	  for	  the	  partial	  treatment	  
of	  single	  cells	  or	  tissue	  specimens.	  The	  simplest	  form	  of	  cell	  treatment	  in	  a	  
microchannel	  is	  to	  secure	  a	  cell	  in	  a	  microchannel	  and	  flow	  the	  treatment	  over	  it,	  
therefore	  exposing	  the	  whole	  cell	  to	  treatment.	  Increasing	  in	  complexity,	  a	  single	  
cell	  can	  be	  subjected	  to	  two	  laminar	  fluid	  streams	  and	  therefore	  two	  different	  
treatments.	  In	  the	  case	  of	  a	  spherical	  cell	  fixed	  within	  a	  microchannel,	  the	  interface	  
between	  streams	  must	  be	  positioned	  exactly	  on	  the	  middle	  of	  the	  cell	  (Figure	  1.21a).	  
If	  the	  interface	  is	  not	  central,	  the	  cell	  will	  only	  be	  exposed	  to	  the	  contents	  of	  one	  
stream	  (Figure	  1.21b).	  The	  contents	  of	  stream	  B	  will	  diffuse	  toward	  the	  cell	  through	  
stream	  A,	  but	  the	  amount	  which	  reaches	  the	  cell	  will	  depend	  on	  the	  flow	  rate	  and	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Figure	  1.21	  Schematic	  diagram	  demonstrating	  how	  laminar	  flow	  allows	  streams	  to	  
flow	  side-­‐by-­‐side	  and	  mix	  only	  by	  diffusion.	  (a)	  Delivering	  a	  compound	  (e.g.,	  stream	  
B)	  to	  a	  cell	  using	  laminar	  flow	  can	  only	  be	  accomplished	  down	  the	  middle	  of	  the	  cell.	  
(b)	  Otherwise,	  the	  cell	  will	  only	  be	  exposed	  to	  stream	  A	  and	  diffusion	  will	  be	  
required	  to	  introduce	  elements	  from	  stream	  B	  to	  the	  cell.	  Adapted	  from	  Walker	  et	  
al.	  (2004).	  
If	  further	  adapted	  for	  whole	  tissue	  culture,	  pieces	  of	  tissue,	  e.g.	  tumour	  
biopsies	  could	  be	  subjected	  to	  several	  different	  treatment	  regimes	  at	  the	  same	  time,	  
in	  order	  to	  determine	  the	  most	  effective	  regime,	  potentially	  revolutionising	  cancer	  
treatment.	  	  In	  addition,	  more	  complex	  tissue	  surfaces	  will	  affect	  flow,	  and	  although	  
laminar,	  will	  alter	  the	  distribution.	  	  	  
1.9.1.2	  	  Transport	  Properties	  
	   Transport	  properties	  within	  micro	  fluidic	  devices	  can	  be	  divided	  into	  directed	  
transport	  and	  statistical	  transport.	  	  Directed	  transport	  is	  controlled	  by	  exerting	  work	  
on	  the	  fluid,	  resulting	  in	  volume	  flow	  of	  the	  fluid	  and	  is	  usually	  characterised	  by	  a	  
direction	  and	  flow	  profile	  (Ong	  et	  al.,	  2008).	  	  This	  flow	  is	  often	  generated	  
mechanically	  by	  a	  pump	  (i.e.	  pressure	  driven	  flow),	  or	  electrically	  by	  applying	  a	  
voltage	  (electro-­‐osmotic	  flow).	  	  Pressure	  driven	  flow	  allows	  fluid	  to	  be	  moved	  via	  
positive	  or	  negative	  displacement	  and	  requires	  either	  a	  syringe	  pump	  mechanism	  (in	  
which	  the	  whole	  fluid	  reservoir	  must	  be	  replaced	  when	  the	  fluid	  is	  exhausted)	  or	  a	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peristaltic	  mechanism	  (where	  the	  reservoir	  is	  external	  to	  the	  pump,	  enabling	  the	  
reservoir	  to	  be	  refilled	  without	  disrupting	  fluid	  flow).	  Electro-­‐osmotic	  flow	  refers	  to	  
the	  flow	  of	  fluid	  induced	  by	  the	  application	  of	  an	  electrical	  potential	  across	  a	  
microchannel,	  causing	  ions	  in	  solution	  to	  migrate	  to	  the	  opposite	  charge	  lining	  the	  
channel	  wall.	  
Conversely	  statistical	  transport	  is	  driven	  by	  entropy,	  where	  transport	  only	  
occurs	  if,	  after	  transport,	  the	  fluid	  is	  more	  disordered	  than	  before.	  In	  the	  micro	  
fluidic	  device	  this	  is	  seen	  as	  diffusion,	  whereby	  molecules	  will	  be	  transported	  from	  
the	  side	  with	  a	  high	  concentration	  to	  the	  side	  with	  a	  lower	  concentration.	  	  This	  
transport	  mechanism	  is	  readily	  seen	  in	  vivo	  for	  example	  in	  alveolar	  gaseous	  
exchange	  of	  oxygen	  and	  carbon	  dioxide,	  glomerular	  filtration	  in	  the	  kidney	  and	  
glucose	  uptake	  into	  cells.	  	  Likewise,	  the	  removal	  of	  waste	  products	  and	  delivery	  of	  
nutrients	  is	  apparent	  within	  the	  micro	  fluidic	  system,	  where	  molecules	  can	  readily	  
diffuse	  into	  and	  out	  of	  the	  constantly	  replenished	  growth	  media.	  	  This	  differs	  greatly	  
from	  traditional	  cell	  and	  tissue	  culture	  models	  where	  cells	  are	  surrounded	  by	  their	  
metabolic	  waste	  until	  the	  media	  is	  changed,	  e.g.	  every	  2-­‐3	  days.	  
1.9.1.3	  	  Shear	  Effects	  
Shear	  stress	  is	  felt	  by	  an	  object	  when	  a	  tangential	  force	  is	  applied	  to	  its	  
surface.	  	  For	  a	  given	  maximum	  fluid	  velocity,	  the	  shear	  stresses	  present	  in	  a	  smaller	  
microchannel	  are	  greater	  than	  those	  in	  a	  larger	  microchannel	  (Walker	  et	  al.,	  2004).	  	  
This	  must	  be	  taken	  into	  consideration	  when	  designing	  microscale	  culture	  methods	  
requiring	  fluid	  flow.	  When	  multiple	  cells	  are	  placed	  in	  a	  microchannel,	  intercellular	  
spacing	  plays	  an	  important	  role	  in	  determining	  the	  fluid	  forces	  on	  each	  cell,	  with	  
mathematical	  models	  available	  to	  predict	  the	  effects	  of	  changing	  cell	  spacing	  
(Sugihara-­‐Seki,	  2000,	  Sugihara-­‐Seki,	  2001).	  From	  these	  models,	  the	  spacing	  between	  
cells	  appears	  critical	  in	  determining	  whether	  or	  not	  the	  drag	  flow	  around	  cells	  is	  
increased.	  
The	  maximal	  amount	  of	  shear	  that	  can	  be	  tolerated	  by	  the	  cells	  will	  depend	  
on	  the	  cell	  type	  (if	  the	  device	  is	  being	  used	  for	  cell	  culture,	  with	  certain	  cells,	  e.g.	  
endothelial)	  requiring	  shear	  stresses	  for	  adequate	  development	  (Nerem	  et	  al.,	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1998).	  	  This	  property	  can	  be	  manipulated	  to	  stimulate	  in	  vivo	  growth	  conditions	  for	  
example	  in	  osteoblastic	  cells	  (Leclerc	  et	  al.,	  2006)	  or	  to	  investigate	  disease	  
processes,	  for	  example	  by	  mimicking	  cellular	  damage	  and	  disease	  progression	  
(Gosgnach	  et	  al.,	  2000).	  
1.9.1.4	  	  Surface	  of	  Microchannels	  
The	  surface	  properties	  of	  the	  microchannel	  are	  crucial	  in	  the	  functioning	  of	  
the	  micro	  fluidic	  device	  and	  its	  ability	  to	  replicate	  the	  in	  vivo	  setting.	  As	  well	  as	  
contributing	  to	  the	  flow	  properties	  within	  the	  channel	  via	  the	  surface	  energy	  of	  the	  
channel	  walls,	  the	  high	  surface	  to	  volume	  ratios	  found	  within	  the	  micro	  fluidic	  
channel	  help	  to	  mimic	  the	  in	  vivo	  setting.	  	  Cells	  are	  often	  grown	  in	  culture	  dishes	  
with	  very	  low	  surface	  area	  to	  volume	  ratios	  (SAV);	  for	  example,	  a	  35mm	  tissue	  
culture	  dish	  with	  1ml	  of	  medium	  in	  has	  a	  SAV	  of	  11cm-­‐1.	  Cells	  cultured	  in	  a	  
microchannel	  of	  dimension	  50µm	  x	  50µm	  x	  3cm	  (H	  x	  W	  x	  L)	  are	  in	  an	  environment	  
with	  a	  SAV	  of	  800cm-­‐1	  (Walker	  et	  al.,	  2004).	  	  This	  high	  ratio	  is	  advantageous,	  
promoting	  efficient	  mass	  transport	  of	  gases	  via	  diffusion	  to	  and	  from	  cells,	  
demonstrated	  in	  vivo,	  by	  the	  alveoli	  network	  of	  the	  human	  lungs	  providing	  a	  surface	  
area	  for	  gaseous	  exchange	  of	  around	  70m2	  (Ganong,	  1999).	  	  This	  also	  enables	  rapid	  
temperature	  change	  and	  improves	  thermal	  transfer	  both	  by	  convective	  heat	  transfer	  
at	  the	  solid/liquid	  interface	  and	  by	  rapid	  heat	  transfer	  in	  small	  fluid	  volume.	  	  	  
1.9.1.5	  	  Device	  Fabrication	  
	  	   Early	  micro	  fluidic	  devices	  were	  based	  on	  silicon	  and	  glass	  substrates,	  
manufactured	  by	  photolithography	  techniques	  and	  chemical	  etching.	  Glass	  based	  
devices	  have	  more	  defined	  surface	  chemistry	  than	  plastics	  and	  better	  performance	  
for	  separation	  purposes	  (Martin	  et	  al.,	  2006),	  can	  be	  easily	  sterilised,	  remain	  
chemically	  robust	  and	  offer	  simple	  surface	  functionalisation	  and	  therefore	  are	  still	  
widely	  used.	  	  They	  are	  however	  difficult	  to	  fabricate	  and	  relatively	  expensive	  to	  
produce	  compared	  with	  poly(dimethylsiloxane)	  (PDMS)	  for	  example.	  	  Following	  the	  
development	  of	  soft	  lithography	  techniques,	  plastics	  and	  elastomers	  have	  become	  
popular	  substrates	  owing	  to	  the	  ease	  and	  speed	  of	  fabrication.	  The	  most	  commonly	  
used	  material	  in	  soft	  lithography	  is	  PDMS,	  a	  silicon-­‐based	  elastomeric	  material	  with	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a	  number	  of	  desirable	  properties.	  	  It	  is	  cheap	  and	  easy	  to	  mould,	  non-­‐toxic	  to	  cells,	  
gas	  permeable,	  and	  has	  excellent	  optical	  properties,	  including	  low	  autofluorescence	  
and	  optical	  transparency	  for	  imaging	  applications	  (Young	  and	  Beebe,	  2010).	  While	  
the	  many	  advantages	  of	  PDMS	  have	  established	  its	  popularity,	  some	  unfavourable	  
characteristics	  have	  recently	  been	  revealed.	  	  The	  porous	  nature	  of	  PDMS	  can	  reduce	  
its	  effectiveness	  when	  detection	  of	  trace	  elements	  is	  required	  and	  fluorescent	  dyes	  
can	  have	  an	  increased	  propensity	  for	  surface	  binding	  (Kim	  et	  al.,	  2007).	  In	  addition,	  
as	  cells	  are	  exposed	  to	  PDMS	  for	  longer	  durations,	  cell	  metabolism	  and	  proliferation	  
are	  affected,	  possibly	  as	  a	  result	  of	  the	  presence	  of	  PDMS	  (Paguirigan	  and	  Beebe,	  
2009).	  	  Recent	  dissatisfaction	  with	  the	  use	  of	  PDMS	  has	  led	  to	  the	  consideration	  of	  
other	  materials	  such	  as	  thermoplastics	  and	  biopolymers	  for	  micro	  fluidic	  use	  (Young	  
and	  Beebe,	  2010).	  
1.9.2	  	  Biomedical	  Applications	  of	  Micro	  Fluidics	  
1.9.2.1	  	  Cell	  culture	  
The	  applications	  of	  micro	  fluidic	  technology	  to	  cell	  culture	  are	  vast.	  A	  key	  
area	  of	  development	  has	  included	  the	  isolation	  and	  enrichment	  of	  selected	  cell	  
types	  from	  a	  heterogenous	  sample	  by	  a	  variety	  of	  means	  including	  deterministic	  
lateral	  placement,	  shear	  stress	  and	  antibodies,	  dielectrophoretic	  field-­‐flow	  
separation	  and	  contactless	  dielectrophoretic	  separation	  (	  Vykoukal	  et	  al.,	  2008,	  
Green	  et	  al.,	  2009,	  Plouffe	  et	  al.,	  2009,	  Shafiee	  et	  al.,	  2010).	  	  
Successful	  cell	  growth	  has	  been	  achieved	  by	  many	  on	  glass	  and	  PDMS	  
platforms,	  however	  recent	  studies	  have	  focused	  on	  the	  development	  of	  three	  
dimensional	  constructs	  to	  better	  represent	  the	  ECM	  interaction,	  cell-­‐cell	  interaction,	  
soluble	  factors	  and	  mechanical	  forces	  seen	  in	  vivo.	  	  Various	  methods	  have	  been	  
adopted	  to	  generate	  3D	  environments	  including	  the	  use	  of	  scaffolds	  (Rowe	  et	  al.,	  
2007,	  Ryu	  et	  al.,	  2007),	  bioreactors	  (Powers	  et	  al.,	  2002,	  Leclerc	  et	  al.,	  2006)	  and	  
microstructured	  channels	  (Leclerc	  et	  al.,	  2006).	  Toh	  et	  al.	  (2007)	  developed	  a	  
transparent	  3D	  micro	  fluidic	  channel-­‐based	  cell	  culture	  system	  that	  enabled	  optical	  
monitoring	  of	  cells	  and	  cellular	  events.	  	  By	  facilitating	  the	  formation	  of	  cell-­‐cell	  and	  
cell-­‐matrix	  interactions	  on	  the	  chip,	  carcinoma	  cells	  lines	  (HepG2,	  MCF7),	  primary	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differentiated	  hepatocytes	  and	  bone	  marrow	  mesenchymal	  stem	  cells	  were	  
maintained	  as	  perfusion	  cultures	  for	  up	  to	  a	  week,	  after	  which	  their	  3D	  
cytoarchitecture,	  cell-­‐specific	  functions	  and	  differentiation	  competence	  were	  well	  
preserved.	  These	  studies	  however	  were	  all	  based	  on	  the	  culture	  of	  homogenous	  cell	  
lines,	  with	  the	  differing	  cells	  of	  the	  true	  tumour	  microenvironment	  not	  represented.	  
1.9.2.2	  	  Clinical	  Diagnostics	  
Micro	  fluidic	  devices	  are	  well	  suited	  to	  the	  handling	  of	  clinical	  samples,	  
benefiting	  from	  rapid	  throughput,	  small	  sample	  size	  and	  accuracy	  and	  the	  
availability	  to	  provide	  low-­‐cost,	  single-­‐use	  devices.	  	  The	  use	  of	  micro	  fluidic	  devices	  
as	  biosensors	  to	  detect	  specific	  cellular	  biochemical	  outputs	  mediated	  by	  isolated	  
enzymes,	  organelles,	  whole	  cells,	  tissues,	  or	  immunosystems	  is	  in	  widespread	  use.	  A	  
multitude	  of	  commercial	  micro	  fluidic	  based	  biosensors	  have	  been	  developed	  for	  
measuring	  various	  body	  compounds	  such	  as	  blood	  gas	  (Lam	  and	  Atkinson,	  2007,	  
Huang,	  2007),	  glucose	  (Huang,	  2007)	  	  and	  cholesterol	  (Aravamudhan	  et	  al.,	  2007).	  	  
One	  of	  the	  advantages	  of	  micro	  fluidic	  technology	  is	  the	  ability	  to	  combine	  
multiple	  functions.	  Mohammed	  et	  al.	  (2009)	  for	  example,	  describe	  a	  micro	  fluidic	  
device	  to	  perfuse	  pancreatic	  islets	  whilst	  simultaneously	  characterising	  
mitochondrial	  membrane	  potential	  and	  intracellular	  calcium,	  as	  well	  as	  off-­‐chip	  
quantification	  of	  secreted	  insulin	  by	  enzyme-­‐linked	  immunosorbent	  assay	  (ELISA),	  
offering	  a	  means	  for	  the	  rapid	  assessment	  of	  tissue	  quality	  immediately	  following	  
donor	  isolation.	  	  This	  is	  however	  yet	  to	  be	  adopted	  into	  clinical	  practice	  as	  the	  in	  
vitro	  functional	  assay	  results	  have	  yet	  to	  be	  correlated	  with	  in	  vivo	  islet	  function.	  	  
In	  this	  context,	  the	  integration	  of	  electrochemical	  detection	  of	  genetic	  and	  
protein	  cancer	  markers	  with	  micro	  fluidic	  technology	  has	  been	  of	  interest.	  The	  
approach	  consists	  of	  the	  immobilisation	  of	  a	  multitude	  of	  marker	  probes	  on	  an	  
electrode	  array,	  each	  electrode	  being	  functionalised	  with	  a	  particular	  probe	  
consisting	  of	  antibodies	  or	  antigens	  in	  the	  case	  of	  immunosensors	  or	  a	  short	  
oligonucleotide	  sequence	  in	  the	  case	  of	  genosensors.	  Henry	  et	  al.	  (2009)	  developed	  
a	  packaged	  micro	  fluidic	  cell	  for	  the	  multiplexed	  detection	  of	  tumour	  markers	  such	  
as	  carcinoembryonic	  antigen	  (CEA)	  and	  prostate-­‐specific	  antigen	  as	  well	  as	  DNA	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breast	  cancer	  markers	  such	  as	  oestrogen	  receptor-­‐α,	  plasminogen	  activator	  
urokinase	  receptor,	  EGFR	  and	  erythroblastic	  leukemia	  viral	  oncogene	  homolog	  2.	  
They	  demonstrated	  that	  several	  parameters	  including	  both	  proteins	  and	  genes	  could	  
be	  detected	  on	  a	  single	  chip	  with	  reproducibility	  (relative	  standard	  deviation	  <8%	  for	  
CEA	  and	  PSA	  detection)	  and	  high	  sensitivity.	  	  
Micro	  fluidic	  based	  analysis	  has	  been	  applied	  to	  automated	  cell	  
quantification	  for	  circulating	  tumour	  cell	  (CTC)	  detection	  (Nagrath	  et	  al.,	  2007),	  cell	  
detection	  in	  biosensors	  (Oh	  et	  al.,	  2007)	  and	  CD4	  counting	  devices	  (Alyassin	  et	  al.,	  
2009).	  	  Alyassin	  et	  al.	  (2009)	  describe	  an	  automated	  micro	  fluidic	  device	  for	  high	  
throughput	  quantification	  of	  florescent	  cell	  image	  analysis	  using	  HIV-­‐infected	  whole	  
blood	  samples.	  	  Compared	  with	  manual	  counting,	  the	  automated	  device	  performed	  
similarly	  in	  terms	  of	  speed	  and	  accuracy	  with	  small	  cell	  numbers,	  however	  the	  micro	  
fluidic	  device	  was	  more	  accurate	  and	  >100	  times	  faster	  for	  multiple-­‐colour	  stained	  
cells,	  or	  when	  large	  numbers	  of	  cells	  (i.e.	  >500)	  were	  present.	  	  Lee	  et	  al.	  (2009)	  
quote	  a	  high	  sensitivity	  and	  detection	  rate	  (comparable	  with	  conventional	  methods	  
of	  flow	  cytometry	  and	  Western	  blot	  analysis)	  for	  the	  measurement	  of	  cancer	  cells	  in	  
tumour	  aspirate.	  	  Using	  a	  diagnostic	  magnetic	  resonance	  sensor,	  as	  few	  as	  2	  cancer	  
cells	  in	  1µl	  of	  tumour	  aspirates	  were	  detected,	  with	  expression	  profiling	  in	  under	  15	  
min.	  Nagrath	  et	  al.	  (2007)	  describe	  a	  microchip	  to	  identify	  CTCs	  in	  the	  peripheral	  
blood	  of	  patients	  with	  metastatic	  lung,	  prostate,	  pancreatic,	  breast	  and	  colon	  
cancer.	  	  The	  CTC	  chip	  identified	  circulating	  tumour	  cells	  in	  115	  of	  116	  (99%)	  samples,	  
with	  a	  range	  of	  5	  -­‐	  1281	  CTCs	  per	  ml	  and	  approximately	  50%	  purity.	  In	  addition,	  CTCs	  
were	  isolated	  in	  7/7	  patients	  with	  early-­‐stage	  prostate	  cancer.	  
1.9.2.3	  	  Point	  of	  Care	  Testing	  
This	  ability	  to	  detect	  a	  variety	  of	  biological	  compounds,	  coupled	  with	  the	  
potential	  for	  automation	  and	  integration	  on	  to	  a	  portable	  device,	  means	  that	  micro	  
fluidic	  devices	  are	  well-­‐suited	  to	  point-­‐of-­‐care	  diagnostic	  instrumentation	  (point	  of	  
care	  testing,	  POCT).	  POCT	  is	  defined	  specifically	  as	  “testing	  at	  or	  near	  the	  site	  of	  
patient	  care”	  (Kost,	  2002).	  	  Historically,	  all	  diagnostic	  testing	  was	  performed	  at	  the	  
patient’s	  bedside,	  however	  modern	  medicine	  has	  dictated	  the	  migration	  of	  
diagnostic	  testing	  to	  the	  central	  laboratory	  due	  to	  size	  and	  expense	  of	  analytical	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equipment	  and	  operator	  dependence.	  One	  rationale	  for	  POCT	  is	  that	  it	  may	  
streamline	  healthcare	  and	  improve	  clinical	  outcomes	  (Price	  and	  Kricka,	  2007).	  For	  
example,	  the	  finding	  of	  a	  high	  blood	  glucose	  level	  in	  a	  diabetic	  patient	  can	  be	  acted	  
upon	  immediately	  by	  administration	  of	  the	  appropriate	  therapy.	  Weigl	  et	  al.	  (2008)	  
suggest	  that	  POCT	  is	  of	  use	  in	  developing-­‐country	  health	  care,	  home	  testing	  in	  
developed	  countries,	  and	  diagnostic	  and	  bioanalytical	  disposables	  for	  use	  in	  natural	  
or	  man-­‐made	  bioemergencies	  by	  first	  responders.	  	  
The	  salient	  features	  of	  a	  point	  of	  care	  device	  include	  the	  following:	  short	  
time	  to	  results,	  ease	  of	  use	  (includes	  sample	  preparation	  and	  fully	  automated	  
sample	  processing),	  portability,	  small	  sample	  volumes	  (<	  30	  μL	  requirement	  allows	  
finger	  stick	  rather	  than	  venous	  sample),	  multifunctionality	  (capable	  of	  combining	  
different	  types	  of	  tests	  required	  along	  the	  path	  of	  care)	  and	  low	  cost	  (Sista	  et	  al.,	  
2008).	  Other	  important	  requirements	  include:	  self-­‐contained	  reagents,	  self-­‐
calibration	  and	  connectivity	  to	  laboratory	  information	  systems.	  
Lateral	  flow	  tests	  were	  among	  the	  first	  successfully	  commercialised	  micro	  
fluidic	  products	  in	  POCT.	  Using	  the	  capillary	  test	  strip	  platform,	  a	  variety	  of	  	  
diagnostic	  application	  are	  possible	  including	  the	  detection	  of	  health	  biomarkers	  in	  
pregnancy	  (Chard,	  1992),	  heart	  attack	  (Clark	  et	  al.,	  2002),	  blood	  glucose	  (Bohme	  et	  
al.,	  2003)	  and	  metabolic	  disorders	  (Lou	  et	  al.,	  1993),	  the	  detection	  of	  small	  
molecules,	  e.g.	  mycotoxins	  in	  food	  (Krska	  and	  Molinelli,	  2009),	  antibiotics	  (Xie	  et	  al.,	  
2009)	  and	  detection	  of	  infectious	  agents	  such	  as	  anthrax	  (Carter	  and	  Cary,	  2007),	  
salmonella	  (Ho	  et	  al.,	  2008)	  and	  viruses	  (Edwards	  and	  Baeumner,	  2009).	  	  
The	  application	  of	  micro	  fluidic-­‐based	  POCT	  to	  immunoassays	  is	  of	  interest.	  
The	  conventional	  ELISA	  approach	  has	  a	  number	  of	  limitations	  for	  its	  use	  in	  resource-­‐
limited	  settings,	  because	  it	  requires	  relatively	  long	  assay	  times	  (4	  –	  6	  hours),	  
cumbersome	  liquid	  handling,	  and	  large	  amounts	  of	  expensive	  reagents	  and	  
equipment.	  Several	  rapid	  diagnostic	  tests	  have	  been	  developed	  for	  detection	  of	  
various	  entities	  using	  immunoassays.	  Herr	  et	  al.	  (2007)	  developed	  a	  clinical	  POC	  
diagnostic	  that	  enabled	  rapid	  quantification	  of	  a	  putative	  biomarker	  of	  periodontal	  
disease	  in	  saliva	  by	  using	  a	  monolithic	  disposable	  cartridge	  designed	  to	  operate	  in	  a	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compact	  analytical	  instrument.	  This	  device	  integrated	  sample	  pretreatment	  
(filtering,	  enrichment,	  mixing)	  with	  electrophoretic	  immunoassays	  to	  measure	  
analyte	  concentrations	  in	  minimally	  pretreated	  saliva	  samples.	  Using	  20µl	  of	  saliva,	  
they	  demonstrated	  rapid	  (<10	  min)	  measurement	  of	  the	  collagen-­‐cleaving	  enzyme	  
matrix	  metalloproteinase-­‐8	  (MMP-­‐8)	  in	  saliva	  from	  healthy	  and	  periodontally	  
diseased	  subjects.	  By	  validation	  with	  conventional	  measurements	  of	  salivary	  MMP-­‐
8,	  the	  authors	  concluded	  that	  their	  device	  provided	  rapid,	  reliable	  measurement	  of	  
proteinaceous	  disease	  biomarkers	  in	  biological	  fluids.	  	  This	  study	  was	  however	  more	  
of	  a	  ‘proof	  of	  concept’	  as	  additional	  investigations	  regarding	  MMP-­‐8	  as	  a	  biomarker	  
for	  periodontal	  disease	  and	  its	  ability	  to	  predict	  disease	  progression,	  as	  well	  as	  a	  
means	  to	  monitor	  therapeutic	  efficacy	  are	  needed.	  
1.9.2.4	  	  Pharmacological	  Studies	  
Drug	  discovery	  is	  often	  impeded	  by	  the	  poor	  predictability	  of	  in	  vitro	  assays	  
for	  drug	  toxicity.	  	  Micro	  fluidic	  devices	  are	  suited	  to	  toxicological	  studies	  and	  drug	  
therapy	  studies	  given	  their	  potential	  for	  the	  faster	  assay	  times	  and	  ability	  to	  handle	  
small	  samples.	  	  They	  also	  pose	  significant	  advantages	  over	  traditional	  in	  vitro	  
models,	  allowing	  human	  tissue	  samples,	  more	  closely	  resembling	  the	  in	  vivo	  state,	  to	  
be	  tested,	  bridging	  the	  gap	  between	  pre-­‐clinical	  and	  clinical	  drug	  testing.	  
Drug	  development	  is	  a	  costly	  and	  time	  consuming,	  with	  approximately	  only	  
one	  in	  ten	  drugs	  entering	  clinical	  trials	  finally	  being	  approved	  (Kola	  and	  Landis,	  
2004),	  one	  of	  the	  main	  causes	  for	  such	  a	  high	  attrition	  rate	  being	  unforeseen	  lack	  of	  
efficacy	  or	  toxicity.	  A	  major	  disadvantage	  of	  conventional	  multi-­‐well	  plate	  assays	  is	  
the	  lack	  of	  multi-­‐organ	  interactions,	  meaning	  that	  the	  pharmacokinetics	  of	  drugs,	  
which	  plays	  a	  significant	  role	  in	  determining	  their	  pharmacological	  effect,	  cannot	  be	  
assessed.	  
Micro	  fluidic	  devices	  with	  perfusion	  cell	  culture	  offer	  a	  great	  potential	  for	  
drug	  screening	  in	  a	  high-­‐throughput	  manner	  and	  can	  be	  useful	  for	  reproducing	  the	  
pharmacokinetics	  of	  drugs.	  Multiple	  components	  such	  as	  a	  metabolizing	  entity	  (e.g.	  
liver)	  and	  a	  target	  structure	  (e.g.	  tumour)	  can	  be	  connected	  with	  fluidic	  channels	  for	  
multi-­‐organ	  interactions.	  Ma	  et	  al.	  (2009)	  developed	  a	  three-­‐layer	  micro	  fluidic	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system	  to	  test	  metabolism-­‐dependent	  toxicity	  of	  drugs,	  consisting	  of	  a	  top-­‐layer	  for	  
feeding	  drugs,	  a	  middle	  layer	  with	  human	  liver	  microsomes,	  and	  a	  bottom-­‐layer	  for	  
cell	  culture	  chambers.	  	  By	  studying	  the	  metabolism	  of	  UDP-­‐glucuronosyltransferase,	  
the	  drug-­‐drug	  interactions	  between	  acetaminophen	  and	  phenytoin	  and	  their	  effect	  
on	  hepG2	  cells	  were	  studied,	  with	  an	  increased	  hepG2	  cytotoxicity	  seen	  in	  response	  
to	  drug	  treatment.	  Sung	  and	  Shuler	  (2009)	  developed	  a	  microscale	  cell	  culture	  
analogue	  (µCCA),	  also	  known	  as	  ‘body-­‐on-­‐a-­‐chip’,	  to	  assess	  the	  effects	  of	  5FU.	  	  Three	  
separate	  cell	  types,	  namely	  liver	  (hepatoma	  calls	  HepG2/C3A),	  tumour	  (colon	  
cancer,	  HCT-­‐116)	  and	  bone	  marrow	  (myeloblasts,	  Kasumi-­‐1)	  were	  cultured	  in	  
separate	  chambers	  on	  a	  single	  chip,	  interconnected	  by	  channels	  mimicking	  the	  
blood	  flow	  pattern.	  The	  device	  was	  able	  to	  reproduce	  the	  metabolism	  of	  the	  oral	  
pro-­‐drug	  tegafur	  in	  the	  liver,	  reproducibly	  initiating	  cell	  death	  by	  5FU,	  while	  96-­‐well	  
plate	  cultures	  were	  unable	  to	  demonstrate	  significant	  cell	  metabolism.	  	  	  
Although	  the	  examples	  above	  used	  micro	  fluidic	  technology	  to	  integrate	  
different	  populations	  of	  cells	  rather	  than	  culture	  whole	  tissue,	  its	  success	  provides	  
proof	  of	  concept	  of	  the	  potential	  of	  micro	  fluidics	  to	  recreate	  in	  vivo	  physiological	  
systems.	  More	  recently,	  Midwoud	  et	  al.	  (2010b)	  have	  designed	  a	  micro	  fluidic	  
system	  for	  the	  perfusion	  of	  precision-­‐cut	  intestinal	  slices,	  and	  for	  the	  sequential	  
perfusion	  of	  intestinal	  and	  liver	  slices	  mimicking	  the	  in	  vivo	  first	  pass	  situation.	  By	  
sequentially	  perfusing	  rat	  intestinal	  and	  liver	  tissue	  slices	  in	  a	  two-­‐compartment	  co-­‐
culture	  perfusion	  system	  with	  a	  continuous	  flow	  of	  medium,	  the	  authors	  directed	  
metabolites	  or	  other	  excreted	  compounds	  formed	  by	  an	  intestinal	  slice	  to	  the	  
second	  compartment	  containing	  a	  liver	  slice.	  The	  interplay	  between	  these	  two	  
organs	  was	  demonstrated	  by	  exposing	  the	  slices	  to	  the	  primary	  bile	  acid,	  
chenodeoxycholic	  acid	  (CDCA).	  CDCA	  induced	  the	  expression	  of	  fibroblast	  growth	  
factor	  15	  in	  the	  intestinal	  slice,	  which	  resulted	  in	  a	  stronger	  down-­‐regulation	  of	  the	  
enzyme,	  cytochrome	  P450	  7A1	  in	  the	  liver	  slice	  in	  the	  second	  compartment	  than	  
when	  the	  liver	  slice	  was	  exposed	  to	  CDCA	  in	  a	  single-­‐microchamber	  biochip.	  
Micro	  fluidic	  devices	  have	  also	  been	  used	  to	  integrate	  the	  study	  of	  drug	  
pharmacokinetics	  (PK)	  and	  pharmacodynamics	  (PD)	  in	  order	  to	  predict	  the	  time-­‐
course	  of	  pharmacological	  effects	  from	  a	  dosage.	  Further	  to	  the	  above	  study,	  Sung	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et	  al.	  (2010),	  by	  combining	  a	  	  mathematical	  modelling	  approach	  (PK–PD	  modelling)	  
with	  their	  in	  vitro	  experimental	  approach,	  demonstrated	  that	  each	  cell	  type	  
exhibited	  differential	  responses	  to	  5FU,	  and	  the	  responses	  in	  the	  micro	  fluidic	  
environment	  were	  different	  from	  those	  in	  static	  environment,	  clearly	  supporting	  the	  
need	  for	  ‘tissue’	  based	  modelling.	  
Micro	  fluidic	  technology	  has	  been	  particularly	  useful	  in	  the	  analysis	  of	  
chemotherapy	  resistance	  cell	  lines,	  particularly	  in	  the	  study	  of	  lung	  cancer.	  By	  
combining	  immunofluorescence	  and	  chip	  electrophoresis,	  glucose-­‐regulated	  protein	  
78	  was	  found	  to	  correlate	  with	  resistance	  to	  topoisomerase	  II	  inhibitor-­‐VP-­‐16	  in	  
human	  lung	  cancer	  cell	  lines	  (Ying-­‐Yan	  et	  al.,	  2008).	  	  Similarly,	  assay	  of	  the	  
expression	  of	  multidrug	  resistance	  related	  protein	  P-­‐gp	  and	  the	  correlation	  between	  
the	  expression	  of	  P-­‐gp	  and	  resistance	  to	  VP-­‐16	  was	  reported	  by	  Zhao	  et	  al.	  (2010).	  
The	  results	  indicated	  that	  the	  cells	  could	  grow	  and	  spread	  well	  for	  4	  days	  in	  the	  
micro	  fluidic	  system.	  Immunofluorescence	  assay	  of	  P-­‐gp	  showed	  weak	  fluorescence	  
for	  the	  verapamil-­‐pretreated	  cells	  compared	  with	  that	  of	  non-­‐pretreated	  cells	  and	  
apoptosis	  analysis	  demonstrated	  a	  twofold	  increase	  in	  the	  percentage	  of	  apoptotic	  
cells	  in	  the	  verapamil-­‐pretreated	  group	  compared	  with	  that	  of	  non	  verapamil	  
pretreated.	  These	  results	  indicate	  that	  P-­‐gp	  plays	  an	  important	  role	  in	  the	  resistance	  
to	  VP-­‐16	  in	  a	  human	  lung	  cancer	  cell	  line	  and	  highlight	  the	  role	  of	  micro	  fluidic	  cell	  
culture	  in	  determining	  mechanisms	  of	  drug	  resistance.	  
1.9.2.5	  	  Tumour	  Spheroids	  in	  Micro	  Fluidic	  Chambers	  
As	  described	  in	  section	  1.8.3,	  spheroids,	  a	  commonly	  used	  tumour	  model	  go	  
some	  way	  to	  recreating	  the	  complex	  multicellular	  tissue	  structure.	  	  Their	  use	  is	  
however	  limited,	  as	  previously	  outlined,	  although	  can	  be	  enhanced	  when	  integrated	  
with	  micro	  fluidic	  technology.	  	  Multicellular	  spheroids	  have	  been	  cultured	  within	  a	  
micro	  fluidic	  device,	  as	  first	  described	  by	  Torisawa	  et	  al.	  (2007).	  	  By	  introducing	  cells	  
in	  suspension	  through	  silicon	  microholes	  into	  microwells,	  cellular	  spheroids	  were	  
formed.	  	  By	  demonstrating	  the	  continued	  production	  of	  albumin	  from	  the	  hepatoma	  
cell	  line	  (HepG2),	  the	  spheroids	  functioned	  within	  the	  device	  for	  2	  weeks.	  	  Similarly,	  
Hsiao	  et	  al.	  (2009)	  used	  a	  two-­‐layer	  micro	  fluidic	  system	  to	  culture	  3D	  multicell	  type	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spheroids	  of	  fluorescently	  labelled	  metastatic	  prostate	  cancer	  cells	  (PC-­‐3	  cell	  line),	  
osteoblasts	  and	  endothelial	  cells.	  	  Culturing	  the	  cells	  in	  this	  environment	  greatly	  
decreased	  the	  proliferation	  rate	  of	  PC-­‐3	  cells	  without	  reducing	  viability,	  suggesting	  
this	  method	  may	  more	  faithfully	  recapitulate	  the	  in	  vivo	  growth	  behaviour	  of	  
malignant	  cancer	  cells	  within	  the	  bone	  metastatic	  prostate	  cancer	  
microenvironment.	  
The	  ability	  to	  manipulate	  the	  flow	  characteristics	  within	  the	  micro	  fluidic	  
device	  has	  been	  utilised	  by	  Hu	  and	  Li	  (2007)	  to	  study	  the	  growth	  dynamics	  of	  
avascular	  tumours.	  A	  three-­‐dimensional	  flow	  and	  nutrient	  transport	  model,	  
incorporating	  the	  MTS	  growth	  model	  was	  used	  to	  study	  the	  influence	  of	  nutrients	  
(oxygen	  and	  glucose)	  supply	  and	  distribution	  on	  the	  MTS	  growth.	  Numerical	  
simulations	  based	  on	  the	  EMT6/Ro	  tumour	  cells	  showed	  that	  the	  continuous-­‐flow	  
perfusion	  was	  a	  more	  efficient	  method	  of	  delivering	  nutrients	  to	  the	  MTS	  than	  the	  
diffusion-­‐only	  static	  culture.	  Additionally,	  the	  flow	  shear	  stress	  exerting	  on	  the	  MTS	  
within	  the	  microchannel	  bioreactor	  was	  estimated	  to	  be	  far	  below	  the	  critical	  value	  
to	  affect	  growth,	  allowing	  for	  an	  increase	  in	  perfusion	  velocity	  to	  satisfy	  the	  higher	  
nutrient	  requirement	  by	  the	  growing	  tumour	  spheroids.	  	  Rosano	  et	  al.	  (2009)	  
developed	  a	  synthetic	  microvascular	  network	  on	  a	  PDMS	  chip	  that	  attempted	  to	  
recreate	  the	  bifurcations,	  tortuosities,	  and	  cross-­‐sectional	  changes	  found	  in	  
microvascular	  networks	  in	  vivo.	  By	  mapping	  microvascular	  networks	  from	  a	  
cremaster	  muscle	  using	  a	  modified	  Geographical	  Information	  System,	  the	  networks	  
were	  successfully	  cultured	  with	  bovine	  aortic	  endothelial	  cells,	  which	  reached	  
confluency	  3-­‐4	  days	  after	  seeding.	  	  
Micro	  fluidic	  devices	  have	  also	  been	  used	  to	  study	  the	  effects	  of	  
chemotherapy	  agents	  when	  the	  in	  vitro	  conditions	  have	  been	  manipulated	  to	  mimic	  
the	  microenvironment	  gradients	  present	  in	  tumours.	  	  Walsh	  et	  al.	  (2009)	  formed	  
tumour	  spheroids	  (from	  colonic	  cancer	  cells)	  within	  micron-­‐scale	  chambers	  exposed	  
to	  medium	  perfusion	  on	  one	  side	  to	  create	  linear	  nutrient	  gradients.	  	  Fluorescence	  
microscopy	  was	  used	  to	  demonstrate	  that	  the	  cell	  mass	  contained	  viable,	  apoptotic,	  
and	  acidic	  regions	  similar	  to	  in	  vivo	  tumours.	  The	  device	  was	  also	  able	  to	  
characterize	  the	  transport	  differences	  between	  a	  passively	  diffusing	  therapeutic	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(doxorubicin)	  and	  actively	  penetrating	  vectors	  (Salmonella	  bacteria)	  aiding	  the	  
understanding	  of	  diffusion	  resistance	  within	  solid	  tumours.	  	  
1.9.2.6	  	  Whole	  Tissue	  Culture	  
Whole	  tissue	  culture	  is	  perhaps	  the	  most	  exciting	  and	  novel	  application	  of	  
micro	  fluidics.	  This	  is	  the	  area	  most	  in	  its	  infancy,	  but	  given	  the	  limitations	  of	  current	  
culture	  techniques,	  has	  the	  ability	  to	  revolutionise	  the	  way	  we	  grow	  tumour	  tissue.	  	  
Culturing	  whole	  tissue	  in	  a	  micro	  fluidic	  device	  can	  offer	  the	  recreation	  of	  the	  
tumour	  microenvironment,	  maintenance	  of	  complex	  cellular	  interactions	  whilst	  
benefiting	  from	  the	  technological	  applications	  of	  micro	  fluidics.	  	  To	  date,	  only	  7	  
papers	  (see	  Table	  1.6)	  have	  been	  published	  on	  whole	  tissue	  culture	  and	  of	  these,	  
only	  1	  (Webster	  et	  al.,	  2010)	  has	  focused	  on	  the	  utilisation	  of	  micro	  fluidic	  devices	  
for	  the	  maintenance	  of	  whole	  pieces	  of	  tumour.	  	  
	  Table	  1.7	  Published	  literature	  on	  the	  use	  of	  micro	  fluidics	  for	  whole	  tissue	  culture,	  to	  January	  2011.	   	  
Tissue	   Application	   Reference	  
Rat	  hippocampus	   600µm	  slices	  perfused	  in	  microfabricated	  glass	  slides	  for	  5hr	  as	  demonstrated	  by	  
eptileptiform	  activity	  
Passeraub	  et	  al.	  
(2003)	  
Rat	  medulla	   700µm	  slices	  perfused	  on	  PDMS	  slices	  for	  3	  hr	  with	  evidence	  of	  respiratory-­‐related	  
motor	  output.	  Solutions	  controlled	  to	  target	  specific	  areas	  demonstrating	  evidence	  
of	  laminar	  flow.	  	  
Blake	  et	  al.	  (2007)	  
Rat	  liver	   4	  mm3	  slices	  perfused	  in	  glass	  micro	  fluidic	  devices	  for	  up	  to	  70	  h.	  	  Viability	  studies	  
by	  Lavacell	  staining,	  pico	  green	  assay	  and	  LDH	  release.	  	  Functionality	  by	  albumin	  
and	  urea	  synthesis	  
Hattersley	  et	  al.	  
(2008)	  	  
Mouse	  brain	  cortex	   700µm	  slices	  perfused	  on	  PDMS	  micro	  fluidic	  devices.	  	  Viability	  up	  to	  5	  days	  
demonstrated	  by	  fluorescent	  nuclear	  staining	  and	  on	  histoarchitectural	  
examination	  
Rambani	  et	  al.	  (2009)	  
Rat	  liver	   100µm	  in	  PDMS	  micro	  fluidic	  devices	  for	  up	  to	  24	  hr	  as	  measured	  by	  viability	  of	  7-­‐
ethoxycoumarin	  and	  LDH	  release	  
Van	  Midwoud	  et	  al.	  
(2010a)	  
	  Rat/human	  heart	   4mm3	  slices	  maintained	  for	  3.5	  –	  5	  hr	  in	  PDMS	  micro	  fluidic	  devices.	  Viability	  
analysis	  by	  effluent	  levels	  of	  LDH	  and	  hydrogen	  peroxide	  in	  combination	  with	  in	  
situ	  electrochemical	  measurement	  of	  the	  release	  of	  reactive	  oxygen	  species.	  
Cheah	  et	  al.	  (2010)	  
Human	  colorectal	  
tumour	  
2mm3	  slices	  maintained	  for	  over	  3	  days	  in	  a	  glass	  micro	  device.	  	  Functionality	  
demonstrated	  by	  changes	  in	  release	  of	  vascular	  endothelial	  growth	  factor	  in	  
response	  to	  hypoxia.	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   The	  majority	  of	  reports	  on	  the	  use	  of	  micro	  fluidic	  devices	  for	  culturing	  whole	  
pieces	  of	  tissue	  have	  centred	  upon	  studies	  using	  brain	  tissue.	  The	  maintenance	  of	  
‘thick’	  slices	  of	  brain	  was	  first	  described	  by	  Passeraub	  et	  al.	  (2003).	  They	  used	  
fabricated	  glass	  with	  arrays	  of	  micropillars	  to	  replace	  the	  nylon	  mesh	  used	  in	  
classical	  interface	  chambers	  in	  order	  to	  confine	  the	  flow	  and	  uphold	  hippocampal	  
slices	  (600µm	  thick)	  at	  the	  interface	  between	  perfusate	  and	  oxygen.	  Using	  a	  zero-­‐
Mg2+	  model	  of	  epileptiform	  activity,	  spontaneous	  single	  and	  multi-­‐spike	  bursts	  in	  the	  
CA3	  region	  of	  a	  rat	  hippocampal	  brain	  slice	  were	  observed	  for	  more	  than	  5	  h.	  	  Blake	  
et	  al.	  (2007)	  used	  a	  three-­‐layer	  PDMS	  micro	  fluidic	  device	  to	  culture	  medullary	  slices	  
(approximately	  700µm	  thick).	  Their	  fabrication	  technique	  included	  rapid	  production	  
of	  PDMS	  layers	  (using	  a	  PDMS	  master	  allowed	  for	  a	  2	  h	  microfabrication	  time	  rather	  
than	  10	  h	  if	  a	  negative	  photoresist	  master	  was	  used)	  that	  could	  be	  applied	  to	  brain	  
slices	  of	  different	  shapes	  and	  sizes.	  The	  slices	  in	  this	  chamber	  spontaneously	  
produced	  rhythmic,	  respiratory-­‐related	  motor	  output	  for	  up	  to	  3	  h.	  They	  also	  
demonstrated	  how	  the	  laminar	  flow	  exhibited	  by	  the	  micro	  fluidic	  chamber	  allowed	  
controlled	  solutions	  to	  target	  specific	  areas	  of	  the	  brain	  slice	  based	  on	  the	  input	  flow	  
rates.	  A	  stream	  of	  Na+-­‐free	  solution	  was	  focused	  on	  one	  half	  of	  a	  medullary	  slice	  to	  
abolish	  spontaneous	  neural	  activity	  in	  that	  part	  of	  the	  brain	  slice,	  whilst	  the	  other	  
half	  remained	  active.	  By	  modifying	  their	  custom-­‐made	  microperfusion	  chamber	  to	  
facilitate	  perfusion	  of	  oxygenated	  nutrient	  medium	  throughout	  the	  tissue	  thickness	  
with	  concomitant	  removal	  of	  depleted	  medium	  and	  catabolites,	  Rambani	  et	  al.	  
(2009)	  enhanced	  the	  viability	  of	  the	  thick	  organotypic	  brain	  slice	  cultures.	  By	  
investigating	  a	  range	  of	  flow	  rates,	  they	  demonstrated	  up	  to	  84.6%	  viability	  after	  5	  
days	  in	  their	  700µm	  thick	  organotypic	  brain	  slices,	  compared	  with	  the	  unperfused	  
control	  cultures.	  Functional	  activity	  was	  confirmed	  by	  demonstrating	  continued	  
spontaneous	  electrical	  activity	  and	  preservation	  of	  in	  vivo	  cyto-­‐architecture	  was	  
studied	  using	  microscopy.	  
	   The	  maintenance	  of	  liver	  tissue	  biopsies	  has	  also	  been	  described	  (Hattersley	  
et	  al.,	  2008,	  van	  Midwoud	  et	  al.,	  2010a).	  	  Using	  a	  glass	  microchip,	  Hattersley	  et	  al.	  
(2008)	  maintained	  pieces	  of	  liver	  tissue	  (4mm3)	  in	  a	  viable	  state	  for	  over	  70	  h.	  	  
Functionality	  was	  demonstrated	  by	  continued	  production	  of	  albumin	  and	  urea.	  	  This	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was	  corroborated	  by	  LavacellTM	  staining	  of	  viable	  cells	  as	  well	  as	  final	  disaggregation	  
on-­‐chip	  using	  a	  collagenase	  digestion	  to	  show	  cell	  viability	  by	  Trypan	  blue	  assay.	  	  	  
Based	  on	  a	  PDMS	  device,	  van	  Midwoud	  et	  al	  (2010a)	  maintained	  precision-­‐cut	  liver	  
slices	  (of	  100µm	  thickness)	  within	  a	  micro	  fluidic	  perfusion	  system.	  	  Liver	  slices	  were	  
viable	  for	  at	  least	  24	  h	  with	  the	  compound,	  7-­‐ethoxycoumarin	  (7-­‐EC)	  used	  to	  
demonstrate	  the	  preservation	  of	  cell	  metabolism.	  
	   Additionally,	  a	  micro	  fluidic	  device	  has	  been	  developed	  to	  maintain	  viable	  
heart	  tissue	  samples	  (Cheah	  et	  al.,	  2010).	  This	  device	  allows	  rat	  or	  human	  heart	  
tissue	  to	  be	  studied	  under	  pseudo	  in	  vivo	  conditions.	  By	  using	  effluent	  levels	  of	  
lactate	  dehydrogenase	  (LDH)	  and	  hydrogen	  peroxide	  as	  markers	  of	  damaged	  tissue	  
in	  combination	  with	  in	  situ	  electrochemical	  measurement	  of	  the	  release	  of	  reactive	  
oxygen	  species,	  heart	  tissue	  (2mm3	  thick)	  was	  maintained	  for	  up	  to	  5	  h.	  	  
	   Most	  recently,	  our	  research	  group	  published	  a	  communication	  relating	  to	  the	  
culture	  of	  human	  colorectal	  tumour	  in	  a	  micro	  fluidic	  device	  (Webster	  et	  al.,	  2010).	  	  
Using	  a	  similar	  glass	  micro	  fluidic	  device	  to	  the	  one	  used	  in	  this	  study	  but	  employing	  
a	  peristaltic	  rather	  than	  a	  syringe-­‐pump	  driven	  perfusion	  system,	  the	  response	  of	  
2mm3	  tumour	  biopsies	  to	  hypoxic	  conditions	  was	  measured	  by	  expression	  of	  VEGF	  
by	  off-­‐chip	  ELISA.	  	  Tumour	  tissue	  showed	  a	  greater	  increase	  of	  VEGF	  compared	  with	  
that	  of	  normal	  tissue	  non-­‐neoplastic	  colorectal	  tissue	  after	  a	  period	  of	  hypoxia	  
(N2/CO2	  gassed	  media).	  	  This	  demonstrated	  both	  biopsy	  viability	  within	  the	  device	  
and	  the	  potential	  use	  of	  VEGF	  as	  a	  biomarker	  for	  monitoring	  response	  of	  tumour	  
biopsies	  to	  changes	  in	  the	  microenvironment.	  
	   Whole	  tissue	  perfusion	  represents	  the	  ultimate	  in	  preservation	  of	  the	  tissue	  
microenvironment.	  	  The	  studies	  listed	  in	  table	  1.7	  and	  highlighted	  above	  
demonstrate	  viability	  and	  functionality	  of	  whole	  tissue	  within	  micro	  fluidic	  devices.	  	  
Furthermore,	  the	  potential	  for	  pharmacology	  studies	  and	  application	  to	  tumour	  
biology	  is	  being	  realised.	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1.10	  	  Study	  Aims	  
	   As	  the	  biological	  application	  of	  micro	  fluidic	  technology	  is	  a	  relatively	  novel	  
concept,	  particularly	  with	  regards	  to	  whole	  tissue	  culture,	  the	  first	  aim	  of	  this	  study	  
was	  to	  determine	  the	  stability	  of	  HNSCC	  biopsies	  within	  a	  micro	  fluidic	  device,	  using	  
markers	  of	  cell	  death	  and	  proliferation.	  	  Lactate	  dehydrogenase	  (LDH)	  and	  
mitochondrial	  metabolism	  of	  water	  soluble	  tetrazolium	  (WST-­‐1)	  were	  assayed	  off-­‐
chip	  to	  determine	  cell	  death	  and	  proliferation	  respectively.	  	  These	  biochemical	  
markers	  were	  coupled	  with	  subjective	  assessment	  of	  histo-­‐architectural	  changes	  
following	  incubation	  within	  the	  micro	  fluidic	  device.	  	  
	   The	  second	  aim	  was	  to	  optimise	  the	  platform	  for	  studying	  chemotherapy	  
administration	  in	  HNSCC.	  	  This	  consisted	  of	  determining	  the	  most	  suitable	  doses	  of	  
chemotherapy	  agents	  to	  use	  on	  HNSCC	  within	  the	  micro	  fluidic	  system	  and	  assessing	  
tumour	  cell	  death	  in	  response	  to	  the	  addition	  of	  various	  chemotherapy	  agents,	  as	  
measured	  by	  LDH	  release.	  
	   Finally	  the	  thesis	  work	  evaluates	  the	  potential	  of	  the	  micro	  fluidic	  approach	  
for	  widespread	  clinical	  applicability,	  highlighting	  the	  key	  advantages,	  as	  well	  as	  the	  
hurdles,	  which	  remain	  to	  be	  overcome	  prior	  to	  implementation.	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2 Materials	  and	  Methods	  
	  
All	  chemicals	  and	  reagents	  were	  supplied	  from	  Sigma-­‐Aldrich	  Ltd,	  Dorset,	  UK	  
and	  were	  of	  tissue	  culture	  or	  molecular	  grade	  as	  appropriate	  unless	  otherwise	  
attributed.	  
2.1	  Obtaining	  Tissue	  for	  Use	  in	  Micro	  fluidic	  Devices	  
2.1.1	  Ethical	  Approval	  
	   Ethical	  approval	  was	  obtained	  from	  the	  Hull	  and	  East	  Yorkshire	  Ethics	  
Committee	  for	  the	  use	  of	  excess	  tissue	  from	  fresh	  surgical	  resections	  undertaken	  as	  
part	  of	  normal	  patient	  treatment	  for	  the	  study	  'Development	  of	  a	  prototype	  micro	  
fluidic	  device	  for	  the	  study	  of	  cell	  functions	  within	  a	  tissue	  environment’	  (LREC	  
07/H1304/105).	  	  This	  was	  also	  approved	  by	  the	  Hull	  and	  East	  Yorkshire	  NHS	  Trust	  
Research	  and	  Development	  Department	  (R0568).	  	  Any	  excess	  tissue	  could	  be	  used,	  
however	  no	  patient	  details	  were	  stored	  in	  association	  with	  the	  tissue;	  only	  the	  
tissue’s	  histological	  details,	  i.e.	  site	  and	  stage,	  were	  recorded.	  	  During	  the	  project,	  
ethical	  approval	  was	  then	  sought	  specifically	  for	  ‘The	  use	  of	  micro	  fluidic	  devices	  for	  
the	  evaluation	  of	  tumour	  biology	  and	  treatment	  response	  in	  head	  and	  neck	  cancer	  
biopsies	  and	  correlations	  with	  patient	  outcome’	  (LREC	  10/H1304/7;	  NHS	  Trust	  R&D	  
R0897).	  This	  enabled	  the	  recording	  of	  patient	  demographics	  and	  treatment	  plans	  to	  
be	  recorded	  allowing	  correlation	  between	  the	  in	  vitro	  findings	  and	  clinical	  
management.	  	  
2.1.2	  Patient	  Selection	  
Patients	  with	  known	  HNSCC,	  undergoing	  a	  primary	  resection	  with	  curative	  
intent	  of	  either	  their	  primary	  tumour	  or	  metastatic	  lymph	  nodes	  (with	  a	  prior	  
diagnosis	  of	  HNSCC	  at	  diagnostic	  biopsy)	  on	  the	  Ear,	  Nose	  and	  Throat	  ward	  at	  Castle	  
Hill	  Hospital,	  Hull	  and	  East	  Yorkshire	  NHS	  Trust	  were	  approached.	  	  For	  the	  tumours	  
used	  in	  sections	  3.1,	  3.2	  and	  3.3,	  the	  tissue	  was	  used	  anonymously.	  	  For	  tumour	  
studies	  in	  section	  3.4	  informed	  consent	  was	  obtained	  prior	  to	  theatre	  and	  an	  
information	  pack	  given	  (Appendix	  II).	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Although	  the	  patients	  were	  largely	  selected	  due	  to	  the	  timing	  of	  their	  
presentation	  for	  surgery,	  some	  patients	  (in	  section	  3.4	  only)	  were	  excluded	  due	  to	  
histopathological	  discrepancies.	  These	  were:	  
1)	  Ambiguous	  primary	  sites	  meaning	  that	  the	  principle	  site	  could	  not	  be	  
definitely	  identified	  
2)	  Unknown	  primary	  site	  
3)	  Non-­‐squamous	  cell	  carcinoma	  or	  mixed	  tumour	  histopathology	  and/or	  
4)	  A	  history	  of	  previous	  chemo	  or	  radiotherapy	  prior	  to	  the	  date	  of	  resection.	  
2.1.3	  Tissue	  Sampling	  
	   Once	  the	  tumour	  specimen	  had	  been	  removed,	  a	  biopsy	  measuring	  
approximately	  1-­‐5	  cm3	  	  (depending	  on	  availability)	  was	  dissected	  by	  the	  Consultant	  
head	  and	  neck	  surgeon	  (Professor	  N	  Stafford	  or	  Mr	  J	  Jose)	  under	  aseptic	  conditions.	  	  
Specimens	  were	  dissected	  from	  either	  or	  both	  the	  primary	  tumour	  and	  involved	  
lymph	  nodes,	  depending	  on	  the	  regional	  spread.	  	  At	  no	  time	  were	  specimens	  
dissected	  if	  it	  was	  felt	  that	  pathological	  staging	  would	  be	  affected.	  The	  head	  and	  
neck	  Consultant	  Histopathologist	  (Dr	  L	  Karsai)	  was	  advised	  of	  the	  removal	  of	  part	  of	  
the	  tumour	  for	  research	  purposes.	  	  
The	  biopsy	  was	  then	  placed	  into	  a	  sterile	  tube	  containing	  20	  ml	  of	  Dulbecco's	  
modiﬁed	  Eagle's	  medium,	  (DMEM,	  PAA	  Laboratories,	  Yeovil,	  Somerset,	  UK)	  
supplemented	  with	  10%	  (v/v)	  heat	  inactivated	  filtered	  (0.22	  µm	  filter,	  MilliporeTM,	  
Watford,	  UK)	  bovine	  serum,	  3%	  (w/v)	  4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	  
acid	  (HEPES	  buffer),	  1%	  (w/v)	  penicillin/streptomycin,	  1%	  (w/v)	  non-­‐essential	  amino	  
acids	  (PAA)	  and	  1%	  (w/v)	  glutamine	  and	  immediately	  transferred	  to	  the	  laboratory.	  
If	  fresh	  pieces	  of	  tumour	  were	  used	  in	  micro	  fluidic	  devices,	  the	  biopsy	  was	  
immediately	  prepared	  and	  placed	  in	  the	  primed	  devices	  as	  described	  below.	  	  For	  
frozen	  tumour	  studies	  or	  for	  any	  excess	  tumour	  from	  fresh	  studies,	  the	  tissue	  was	  
divided	  into	  1cm3	  pieces	  under	  aseptic	  conditions,	  wrapped	  in	  silver	  foil,	  snap	  frozen	  
in	  liquid	  nitrogen	  (-­‐196°C)	  within	  15	  minutes	  of	  tumour	  dissection	  in	  theatre,	  then	  
stored	  at	  -­‐80°C	  until	  required.	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2.2	  Device	  Fabrication	  	  
All	  of	  the	  glass	  micro	  devices	  used	  in	  this	  study	  were	  manufactured	  by	  Dr.	  S	  
Clark	  in	  the	  Department	  of	  Chemistry	  at	  the	  University	  of	  Hull,	  using	  a	  
photolithographic	  technique	  in	  accordance	  with	  published	  literature	  (McCreedy,	  
2001).	  Photolithography	  refers	  to	  the	  selective	  removal	  of	  parts	  of	  a	  thin	  film	  or	  the	  
bulk	  of	  a	  substrate,	  using	  light	  to	  transfer	  a	  geometric	  pattern	  from	  a	  photo	  mask	  to	  
a	  light-­‐sensitive	  chemical	  photo	  resist,	  or	  simply	  "resist",	  on	  the	  substrate.	  	  
To	  draw	  the	  required	  channel	  structure,	  AutoCAD	  LT	  software	  computer	  
assisted	  design	  (CAD)	  software	  package	  was	  used.	  The	  geometric	  channel	  pattern	  
outline	  was	  then	  transferred	  to	  a	  mask	  or	  thin	  film	  (the	  photo	  mask),	  leaving	  a	  blank	  
geometric	  pattern	  on	  a	  black	  background.	  	  This	  allows	  light	  to	  penetrate	  through	  the	  
mask	  in	  order	  to	  expose	  the	  channel	  design	  on	  the	  glass	  wafers	  (Telic,	  Valencia,	  US).	  	  
Glass	  wafers	  of	  1	  mm	  thickness	  coated	  with	  the	  chromium	  layer	  and	  a	  
photoresist	  layer	  were	  used	  as	  illustrated	  in	  Figure	  2.1.	  Exposure	  was	  achieved	  by	  
placing	  the	  mask	  on	  a	  ultra-­‐violet	  (UV)	  exposure	  unit	  with	  glass	  wafers	  placed	  on	  top	  
of	  the	  channel	  design,	  in	  a	  process	  known	  as	  	  ‘contact	  printing’,	  commonly	  used	  for	  
small	  volume	  production.	  The	  exposed	  glass	  wafer	  was	  then	  immersed	  in	  developer	  
solution	  (Chestech	  Ltd.,	  Rugby,	  Warickshire,	  UK)	  for	  60	  s,	  rinsed	  under	  running	  water	  
and	  then	  dried	  by	  nitrogen	  (N2)	  exposure.	  	  Following	  this,	  the	  glass	  wafer	  was	  
immersed	  in	  Chrome	  Etch	  MS8	  solution	  (Chestech)	  for	  60	  s,	  or	  until	  the	  pattern	  was	  
fully	  exposed	  on	  the	  glass.	  	  The	  plate	  was	  then	  rinsed	  with	  deionised	  water	  and	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Figure	  	  2.1	  	  Diagram	  of	  the	  photolithography	  and	  wet	  etching	  method	  of	  micro	  
fluidic	  chip	  fabrication	  
	  
The	  wet	  etching	  process	  then	  followed	  using	  hydrofluoric	  acid	  (48	  %	  v/v),	  
ammonium	  fluoride	  (40	  %	  v/v),	  hydrochloric	  acid	  (38	  %	  v/v)	  and	  deionised	  water.	  	  
Etching	  time	  was	  dependant	  on	  the	  depth	  of	  the	  channel	  required.	  For	  this	  study,	  
the	  channel	  dimensions	  were	  of	  190	  µm	  width	  and	  70	  µm	  depth	  (Figure	  2.2).	  The	  
depth	  was	  subsequently	  verified	  using	  light	  microscopy.	  	  Due	  to	  the	  nature	  of	  the	  
etching	  process,	  etching	  occurs	  both	  widthways	  as	  well	  as	  down-­‐wards,	  creating	  
channels	  with	  a	  trapezoidal	  shaped	  cross	  section.	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Figure	  2.2	  Schematic	  diagram	  of	  the	  etched	  base	  glass	  plate	  with	  a	  channel	  width	  of	  
190	  µm	  and	  depth	  of	  70	  µm.	  
	  
The	  glass	  beneath	  the	  photoresist	  and	  chrome	  layers	  was	  etched	  whilst	  the	  
top	  two	  layers	  remained	  intact.	  	  The	  photoresist	  layer	  was	  removed	  from	  the	  etched	  
plates	  by	  immersion	  in	  acetone	  for	  several	  minutes	  until	  all	  of	  the	  photoresist	  was	  
removed.	  The	  glass	  plates	  were	  then	  rinsed	  with	  water	  and	  dried	  with	  N2	  gas.	  To	  
remove	  the	  chrome	  plate,	  the	  plates	  were	  placed	  in	  the	  chromium	  etchant,	  Chrome	  
Etch	  MS8,	  for	  several	  minutes	  then	  removed	  and	  allowed	  to	  dry.	  At	  this	  stage,	  
access	  holes	  were	  drilled	  in	  the	  3	  mm	  thick	  top	  plate,	  using	  1.5	  mm	  drill	  bits	  by	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Figure	  2.3	  Schematic	  representation	  of	  the	  micro	  fluidic	  device	  used	  (Courtesy	  of	  S.	  
Hattersley)	  
	  
A	  central	  hole	  with	  a	  diameter	  of	  3mm	  was	  drilled	  into	  the	  top	  plate	  to	  
provide	  a	  chamber	  for	  the	  tissue.	  The	  tissue	  chamber	  is	  cylindrical	  with	  an	  internal	  
volume	  of	  21	  µl.	  The	  top	  plate	  with	  the	  drilled	  holes	  was	  then	  thermally	  bonded	  
onto	  the	  etched	  bottom	  plate	  in	  a	  furnace	  at	  590	  °C	  for	  3	  h.	  	  
A	  microport	  fitting	  (Anachem	  Ltd,	  Luton,	  Bedfordshire,	  UK)	  was	  finally	  
bonded	  to	  the	  surface	  of	  the	  top	  3	  mm	  glass	  layer	  (described	  in	  section	  2.3.2)	  so	  that	  
the	  circular	  tissue	  cavity	  could	  be	  sealed	  by	  way	  of	  an	  English	  threaded	  adapter	  
(Anachem).	  The	  adapter	  was	  filled	  with	  PDMS	  (Dow	  Corning	  Ltd,	  Barry,	  Vale	  of	  
Glamorgen,	  UK)	  to	  allow	  gaseous	  exchange	  to	  occur	  (Ng	  et	  al.,	  2002)	  as	  shown	  in	  
Figure	  2.4.	  	  The	  PDMS	  was	  made	  in	  accordance	  with	  manufacturer’s	  instructions	  
(Dow-­‐Corning	  and	  Information,	  2005);	  mixing	  1	  part	  curing	  agent	  to	  10	  parts	  base.	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Figure	  2.4	  Images	  of	  the	  micro	  fluidic	  devices	  a)	  with	  the	  threaded	  adapter	  along	  
side,	  b)	  top	  view	  of	  the	  PDMS	  threaded	  adaptor	  screwed	  into	  the	  microport	  fitting	  
and	  c)	  side	  view	  of	  b).	  
2.3	  	  The	  Micro	  fluidic	  System	  
2.3.1	  	  System	  Components	  
The	  micro	  fluidic	  system	  used	  during	  the	  study	  comprised	  of	  the	  glass	  device	  
(with	  microport	  and	  PDMS	  bung),	  Teflon®	  tubing,	  incubator	  and	  hydrodynamic	  
pumps.	  	  
A	  Harvard	  PhD	  2000	  syringe	  pump	  (Harvard	  Apparatus	  Ltd,	  Kent,	  UK)	  was	  
connected	  to	  the	  device	  via	  0.8	  mm	  ID	  x	  1.58	  OD	  TFE	  Teflon®	  (Sigma).	  The	  length	  of	  
the	  tubing	  from	  the	  20	  ml	  syringe	  (BDTM,	  UK)	  to	  the	  device	  was	  30	  cm	  and	  outlet	  
tubing	  was	  8	  cm	  long	  as	  shown	  in	  Figure	  2.5.	  A	  0.22	  µm	  filter	  (MilliporeTM)	  was	  fitted	  
between	  the	  syringe	  and	  the	  tubing	  to	  reduce	  the	  possibility	  of	  bacterial	  and	  
particulate	  contamination	  as	  well	  as	  minimising	  the	  occurrence	  of	  bubbles	  into	  the	  
device.	  To	  connect	  the	  tubing	  to	  the	  filter,	  a	  3-­‐part	  adaptor	  (Upchurch	  Scientific,	  
a)	   b)	  
c)	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WA,	  US)	  was	  used.	  	  For	  overnight	  effluent	  collection,	  a	  1.5	  ml	  polypropylene	  
centrifuge	  tube,	  with	  a	  hole	  in	  the	  lid	  covered	  with	  parafilm	  to	  stop	  contamination	  
and	  leakage,	  was	  placed	  on	  the	  end	  of	  each	  outlet	  tubing	  to	  collect	  effluent.	  	  For	  2	  
hourly	  sample	  collections,	  a	  0.5	  ml	  tube	  was	  used	  (Figure	  2.5b).	  The	  micro	  fluidic	  
devices	  attached	  to	  outlet	  tubing	  and	  collection	  tubes	  plus	  the	  majority	  of	  the	  inlet	  
tubing	  was	  placed	  in	  warm	  air	  box,	  maintained	  at	  37°C	  (Figure	  2.5a).	  
2.3.2	  	  Device	  Assembly	  and	  Priming	  	  	  
Before	  use,	  the	  glass	  microchips,	  tubing,	  3-­‐part	  adaptor	  and	  microport	  
adaptor	  were	  autoclaved	  at	  121°C	  for	  20	  minutes.	  	  Once	  sterilised,	  the	  microport	  
adaptor	  was	  bonded	  to	  the	  glass	  chip	  using	  Araldite®	  Precision	  Adhesive	  (Huntsman	  
Advanced	  Materials,	  Basel,	  Switzerland)	  and	  allowed	  to	  set	  at	  60°C	  for	  4	  hours.	  	  
Similarly,	  the	  cut	  end	  of	  a	  200	  µl	  pipette	  tip	  was	  bonded	  to	  one	  end	  of	  the	  inlet	  and	  
outlet	  tubing	  lengths.	  	  Once	  assembled	  as	  shown	  in	  Fig.	  2.5,	  the	  system	  was	  primed	  
with	  70%	  (v/v)	  ethanol/water,	  pumped	  through	  the	  device	  for	  15	  minutes	  at	  10	  µl	  
min-­‐1	  followed	  by	  a	  rinse	  with	  autoclaved,	  distilled	  water	  for	  15	  minutes	  at	  10	  µl	  min-­‐
1.	  Following	  this,	  the	  standard	  supplemented	  media	  as	  described	  in	  section	  2.1.3	  was	  
pumped	  through	  the	  system	  for	  a	  minimum	  of	  30	  minutes	  at	  5µl	  min-­‐1.	  
	  The	  tumour,	  either	  fresh	  or	  if	  frozen,	  allowed	  to	  defrost	  for	  2	  minutes,	  was	  
cut	  into	  approximately	  4	  mm3	  slices	  and	  individually	  weighed	  in	  aseptic	  conditions.	  	  
The	  weight	  of	  each	  slice	  was	  recorded	  with	  a	  weight	  of	  approximately	  5-­‐10	  mg	  being	  
aimed	  for.	  	  The	  tumour	  was	  then	  placed	  in	  the	  central	  well	  of	  the	  glass	  micro	  fluidic	  
device	  under	  aseptic	  conditions.
	  	  
	  
Figure	  2.5	  Components	  of	  the	  micro	  fluidic	  system,	  a),b)	  hydrodynamic	  pump,	  syringe,	  filter,	  3	  part	  adaptor,	  tubing	  and	  incubators,	  c)	  
syringe,	  filter	  and	  tubing	  attached	  to	  device	  with	  outlet	  tubing	  and	  collecting	  tubes,	  d)	  4	  micro	  fluidic	  devices	  within	  the	  incubator.
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2.3.3	  	  Effluent	  Collection	  
Once	  the	  tumour	  was	  placed	  within	  the	  central	  well,	  the	  flow	  rate	  of	  media	  
was	  reduced	  to	  2	  µl	  min-­‐1.	  	  The	  effluent	  collected	  over	  the	  first	  hour	  was	  collected	  
and	  after	  this,	  effluent	  was	  collected	  in	  2	  hourly	  aliquots,	  each	  of	  240	  µl	  for	  up	  to	  9	  
days.	  
2.4	  Materials	  
2.4.1	  	  Chemotherapy	  Agents	  
All	  drug	  preparation	  was	  carried	  out	  in	  aseptic	  conditions	  prior	  to	  addition	  to	  
the	  standard	  supplemented	  culture	  media	  described	  in	  section	  2.1.3.	  	  
Chemotherapy	  agents	  were	  added	  to	  the	  micro	  fluidic	  system	  via	  the	  buffer	  inlet	  
following	  a	  22	  h	  incubation	  period	  with	  culture	  media	  alone	  when	  used.	  
2.4.1.1	  	  Cisplatin	  
Cisplatin	  (TEVA,	  Castleford,	  West	  Yorkshire,	  UK)	  1mg/ml	  solution	  for	  
intravenous	  injection	  was	  used.	  Cisplatin	  concentrations	  of	  1	  µg/ml	  -­‐	  25	  µg/ml	  were	  
studied.	  	  	  
2.4.1.2	  	  5-­‐Fluorouracil	  
5-­‐Fluorouracil	  (5FU,	  Mayne	  Pharma	  Plc,	  Melbourne,	  Australia)	  25	  mg/ml	  
solution	  for	  venous	  injection	  was	  used.	  	  A	  1	  in	  100	  dilution	  was	  prepared	  by	  adding	  
50	  µl	  5FU	  to	  5	  ml	  phosphate	  buffered	  saline	  (10	  mM	  phosphate,	  150	  mM	  sodium	  
chloride,	  pH	  7.2	  to	  7.3,	  Invitrogen	  Ltd,	  Paisley	  UK).	  5FU	  concentrations	  of	  1	  µg/ml	  -­‐	  
25	  µg/ml	  were	  studied.	  	  
2.4.1.3	  	  Docetaxel	  
Docetaxel	  (Taxotere®,	  Sanofi-­‐Aventis,	  Guildford,	  Surrey,	  UK)	  80	  mg	  in	  2	  ml	  
solution	  for	  intravenous	  injection	  was	  used.	  The	  diluent	  13%	  (v/v)	  ethanol	  in	  water	  
for	  injection	  was	  added	  (fill	  range	  6.96	  –	  7.70	  ml)	  to	  give	  a	  final	  concentration	  of	  10	  
mg/ml	  as	  per	  manufacturer’s	  instructions.	  Docetaxel	  concentrations	  of	  1.5	  µg/ml	  -­‐
37.5	  µg/ml	  were	  studied.	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2.4.2	  	  Cell	  Death	  Analysis	  
To	  analyse	  cell	  death	  occurring	  within	  the	  tumour	  biopsy,	  the	  excretion	  of	  
lactate	  dehydrogenase	  (LDH)	  into	  the	  effluent	  was	  quantified	  using	  a	  colorimetric	  
cytotoxicity	  assay	  (Cytotoxicity	  Detection	  Kit	  Plus,	  Roche	  Diagnostics,	  Burgess	  Hill,	  
West	  Sussex,	  UK).	  LDH	  is	  a	  stable	  cytoplasmic	  enzyme	  present	  in	  all	  somatic	  cells	  
(Voet	  and	  Voet,	  2004).	  In	  vivo,	  LDH	  catalyzes	  the	  inter-­‐conversion	  of	  pyruvate	  and	  
lactate	  with	  concomitant	  inter-­‐conversion	  of	  nicotinamide	  adenine	  dinucleotide	  
(NAD)	  and	  NADH	  +.	  It	  converts	  pyruvate,	  the	  final	  product	  of	  glycolysis	  to	  lactate	  
when	  oxygen	  is	  absent	  or	  in	  short	  supply,	  and	  it	  performs	  the	  reverse	  reaction	  
during	  the	  Cori	  cycle	  in	  the	  liver	  (Voet	  and	  Voet,	  2004).	  It	  is	  rapidly	  released	  into	  the	  
cell	  culture	  supernatant,	  i.e.	  effluent,	  when	  the	  plasma	  membrane	  is	  damaged	  and	  
can	  therefore	  be	  used	  as	  a	  marker	  of	  cell	  death.	  	  
Using	  this	  assay,	  LDH	  activity	  is	  determined	  by	  a	  coupled	  enzymatic	  reaction	  
whereby	  LDH	  firstly	  catalyzes	  the	  inter-­‐conversion	  of	  pyruvate	  and	  lactate	  with	  
concomitant	  inter-­‐conversion	  of	  nicotinamide	  adenine	  dinucleotide	  (NAD+)	  and	  
NADH	  (Figure	  2.6).	  Secondly,	  the	  tetrazolium	  salt	  Iodotetrazolium	  chloride	  (INT)	  is	  
reduced	  to	  formazan	  by	  the	  transfer	  of	  2	  hydrogen	  ions	  and	  the	  actions	  of	  the	  
catalyst	  (Fig.	  2.6).	  The	  increase	  in	  the	  amount	  of	  enzyme	  activity	  in	  the	  effluent	  
directly	  correlates	  to	  the	  amount	  of	  formazan	  formed	  during	  a	  limited	  time	  period.	  	  
The	  formazan	  dye	  formed	  is	  water-­‐soluble	  and	  shows	  a	  broad	  absorption	  maximum	  
at	  approximately	  500	  nm.	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Figure	  2.6	  Diagram	  showing	  the	  assay	  of	  released	  LDH.	  In	  the	  first	  step,	  LDH	  reduces	  
NAD+	  to	  NADH+/H+	  by	  oxidizing	  lactate	  to	  pyruvate.	  In	  the	  second	  enzymatic	  reaction	  
2	  hydrogens	  are	  transferred	  from	  NADH+/H+	  to	  the	  yellow	  tetrazolium	  salt	  INT	  (2-­‐[4-­‐
iodophenyl]-­‐3-­‐[4	  nitrophenyl]-­‐5-­‐phenyltetrazolium	  chloride)	  by	  a	  catalyst.	  
The	  assay	  was	  carried	  out	  according	  to	  the	  manufacturer’s	  protocol;	  50	  µl	  of	  
‘reaction	  mixture’	  (lyophilizate,	  stabilized	  Diaphorase/NAD+	  mixture	  with	  INT	  and	  
sodium	  lactate)	  was	  added	  to	  50	  µl	  tumour	  effluent	  per	  well	  in	  duplicate	  for	  each	  
aliquot.	  Following	  incubation	  at	  37	  °C	  for	  30	  minutes	  and	  then	  the	  addition	  of	  25	  µl	  
of	  ‘stop’	  solution	  (1M	  Hydrochloric	  acid	  to	  stop	  the	  LDH	  reaction	  as	  per	  
manufacturer’s	  protocol),	  the	  absorbance	  of	  the	  samples	  was	  determined	  at	  492	  nm	  
with	  a	  reference	  of	  620	  nm	  (to	  allow	  for	  plate	  differences	  and	  imperfections).	  The	  
absorbance	  blank	  was	  set	  on	  the	  relevant	  media.	  The	  results	  are	  expressed	  as	  an	  
average	  determined	  from	  duplicate	  samples	  and	  expressed	  per	  µg	  of	  tumour	  tissue	  
used	  in	  each	  micro	  fluidic	  device.	  An	  example	  of	  the	  calculations	  is	  shown	  below:	  
	   Sample	  1	   Sample	  2	   Total	   Average	   Control	   Minus	  Control	   Biopsy	  (mg)	   Per	  mg	   Per	  ug	  
1	   3.219	   3.223	   3.221	   3.221	   0.9215	   2.2995	   3.6	   0.63875	   638.75	  
2	   1.55	   1.479	   3.029	   1.5145	   0.9215	   0.593	   3.6	   0.16472	   164.72	  
3	   1.698	   1.612	   3.31	   1.655	   0.9215	   0.7335	   3.6	   0.20375	   203.75	  
4	   1.093	   1.114	   2.207	   1.1035	   0.9215	   0.182	   3.6	   0.05055	   50.55	  
Table	  2.7	  Example	  of	  calculations	  of	  LDH	  activity	  for	  individual	  aliquots	  
2.4.3	  	  Cell	  Viability	  Analysis	  
To	  analyse	  cell	  viability,	  a	  colorimetric	  cell	  proliferation	  assay	  using	  a	  water	  
soluble	  tetrazolium	  salt,	  4-­‐[3-­‐[4	  -­‐	  lodophenyl]	  -­‐	  2	  -­‐	  4	  (4-­‐nitrophenyl)-­‐	  2H-­‐	  5-­‐
tetrazolio-­‐1,	  3-­‐benzene	  disulfonate	  (WST-­‐1)	  (Roche)	  was	  carried	  out.	  When	  added	  to	  
the	  culture	  medium,	  the	  stable	  tetrazolium	  salt	  WST-­‐1	  is	  cleaved	  to	  a	  soluble	  
formazan	  by	  a	  cellular	  mechanism	  that	  occurs	  primarily	  at	  the	  cell	  surface	  (Berridge	  
et	  al.,	  2005).	  This	  bioreduction	  is	  largely	  dependent	  on	  the	  glycolytic	  production	  of	  
NAD(P)H	  in	  viable	  cells	  (Figure	  2.7).	  WST-­‐1	  is	  a	  chromogenic	  indicator	  for	  the	  cell’s	  
bio-­‐reducibility	  in	  viability	  assays	  as	  the	  amount	  of	  formazan	  dye	  present	  in	  the	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effluent	  directly	  correlates	  to	  the	  number	  of	  metabolically	  active	  cells	  present	  in	  the	  
culture	  system	  (Roche,	  2007).	  	  	  
	  
Figure	  2.7	  Diagram	  showing	  the	  conversion	  of	  the	  tetrazolium	  salt,	  WST-­‐1,	  to	  
formazan	  which	  occurs	  in	  viable	  cells.	  EC;	  electron	  coupling	  reagent,	  RS;	  
mitochondrial	  succinate-­‐tetrazolium-­‐reductase	  system.	  
In	  viability	  studies,	  10%	  v/v	  WST-­‐1	  was	  used	  and	  added	  to	  the	  culture	  media	  
at	  18	  h	  of	  incubation.	  The	  assay	  consisted	  of	  a	  direct	  colourimetric	  analysis;	  100	  µl	  
effluent	  was	  added	  to	  each	  well	  in	  duplicate	  for	  each	  aliquot	  and	  absorbance	  was	  
measured	  at	  450	  nm	  with	  a	  reference	  of	  620nm.	  The	  absorbance	  blank	  was	  set	  on	  
the	  relevant	  media.	  The	  results	  are	  again	  expressed	  per	  µg	  of	  tumour	  tissue	  used	  in	  
each	  micro	  fluidic	  device.	  	  
WST-­‐1	  has	  several	  advantages	  over	  other	  tetrazolium	  salts	  such	  as	  3-­‐(4,5-­‐
Dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyltetrazolium	  bromide,	  (MTT)	  and	  2,3-­‐bis-­‐(2-­‐
methoxy-­‐4-­‐nitro-­‐5-­‐sulfophenyl)-­‐2H-­‐tetrazolium-­‐5-­‐carboxanilide	  (XTT).	  In	  contrast	  to	  
MTT,	  which	  is	  cleaved	  to	  water-­‐insoluble	  formazan	  crystal	  and	  therefore	  has	  to	  be	  
solubilised	  after	  cleavage,	  WST-­‐1	  yields	  water-­‐soluble	  cleavage	  products	  that	  can	  be	  
measured	  without	  an	  additional	  solubilisation	  step	  (Berridge	  et	  al.,	  2005).	  In	  
contrast	  to	  XTT,	  WST-­‐1	  is	  more	  stable	  and	  can	  therefore	  be	  used	  as	  a	  ready-­‐to-­‐use	  
solution.	  It	  should	  be	  noted	  that	  LDH	  and	  WST-­‐1	  based	  redox	  reactions	  are	  
tetrazolium	  salt	  specific.	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2.4.4	  	  Histo-­‐architectural	  Analysis	  
To	  visualize	  cell	  architecture	  within	  the	  tissue,	  fresh	  frozen	  sectioning	  and	  
haematoxylin	  and	  eosin	  (H&E)	  staining	  was	  carried	  out	  on	  tumour	  prior	  to,	  and	  
following	  incubation	  within	  the	  micro	  fluidic	  device	  at	  2	  and	  4	  days.	  H&E	  staining	  is	  
commonly	  used	  to	  differentiate	  tumour	  from	  normal	  tissue	  (Bancroft	  and	  Stevens,	  
1996).	  	  Haematoxylin,	  a	  basic	  dye,	  is	  principally	  employed	  to	  demonstrate	  nuclear	  
structures,	  through	  a	  blue-­‐black	  staining.	  Eosin,	  an	  acidic	  dye,	  has	  affinity	  for	  
positively	  charged	  structures	  such	  as	  mitochondria,	  staining	  these	  areas	  pink	  or	  
orange	  (Young	  et	  al.,	  2000).	  	  
The	  tumour	  biopsy	  (5-­‐10	  mg,	  approx	  4mm3)	  was	  first	  embedded	  and	  covered	  
with	  Tissue-­‐Tek®	  (Sakura,	  Netherlands)	  on	  a	  2	  cm	  x	  2	  cm	  cork	  tile	  before	  immediate	  
immersion	  in	  a	  liquid	  nitrogen	  cooled	  2-­‐methyl	  butane	  solution.	  	  Samples	  were	  then	  
stored	  at	  -­‐20	  °C	  before	  sectioning	  and	  staining.	  Tissue	  sections	  of	  12	  µm	  thickness	  
were	  prepared	  using	  a	  Microm	  HM505E	  cryostat	  and	  dry	  mounted	  on	  microscope	  
slides	  (Colorfrost	  Plus®,	  Thermo	  Shandon	  Ltd,	  Runcorn,	  Cheshire,	  UK)	  which	  could	  
then	  be	  stored	  again	  at	  -­‐20	  °C	  until	  staining.	  	  	  
H&E	  staining	  was	  performed	  in	  accordance	  with	  published	  protocol	  (Bancroft	  
and	  Stevens,	  1996).	  	  Sections	  from	  the	  edge,	  centre	  and	  ‘intermediate’	  area	  of	  the	  
tumour	  were	  selected	  for	  staining	  and	  allowed	  to	  air	  dry	  at	  room	  temperature	  for	  10	  
minutes.	  The	  sections	  were	  then	  fixed	  with	  10%	  (v/v)	  formalin	  for	  10	  minutes,	  
stained	  with	  Delafield’s	  Haematoxylin	  for	  3	  minutes	  before	  rinsing	  with	  running	  cold	  
tap	  water.	  	  After	  rinsing	  for	  10	  minutes	  the	  tissue	  was	  dehydrated	  with	  sequentially	  
higher	  concentrations	  of	  25%,	  50%,	  75%,	  85%	  and	  95%	  (v/v)	  ethanol	  over	  8	  minutes.	  
The	  tissue	  was	  then	  stained	  with	  100%	  eosin	  for	  1	  minute	  before	  being	  quickly	  
dipped	  in	  95%	  (v/v)	  and	  then	  absolute	  ethanol.	  	  The	  tissue	  was	  finally	  placed	  in	  
Histo-­‐clear	  (Fisher-­‐Scientific,	  Loughborough,	  Leicestershire,	  UK)	  for	  five	  minutes	  to	  
remove	  any	  excess	  stain	  and	  non-­‐specific	  stain	  and	  then	  mounted	  using	  
Histomount	  (National	  Diagnostics,	  Hull,	  East	  Yorkshire,	  UK)	  using	  a	  coverslip	  and	  
allowed	  to	  dry	  for	  24	  hrs	  at	  room	  temperature.	  	  The	  tissue	  was	  imaged	  by	  light	  
microscopy	  and	  photographed.	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3.0	  	  Results	  
3.1	  	  Optimisation	  Studies	  
3.1.1	  	  Aims	  
	  
• To	  determine	  the	  stability	  of	  LDH	  in	  the	  effluent	  when	  stored	  prior	  to	  
analysis	  
• To	  assess	  cell	  death	  within	  HNSCC	  biopsies	  over	  a	  4	  day	  period	  of	  incubation	  
using	  analysis	  of	  LDH	  in	  the	  tumour	  effluent	  
• To	  assess	  cell	  viability	  within	  HNSCC	  biopsies	  over	  a	  4	  day	  period	  using	  
metabolism	  of	  the	  cell	  proliferation	  agent	  WST-­‐1	  
• To	  detect	  the	  presence	  of	  any	  bacterial	  contamination	  in	  the	  tumour	  effluent	  	  
3.1.2	  	  Introduction	  
The	  various	  methods	  of	  tissue	  culture	  have	  been	  outlined	  in	  section	  1.8	  and	  
in	  particular,	  the	  current	  limitations	  of	  whole	  tissue	  culture	  techniques	  have	  been	  
discussed.	  	  The	  relatively	  short-­‐lived	  tissue	  viability	  seen	  in	  organ	  cultures	  and	  
tumour	  spheroids	  has	  been	  demonstrated	  using	  various	  markers	  of	  cell	  death	  for	  
example	  lactate	  accumulation,	  DNA	  strand	  breaks	  associated	  with	  apoptosis	  and	  
necrosis	  and	  changes	  in	  glucose	  and	  adenosine	  triphosphate	  (ATP)	  distribution	  
(Hirschhaeuser	  et	  al.,	  2010).	  	  The	  majority	  of	  these	  indices	  require	  termination	  of	  
incubation	  for	  analysis.	  However,	  one	  of	  the	  major	  advantages	  of	  the	  micro	  fluidic	  
perfusion	  technique	  is	  the	  constant	  removal	  of	  metabolic	  waste	  and	  the	  ability	  to	  
collect	  aliquots	  of	  this	  waste	  for	  analysis	  at	  time	  intervals	  with	  no	  detriment	  to	  the	  
tissue	  biopsy.	  	  
As	  described	  in	  section	  2.4.2,	  LDH	  is	  a	  stable	  cytoplasmic	  enzyme	  that	  is	  
rapidly	  released	  when	  the	  plasma	  membrane	  is	  damaged.	  	  It	  would	  therefore	  be	  
expected	  to	  be	  rapidly	  detected	  in	  the	  tumour	  effluent	  after	  deliberate	  tissue	  insult	  
or	  to	  be	  gradually	  excreted	  over	  time,	  proportional	  to	  the	  number	  of	  dying	  cells.	  	  
The	  production	  of	  LDH	  and	  its	  presence	  in	  tissue	  effluent	  using	  a	  micro	  fluidic	  
culture	  method	  has	  been	  used	  previously	  to	  evaluate	  cell	  death	  within	  rat	  liver	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biopsies	  (Hattersley	  et	  al.,	  2008,	  van	  Midwoud	  et	  al.,	  2010a)	  rat	  heart	  tissue	  (Cheah	  
et	  al.,	  2010)	  and	  human	  colorectal	  tumour	  biopsies	  (Webster	  et	  al.,	  2010).	  	  The	  
induction	  of	  LDH	  excretion	  by	  use	  of	  lysis	  buffer	  to	  deliberately	  rupture	  the	  plasma	  
membrane	  of	  viable	  cells	  at	  the	  end	  of	  an	  incubation	  period	  can	  be	  used	  both	  to	  
demonstrate	  the	  tissue	  viability	  as	  indicated	  by	  the	  magnitude	  of	  LDH	  response	  after	  
addition	  of	  detergent	  to	  the	  system	  and	  secondly,	  when	  added	  throughout	  the	  
incubation	  process,	  to	  provide	  comparative	  levels	  attributable	  to	  maximal	  tissue	  
death.	  
Similarly,	  the	  cell	  proliferation	  agent	  WST-­‐1	  is	  a	  water-­‐soluble	  salt	  that	  can	  
be	  analysed	  in	  the	  tumour	  effluent	  rather	  than	  requiring	  destructive	  intra-­‐cellular	  
extraction.	  The	  use	  of	  lysis	  buffer,	  as	  in	  the	  LDH	  studies	  can	  be	  applied	  to	  cause	  loss	  
of	  viability,	  demonstrated	  by	  the	  marked	  reduction	  in	  WST-­‐1	  metabolism	  on	  its	  
addition.	  Correlating	  LDH	  and	  WST-­‐1	  data	  was	  expected	  to	  show	  an	  inverse	  
relationship	  
As	  the	  aliquots	  of	  tumour	  effluent	  were	  stored	  at	  +2	  to	  +8°C	  for	  up	  to	  9	  days	  
prior	  to	  assay,	  the	  stability	  of	  LDH	  over	  time	  needs	  to	  be	  assessed	  first.	  	  The	  LDH	  
assay	  product	  literature	  advised	  that	  ‘the	  cell-­‐free	  culture	  supernatant	  can	  be	  stored	  
at	  +2to	  +8°C	  for	  a	  few	  days	  without	  loss	  of	  LDH	  activity’	  however	  it	  was	  necessary	  to	  
ensure	  that	  the	  LDH	  activity	  when	  assayed	  was	  representative	  of	  the	  true	  tumour	  
effluent	  at	  the	  time	  of	  collection.	  	  Once	  the	  stability	  of	  LDH	  over	  time	  had	  been	  
determined,	  the	  viability	  of	  tumour	  biopsies	  over	  a	  4-­‐day	  period	  was	  ascertained	  
using	  LDH	  and	  WST-­‐1	  assays	  of	  the	  tumour	  effluent.	  
Although	  great	  care	  was	  taken	  to	  avoid	  any	  potential	  bacterial	  contamination	  
within	  the	  system,	  there	  was	  always	  a	  risk	  of	  infection,	  either	  due	  to	  the	  tumour	  
itself	  or	  during	  incubation.	  	  This	  could	  potentially	  confound	  the	  results	  as	  some	  or	  
part	  of	  the	  production	  of	  LDH	  or	  metabolism	  of	  WST-­‐1	  could	  be	  attributed	  to	  
bacteria.	  	  To	  demonstrate	  the	  absence	  of	  bacteria	  within	  the	  micro	  fluidic	  system,	  
final	  aliquots	  of	  culture	  media	  were	  plated	  on	  nutrient	  agar	  and	  examined	  after	  
incubation.	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3.1.3	  	  Materials	  and	  methods	  
Tissue	  samples	  were	  taken	  from	  those	  patients	  undergoing	  curative	  
resection	  of	  their	  primary	  tumour	  or	  metastatic	  lymph	  nodes	  for	  proven	  HNSCC	  at	  
Castle	  Hill	  Hospital	  after	  informed	  consent	  had	  been	  gained	  as	  described	  in	  section	  
2.1.2.	  Samples	  were	  processed	  as	  described	  in	  section	  2.1.3	  and	  incubated	  within	  
the	  micro	  fluidic	  device	  as	  described	  with	  the	  addition	  of	  10%	  v/v	  WST-­‐1	  or	  10%	  v/v	  
lysis	  buffer	  to	  the	  culture	  media	  as	  appropriate.	  	  Lysis	  buffer	  (10%	  v/v)	  was	  added	  at	  
the	  end	  of	  the	  incubation	  period	  (68	  h)	  except	  in	  those	  studies	  when	  it	  was	  used	  
continually	  from	  the	  start	  of	  the	  incubation	  period.	  
To	  determine	  the	  stability	  of	  LDH	  activity	  within	  the	  tumour	  effluent,	  fluid	  
was	  collected	  from	  1	  to	  10	  h	  of	  incubation,	  assayed	  at	  the	  time	  of	  collection,	  stored	  
at	  +2to	  +8°C	  for	  up	  to	  8	  days	  and	  repeatedly	  assayed	  every	  48	  h.	  
For	  the	  identification	  of	  the	  presence	  of	  any	  bacteria	  in	  the	  tumour	  effluent,	  
samples	  of	  effluent	  were	  plated	  on	  nutrient	  agar	  and	  incubated	  for	  48	  h	  days	  at	  
37°C.	  
3.1.4	  	  Results	  
A	  total	  of	  9	  different	  fresh	  tumours	  were	  used	  for	  optimisation	  studies:	  with	  
8	  chips	  run,	  on	  average,	  per	  tumour	  sample,	  for	  up	  to	  4	  days	  duration.	  The	  numbers	  
of	  chips	  per	  experiment	  for	  each	  variable	  i.e.	  LDH	  analysis,	  WST-­‐1	  analysis	  or	  
addition	  of	  lysis	  buffer,	  and	  the	  sub-­‐site	  of	  the	  tumour	  used	  is	  summarised	  in	  Table	  
3.1.	  	  Also	  represented	  is	  the	  number	  of	  ‘successful’	  chips.	  	  This	  refers	  to	  the	  number	  
of	  chips	  in	  which	  the	  buffer	  flowed	  without	  blockages	  over	  the	  4-­‐day	  incubation	  
period.	  An	  unsuccessful	  chip	  is	  one	  that	  blocks	  during	  the	  experiments	  or	  had	  
insufficient	  media	  in-­‐flow	  for	  longer	  than	  a	  10	  minute	  period.	  	  Data	  from	  any	  
‘unsuccessful’	  chip	  was	  excluded	  from	  the	  final	  analysis.	  
	  
	  














1	   Larynx	   3	   2	   2	   1	   2	   1	  
2	   Larynx	   3	   2	   2	   1	   2	   1	  
3	   Larynx	   3	   2	   3	   2	   2	   0	  
4	   Oropharynx	   3	   0	   3	   0	   2	   0	  
5	   Hypopharynx	   3	   0	   3	   0	   3	   0	  
6	   Node	   3	   1	   2	   1	   2	   1	  
7	   Node	   3	   1	   3	   1	   2	   1	  
8	   Node	   3	   3	   2	   0	   2	   0	  
9	   Node	   3	   0	   2	   1	   2	   1	  
Total	   	   27	   11	  (41%)	   22	  	   7	  (32%)	   19	   5	  (26%)	  
Table	  3.1	  Summary	  of	  number	  of	  experiments,	  tumour	  sub	  sites	  and	  successful	  chips	  run	  for	  optimisation	  studies	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3.1.4.1	  	  Stability	  of	  LDH	  
	   Tumour	  effluent	  (from	  4	  independent	  tumours)	  collected	  between	  1	  and	  10	  
h	  incubation	  was	  assayed	  in	  duplicates	  for	  LDH	  activity	  over	  8	  days	  and	  the	  results	  
demonstrated	  in	  figure	  3.1.	  	  The	  percentage	  change	  in	  absorbance	  is	  also	  shown;	  the	  
average	  change	  being	  4.1%	  from	  day	  0	  compared	  with	  day	  8.	  As	  maintenance	  of	  LDH	  
activity	  was	  observed,	  samples	  could	  be	  stored	  prior	  to	  analysis	  at	  the	  end	  of	  each	  
experiment.	  
	  	  
Figure	  3.1	  Graph	  to	  show	  the	  stability	  of	  LDH	  activity	  within	  tumour	  effluent	  over	  8	  
days.	  Four	  different	  tumour	  samples	  are	  represented,	  each	  point	  representing	  the	  
mean	  of	  a	  duplicate	  well,	  with	  the	  LDH	  calculated	  per	  piece	  of	  tissue	  (not	  
standardised	  for	  weight)	  Percentage	  change	  from	  day	  0	  to	  8	  is	  shown	  for	  each	  
sample.	  
3.1.4.2	  	  Cell	  Death	  Analysis	  
The	  cumulative	  results	  of	  LDH	  release	  for	  11	  chips	  from	  6	  different	  tumours	  
are	  shown	  in	  Figure	  3.2.	  LDH	  is	  high	  in	  the	  tumour	  effluent	  after	  the	  1st	  hour	  of	  
incubation.	  This	  then	  falls	  over	  the	  next	  2	  h,	  remaining	  at	  a	  stable,	  minimal,	  level	  
over	  subsequent	  hours	  until	  the	  addition	  of	  lysis	  buffer	  to	  the	  system	  at	  68	  h	  giving	  
the	  anticipated	  increase	  in	  LDH	  release.	  
The	  results	  of	  adding	  10%	  (v/v)	  lysis	  buffer	  throughout	  the	  whole	  incubation	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initial	  LDH	  peak	  at	  1-­‐3	  h	  incubation,	  levels	  of	  LDH	  fell	  but	  remained	  at	  a	  higher	  level	  
than	  without	  the	  addition	  of	  lysis	  buffer	  throughout	  the	  period	  the	  incubation.	  	  
Levels	  averaged	  116.1	  a.u.	  when	  lysis	  buffer	  was	  added,	  compared	  with	  62.7	  a.u.	  
without	  between	  20-­‐26	  h.	  Similarly,	  between	  44-­‐50	  h,	  LDH	  levels	  averaged	  93.6	  
when	  lysis	  buffer	  was	  present,	  compared	  with	  57.3	  without.	  There	  was	  also	  no	  




Figure	  3.2	  Graph	  depicting	  the	  pattern	  of	  LDH	  release	  per	  µg	  of	  tissue	  over	  74	  h	  
incubation	  of	  fresh	  tumour	  biopsies	  (n=11	  chips	  from	  n=6	  tumours)	  with	  addition	  of	  
10%(	  v/v)	  lysis	  buffer	  at	  68	  h.	  Continuous	  line	  indicates	  LDH	  release	  as	  a	  mean	  of	  
replicate	  experiments.	  Breaks	  in	  lines	  signify	  periods	  where	  samples	  were	  not	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Figure	  3.3	  Graph	  depicting	  the	  pattern	  of	  LDH	  release	  per	  µg	  of	  tissue	  over	  74	  h	  
incubation	  of	  fresh	  tumour	  biopsies	  (n=5	  chips	  from	  n=5	  tumours)	  with	  addition	  of	  
10%	  (v/v)	  lysis	  buffer	  throughout	  incubation.	  Continuous	  line	  indicates	  LDH	  release	  
as	  a	  mean	  of	  replicate	  experiments.	  Breaks	  in	  lines	  signify	  periods	  where	  samples	  
were	  not	  collected.	  	  Error	  bars	  show	  standard	  deviation.	  
3.1.4.3	  	  Cell	  Viability	  Analysis	  
The	  cumulative	  results	  for	  WST-­‐1	  metabolism	  for	  7	  chips	  from	  6	  different	  
tumours	  are	  shown	  in	  Figure	  3.4.	  	  Two	  hours	  after	  the	  addition	  of	  WST-­‐1,	  the	  
presence	  of	  the	  metabolised	  salt	  in	  the	  tumour	  effluent	  can	  be	  seen	  to	  increase,	  
with	  a	  maximum	  occurring	  in	  the	  second	  day	  following	  addition.	  	  The	  relatively	  high	  
levels	  are	  maintained	  until	  the	  addition	  of	  10%	  (v/v)	  lysis	  buffer	  at	  68	  h,	  which	  
results	  in	  a	  reduction	  in	  its	  presence	  to	  minimal	  levels.	  	  The	  relatively	  large	  variation	  
in	  results	  most	  probably	  reflects	  the	  inherent	  variability	  in	  metabolic	  activity	  of	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Figure	  3.4	  Graph	  depicting	  the	  pattern	  of	  WST-­‐1	  detection	  per	  µg	  of	  tissue	  over	  74	  h	  
incubation	  of	  fresh	  tumour	  biopsies	  (n=7	  chips	  from	  n=6	  tumours)	  with	  addition	  of	  
10%	  (v/v)	  lysis	  buffer	  at	  68	  h	  incubation.	  Continuous	  line	  indicates	  WST-­‐1	  release	  as	  
a	  mean	  of	  replicate	  experiments.	  Breaks	  in	  lines	  signify	  periods	  where	  samples	  were	  
not	  collected.	  	  Error	  bars	  show	  standard	  deviation.	  
3.1.4.4	  	  Assessment	  of	  Bacterial	  Contamination	  
	   Final	  aliquots	  of	  tumour	  effluent	  from	  2	  chips	  from	  experiments	  5	  and	  7	  
plated	  onto	  nutrient	  agar	  and	  incubated	  at	  37°C	  for	  48	  h	  did	  not	  show	  any	  bacterial	  
presence.	  	  It	  is	  worth	  noting	  that	  all	  chips	  in	  experiment	  3	  did	  appear	  to	  become	  
infected	  due	  to	  the	  fact	  that	  media	  became	  opaque	  and	  changed	  from	  pink	  to	  
yellow	  colour	  in	  the	  effluent,	  reflecting	  a	  highly	  acidic	  environment	  due	  to	  extensive	  
respiration	  and	  replication	  of	  the	  micro-­‐organisms	  (Freshney,	  2005).	  This	  
opaqueness	  and	  media	  colour	  change	  was	  not	  seen	  in	  any	  of	  the	  other	  experiments.	  
3.1.5	  	  Discussion	  
Initial	  studies	  on	  the	  stability	  of	  LDH	  when	  effluent	  was	  immediately	  stored	  
at	  4°C	  dictated	  that	  samples	  could	  be	  maintained	  at	  4°C	  for	  up	  to	  8	  days	  prior	  to	  
analysis.	  	  This	  meant	  that	  the	  LDH	  assay	  on	  all	  samples	  could	  be	  carried	  out	  the	  end	  
of	  the	  incubation	  period,	  reducing	  the	  potential	  for	  variation	  between	  assays	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Interpretation	  of	  the	  LDH	  studies,	  combined	  with	  evidence	  of	  WST-­‐1	  
metabolism	  by	  the	  tumour	  demonstrates	  tissue	  viability	  within	  this	  ex	  vivo	  device.	  
As	  predicted,	  the	  pattern	  of	  WST-­‐1	  metabolism,	  was	  inverseley	  related	  to	  LDH	  
excretion,	  demonstrating	  continued	  viability	  and	  	  reduced	  cell	  death	  throughout	  the	  
incubation	  period.	  	  
LDH	  has	  been	  used	  in	  several	  studies	  involving	  whole	  tissue	  culture	  within	  a	  
micro	  fluidic	  device	  as	  a	  marker	  of	  cell	  death	  (Hattersley	  et	  al.,	  2008,	  van	  Midwoud	  
et	  al.,	  2010a,	  van	  Midwoud	  et	  al.,	  2010b,	  Webster	  et	  al.,	  2010,	  Cheah	  et	  al.,	  2010).	  A	  
similar	  trend	  in	  the	  pattern	  of	  LDH	  release	  seems	  to	  exist,	  in	  that	  a	  relatively	  high	  
percentage	  of	  LDH	  leakage	  was	  found	  at	  the	  start	  of	  incubation.	  Van	  Midwoud	  et	  al.	  
(2010a)	  estimated	  this	  amount	  of	  leakage	  to	  be	  equivalent	  to	  around	  9%	  of	  the	  total	  
LDH,	  attributed	  to	  slicing	  and	  slice	  handling	  procedures.	  	  Although	  this	  was	  based	  on	  
rat	  liver	  slices	  of	  100	  µm	  (6	  cell	  layers)	  within	  a	  PDMS	  rather	  than	  glass	  based	  micro	  
fluidic	  device,	  this	  trend	  generally	  seems	  comparable	  with	  the	  finding	  of	  the	  current	  
study.	  	  This	  trend	  was	  also	  seen	  in	  rat	  and	  human	  heart	  tissue	  in	  a	  PDMS	  micro	  
fluidic	  device	  (Cheah	  et	  al.,	  2010),	  additionally,	  the	  removal	  of	  oxygen,	  cesation	  of	  
electrical	  stimuation	  or	  the	  addition	  of	  Triton-­‐X100	  resulted	  in	  a	  sharp	  LDH	  increase	  
within	  10-­‐15	  minutes,	  again	  verifying	  the	  viability	  of	  tissue	  prior	  to	  induction	  of	  
damage.	  	  
	   Tissue	  viability	  within	  micro	  fluidic	  devices	  can	  also	  be	  inferred	  by	  the	  
continued	  ‘functioning’	  of	  tissue.	  	  Hattersley	  et	  al.	  (2008)	  demonstrated	  that	  
albumin	  and	  urea	  were	  continually	  synthesised	  and	  released	  into	  the	  effluent	  by	  rat	  
liver	  tissue	  within	  a	  micro	  fluidic	  system.	  	  This	  also	  highlights	  an	  advantage	  of	  the	  
micro	  fluidic-­‐based	  approach;	  tissue	  function	  can	  be	  observed	  as	  a	  dynamic	  process,	  
whereby	  changes	  in	  the	  tissue	  microenvironment	  can	  be	  studied	  by	  real-­‐time	  
evaluation	  of	  changes	  in	  the	  effluent.	  	  This	  is	  potentially	  an	  extremely	  powerful	  
concept	  in	  relation	  to	  tumour	  biology.	  
	   Tumours	  are	  known	  to	  release	  a	  variety	  of	  factors	  as	  a	  means	  of	  
manipulating	  their	  microenvironment	  to	  promote	  tumour	  growth	  and	  metastasis.	  	  
The	  application	  of	  micro	  fluidic	  devices	  for	  the	  detection	  of	  tumour	  markers	  has	  
already	  been	  appreciated,	  such	  as	  the	  work	  of	  Henry	  and	  colleagues	  (Henry	  et	  al.,	  
2009),	  who	  developed	  a	  packaged	  micro	  fluidic	  cell	  for	  the	  multiplexed	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electrochemical	  detection	  of	  cancer	  markers	  (described	  in	  section	  1.9.2.2)	  however	  
micro	  fluidic	  based	  tissue	  culture	  offers	  the	  possibility	  of	  real	  time	  evaluation	  of	  
tumour	  response	  to	  changes	  in	  the	  microenvironment.	  	  To	  this	  effect,	  Webster	  et	  al.	  
(2010)	  used	  the	  biomarker	  VEGF	  as	  a	  marker	  of	  tissue	  viability.	  	  VEGF,	  a	  fundamental	  
neovascularisation	  factor	  (Tokunaga	  et	  al.,	  1998),	  is	  expressed	  by	  tumours,	  in	  which	  
its	  release	  can	  be	  modified	  by	  environmental	  manipulation.	  The	  generation	  of	  low	  
gaseous	  supply	  to	  create	  a	  hypoxic	  environment	  has	  been	  used	  to	  stimulate	  tumours	  
to	  express	  VEGF	  (Kuwai	  et	  al.,	  2003)	  and	  based	  on	  this	  principle,	  Webster	  and	  
colleagues	  demonstrated	  increased	  VEGF	  release	  of	  colorectal	  tumour	  biopsies	  in	  
response	  to	  induced	  hypoxic	  conditions	  compared	  with	  normal	  tissues,	  with	  a	  
reduction	  of	  VEGF	  release	  on	  return	  to	  normoxia.	  	  
Although	  the	  measurement	  of	  tumour	  related	  factors	  expressed	  in	  the	  
effluent	  has	  not	  been	  evaluated	  in	  this	  study,	  future	  work	  could	  be	  undertaken	  on	  
stored	  effluent	  from	  HNSCC,	  subject	  to	  ethical	  approval.	  Such	  work	  could	  be	  carried	  
out	  on	  the	  effluent	  from	  viability	  studies	  and	  the	  same	  principle	  applied	  to	  those	  
samples	  from	  tumour	  treated	  with	  chemotherapy	  agents	  as	  described	  in	  subsequent	  
sections.	  Although	  in	  HNSCC	  no	  ‘useful’	  secreted	  biomarkers	  have	  been	  identified	  as	  
predictors	  of	  chemo/radiosensitivity	  (Dietz	  et	  al.,	  2010),	  surrogate	  markers	  such	  as	  
VEGF	  could	  provide	  an	  interesting	  alternative	  until	  such	  factors	  are	  determined.	  
As	  shown	  in	  table	  3.1,	  only	  around	  one	  third	  of	  chips	  were	  ‘successful’,	  i.e.	  
ran	  throughout	  the	  entire	  incubation	  period.	  	  The	  most	  commonly	  encountered	  
problem	  was	  blockage	  and	  therefore	  the	  cessation	  of	  flow	  of	  effluent.	  	  This	  was	  
thought	  to	  be	  due	  to	  pieces	  of	  tumour	  detaching	  from	  the	  biopsy	  and	  blocking	  the	  
downstream	  channel.	  	  This	  may	  be	  improved	  by	  modifying	  the	  chip;	  changing	  the	  
channel	  dimensions	  could	  potentially	  reduce	  shear	  forces	  on	  the	  tumour	  biopsy	  (and	  
therefore	  reduce	  the	  amount	  of	  detachment)	  and	  an	  increase	  in	  channel	  diameter	  
could	  reduce	  the	  potential	  for	  blockage.	  	  Care	  would	  however	  have	  to	  be	  taken	  to	  
ensure	  that	  any	  changes	  were	  not	  at	  the	  expense	  of	  tumour	  viability,	  as	  the	  micro	  
channel	  flow	  characteristics	  and	  therefore	  diffusion	  properties	  would	  alter.	  	  
Another	  problem	  was	  leakage	  of	  buffer/effluent	  from	  around	  the	  tubing	  
inlet/outlet	  ports.	  	  Although	  not	  as	  common	  a	  problem	  as	  device	  blockage,	  a	  slight	  
adaptation	  in	  the	  methods	  of	  tubing	  attachment	  on	  to	  the	  device	  could	  reduce	  this	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problem.	  	  Further	  work	  could	  focus	  on	  the	  development	  of	  a	  ‘second	  generation’	  
microchip	  to	  address	  these	  engineering/fabrication	  concerns.	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3.2	  	  Comparative	  Studies	  on	  Fresh	  and	  Frozen	  Tissue	  
3.2.1	  	  Aims	  
• To	  compare	  cell	  death	  and	  viability	  in	  fresh	  and	  frozen	  primary	  tumour	  
biopsies.	  
3.2.2	  	  Introduction	  
	   The	  optimisation	  studies	  demonstrated	  that	  the	  micro	  fluidic	  system	  could	  
maintain	  fresh	  pieces	  of	  HNSCC	  tumour	  for	  up	  to	  4	  days.	  The	  ability	  to	  store	  pieces	  
of	  tumour	  prior	  to	  use	  (i.e.	  as	  snap	  frozen	  samples)	  is	  advantageous	  if	  biological	  
properties	  are	  preserved	  and	  can	  increase	  the	  clinical	  applicability	  of	  this	  system.	  
Successful	  cryopreservation	  would	  offer	  a	  possibility	  to	  store	  tissue	  biopsies,	  
forming	  a	  tissue	  bank,	  from	  which	  tumours	  could	  be	  tested	  at	  any	  desired	  time-­‐
point.	  This	  is	  of	  particular	  use	  in	  HNSCC,	  in	  which	  the	  supply	  of	  newly	  presenting	  
tumours	  is	  limited	  and	  irregular.	  The	  following	  experiments	  were	  therefore	  
undertaken	  to	  determine	  tumour	  viability	  following	  cryopreservation.	  
The	  loss	  of	  cellular	  viability	  caused	  by	  rapid	  freezing	  of	  biological	  tissues	  
using	  various	  cryoprotectants	  is	  well	  documented.	  	  Potential	  problems	  include	  
intracellular	  ice	  formation	  and	  cellular	  toxicity	  attributed	  to	  cryotherapy	  agents	  (de	  
Graaf	  et	  al.,	  2007),	  however	  such	  analysis	  is	  usually	  based	  on	  thawing	  of	  samples	  
and	  analysis	  after	  a	  period	  of	  incubation.	  	  Studies	  were	  therefore	  undertaken	  to	  
determine	  whether	  tissue	  viability,	  as	  measured	  by	  LDH	  excretion	  with	  immediate	  
incubation	  via	  a	  micro	  fluidic-­‐based	  approach	  on	  thawing,	  could	  be	  preserved	  in	  
small	  biopsies.	  
3.2.3	  	  Materials	  and	  Methods	  
Tumour	  samples	  were	  transported	  as	  described	  in	  section	  2.1.3.	  	  After	  
transportation	  of	  the	  tissue	  sample	  to	  the	  laboratory,	  half	  of	  the	  tissue	  was	  
processed	  and	  immediately	  placed	  in	  the	  micro	  fluidic	  system	  for	  incubation	  (within	  
15	  minutes	  of	  surgical	  dissection).	  	  The	  other	  half	  was	  snap	  frozen	  in	  cryoprotectant	  
(within	  15	  minutes	  of	  surgical	  dissection)	  as	  described	  in	  section	  2.1.3	  and	  stored	  at	  	  
-­‐80°C	  for	  2	  weeks	  until	  thawing	  and	  subsequent	  incubation	  in	  the	  micro	  fluidic	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device.	  The	  LDH	  activity	  in	  the	  tumour	  effluent	  was	  evaluated	  for	  the	  fresh	  and	  
frozen	  tissue	  of	  each	  tumour.	  
3.2.4	  	  Results	  
A	  total	  of	  3	  different	  tumours	  were	  incubated	  when	  fresh	  (1a,	  2a,	  3a)	  and	  
following	  freezing	  and	  storage	  for	  2	  weeks	  (1b,	  2b,	  3b),	  with	  4	  chips	  run,	  on	  average,	  
per	  tumour	  incubation,	  for	  up	  to	  4	  days.	  The	  numbers	  of	  chips	  per	  experiment	  (LDH	  
analysis	  and	  WST-­‐1	  metabolism	  only)	  and	  the	  sub-­‐site	  of	  the	  tumour	  used	  are	  
summarised	  in	  Table	  3.2.	  	  Also	  shown,	  is	  the	  number	  of	  ‘successful’	  chips.	  	  This	  
refers	  to	  the	  number	  of	  chips	  that	  ran	  successfully	  throughout	  the	  4-­‐day	  incubation	  
period.	  	  
3.2.4.1	  	  Cell	  Death	  Analysis	  
The	  cumulative	  results	  of	  LDH	  release	  for	  10	  chips	  (4	  fresh,	  6	  frozen)	  from	  
the	  3	  different	  tumours	  are	  shown	  in	  Figure	  3.5.	  LDH	  is	  maximal	  in	  the	  tumour	  
effluent	  after	  the	  1st	  hour	  of	  incubation.	  The	  results	  demonstrate	  a	  similar	  LDH	  peak	  
at	  the	  start	  of	  the	  experiment	  in	  both	  tissue	  groups.	  	  The	  two	  groups	  then	  show	  a	  
very	  similar	  response	  with	  the	  amount	  of	  LDH	  released	  from	  the	  frozen	  tumour	  
biopsy	  being	  slightly	  higher	  in	  the	  first	  24	  h	  and	  then	  falling	  to	  lower	  levels	  after	  this.	  	  
Both	  groups	  responded	  to	  the	  addition	  of	  10%	  (v/v)	  lysis	  buffer	  in	  a	  similar	  fashion;	  
LDH	  release	  increased.	  	  This	  was	  greatest	  in	  the	  fresh	  group,	  presumed	  to	  represent	  
the	  greater	  number	  of	  viable	  cell	  present	  at	  this	  time.	  
	  	  
Experiment	   Sub	  site	   LDH	  Set-­‐up	   LDH	  Successful	   WST-­‐1	  Set-­‐up	   WST-­‐1	  Successful	  
1a	   Node	  -­‐	  fresh	   2	   1	   2	   1	  
1b	   Node	  -­‐	  frozen	   2	   2	   2	   1	  
2a	   Larynx	  –	  fresh	   2	   1	   2	   1	  
2b	   Larynx	  -­‐	  frozen	   2	   2	   2	   1	  
3a	   Larynx	  –	  fresh	   2	   2	   2	   2	  
3b	   Larynx	  -­‐	  frozen	   3	   2	   2	   0	  
Total	   	   13	   10	  (77%)	   12	   6	  (50%)	  
Table	  3.2	  Summary	  of	  number	  of	  experiments,	  tumour	  sub-­‐sites	  and	  successful	  chips	  run	  for	  fresh	  versus	  frozen	  studies	  




Figure	  3.5	  Graph	  depicting	  the	  pattern	  of	  LDH	  release	  per	  µg	  of	  tissue	  over	  74	  h	  
incubation	  of	  fresh	  (n=4	  chips	  from	  n=3	  tumours)	  and	  frozen	  (n=6	  chips	  from	  n=3	  
tumours)	  tumour	  biopsies	  with	  addition	  of	  10%	  (v/v)	  lysis	  buffer	  at	  68	  h	  incubation.	  
Red	  line	  indicates	  LDH	  release	  from	  fresh	  tumour,	  blue	  line	  from	  frozen.	  Breaks	  in	  
lines	  signify	  periods	  where	  samples	  were	  not	  collected.	  	  Error	  bars	  show	  standard	  
deviation.	  
3.2.4.2	  	  Cell	  Viability	  Analysis	  
The	  cumulative	  results	  for	  WST-­‐1	  metabolism	  for	  6	  chips	  (4	  fresh,	  2	  frozen)	  
from	  the	  3	  tumours	  are	  shown	  in	  figure	  3.6.	  Two	  hours	  after	  the	  addition	  of	  WST-­‐1	  
at	  18h	  of	  incubation,	  the	  presence	  of	  the	  metabolised	  salt	  in	  the	  tumour	  effluent	  can	  
be	  seen	  to	  increase	  in	  both	  of	  the	  tissue	  groups	  but	  more	  so	  in	  the	  fresh.	  	  At	  the	  
later	  time	  periods	  levels	  continue	  to	  increase	  with	  time	  in	  both	  groups,	  with	  the	  
fresh	  tissue	  reaching	  a	  greater	  maximal	  peak	  than	  the	  frozen	  until	  the	  addition	  of	  
lysis	  buffer	  at	  68	  h	  that	  results	  in	  a	  reduction	  in	  WST-­‐1	  release	  returning	  to	  minimal	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Figure	  3.6	  Graph	  depicting	  the	  pattern	  of	  WST-­‐1	  metabolism	  per	  µg	  of	  tissue	  after	  
addition	  at	  18	  h	  incubation	  over	  74	  h	  incubation	  of	  fresh	  (n=4	  chips	  from	  n=3	  
tumours)	  and	  frozen	  (n=2	  chips	  from	  n=2	  tumours)	  tumour	  biopsies	  with	  addition	  of	  
10%	  v/v	  lysis	  buffer	  at	  68	  h	  incubation.	  Red	  line	  indicates	  WST-­‐1	  release	  from	  fresh	  
tumour,	  blue	  line	  from	  frozen.	  Breaks	  in	  lines	  signify	  periods	  where	  samples	  were	  
not	  collected.	  	  Error	  bars	  show	  standard	  deviation.	  
3.2.5	  	  Discussion	  
The	  release	  of	  LDH	  release	  from	  fresh	  tissue	  differed	  only	  slightly	  compared	  
with	  the	  release	  from	  frozen	  tissue,	  with	  more	  LDH	  released	  from	  the	  frozen	  tissue	  
in	  the	  first	  24	  h	  presumably	  due	  to	  increased	  damage	  associated	  with	  freezing	  and	  
thawing.	  	  Additionally,	  less	  LDH	  was	  released	  from	  the	  frozen	  tissue	  on	  the	  addition	  
of	  cell	  lysis	  buffer	  at	  the	  end	  of	  the	  experiment	  to	  rupture	  the	  membranes	  of	  any	  
remaining	  viable	  cells.	  This	  suggests	  that	  frozen	  tissue	  had	  a	  reduced	  number	  of	  
viable	  cells	  at	  the	  end	  of	  the	  experiment,	  presumably	  as	  there	  was	  increased	  cell	  
degradation	  at	  the	  beginning	  of	  the	  incubation	  period	  associated	  with	  freezing	  and	  
thawing.	  What	  proportion	  of	  cell	  death	  can	  be	  attributed	  to	  the	  cryopreservation	  
process	  and	  how	  much	  cell	  viability,	  or	  ‘rejuvenation’	  can	  be	  attributed	  to	  the	  micro	  	  
fluidic	  process	  remains	  to	  be	  determined.	  The	  pattern	  of	  WST-­‐1	  metabolism	  would	  
also	  suggest	  this;	  metabolism	  was	  greatest	  in	  the	  ‘fresh’	  samples,	  although	  the	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the	  addition	  of	  lysis	  buffer.	  	  Of	  note,	  the	  sample	  numbers	  used	  in	  the	  WST-­‐1	  were	  
lower	  than	  for	  LDH	  studies.	  	  This	  explains	  the	  larger	  standard	  deviation	  displayed	  in	  
Figure	  3.6.	  	  An	  increased	  number	  of	  repeats	  would	  enhance	  the	  validity	  of	  he	  LDH	  
and	  more	  importantly	  the	  WST-­‐1	  studies	  above.	  	  	  
Many	  different	  techniques	  for	  cryopreservation	  exist	  and	  can	  be	  broadly	  
categorised	  in	  to	  ultra-­‐rapid	  freezing	  and	  thawing,	  controlled-­‐rate	  freezing,	  freezing	  
with	  non-­‐penetrating	  polymers,	  vitrification,	  and	  equilibrium	  freezing	  (Meryman,	  
2007).	  	  In	  this	  study,	  ultra-­‐rapid	  freezing	  was	  used	  for	  cryopreservation,	  as	  in	  the	  
study	  of	  whole	  rat	  liver	  biopsies	  by	  Hattersley	  et	  al.	  (2008).	  This	  was	  however	  
criticised	  by	  van	  Midwoud	  et	  al.	  (2010a)	  in	  their	  study	  of	  rat	  liver	  slices	  maintained	  in	  
micro	  fluidic	  devices,	  stating	  that	  fresh	  tissue	  slices	  are	  necessary	  for	  proper	  viability	  
and	  metabolic	  function.	  	  Undoubtedly	  some	  viability	  and	  metabolic	  functioning	  will	  
have	  been	  lost	  during	  the	  cryopreservation	  and	  thawing	  process	  and	  perhaps	  this	  
may	  have	  been	  optimised	  by	  a	  trial	  of	  various	  techniques	  and	  protocols,	  but	  
importantly,	  the	  overall	  trend	  in	  LDH	  production	  and	  WST-­‐1	  metabolism	  was	  
reproducibly	  maintained	  in	  the	  frozen	  tissue	  biopsies.	  	  As	  the	  trend	  in	  LDH	  release	  
was	  maintained,	  it	  can	  therefore	  be	  argued	  that	  frozen	  tissue	  may	  be	  used	  within	  
the	  micro	  fluidic	  device	  making	  a	  widely	  applicable	  platform	  technology	  as	  a	  way	  of	  
measuring	  the	  relative	  changes	  in	  LDH	  release/WST-­‐1	  production	  attributed	  to	  
different	  treatment	  regimens.	  	  This	  enhances	  the	  clinical	  applicability;	  tissue	  can	  be	  
collected	  from	  the	  patient	  at	  the	  point	  of	  diagnostic	  biopsy	  and	  stored	  until	  
diagnosis	  and	  clinical	  management	  have	  been	  decided	  upon,	  therefore	  allowing	  the	  
micro	  fluidic	  device	  to	  be	  used	  as	  a	  testing	  platform	  for	  proposed	  treatment.	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3.3	  	  Histo-­‐architectural	  studies	  
3.3.1	  	  Aims	  
• To	  study	  the	  basic	  histo-­‐architectural	  structure	  of	  HNSCC	  tissue	  following	  the	  
incubation	  of	  fresh	  tissue	  within	  a	  micro	  fluidic	  device	  
3.3.2	  	  Introduction	  
	   The	  qualitative	  analysis	  of	  tissue	  morphology	  adds	  to	  the	  evidence	  for	  
preservation	  of	  tissue	  viability	  within	  the	  micro	  fluidic	  device.	  Morphological	  
integrity	  of	  tissues	  is	  generally	  defined	  as	  preservation	  of	  general	  architecture	  
including	  epithelial	  structures	  and	  their	  spatial	  relationships	  to	  stroma	  (Vaira	  et	  al.,	  
2010).	  	  The	  most	  obvious	  histological	  feature	  of	  cell	  death	  (i.e.	  necrosis)	  is	  nuclear	  
degeneration	  (Young	  et	  al.,	  2000).	  	  The	  first	  sign,	  known	  as	  pyknosis,	  results	  from	  
condensation	  of	  the	  chromatin	  into	  a	  small,	  densely	  staining	  (Haematoxylin)	  mass.	  	  
Later	  the	  nuclear	  material	  becomes	  fragmented	  (karyorrhexis)	  and	  ultimately	  breaks	  
down	  with	  a	  loss	  of	  the	  nucleus	  altogether	  (karyolysis).	  At	  the	  same	  time,	  
denaturation	  of	  cytoplasmic	  proteins	  results	  in	  the	  formation	  of	  an	  amorphous	  
cytoplasmic	  mass,	  which	  stains	  intensely	  with	  eosin	  (bright	  pink).	  	  With	  the	  
dissolution	  of	  the	  cell	  membrane,	  the	  cellular	  outline	  becomes	  increasingly	  difficult	  
to	  distinguish	  (cytolysis)	  (Burkitt	  et	  al.,	  1993)	  
	   Taking	  cryostat	  sections	  of	  tissues	  enables	  the	  study	  of	  architecture	  at	  
various	  levels	  through	  the	  biopsy.	  	  One	  of	  the	  disadvantages	  of	  traditional	  culture	  
models	  is	  the	  limited	  size	  of	  tissue	  that	  can	  be	  cultured	  or	  maintained	  as	  a	  3D	  
construct.	  	  As	  previously	  discussed,	  unfavourable	  diffusion	  properties	  prevent	  the	  
optimal	  diffusion	  of	  nutrients	  in,	  and	  metabolic	  waste	  out,	  of	  the	  centre	  of	  the	  
tissue.	  	  It	  is	  hypothesised	  that	  the	  favourable	  diffusion	  properties	  associated	  with	  
the	  laminar	  flow	  within	  micro	  fluidic	  devices,	  coupled	  with	  the	  use	  of	  relatively	  small	  
tumour	  biopsies	  will	  avoid	  this	  problem.	  
3.3.3	  	  Materials	  and	  Methods	  
Tumour	  biopsies	  were	  obtained	  and	  processed	  as	  described	  in	  section	  2.1	  
and	  placed	  fresh	  into	  the	  micro	  fluidic	  device	  for	  perfusion.	  	  Tissue	  was	  either	  then	  
removed	  at	  48	  h	  incubation	  or	  at	  96	  h	  incubation,	  at	  which	  point,	  snap	  freezing	  in	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preparation	  for	  cryostat	  sectioning	  was	  performed	  as	  described	  in	  section	  2.4.4.	  	  All	  
pieces	  of	  tumour	  were	  stored	  at	  -­‐20°C	  until	  sectioning,	  at	  which	  point	  cryostat	  
sectioning,	  followed	  by	  Haematoxylin	  and	  Eosin	  (H&E)	  staining,	  was	  carried	  out.	  	  
Sectioning	  of	  the	  tissue	  blocks	  resulted	  in	  between	  15	  and	  35	  slides	  with	  2	  to	  3	  
sections	  of	  12	  µm	  thickness	  on	  each	  slide.	  	  The	  distance	  of	  section	  from	  the	  surface	  
of	  the	  tumour	  was	  recorded	  for	  each	  section	  and	  categorised	  as	  ‘edge’	  (outer	  third	  
of	  the	  biopsy),	  ‘centre’	  (core	  third)	  or	  ‘intermediate’	  (area	  in	  between).	  
Approximately	  4	  slides	  for	  each	  category	  per	  tissue	  block	  were	  selected	  for	  H&E	  
staining.	  
3.3.4	  	  Results	  
Three	  different	  tumours	  were	  used	  for	  these	  studies,	  in	  each	  case	  pieces	  of	  
tissue	  were	  snap	  frozen	  before	  perfusion	  and	  following	  48	  h	  and	  96	  h	  of	  perfusion.	  	  
The	  summary	  of	  sub	  sites,	  number	  of	  chips	  run	  and	  numbers	  of	  biopsy	  pieces	  snap	  
frozen	  at	  each	  time	  point	  are	  shown	  in	  Table	  3.3.	  
	  
Table	  3.3	  Summary	  of	  number	  of	  experiments,	  tumour	  sub-­‐sites	  number	  of	  pieces	  of	  
tissue	  frozen	  at	  each	  time	  point	  for	  histo-­‐architectural	  interpretation.	  
	  
All	  tissue	  from	  experiment	  2	  was	  identified	  as	  connective/scar	  tissue	  on	  H&E	  
staining,	  rather	  than	  HNSCC	  (confirmed	  with	  Dr	  Karsai,	  Consultant	  Histopathologist),	  
therefore	  results	  are	  not	  shown	  or	  discussed.	  	  
Figures	  3.7a,	  b,	  and	  c	  from	  0	  h,	  displaying	  areas	  of	  SCC	  and	  nodal	  tissue,	  
show	  intact,	  viable	  cells	  with	  rounded	  nuclei	  and	  maintenance	  of	  cell-­‐cell	  contact	  
and	  cell	  membrane	  preservation.	  Figures	  showing	  tissue	  after	  48	  h	  (Figure	  3.8)	  and	  
96	  h	  (Figure	  3.9)	  perfusion,	  do	  show	  some	  areas	  with	  loss	  of	  cell	  cohesion	  and	  nuclei	  
degradation,	  however,	  large	  sections	  of	  apparently	  similar	  tissue	  structure	  of	  
Experiment	   Sub	  site	   Before	  Perfusion	   Chips	  Run	   Tissue	  48	  h	   Tissue	  96	  h	  
1	   Node	   2	   4	   2	   1	  
2	   Node	   2	   4	   2	   2	  
3	   Node	   3	   5	   2	   2	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epithelium	  and	  ECM	  to	  tissue	  at	  0	  h	  are	  present.	  There	  is	  no	  great	  difference	  in	  
architecture	  between	  section	  from	  the	  edge	  of	  tumour	  (i.e.	  the	  biopsy	  surface	  and	  
those	  from	  the	  core	  of	  the	  tumour	  biopsy	  (Figs	  3.7,	  3.8,	  3.9),	  suggesting	  diffusion	  of	  
nutrients	  into	  the	  centre	  is	  maintained.	  	  Additional	  figures	  for	  section	  from	  the	  
tumour	  edge	  and	  intermediate	  areas	  (between	  the	  outer	  third	  and	  inner	  core	  third)	  
are	  shown	  in	  Appendix	  3.	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Figure	  3.7	  Image	  of	  central	  area	  of	  tumour/node	  prior	  to	  perfusion	  at	  a)	  x5,	  b)	  x20,	  
c)	  x40	  magnification.	  Areas	  of	  SCC	  (left	  side)	  with	  a	  characteristic	  keratin	  pearl	  
(arrow)	  and	  a	  discrete	  area	  of	  nodal	  tissue	  far	  right.	  Representative	  of	  5	  tumour	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Figure	  3.8	  Image	  of	  central	  area	  of	  tumour/node	  at	  48	  h	  at,	  a)	  x5,	  b)	  x20,	  c)	  x40	  
magnification.	  Areas	  of	  cell	  viability	  with	  cohesion	  maintained.	  	  Areas	  of	  tissue	  
separation	  evident	  but	  possibly	  due	  to	  the	  sectioning	  process.	  	  Representative	  of	  4	  
tumour	  biopsies	  from	  2	  different	  tumours.	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Figure	  3.9	  Image	  of	  central	  area	  of	  tumour/node	  at	  96	  h,	  at	  a)	  x5,	  b)	  x20,	  c)	  x40	  
magnification.	  Areas	  of	  intact	  nuclei	  identifiable	  with	  cohesion	  maintained	  in	  some	  





X	  5	  magnification	  
X	  20	  magnification	  
X	  40	  magnification	  
	   	  121	  
3.3.5	  	  Discussion	  
Histological	  analysis	  of	  tissue	  samples	  is	  one	  of	  the	  primary	  tools	  of	  diagnosis	  
of	  HNSCC	  and	  has	  also	  been	  applied	  to	  the	  study	  of	  tissue	  within	  micro	  fluidic	  
devices	  and	  alternative	  tissue	  perfusion	  systems	  to	  demonstrate	  the	  preservation	  of	  
tissue	  architecture.	  Tissue	  architecture	  was	  preserved	  throughout	  the	  incubation	  
and	  importantly	  this	  was	  evident	  in	  the	  centre	  or	  ‘core’	  of	  the	  tissue	  biopsy.	  	  This	  is	  
further	  evidence	  that	  the	  diffusion	  properties	  of	  micro	  fluidic	  devices,	  attributed	  
principally	  to	  laminar	  flow,	  maintain	  sufficient	  nutrient	  delivery	  and	  waste	  removal	  
throughout	  the	  tissue	  biopsy.	  Such	  findings	  were	  present	  in	  all	  samples	  subjected	  to	  
histological	  examination	  (7	  biopsies	  from	  2	  different	  tumours),	  demonstrating	  
reproducibility	  and	  reliability	  in	  the	  micro	  fluidic	  techniques.	  	  It	  should	  however	  be	  
stressed	  that	  these	  studies	  were	  only	  performed	  in	  n=2	  tumours.	  	  Furthermore,	  
comparison	  with	  non-­‐perfused	  tumour	  (similarly	  left	  for	  up	  to	  96)	  would	  add	  to	  the	  
validity	  of	  the	  micro	  fluidic	  technique,	  but	  was	  not	  performed	  in	  this	  study.	  
This	  preservation	  of	  tissue	  morphology	  was	  also	  seen	  by	  Rambani	  et	  al.	  
(2009),	  when	  culturing	  brain	  slices	  (>700μm)	  in	  micro	  fluidic	  perfusion	  chambers	  for	  
5	  days.	  Perfused	  and	  unperfused	  tissues	  were	  cut	  into	  20	  or	  50	  µm	  thick	  transverse	  
sections	  throughout	  the	  length	  and	  stained	  with	  H&E	  as	  in	  this	  study.	  They	  found	  
that	  the	  overall	  structure,	  cell	  sizes	  and	  shapes	  of	  the	  perfused	  slices	  were	  
comparable	  with	  those	  of	  the	  fresh	  tissue	  (baseline)	  slices	  that	  had	  been	  fixed	  
immediately	  after	  cutting	  and	  stained	  identically,	  while	  the	  unperfused	  slices	  
showed	  impaired	  cell	  health	  and	  poor	  overall	  structure.	  	  Notably,	  in	  these	  
unperfused	  slices,	  the	  dendritic	  network	  was	  sparse	  and	  soma	  size	  comparatively	  
smaller	  throughout	  the	  culture	  thickness,	  with	  these	  changes	  of	  poor	  health	  most	  
significantly	  appreciated	  in	  the	  middle	  of	  the	  cultures.	  	  It	  was	  also	  found	  in	  the	  brain	  
tissue	  that	  in	  the	  unperfused	  cultures,	  cell	  death	  occurred	  from	  the	  centre	  
outwards.	  	  
The	  histo-­‐architectural	  changes	  following	  perfusion	  have	  also	  been	  studied	  in	  
rat	  liver	  tissue	  (Hattersley	  et	  al.,	  2008).	  	  Slices	  of	  12	  µm	  thickness	  from	  4mm3	  pieces	  
of	  tumour	  were	  stained	  with	  H&E	  and	  Lavacellfluorescence	  imaging	  used	  to	  
evaluate	  tissue	  architecture	  after	  70	  h	  of	  perfusion	  within	  the	  micro	  fluidic	  device.	  In	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sections	  of	  tissue	  taken	  throughout	  the	  tissue	  biopsies,	  the	  rounded	  appearances	  of	  
the	  cell	  nuclei	  were	  maintained,	  as	  was	  the	  cell	  membrane	  and	  the	  hexagonal	  shape	  
of	  the	  hepatocytes	  and	  the	  extracellular	  matrix.	  	  Fluorescent	  imaging	  of	  the	  liver	  
tissue	  after	  staining	  with	  calcein	  demonstrated	  cell	  viability	  as	  shown	  by	  the	  
retention	  of	  cleaved	  fluorescent	  probe	  calcein	  in	  the	  cytosol	  of	  viable	  cells.	  	  
Conversely,	  the	  absence	  of	  staining	  with	  propidium	  iodide	  (which	  fluoresces	  red	  at	  
488	  nm	  wavelength	  light	  when	  intercalated	  within	  DNA,	  having	  entered	  the	  cells	  
through	  damaged	  membranes)	  demonstrated	  the	  absence	  of	  many	  non-­‐viable	  cells.	  	  
This	  appearance	  was	  reversed	  on	  the	  addition	  of	  10%	  lysis	  buffer	  when	  staining	  
indicated	  the	  presence	  of	  non-­‐viable	  cells	  only.	  
To	  corroborate	  the	  observed	  results,	  an	  additional	  approach	  would	  be	  to	  use	  
immunohistochemical	  (IHC)	  markers	  to	  demonstrate	  viability	  within	  the	  prepared	  
tissue	  slices.	  	  This	  has	  yet	  to	  be	  applied	  to	  any	  micro	  fluidic-­‐based	  tissue	  studies	  but	  
has	  been	  applied	  to	  many	  alternative	  tissue	  culture	  methods.	  	  Vaira	  et	  al.	  (2010),	  
acknowledging	  the	  benefits	  of	  whole	  tissue	  tumour	  culture	  to	  maintain	  the	  tumour	  
microenvironment	  and	  its	  potential	  use	  as	  a	  predictor	  of	  chemotherapy	  response,	  
used	  organotypic	  culture	  methods	  to	  maintain	  pieces	  of	  lung	  and	  colorectal	  tumour.	  
Although	  these	  slices	  were	  only	  of	  400	  µm	  thickness,	  viability	  in	  a	  non-­‐perfusate	  
system	  for	  a	  120	  h	  incubation	  period	  was	  demonstrated	  by	  Ki-­‐67	  immunostaining	  for	  
proliferative	  activity.	  The	  percentage	  of	  proliferating	  cells	  was	  approximately	  82%	  in	  
the	  first	  24	  h	  that	  reduced	  to	  around	  62%	  on	  day	  5.	  	  The	  authors	  maintain	  however	  
that	  proliferative	  activity	  ‘was	  found	  to	  be	  stable	  across	  all	  time	  points	  without	  a	  
significant	  decrease	  up	  to	  120	  h’.	  Furthermore,	  examination	  of	  their	  stained	  images	  
shows	  that	  with	  progression	  of	  time,	  proliferative	  activity	  becomes	  absent	  from	  the	  
centre	  of	  the	  tissue	  slice	  and	  is	  only	  present	  at	  the	  tissue	  periphery.	  Apoptotic	  
activity	  was	  also	  studied	  by	  TUNEL	  assay.	  This	  method	  detects	  DNA	  fragmentation	  
from	  apoptotic	  signalling	  cascades	  by	  labelling	  the	  terminal	  end	  of	  nucleic	  acids	  by	  
the	  addition	  of	  modified	  nucleotides	  that	  are	  secondarily	  labelled	  with	  a	  marker.	  
Apoptotic	  activity	  was	  measured	  as	  25%	  at	  24	  h,	  rising	  to	  42%	  by	  day	  5,	  however	  the	  
distribution	  of	  apoptosis	  throughout	  the	  tissue	  slice	  was	  not	  shown.	  
The	  application	  of	  IHC	  staining	  to	  tissue	  cultured	  within	  a	  micro	  fluidic	  device	  
is	  an	  interesting	  future	  area	  of	  research.	  As	  well	  as	  studying	  markers	  of	  proliferation,	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IHC	  could	  be	  used	  to	  further	  investigate	  mechanisms	  of	  cell	  death	  and	  apoptosis	  
within	  tumour	  tissue,	  for	  example	  Bcl/Bax	  pathways,	  as	  these	  factors	  have	  been	  
extensively	  studies	  on	  conventionally	  prepared	  tissue	  (Gold	  and	  Kim,	  2009).
	   	  124	  
3.4	  	  Chemotherapy	  Studies	  
3.4.1	  	  Aims	  
• To	  assess	  the	  effects	  of	  single	  and	  multiple	  chemotherapy	  agents	  on	  HNSCC	  
biopsies	  within	  the	  micro	  fluidic	  system	  
3.4.2	  	  Introduction	  
	   Optimisation	  and	  histo-­‐architectural	  studies	  have	  demonstrated	  the	  
maintenance	  of	  tissue	  viability	  and	  structure	  when	  perfused	  in	  the	  micro	  fluidic	  
device.	  	  Furthermore,	  studies	  comparing	  the	  behaviour	  of	  fresh	  and	  frozen	  studies	  
have	  demonstrated	  the	  preservation	  of	  biological	  properties	  when	  snap	  frozen	  in	  
cryoprotectant	  and	  stored,	  increasing	  the	  clinical	  applicability	  of	  the	  approach.	  The	  
ability	  to	  maintain	  a	  tumour	  with	  its	  intact	  in	  vivo	  structure	  within	  a	  
microenvironment	  where	  flow	  characteristics	  are	  mimicked	  provides	  an	  ideal	  
platform	  for	  the	  testing	  of	  a	  tumour’s	  response	  to	  chemotherapy	  agents	  in	  a	  tissue-­‐
specific	  manner.	  	  
	   The	  evidence	  for	  the	  use	  of	  chemotherapy	  drugs	  in	  HNSCC	  is	  outlined	  in	  
section	  1.7,	  however	  individual	  tumours	  are	  known	  to	  be	  heterogenous	  in	  their	  
response	  to	  commonly	  used	  agents	  and	  the	  problems	  of	  chemoresistance	  are	  too	  
often	  seen	  in	  clinical	  practice.	  	  This	  highlights	  the	  need	  for	  a	  method	  of	  testing	  
clinically	  relevant	  drugs	  on	  tissue	  biopsy	  in	  order	  to	  predict	  individual	  response.	  
	  
When	  used	  clinically,	  the	  following	  local	  policy	  is	  adopted:	  
• Induction	  chemotherapy	  (given	  prior	  to	  surgery	  or	  radiotherapy)	  in	  locally	  
advanced	  disease	  (docetaxel	  is	  excluded	  in	  nasopharyngeal	  carcinoma)	  
o Docetaxel	  75	  mg/m2	  intravenous	  (i.v.)	  day	  1,	  cisplatin	  100	  mg/m2	  i.v	  day	  
1,	  followed	  by	  5FU	  1	  g/m2	  daily	  for	  4	  days	  i.v.	  
o A	  total	  of	  3	  cycles	  given	  (at	  3	  weekly	  intervals)	  
or,	  if	  >65	  or	  serious	  co-­‐morbidities,	  
o Docetaxel	  75	  mg/m2	  i.v.	  day	  1,	  cisplatin	  100	  mg/m2	  i.v.	  day	  1,	  followed	  
by	  5FU	  750	  mg/m2	  daily	  for	  5	  days	  i.v.	  
o A	  total	  of	  4	  cycles	  given	  (at	  3	  weekly	  intervals)	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• Concurrent	  chemotherapy	  (locally	  advanced	  HNSCC	  i.e.	  oropharyngeal/	  
hypopharyngeal,	  not	  commonly	  used	  for	  laryngeal	  malignancies)	  
o Cisplatin	  40	  mg/m2	  i.v	  weekly,	  concurrent	  with	  radiotherapy	  for	  6	  
cycles	  
o Cetuximab	  400	  mg/m2	  i.v	  followed	  by	  Cetuximab	  250	  mg/m2	  
concurrent	  with	  radiotherapy	  for	  6-­‐7	  cycles	  if	  platinum-­‐based	  
chemotherapy	  treatment	  is	  contra-­‐indicated.	  
	  
To	  maximise	  the	  clinical	  applicability	  of	  the	  study,	  It	  was	  therefore	  decided	  to	  
use	  cisplatin,	  5FU	  and	  docetaxel	  alone	  and	  combinations	  of	  a)	  cisplatin	  and	  
docetaxel,	  as	  administered	  on	  the	  same	  days	  in	  clinical	  practice	  and	  b)	  cisplatin,	  5FU	  
and	  docetaxel,	  as	  given	  overall.	  	  Cetuximab	  was	  not	  studied	  in	  the	  current	  
investigation,	  as	  it	  is	  not	  a	  cytototoxic	  agent,	  but	  rather	  as	  a	  radiation	  sensitizer	  
when	  given	  concurrently	  with	  radiotherapy	  (Bonner	  et	  al.,	  2006).	  
For	  chemotherapy	  drugs	  to	  be	  introduced	  into	  the	  micro	  fluidic	  system,	  some	  
consideration	  is	  required	  regarding	  their	  dosage	  and	  distribution.	  	  Information	  
regarding	  their	  pharmacokinetic	  properties	  is	  derived	  from	  animal	  models	  and	  early-­‐
phase	  clinical	  trials,	  allowing	  the	  mean	  drug	  concentration	  to	  be	  determined	  in	  
plasma	  and	  in	  various	  tissues	  of	  the	  body,	  including	  tumours,	  as	  a	  function	  of	  time	  
after	  administration.	  	  Having	  an	  appreciation	  of	  the	  plasma	  dose	  for	  example,	  and	  
appreciating	  the	  distribution	  of	  chemotherapy	  agents	  within	  tumours	  in	  vivo	  will	  
enable	  a	  comparable	  chemotherapy	  regimen	  to	  be	  used	  within	  the	  micro	  fluidic	  
device.	  
In	  the	  in	  vivo	  setting,	  chemotherapy	  agents	  distribute	  within	  tumours,	  
forming	  gradients	  from	  tumour	  blood	  vessels,	  that	  change	  with	  time,	  as	  the	  drug	  is	  
cleared	  from	  the	  body	  (Minchinton	  and	  Tannock,	  2006).	  The	  permeability	  of	  vessel	  
walls	  influences	  drug	  penetration,	  but	  this	  is	  thought	  to	  be	  relatively	  insignificant	  in	  
many	  tumours	  where	  blood-­‐vessel	  fenestrations	  have	  been	  observed,	  i.e.	  the	  
chaotic	  leaky	  vasculature	  allows	  ready	  transfer	  of	  chemotherapy	  drugs	  (Jain	  et	  al.,	  
2002).	  Drugs	  penetrate	  normal	  tissues	  by	  both	  diffusion	  and	  convection,	  with	  a	  net	  
flow	  of	  fluid	  from	  blood	  vessels	  balanced	  by	  resorption	  into	  lymphatics	  (Minchinton	  
and	  Tannock,	  2006).	  However,	  the	  lack	  of	  functional	  lymphatics	  commonly	  found	  in	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tumours	  (Leu	  et	  al.,	  2000,	  Jain	  et	  al.,	  2002,	  Fukumura	  et	  al.,	  2010),	  especially	  more	  
advanced	  malignancies,	  can	  lead	  to	  increased	  levels	  of	  interstitial	  fluid	  pressure,	  
which	  in	  turn	  is	  likely	  to	  reduce	  convection	  and	  thereby	  inhibit	  the	  distribution	  of	  
macromolecules	  (Jain,	  1997).	  	  	  
The	  physicochemical	  properties	  of	  drugs	  (e.g.	  molecular	  weight,	  shape,	  
charge	  and	  aqueous	  solubility)	  also	  influence	  the	  rate	  of	  diffusion	  through	  tissue.	  In	  
vivo,	  drug	  penetration	  is	  also	  affected	  by	  consumption	  in	  proximal	  tumour	  cells	  
(Tredan	  et	  al.,	  2007)	  as	  well	  as	  binding	  to	  tissue	  elements	  (both	  specific	  and	  non-­‐
specific	  target	  receptors)	  (Thurber	  et	  al.,	  2008).	  The	  penetration	  of	  paclitaxel	  (a	  
similar	  agent	  to	  docetaxel)	  for	  example,	  is	  determined	  by	  multiple	  factors.	  
Penetration	  is	  independent	  of	  biological	  changes	  in	  tumour	  cells	  induced	  by	  
paclitaxel	  (e.g.	  ratio	  of	  EC	  and	  IC	  concentrations	  and	  drug	  binding	  to	  EC	  and	  IC	  
macromolecules)	  (Minchinton	  and	  Tannock,	  2006).	  Additionally,	  penetration	  is	  
affected	  by	  time-­‐	  and	  drug	  concentration-­‐dependent	  biological	  changes	  (e.g.	  
induction	  of	  apoptosis,	  enhancement	  of	  tubulin/microtubule	  production,	  and	  
induction	  of	  Pgp	  expression)	  in	  histoculture	  models	  (Jang	  et	  al.,	  2001)	  and	  
multicellular	  spheroids	  (Nicholson	  et	  al.,	  1997).	  	  
Although	  tumours	  require	  angiogenesis	  for	  growth,	  this	  is	  a	  dysfunctional	  
process	  compared	  with	  the	  organised	  vessel	  formation	  in	  normal	  tissue.	  	  
Furthermore,	  due	  to	  the	  rapid	  proliferation	  of	  tumour	  cells,	  vessels	  are	  forced	  apart	  
reducing	  vascular	  density	  and	  creating	  a	  population	  of	  cells	  that	  are	  relatively	  distant	  
(>100	  µm)	  from	  blood	  vessels	  (Thomlinson	  and	  Gray,	  1955).	  Close	  to	  the	  vessel	  wall,	  
the	  tumour	  tissue	  is	  well	  supplied	  with	  nutrients	  and	  rapidly	  proliferates.	  Further	  
from	  the	  blood	  supply,	  the	  concentrations	  of	  nutrients	  decrease	  and	  cells	  become	  
quiescent	  apoptotic	  and	  eventually	  necrotic	  (Sutherland,	  1988).	  	  In	  addition,	  
extracellular	  pH	  decreases	  with	  increasing	  distance	  from	  blood	  vessels,	  Helmlinger	  
et	  al.	  (1997)	  for	  example,	  finding	  the	  interstitial	  pH	  profile	  exhibited	  a	  mean	  drop	  of	  
0.32	  units	  10	  µm	  (pH	  =	  7.24)	  to	  100	  µm	  (pH	  =	  6.92)	  away	  from	  the	  vessel	  wall.	  	  
Constraining	  a	  cell	  mass	  within	  a	  square	  box	  would	  force	  linear	  microenvironment	  
gradients	  to	  form	  perpendicular	  to	  a	  nutrient	  source	  (Figure	  3.10)	  (Walsh	  et	  al.,	  
2009)	  and	  although	  these	  linear	  microenvironment	  gradients	  would	  not	  mimic	  the	  
complex	  radial	  and	  longitudinal	  gradients	  present	  in	  tumours	  (Dewhirst	  et	  al.,	  1999),	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they	  would	  predictably	  reproduce	  the	  diversity	  of	  cell-­‐types	  and	  environments	  




Figure	  3.10	  Diagram	  of	  tumour	  microenvironent	  gradients,	  A)	  the	  linear,	  observable	  
microenvironment	  gradients	  in	  the	  micro	  fluidic	  device	  have	  a	  similar	  pattern	  to	  
those	  surrounding	  blood	  vessels	  in	  tumours:	  proliferating	  (green),	  quiescent	  
(transition),	  and	  necrotic	  (red).	  B)	  Conceptual	  concentration	  profiles	  of	  nutrients	  
(green),	  drugs	  (green),	  and	  wastes	  (blue)	  around	  blood	  vessels	  can	  be	  emulated	  by	  
micro	  fluidic	  devices;	  regions	  far	  from	  blood	  or	  culture	  medium	  are	  low	  in	  nutrients	  
and	  drugs,	  and	  high	  in	  wastes.	  Adapted	  from	  Walsh	  et	  al.,	  2009.	  
	  
Although	  the	  micro	  fluidic	  system	  does	  go	  some	  way	  to	  replicating	  the	  in	  vivo	  
conditions,	  with	  so	  many	  variables	  to	  consider	  with	  regards	  to	  drug	  diffusion	  and	  
penetration,	  dose	  response	  experiments	  were	  performed	  initially	  based	  on	  in	  vivo	  
plasma	  dose	  levels.	  	  
With	  regards	  to	  cisplatin,	  peak	  plasma	  concentrations	  ranging	  from	  2.5–5.3	  
and	  0.22–0.73	  µg/ml	  respectively	  (Vermorken	  et	  al.,	  1984,	  Vermorken	  et	  al.,	  1986),	  
a	  mean	  observed	  peak	  concentration	  (Cmax)	  of	  2.9	  µg	  /ml	  and	  area	  under	  the	  curve	  
(AUC)	  of	  347	  µg	  h	  l-­‐1	  (Johnsson	  et	  al.,	  1996)	  have	  all	  been	  reported	  following	  doses	  of	  
100-­‐mg/m2	  in	  HNSCC	  patients.	  In	  order	  to	  determine	  the	  optimal	  dose	  for	  use	  in	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micro	  fluidic-­‐based	  studies,	  based	  on	  these	  clinical	  studies	  it	  was	  therefore	  decided	  
to	  use	  concentrations	  of	  1,	  5,	  10	  and	  25	  µg/ml.	  
A	  consistent	  target	  range	  of	  AUC	  for	  5FU	  infusion-­‐based	  regimens	  has	  been	  
established	  as	  20	  –	  25	  mg/l	  h-­‐1	  in	  studies	  largely	  of	  colorectal	  cancer	  patients,	  
independent	  of	  administration	  modes	  (bolus	  vs	  infusion)	  and	  schedules	  (several	  
hours	  to	  several	  days)	  (Ychou	  et	  al.,	  1999,	  Ychou	  et	  al.,	  2003,	  Di	  Paolo	  et	  al.,	  2008,	  
Gamelin	  et	  al.,	  2008).	  	  This	  equates	  to	  a	  plasma	  concentration	  of	  450-­‐550	  µg/l	  (Saif	  
et	  al.,	  2009),	  although	  evidence	  suggests	  that	  when	  combined	  with	  other	  cytotoxic	  
agents	  (e.g.	  cisplatin	  as	  in	  the	  case	  of	  HNSCC),	  a	  regime	  equating	  to	  an	  AUC	  of	  25-­‐30	  
mg/l	  h-­‐1	  should	  be	  used	  (Ploylearmsaeng	  et	  al.,	  2006).	  	  This	  is	  achieved	  by	  generating	  
a	  steady	  state	  plasma	  concentration	  of	  0.55-­‐0.65	  µg/ml	  (Saif	  et	  al.,	  2009).	  	  
Additionally,	  a	  dosage	  of	  1000mg/m2	  generated	  an	  average	  Cmax	  of	  2	  µg/ml	  (Saif	  et	  
al.,	  2009).	  	  Based	  on	  these	  findings,	  once	  again	  concentrations	  of	  1,	  5,	  10	  and	  25	  
µg/ml	  were	  used	  in	  this	  study.	  
Studies	  of	  the	  administration	  of	  1	  h	  infusions	  of	  100	  mg/m2	  of	  docetaxel	  have	  
demonstrated	  a	  Cmax	  of	  4.7	  µmol/l	  and	  an	  AUC	  of	  5.69	  µmol/l	  (Eisenhauer	  and	  
Vermorken,	  1998).	  Phase	  1	  drug	  studies	  using	  a	  similar	  dose	  reported	  a	  Cmax	  of	  3.7	  
µg/ml	  and	  an	  AUC	  of	  4.6	  µg	  h	  l-­‐1	  (Bridgewater,	  2010).	  	  Concentrations	  of	  1.5,	  7.5,	  15	  
and	  37.5	  µg/ml	  were	  therefore	  tested	  in	  the	  micro	  fluidic	  device.	  
3.4.3	  	  Materials	  and	  Methods	  
	   Tumour	  biopsies	  were	  treated	  as	  previously	  described	  (section	  2.1)	  The	  
tumour	  was	  prepared	  into	  4mm3	  sized	  biopsy	  pieces,	  snap	  frozen	  and	  stored	  prior	  to	  
use	  as	  out-­‐lined	  in	  section	  2.1.3.	  	  On	  use,	  the	  tumour	  was	  prepared	  and	  micro	  fluidic	  
devices	  were	  set	  and	  tested	  as	  in	  the	  viability	  studies	  (section	  3.1).	  	  The	  appropriate	  
chemotherapy	  regimen	  was	  added	  to	  the	  media,	  following	  22	  h	  incubation	  of	  media	  
alone	  to	  allow	  the	  tumour	  to	  stabilise	  and	  the	  initial	  peak	  in	  LDH	  release	  to	  subside.	  
Drugs	  alone	  and	  in	  combination	  were	  infused	  continually	  throughout	  the	  remainder	  
of	  the	  incubation	  period.	  
Studies	  concerned	  with	  dosage	  of	  chemotherapy	  agent	  were	  performed	  over	  
4	  days	  with	  effluent	  collection	  as	  in	  optimisation	  studies	  (section	  3.1).	  	  Initial	  studies	  
on	  different	  chemotherapy	  agents	  were	  performed	  over	  5	  days	  (short-­‐term)	  as	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viability	  studies	  had	  demonstrated	  the	  persistence	  of	  cell	  viability	  throughout	  this	  
period.	  Finally	  studies	  were	  performed	  over	  a	  9-­‐day	  period	  (long-­‐term)	  with	  effluent	  
collection	  on	  days	  1,	  2,	  5,	  6,	  7,	  8	  and	  9	  only,	  so	  that	  the	  continuing	  effects	  of	  the	  
chemotherapy	  agents	  on	  days	  5	  to	  9	  could	  be	  elucidated.	  For	  these	  long-­‐term	  
studies,	  a	  fresh	  batch	  of	  chemotherapy	  agents	  was	  prepared	  and	  added	  to	  the	  micro	  
fluidic	  system	  on	  day	  5	  of	  incubation	  to	  minimise	  reduction	  in	  drug	  efficacy	  
associated	  with	  exposure	  to	  light	  and	  potential	  breakdown	  over	  a	  prolonged	  period.	  
Results	  for	  the	  short	  and	  long	  term	  effects	  of	  chemotherapy	  were	  analysed	  as	  an	  
average	  over	  a	  24	  h	  period.	  	  The	  effect	  of	  chemotherapy	  on	  cell	  death	  was	  
determined	  by	  relative	  increase	  in	  cell	  death	  compared	  with	  the	  control	  and	  /or	  
increasing	  drug	  concentration.	  
3.4.4	  	  Results	  
3.4.4.1	  	  Dose	  response	  	  
A	  metastatic	  lymph	  node	  from	  a	  tonsillar	  SCC	  was	  used	  to	  test	  the	  dose	  
responses	  for	  all	  agents.	  Two	  micro	  fluidic	  chips	  were	  used	  as	  a	  control	  for	  each	  
chemotherapy	  drug	  (a	  total	  of	  6	  chips).	  Four	  different	  doses	  were	  tested	  for	  each	  of	  
the	  3	  agents	  in	  duplicate	  (24	  chips).	  The	  results	  shown	  (Figure	  3.11)	  are	  taken	  from	  
one	  chip	  for	  each	  series	  as	  in	  most	  cases	  only	  one	  chip	  was	  successful.	  
All	  cisplatin	  concentrations	  caused	  an	  increase	  in	  LDH	  compared	  with	  control	  
(Figure	  3.11).	  	  This	  effect	  reduced	  over	  time,	  being	  maximal	  on	  days	  2	  and	  3	  of	  
incubation.	  	  The	  greatest	  effect	  was	  seen	  on	  the	  addition	  of	  5	  µg/ml	  and	  above,	  











































	  	  	  

















Figure	  3.11	  Graph	  depicting	  LDH	  release	  per	  µg	  of	  tissue	  after	  addition	  (22	  h)	  and	  
continued	  perfusion	  (to	  74	  h)	  with	  differing	  concentrations	  of	  cisplatin.	  10%	  (v/v)	  
lysis	  buffer	  was	  added	  at	  68	  h	  incubation.	  	  Each	  result	  is	  representative	  of	  one	  micro	  
device	  only.	  Breaks	  in	  lines	  signify	  periods	  where	  samples	  were	  not	  collected.	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On	  the	  addition	  of	  5FU	  of	  any	  concentration,	  an	  increase	  in	  cell	  death,	  as	  
measured	  by	  LDH	  release,	  was	  seen	  in	  a	  similar	  manner	  to	  cisplatin	  (Figure	  3.12).	  	  
Cell	  death	  was	  maximal	  on	  days	  1	  and	  2	  following	  addition	  and,	  overall,	  the	  resultant	  
cell	  death	  decreased	  over	  time.	  	  Although	  at	  25	  µg/ml,	  cell	  death	  appeared	  to	  be	  
maximal,	  the	  greater	  variability	  when	  compared	  with	  the	  other	  doses	  and	  missing	  
points	  limited	  the	  data	  set.	  Again,	  5	  µg/ml	  was	  chosen	  as	  this	  value	  gave	  a	  cytotoxic	  
effect	  and	  was	  within	  the	  plasma	  dose	  range	  found	  in	  the	  literature,	  accepting	  that	  
higher	  doses	  may	  cause	  greater	  toxicity.	  	  
	  
Figure	  3.12	  Graph	  depicting	  LDH	  release	  per	  µg	  of	  tissue	  after	  addition	  (22	  h)	  and	  
continued	  perfusion	  (to	  74	  h)	  with	  differing	  concentrations	  of	  5FU.	  10%	  (v/v)	  lysis	  
buffer	  was	  added	  at	  68	  h	  incubation.	  Each	  result	  is	  representative	  of	  one	  micro	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On	  the	  addition	  of	  docetaxel	  of	  any	  concentration,	  an	  increase	  in	  cell	  death,	  
as	  measured	  by	  LDH	  release	  was	  seen	  (Figure	  3.13).	  	  Cell	  death	  was	  maximal	  on	  days	  
2	  and	  3	  following	  addition	  of	  drug,	  similar	  to	  the	  other	  chemotherapy	  agents.	  	  As	  
with	  the	  other	  agents,	  the	  resultant	  cell	  death	  decreased	  over	  time.	  	  Although	  at	  1.5	  
µg/ml,	  there	  was	  an	  apparent	  increase	  in	  cell	  death,	  this	  could	  have	  been	  related	  to	  
interrupted	  flow	  (as	  was	  observed	  during	  this	  experiment)	  rather	  than	  an	  increased	  
LDH	  due	  to	  the	  effects	  of	  the	  drug.	  It	  was	  therefore	  thought	  that	  the	  7.5	  µg/ml	  was	  a	  
better	  representation	  of	  increased	  cell	  death,	  again	  this	  value	  being	  comparable	  




Figure	  3.13	  Graph	  depicting	  LDH	  release	  per	  µg	  of	  tissue	  after	  addition	  (22	  h)	  and	  
continued	  perfusion	  (to	  74	  h)	  with	  differing	  concentrations	  of	  docetaxel.	  10%	  (v/v)	  
lysis	  buffer	  was	  added	  at	  68	  h	  incubation.	  Each	  result	  is	  representative	  of	  one	  micro	  
device	  only.	  	  Breaks	  in	  lines	  signify	  periods	  where	  samples	  were	  not	  collected	  and	  
analysed.	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3.4.4.2	  	  Short	  Term	  Chemotherapy	  
	   Two	  different	  HNSCC	  metastatic	  nodes	  were	  assessed	  in	  duplicate	  for	  LDH	  
response	  to	  chemotherapy	  agents	  when	  given	  alone	  and	  in	  combination	  when	  
added	  after	  22	  h	  of	  incubation	  (day	  1),	  perfused	  continually	  with	  the	  agent(s),	  and	  
assessed	  over	  the	  following	  4	  days	  (days	  2	  to	  5).	  	  The	  number	  of	  chips	  tested,	  
successful	  and	  otherwise	  are	  shown	  in	  Table	  3.4.	  	  	  
The	  increased	  cell	  death	  was	  most	  rapid	  following	  the	  addition	  of	  cisplatin,	  
whereas	  the	  effect	  of	  docetaxel	  seemed	  to	  increase	  proportionally	  over	  time.	  	  The	  
cell	  death	  associated	  with	  5FU	  was	  more	  variable	  with	  a	  fairly	  rapid	  response	  and	  
subsequent	  fall	  but	  evidence	  of	  an	  increase	  in	  cell	  death	  again	  on	  day	  5.	  	  A	  similar	  
pattern	  was	  seen	  on	  the	  addition	  of	  combined	  cisplatin	  and	  docetaxel;	  the	  early	  
peak	  in	  cell	  death	  on	  day	  2	  perhaps	  being	  explained	  by	  the	  possible	  more	  rapid	  
effects	  of	  cisplatin,	  with	  the	  late	  peak	  on	  day	  5	  by	  the	  slower	  effects	  of	  docetaxel	  
causing	  an	  increase	  of	  cell	  death	  again	  with	  prolonged	  incubation.	  	  
The	  greatest	  increase	  in	  cell	  death	  is	  seen	  on	  the	  addition	  of	  all	  three	  agents.	  	  
This	  was	  maximal	  on	  days	  4	  and	  5	  of	  incubation	  although	  a	  modest	  effect	  was	  seen	  
on	  earlier	  days.	  	  As	  cell	  death	  seemed	  to	  increase	  with	  prolonged	  incubation	  for	  
some	  of	  the	  agents	  and	  in	  particular,	  for	  combined	  agents,	  further	  studies	  were	  
undertaken	  on	  the	  effects	  of	  cell	  death	  over	  a	  prolonged	  period	  of	  incubation.	  	  
The	  2	  tumours	  in	  this	  experiment	  seem	  to	  have	  behaved	  differently	  from	  
those	  in	  section	  3.4.4.1.	  	  In	  the	  dose	  response	  experiments	  cell	  death	  was	  greatest	  
on	  the	  first	  2	  days	  of	  incubation	  and	  had	  reduced	  on	  the	  third	  day	  for	  all	  three	  
agents	  to	  minimal	  levels	  despite	  the	  addition	  of	  lysis	  buffer	  at	  68	  h.	  	  In	  these	  short-­‐
term	  chemotherapy	  experiments,	  cell	  death	  was	  greatest	  on	  day	  3	  for	  cisplatin,	  
continued	  increasing	  on	  day	  3	  and	  beyond	  for	  docetaxel	  and	  the	  combinations	  of	  
agents	  and	  was	  variable	  for	  5FU.	  	  Only	  the	  control	  tumour	  demonstrated	  a	  reduction	  
in	  cell	  death	  with	  time.	  	  This	  variation	  could	  be	  accounted	  for	  by	  tumour	  
heterogeneity.	  	  	  Additionally,	  as	  the	  tumour	  in	  the	  dose	  experiments	  was	  incubated	  
for	  shorter	  time	  periods	  and	  was	  ‘lysed’	  at	  68	  h,	  the	  results	  are	  not	  directly	  
comparable.	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Figure	  3.14	  Graph	  depicting	  LDH	  release	  per	  µg	  of	  tissue	  of	  control	  (n=4	  chips	  from	  
n=2	  tumours)	  and	  after	  addition	  (22	  h)	  and	  continued	  perfusion	  (to	  98	  h)	  with	  
cisplatin	  (n=3	  chips	  from	  n=2	  tumours),	  5FU	  (n=3	  chip	  from	  n=2	  tumours),	  docetaxel	  
(n=2	  chips	  from	  n=2	  tumours),	  cisplatin	  plus	  docetaxel	  (n=2	  chips	  from	  n=2	  tumours)	  

























































1	   Node	  1	   2	  (2)	   1	  (1)	   1	  (1)	   1	  (1)	   1	  (1)	   2	  (1)	  
2	   Node	  1	   2	  (0)	   1	  (1)	   1	  (1)	   1	  (0)	   0	   2(2)	  
3	   Node	  2	   2	  (2)	   1	  (1)	   1	  (1)	   1	  (1)	   1	  (1)	   2	  (2)	  
4	   Node	  2	   2	  (0)	   1	  (0)	   1	  (0)	   1	  (0)	   2	  (0)	   2	  (0)	  
Total	   	   8	  (4)	   4	  (3)	   4	  (3)	   4	  (2)	   4	  (2)	   8	  (5)	  
Table	  3.4	  Summary	  of	  number	  of	  experiments,	  tumour	  sub-­‐sites	  and	  successful	  chips	  for	  short	  term	  chemotherapy	  studies.	  In	  
experiment	  4	  a	  power	  cut	  resulted	  in	  the	  stopping	  of	  media	  in	  flow	  for	  a	  period	  of	  2	  hours	  on	  day	  4.	  	  Results	  for	  this	  experiment	  
	  were	  therefore	  not	  included.	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3.4.4.3	  	  Longer	  Term	  Chemotherapy	  
To	  assess	  the	  effects	  of	  the	  chemotherapy	  agents	  over	  a	  longer	  incubation	  
(up	  to	  195	  h),	  two	  different	  metastatic	  lymph	  nodes	  were	  each	  subjected	  to	  
chemotherapy	  agents	  in	  duplicate	  and	  are	  summarised	  in	  Table	  3.5.	  Effluent	  was	  
only	  collected	  on	  days	  1,2	  and	  5	  to	  9	  as	  information	  regarding	  the	  effects	  of	  
chemotherapy	  agents	  on	  days	  3	  and	  4	  had	  been	  gained	  from	  the	  short-­‐term	  
experiments.	  	  
As	  found	  in	  optimisation	  studies	  and	  short	  term	  incubation	  with	  
chemotherapy	  agents,	  in	  the	  control	  tumours,	  cell	  death	  decreases	  over	  time	  to	  
minimal	  levels	  (Figure	  3.15),	  and	  this	  remains	  the	  case	  at	  days	  5	  to	  9.	  The	  addition	  of	  
chemotherapy	  agents	  caused	  an	  increase	  in	  cell	  death	  on	  most	  days	  up	  to	  and	  
including	  the	  final	  day	  of	  incubation.	  As	  in	  the	  short-­‐term	  incubation	  studies,	  again	  
cisplatin	  caused	  the	  most	  rapid	  increase	  in	  cell	  death,	  peaking	  on	  day	  5	  and	  then	  
falling	  to	  moderate	  levels,	  then	  sustained	  though	  out	  the	  remaining	  incubation.	  	  
Interestingly,	  the	  effects	  of	  docetaxel	  seemed	  to	  decrease	  proportionally	  over	  time	  
after	  day	  5,	  whereas	  in	  the	  short-­‐term	  studies	  an	  increase	  had	  been	  seen	  between	  
days	  2	  and	  5,	  perhaps	  accounted	  for	  by	  tumour	  heterogeneity.	  	  In	  contrast,	  the	  
effect	  of	  5FU	  modestly	  increased	  from	  days	  5	  to	  9.	  Again,	  an	  additive	  cytotoxic	  effect	  
was	  seen	  on	  the	  addition	  of	  all	  three	  agents.	  This	  increased	  proportionally	  over	  time	  
and	  was	  maximal	  on	  day	  9.	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Figure	  3.15	  Graph	  depicting	  LDH	  release	  per	  µg	  of	  tissue	  of	  control	  (n=7	  chips	  from	  
n=2	  tumours)	  and	  after	  addition	  (22	  h)	  and	  continued	  perfusion	  (to	  195	  h)	  with	  
cisplatin	  (n=7	  chips	  from	  n=2	  tumours),	  5FU	  (n=5	  chips	  from	  n=2	  tumours),	  
docetaxel	  (n=4	  chips	  from	  n=2	  tumours),	  cisplatin	  plus	  docetaxel	  (n=3	  chips	  from	  
































































1	   Node	  1	   3	  (3)	   2	  (2)	   1	  (1)	   1	  (1)	   1	  (0)	   2	  (1)	  
2	   Node	  1	   3	  (2)	   1	  (1)	   1	  (1)	   1	  (1)	   2	  (2)	   2	  (2)	  
3	   Node	  2	   2	  (2)	   2	  (2)	   2	  (1)	   2	  (1)	   1	  (0)	   2	  (1)	  
4	   Node	  2	   2	  (0)	   2	  (2)	   2	  (2)	   2	  (1)	   2	  (1)	   2	  (1)	  
Total	   	   10	  (7)	   7(7)	   6	  (5)	   6	  (4)	   6	  (3)	   8	  (5)	  
Table	  3.5	  Summary	  of	  number	  of	  experiments,	  tumour	  sub-­‐sites	  and	  successful	  chips	  for	  long	  term	  chemotherapy	  studies.	  	  
A	  further	  experiment	  (experiment	  5)	  with	  oropharyngeal	  SCC	  was	  attempted,	  however,	  due	  to	  stalling	  on	  the	  pumps	  on	  	  
day	  4	  of	  incubation,	  the	  experiment	  was	  abandoned.
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3.4.5	  	  Discussion	  
These	  results	  show	  the	  utility	  of	  the	  micro	  fluidic	  device	  as	  a	  platform	  to	  test	  
a	  variety	  of	  chemotherapy	  agents	  as	  single	  and	  combined	  therapies	  on	  individual	  
tumour	  biopsies.	  	  Although	  the	  short	  and	  longer-­‐term	  studies	  were	  only	  carried	  out	  
on	  two	  different	  tumours	  in	  duplicate,	  results	  demonstrated	  a	  remarkable	  similarity	  
in	  trend	  on	  the	  addition	  of	  the	  chemotherapy	  agents.	  	  This	  is	  the	  only	  study	  to	  date	  
that	  has	  combined	  whole	  tumour	  culture	  within	  a	  micro	  fluidic	  device	  with	  the	  
testing	  of	  chemotherapy	  agents.	  
This	  study	  is	  however	  limited	  by	  the	  number	  of	  experiments	  performed.	  	  
Regarding	  the	  chemotherapy	  dosage	  experiments,	  only	  one	  chip	  was	  used	  for	  each	  
drug	  dose	  and	  control.	  	  Ideally	  this	  should	  have	  been	  duplicated,	  especially	  as	  some	  
of	  the	  chips	  exhibited	  variable	  flow	  patterns	  (and	  therefore	  questionable	  LDH	  
levels).	  In	  addition,	  only	  one	  tumour	  biopsy	  was	  used	  for	  all	  experiments.	  As	  has	  
already	  been	  alluded	  to,	  tumours	  demonstrate	  great	  heterogeneity	  in	  their	  response	  
to	  chemotherapy	  agents.	  	  Although	  a	  seemingly	  appropriate	  response	  was	  seen	  with	  
the	  addition	  of	  all	  chemotherapy	  agents	  in	  these	  experiments,	  how	  this	  would	  
compare	  with	  different	  tumour	  sub	  sites	  or	  even	  tumours	  of	  the	  same	  sub	  site	  
remains	  unknown.	  	  These	  experiments	  were	  used	  to	  determine	  the	  optimal	  
chemotherapy	  dosage	  to	  be	  used	  in	  further	  experiments,	  and	  although	  the	  literature	  
pertaining	  to	  in	  vivo	  plasma	  drug	  levels	  was	  considered,	  repeat	  experiments	  on	  
different	  tumour	  sub	  sites	  should	  have	  ideally	  been	  performed	  and	  would	  have	  been	  
if	  time	  had	  permitted.	  
Such	  limitations	  are	  also	  applicable	  to	  the	  short-­‐term	  and	  longer-­‐term	  
chemotherapy	  studies.	  	  Two	  different	  samples	  of	  nodal	  tissue	  containing	  metastatic	  
SCC	  were	  used	  for	  both	  experiments.	  	  Although	  the	  presence	  of	  nodal	  metastasis	  is	  
often	  an	  indication	  for	  the	  addition	  of	  chemotherapy	  to	  a	  treatment	  regimen,	  the	  
effect	  of	  chemotherapy	  agents	  on	  the	  primary	  tumour	  within	  a	  micro	  fluidic	  device	  
remains	  unknown	  and	  is	  the	  ongoing	  study	  of	  other	  post-­‐graduate	  students	  in	  the	  
laboratory.	  Although	  these	  experiments	  were	  duplicated,	  further	  experiments	  are	  
essential	  to	  demonstrate	  the	  robustness	  and	  reproducibility	  of	  this	  technique	  as	  well	  
to	  investigate	  the	  tumour	  variability.	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To	  investigate	  the	  cytotoxic	  effects	  of	  the	  various	  chemotherapy	  agents,	  LDH	  
alone	  was	  used,	  whereas	  in	  the	  viability	  studies,	  the	  addition	  of	  WST-­‐1	  to	  the	  media	  
fluid	  further	  validated	  the	  results.	  	  WST-­‐1	  was	  not	  used	  in	  the	  chemotherapy	  studies	  
due	  to	  time	  constraints,	  however	  future	  studies	  would	  be	  of	  great	  interest.	  	  The	  
additional	  inclusion	  of	  a	  measure	  of	  viability	  would	  strengthen	  the	  conclusions	  of	  
the	  chemotherapy	  effects,	  as	  seen	  in	  the	  complementary	  behaviour	  of	  LDH	  and	  
WST-­‐1	  in	  the	  initial	  validation	  study.	  
Another	  technique	  for	  assessing	  the	  response	  of	  tissue	  to	  chemotherapy	  
agents	  would	  be	  to	  use	  IHC.	  Changes	  in	  protein	  expression	  of	  single	  cell	  cultures	  in	  
response	  to	  chemotherapy	  have	  been	  studied	  in	  HNSCC	  as	  described	  in	  section	  1.7	  
however	  these	  are	  yet	  to	  be	  demonstrated	  in	  tissue	  culture	  methods.	  Vaira	  et	  al.	  
(2010)	  used	  changes	  in	  the	  PI3K/Akt	  signalling	  pathway	  as	  proof	  of	  concept	  of	  the	  
chemotherapy	  effects	  in	  their	  ex	  vivo	  organotypic	  culture	  model.	  Untreated	  lung,	  
prostate,	  and	  colon	  tumours	  showed	  constant	  levels	  of	  p-­‐Akt	  andp-­‐S6RP	  that	  
decreased	  dramatically	  after	  ex	  vivo	  treatment	  with	  the	  PI3K	  inhibitor	  LY294002	  in	  a	  
dose-­‐dependent	  manner.	  Such	  techniques	  enable	  the	  interpretation	  of	  these	  
surrogate	  markers	  of	  effect.	  
Based	  on	  the	  methodology	  used	  for	  histo-­‐architectural	  as	  described	  in	  section	  
3.3.3	  tissue	  could	  be	  removed	  from	  the	  device	  post	  chemotherapy	  treatment	  and	  
stained	  for	  potential	  prognostic	  markers.	  	  As	  described	  in	  section	  1.7.1,	  the	  role	  of	  
p53	  and	  p16	  in	  the	  cytotoxic	  action	  of	  cisplatin	  may	  have	  significance	  as	  prognostic	  
markers	  to	  predict	  a	  tumour’s	  chemosensitivity	  with	  status	  or	  indeed	  changes	  in	  
expression	  of	  p53	  and	  p16	  following	  chemotherapy	  treatment	  in	  vitro	  of	  potential	  
value	  for	  treatment	  planning	  (Yip	  et	  al.,	  2006).	  	  Other	  potential	  proteins	  of	  interest	  
include	  the	  changes	  in	  expression	  of	  p53,	  Rb	  protein	  and	  p21WAF1/CIP1	  protein	  with	  
5FU	  exposure	  (Lee	  et	  al.,	  2005,	  Liu	  et	  al.,	  2006)	  and	  the	  correlation	  of	  Bcl-­‐2/Bax	  
status	  with	  sensitivity	  to	  docetaxel	  (Kawakami	  et	  al.,	  1999).	  	  Examining	  these	  changes	  
in	  protein	  expression	  (e.g.	  p16)	  with	  particular	  reference	  to	  HPV	  status	  would	  also	  be	  
of	  interest,	  as	  well	  as	  differences	  in	  general	  chemosensitivity	  between	  HPV	  negative	  
and	  positive	  tumours.	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In	  addition,	  measuring	  changes	  in	  tumour-­‐mediated	  factors	  in	  response	  to	  
chemotherapy	  is	  an	  area	  of	  research	  with	  great	  potential	  to	  increase	  our	  
understanding	  of	  drug/tumour	  interactions.	  As	  demonstrated	  by	  the	  work	  of	  
Webster	  et	  al.	  (2010)	  on	  colorectal	  tumour	  biopsies	  within	  a	  micro	  fluidic	  device,	  the	  
quantification	  of	  the	  tumour	  mediated	  factors	  VEGF	  in	  response	  to	  changes	  in	  the	  
tumour	  microenvironment	  presents	  an	  alternative	  means	  of	  analysis.	  Although,	  no	  
suitable,	  soluble	  biomarkers	  have	  been	  identified	  as	  of	  prognostic	  relevance	  in	  
HNSCC	  as	  yet,	  the	  HNSCC	  expression	  of	  surrogate	  markers	  important	  in	  other	  solid	  
tumours	  would	  be	  of	  interest.	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4.0	  Thesis	  Summary	  and	  Future	  Work	  
	  
The	  initial	  aim	  of	  this	  thesis	  was	  to	  validate	  and	  optimise	  the	  micro	  fluidic	  
system	  for	  the	  interrogation	  of	  HNSCC	  throughout	  a	  prolonged	  incubation	  period,	  by	  
analysing	  markers	  of	  cell	  death	  and	  proliferation.	  	  This	  was	  achieved,	  with	  changes	  
in	  LDH	  excretion	  into	  the	  tumour	  effluent	  and	  increases	  in	  WST-­‐1	  proliferation	  
showing	  a	  reproducible	  trend,	  comparable	  with	  published	  literature	  on	  liver	  biopsies	  
incubated	  in	  a	  similar	  manner	  (Hattersley	  et	  al.,	  2008,	  van	  Midwoud	  et	  al.,	  2010a).	  	  A	  
total	  of	  9	  different	  tumours	  representing	  common	  HNSCC	  sub	  sites	  and	  metastatic	  
nodal	  tissue	  were	  assessed	  for	  changes	  in	  LDH	  production	  and	  WST-­‐1	  proliferation	  
within	  the	  device	  in	  various	  situations	  (buffer	  alone	  and	  with	  lysis	  throughout).	  	  
In	  this	  study,	  changes	  in	  tissue	  architecture	  were	  subjectively	  analysed;	  the	  
changes	  associated	  with	  cell	  death	  and	  apoptosis	  were	  described	  in	  terms	  of	  the	  
preservation	  of	  the	  cell	  nuclei	  and	  cell-­‐to-­‐cell	  cohesion.	  	  Although	  there	  was	  very	  
little	  change	  in	  architecture	  (Dr	  Karsai,	  Consultant	  Histopathologist	  in	  Head	  and	  
Neck	  Cancer,	  assessed	  ‘no	  difference’	  in	  incubated	  samples	  compared	  to	  those	  
immediately	  frozen),	  a	  more	  objective	  approach	  would	  be	  used	  in	  future	  studies	  
given	  sufficient	  time	  and	  resources.	  	  For	  example	  staining	  techniques	  such	  as	  
Lavacell™,	  based	  on	  the	  binding	  of	  the	  fluorescent	  calcein	  probe	  to	  the	  cytosol	  of	  
viable	  cells	  as	  a	  marker	  of	  cell	  viability	  coupled	  with	  binding	  of	  the	  fluorescent	  
propidium	  iodide	  to	  damaged	  intracellular	  DNA,	  as	  a	  demonstration	  of	  apoptosis,	  
could	  be	  incorporated.	  
To	  confirm	  the	  advantages	  of	  the	  micro	  fluidic	  technique,	  changes	  in	  tissue	  
architecture	  and	  viability	  need	  to	  be	  directly	  compared	  with	  tumour	  cultured	  by	  
existing,	  commonly	  used,	  methods.	  	  As	  described	  in	  section	  1.8	  tissue	  culture	  
techniques	  such	  as	  organotypic	  and	  histotypic	  culture	  are	  often	  employed.	  	  A	  major	  
limiting	  factor	  regularly	  reported,	  particularly	  of	  whole	  tissue	  (organ)	  culture,	  is	  the	  
lack	  of	  effective	  tissue	  perfusion.	  	  Micro	  fluidic-­‐based	  tissue	  culture	  is	  most	  similar	  
to	  organ	  culture	  techniques	  as	  both	  preserve	  the	  tumour	  microenvironment.	  	  Thus	  a	  
systematic	  comparison	  of	  the	  tissue	  is	  required.	  	  As	  organ	  culture	  typically	  uses	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smaller	  biopsies	  than	  the	  micro	  fluidic	  technique	  (e.g.	  1mm3	  samples	  of	  UADT	  
mucosa	  as	  used	  by	  Kleinsasser	  and	  colleagues	  (2004)),	  biopsies	  of	  various	  sizes	  of	  
HNSCC	  tissue	  incubated	  using	  organ	  culture	  techniques	  (e.g.	  filter	  well	  inserts	  or	  
grown	  on	  a	  stainless	  steel	  grid)	  should	  be	  compared	  to	  the	  4mm3	  micro	  fluidic	  
grown	  samples.	  	  Examining	  the	  histo-­‐architectural	  changes	  of	  HNSCC	  tissue,	  taken	  
from	  the	  same	  initial	  biopsy,	  cultured	  by	  these	  alternative	  methods	  will	  allow	  critical	  
evaluation	  of	  the	  effectiveness	  of	  the	  micro	  fluidic	  system.	  In	  addition,	  it	  would	  be	  
very	  interesting	  to	  perform	  an	  mRNA	  genome	  screen	  of	  tissue	  biopsies	  maintained	  
in	  the	  micro	  fluidic	  device	  over	  time,	  as	  compared	  with	  tissue	  samples,	  and	  those	  
maintained	  in	  static	  culture.	  	  This	  analysis	  would	  allow	  assessment	  of	  both	  
“adaption”	  to	  culture	  in	  the	  micro	  fluidic	  device	  as	  well	  as	  key	  changes	  between	  
culture	  methods.	  	  Obviously	  the	  mRNA	  screen	  would	  require	  verification	  at	  the	  
protein	  level	  by	  Western	  blot	  or	  IHC.	  	  
The	  second	  aim	  of	  the	  work	  was	  to	  optimise	  the	  platform	  for	  studying	  
chemotherapy	  administration	  in	  HNSCC.	  	  In	  these	  studies,	  the	  most	  suitable	  doses	  of	  
chemotherapy	  agents	  to	  use	  on	  HNSCC	  within	  the	  micro	  fluidic	  system	  were	  
determined.	  	  Although	  these	  experiments	  were,	  to	  some	  extent,	  limited	  by	  a	  lack	  of	  
experimental	  replication,	  the	  fact	  that	  the	  tissue	  did	  respond	  in	  a	  seemingly	  dose	  
dependent	  manner	  at	  concentrations	  comparable	  to	  those	  found	  in	  vivo	  is	  evidence	  
of	  the	  ability	  of	  micro	  fluidic	  devices	  to	  mimic	  in	  vivo	  physiological	  conditions	  and	  
tumour	  microenvironment.	  	  Furthermore,	  all	  of	  the	  tumours	  tested	  did	  respond	  to	  
the	  chemotherapy	  agents,	  as	  predicted,	  by	  an	  increase	  in	  cell	  death	  compared	  with	  
control.	  	  Such	  findings	  do	  not	  only	  demonstrate	  the	  role	  of	  tissue	  culture	  within	  
micro	  fluidic	  devices	  but	  also	  show	  the	  potential	  integration	  of	  ‘whole	  tissue’	  culture	  
and	  pharmacological	  studies	  using	  micro	  fluidic	  based	  tissue	  culture.	  	  	  
As	  described	  in	  section	  1.9.2.4	  the	  application	  of	  micro	  fluidic	  technology	  to	  
pharmacological	  studies	  has	  already	  been	  studied,	  with	  areas	  of	  interest	  including	  
drug	  discovery	  and	  pre-­‐clinical	  toxicology	  studies	  on	  multi-­‐organ	  micro	  fluidic	  
devices,	  pharmacodynamic	  studies	  and	  the	  analysis	  of	  chemotherapy	  resistance	  in	  
cell	  lines.	  	  To	  date	  such	  studies	  are	  mostly	  based	  on	  cell	  cultures	  however	  the	  
integration	  of	  whole	  tissue	  maintenance,	  with	  its	  enhanced	  ability	  to	  recreate	  the	  in	  
vivo	  microenvironment	  of	  numerous	  tissue	  types,	  provides	  a	  highly	  applicable	  and	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versatile	  platform	  for	  pharmacological	  studies.	  	  An	  area	  of	  particular	  interest	  is	  that	  
of	  resistance	  to	  chemotherapy	  by	  HNSCC	  and	  potential	  molecular	  mechanisms	  
involved.	  	  Using	  a	  micro	  fluidic-­‐based	  approach,	  HNSCC	  tissue	  can	  be	  stratified	  by	  its	  
cytotoxic	  response	  to	  chemotherapy	  and	  can	  be	  further	  evaluated	  by	  IHC	  for	  
differences	  in	  expression	  of	  known	  key	  proteins	  e.g.	  p16	  (Yip	  et	  al.,	  2006),	  p53,	  Rb	  
and	  p21	  (Lee	  et	  al.,	  2005,	  Liu	  et	  al.,	  2006)	  and	  Bcl-­‐2/Bax	  (Kawakami	  et	  al.,	  1999).	  
The	  final	  aim	  of	  this	  thesis	  was	  to	  evaluate	  the	  potential	  of	  the	  micro	  fluidic	  
approach	  for	  widespread	  clinical	  applicability.	  	  The	  response	  of	  individual	  tumour	  
biopsies	  to	  single,	  and	  combination	  chemotherapy	  agents,	  although	  in	  its	  infancy	  
demonstrated	  proof	  of	  concept.	  	  Undoubtedly	  these	  experiments	  need	  repeating,	  
especially	  incorporating	  other	  HNSCC	  tumour	  sub	  sites,	  however	  the	  potential	  
application	  includes	  the	  individualisation	  of	  chemotherapy	  treatment	  for	  not	  just	  
HNSCC	  but	  all	  solid	  tumour	  types.	  	  	  
The	  potential	  for	  micro	  fluidic	  technology	  for	  automation	  and	  integration	  on	  
to	  a	  portable	  device	  has	  already	  seen	  the	  development	  of	  devices	  for	  point-­‐of-­‐care	  
diagnostic	  instrumentation	  (Herr	  et	  al.,	  2007).	  	  Ultimately,	  incorporating	  the	  findings	  
of	  this	  thesis	  with	  the	  applicability	  of	  micro	  fluidic	  technology,	  an	  automated	  device	  
could	  be	  developed	  to	  test	  individual	  patient	  biopsy	  samples	  in	  order	  to	  generate	  
tumour	  specific	  response	  to	  chemotherapy.	  	  Once	  validated	  it	  is	  proposed	  that	  data	  
generated	  from	  the	  micro	  fluidic	  interrogation	  of	  biopsies,	  obtained	  from	  potentially	  
any	  solid	  tumour	  commonly	  treated	  with	  chemotherapy	  agents,	  would	  allow	  
determination	  of	  the	  chemosensitivity	  and	  best	  drug	  combination	  allowing	  tailoring	  
of	  each	  patient’s	  treatment	  to	  their	  individual	  tumour	  response.	  	  Furthermore,	  this	  
could	  all	  be	  achieved	  within	  a	  realistic	  time	  frame.	  
In	  practice	  this	  would	  mean	  tissue	  will	  be	  obtained	  at	  the	  time	  of	  diagnostic	  
biopsy	  of	  a	  suspected	  new	  or	  recurrent	  HNSCC	  and	  placed	  in	  a	  micro	  fluidic	  device.	  	  
The	  tissue	  samples	  will	  be	  cultured	  and	  subjected	  to	  chemotherapy	  agents	  whist	  the	  
diagnostic	  biopsy	  is	  undergoing	  formal	  histological	  examination	  and	  additional	  
radiological	  imaging	  is	  performed	  to	  determine	  nodal	  and	  distant	  metastatic	  spread.	  	  
Based	  on	  histological,	  radiological	  and	  patient	  information,	  the	  treatment	  plan	  is	  
then	  determined	  by	  the	  multidisciplinary	  team	  at	  1	  to	  3	  weeks	  after	  the	  diagnostic	  
biopsy.	  	  As	  this	  thesis	  has	  shown	  that	  response	  to	  chemotherapy	  can	  be	  determined	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over	  a	  9-­‐day	  period,	  information	  derived	  from	  micro	  fluidic	  studies	  (e.g.	  
chemosensitivity	  or	  most	  cytotoxic	  regime)	  can	  be	  incorporated	  into	  discussions.	  	  It	  
is	  envisaged	  that	  a	  limitation	  to	  this	  approach	  may	  be	  the	  physical	  amount	  of	  tissue	  
biopsy	  available	  to	  be	  studied.	  
As	  described	  in	  section	  1.6,	  radiotherapy	  is	  often	  used	  as	  a	  primary	  modality	  
(e.g.	  in	  early	  glottic	  tumours)	  or	  as	  an	  adjunct	  to	  surgery	  to	  reduce	  local	  recurrent.	  	  
The	  relative	  portability	  of	  the	  micro	  fluidic	  device	  setup	  will	  allow	  tumour	  biopsies	  to	  
be	  irradiated	  ‘on	  chip’.	  	  The	  cytotoxic	  effects	  of	  radiotherapy	  can	  be	  measured	  by	  
means	  of	  LDH	  assay	  on	  the	  incubating	  tumour	  biopsies.	  	  Radiotherapy	  can	  also	  be	  
combined	  with	  chemotherapy	  (incorporating	  the	  use	  of	  cetuximab	  for	  example),	  
allowing	  for	  the	  complete	  in	  vitro	  replication	  of	  clinical	  management.	  	  Colleagues	  in	  
the	  department	  have	  commenced	  these	  studies	  that	  are	  running	  in	  parallel	  with	  the	  
chemotherapy	  experiments.	  
This	  thesis	  has	  demonstrated	  the	  possible	  applications	  of	  micro	  fluidic	  
technology	  and	  although	  as	  a	  ‘proof	  of	  concept’	  a	  real	  clinical	  application	  seems	  
possible,	  there	  is	  one	  unfulfilled	  aim.	  	  The	  true	  correlation	  with	  the	  in	  vivo	  tumour	  
behaviour	  is	  yet	  to	  be	  demonstrated.	  	  The	  key	  ongoing	  work	  from	  this	  thesis	  is	  
therefore	  to	  correlate	  the	  response	  to	  chemotherapy	  of	  the	  individual	  tumour	  on	  
chip	  to	  the	  overall	  clinical	  response	  of	  the	  patient.	  	  This	  has	  commenced;	  to	  date	  6	  
tumour	  biopsies	  have	  been	  stored	  (1	  of	  which	  was	  used	  for	  section	  3.4.4.3)	  for	  
patients	  undergoing	  chemotherapy	  as	  part	  of	  their	  treatment	  for	  HNSCC.	  	  Further	  
work	  needs	  to	  be	  undertaken	  to	  evaluate	  the	  response	  of	  these	  tumours	  to	  
chemotherapy	  within	  the	  micro	  fluidic	  device.	  	  The	  clinical	  response	  of	  these	  
patients	  will	  be	  followed	  for	  three	  years	  for	  maximal	  correlation	  and	  validation	  with	  
in	  vitro	  findings.	  	  The	  continuation	  of	  this	  work,	  based	  on	  the	  current	  throughput	  of	  
the	  department,	  would	  equate	  to	  the	  collection	  and	  evaluation	  of	  300	  individual	  
patient	  biopsies	  over	  a	  3-­‐year	  period.	  	  
Micro	  fluidic	  technology	  has	  the	  potential	  to	  revolutionise	  both	  our	  
understanding	  of	  the	  basic	  science,	  and	  our	  clinical	  management	  of	  tumours.	  	  Its	  
ability	  to	  replicate	  the	  tumour	  microenvironment	  in	  vitro	  and	  provide	  a	  testing	  
platform	  provides	  almost	  endless	  opportunities	  to	  study	  tumour	  behaviour,	  genetics	  
and	  pharmacology	  to	  name	  but	  a	  few.	  	  With	  further	  refinement	  of	  this	  technology,	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its	  immediacy	  and	  simplicity	  will	  allow	  for	  ‘personalised	  chemotherapy	  at	  the	  
bedside’	  in	  years	  to	  come.	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  Appendix	  	  
I	  	  Staging	  of	  Head	  and	  Neck	  Sub	  Sites	  	  
1.1	  	  Oropharynx	  
T1	   Tumour	  ≤	  2cm	  
T2	   Tumour	  >2cm	  but	  ≤	  4cm	  
T3	   Tumour	  >4cm	  
T4a	   Invades	  any	  of	  the	  following:	  deep	  muscles	  of	  the	  tongue,	  larynx,	  medial	  pterygoid,	  mandible	  and	  hard	  palate	  
T4b	   Invades	  any	  of	  the	  following:	  lateral	  pterygoid	  muscle,	  pterygoid	  plates,	  lateral	  nasopharynx,	  skull	  base;	  or	  encases	  the	  
carotid	  artery	  
1.2	  	  Nasopharynx	  
T1	   Tumour	  confined	  to	  the	  nasopharynx	  
T2a	   Tumour	  extends	  to	  soft	  tissues	  of	  oropharynx	  and/or	  nasal	  cavity	  without	  parapharyngeal	  extension	  
T2b	   Tumour	  extends	  to	  soft	  tissues	  of	  oropharynx	  and/or	  nasal	  cavity	  with	  parapharyngeal	  extension	  
T3	   Tumour	  invades	  bony	  structures	  and/or	  paranasal	  sinuses	  
T4	   Tumours	  with	  intracranial	  extension	  and/or	  involvement	  of	  cranial	  nerves,	  infratemporal	  fossa,	  hypopharynx,	  orbit	  or	  
masseter	  space	  
1.3	  	  Hypopharynx	  
T1	   Tumour	  limited	  to	  one	  sub	  site	  of	  hypopharynx	  ≤	  2cm	  
T2	   Tumour	  invades	  more	  than	  one	  sub	  site	  of	  hypopharynx	  or	  an	  adjacent	  site,	  or	  measures	  2–4 cm,	  without	  fixation	  of	  
hemi	  larynx	  
T3	   Tumour	  	  >	  4cm,	  or	  with	  fixation	  of	  hemi	  larynx	  
T4a	   Tumour	  invades	  any	  of	  the	  following:	  thyroid/cricoid	  cartilage,	  hyoid	  bone,	  thyroid	  gland,	  oesophagus,	  central	  
compartment	  soft	  tissue	  
T4b	   Tumour	  invades	  prevertebral	  fascia,	  encases	  carotid	  artery	  or	  invades	  mediastinal	  structures	  
1.4	  	  Larynx	  
T1a	   Tumour	  limited	  to	  one	  vocal	  cord	  (may	  involve	  anterior	  or	  posterior	  commissure)	  with	  normal	  mobility	  
T1b	   Tumour	  involves	  both	  vocal	  cords	  (may	  involve	  anterior	  or	  posterior	  commissure)	  with	  normal	  mobility	  
T2	   Tumour	  extends	  to	  supraglottis	  and	  or	  subglottis,	  and/or	  with	  impaired	  vocal	  cord	  mobility	  
T3	   Tumour	  limited	  to	  larynx	  with	  vocal	  cord	  fixation	  and/or	  invades	  paraglottic	  space,	  and/or	  with	  minor	  thyroid	  
cartilage	  erosion	  (inner	  cortex)	  
T4a	   Tumour	  invades	  through	  thyroid	  cartilage	  or	  invades	  tissues	  beyond	  the	  larynx,	  e.g.	  trachea,	  soft	  tissues	  of	  neck	  
including	  deep	  muscles	  of	  tongue,	  strap	  muscles,	  thyroid	  and	  oesophagus	  
T4b	   Tumour	  invades	  prevertebral	  space,	  mediastinal	  structures,	  or	  encases	  carotid	  artery	  
	  TNM	  classification	  of	  HNSCC,	  common	  sites	  (Sobin	  et	  al.,	  2002)	  
	  II	  	  Information	  Sheets	  and	  Consent	  Forms	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  	  	  	  	  	  	  Research	  Participant	  Information	  Sheet	  
The	  use	  of	  micro	  fluidic	  devices	  for	  head	  and	  neck	  cancer	  biopsies	  in	  the	  




We	  would	  like	  to	  invite	  you	  to	  take	  part	  in	  a	  research	  study.	  	  Before	  you	  decide	  you	  need	  to	  
understand	  why	  the	  research	  is	  being	  done	  and	  what	  it	  would	  involve	  for	  you.	  	  Please	  take	  time	  to	  
read	  the	  following	  information	  carefully.	  	  Talk	  to	  others	  about	  the	  study	  if	  you	  wish.	  	  Ask	  us	  if	  there	  is	  
anything	  that	  is	  not	  clear,	  or	  you	  would	  like	  more	  information.	  	  	  
	  
Purpose	  of	  the	  study	  
This	  study	  forms	  the	  basis	  of	  a	  Medical	  Doctorate	  project.	  
The	  University	  of	  Hull	  has	  developed	  a	  method	  to	  keep	  small	  pieces	  of	  tissue	  functioning	  for	  a	  
number	  of	  days	  outside	  of	  the	  body	  on	  a	  micro-­‐chip.	  We	  feel	  that	  investigating	  the	  effects	  of	  drug	  
treatments	  on	  this	  tissue	  can	  give	  us	  better	  information	  as	  to	  how	  drug	  treatments	  work	  on	  tissue	  in	  
the	  body,	  and	  the	  potential	  to	  develop	  a	  system	  for	  giving	  ‘personalised	  chemotherapy’.	  
	  
Why	  have	  I	  been	  chosen?	  
We	  are	  inviting	  you	  to	  take	  part	  in	  this	  study	  as	  you	  are	  undergoing	  a	  procedure	  in	  which	  your	  
surgeon	  may	  take	  a	  biopsy	  of	  tissue	  for	  diagnostic	  purposes	  or	  as	  part	  of	  your	  operation.	  	  This	  piece	  
of	  tissue	  will	  be	  useful	  to	  us	  regardless	  of	  your	  diagnosis.	  
	  
Do	  I	  have	  to	  take	  part?	  
It	  is	  up	  to	  you	  to	  decide.	  	  We	  will	  describe	  the	  study	  and	  go	  through	  this	  information	  sheet,	  which	  we	  
will	  then	  give	  you	  to	  keep.	  	  If	  you	  decide	  to	  take	  part	  we	  will	  ask	  you	  to	  sign	  a	  consent	  form,	  to	  show	  
you	  have	  agreed	  to	  take	  part.	  	  
	  
Am	  I	  free	  to	  withdraw	  at	  anytime?	  
You	  are	  free	  to	  withdraw	  at	  any	  time	  without	  giving	  a	  reason	  for	  your	  withdrawal.	  	  This	  will	  not	  affect	  
the	  standard	  of	  care	  you	  receive.	  Samples	  already	  collected	  will	  continue	  to	  be	  stored	  and	  any	  
information	  gained	  from	  these	  used	  in	  this	  study.	  	  
	  
What	  will	  happen	  to	  me	  if	  I	  take	  part?	  
If	  you	  agree	  to	  take	  part,	  an	  extra	  sample	  of	  tissue	  will	  be	  taken	  for	  our	  study	  in	  addition	  to	  that	  
taken	  for	  routine	  diagnostic	  testing.	  Once	  your	  samples	  are	  taken	  they	  will	  be	  only	  identifiable	  by	  a	  
number:	  non-­‐clinical	  laboratory	  staff	  will	  not	  have	  any	  access	  to	  your	  personal	  details.	  	  Information	  
regarding	  your	  response	  to	  treatment	  and	  outcome	  (if	  applicable)	  will	  be	  accessed	  by	  the	  clinical	  staff	  
involved	  with	  your	  treatment,	  and	  possibly	  communicated	  with	  the	  research	  staff.	  You	  will	  not	  be	  
contacted	  by	  the	  research	  team	  after	  today.	  
	  
Expenses	  and	  Payment	  
	  You	  should	  not	  incur	  any	  expenses	  during	  participation.	  	  There	  will	  not	  be	  any	  financial	  benefit	  if	  this	  
research	  leads	  to	  the	  development	  of	  a	  new	  treatment	  or	  test.	  
	  
What	  are	  the	  possible	  risks	  of	  taking	  part?	  
There	  are	  no	  risks	  to	  you	  or	  your	  treatment	  if	  you	  take	  part.	  
	  
What	  are	  the	  benefits	  of	  taking	  part?	  
There	  will	  be	  no	  direct	  benefit	  to	  you	  for	  taking	  part.	  	  The	  information	  we	  get	  from	  studying	  your	  
sample	  will	  potentially	  help	  us	  with	  treatments	  for	  other	  patients	  in	  the	  future.	  
	  
What	  do	  I	  do	  if	  I	  have	  a	  complaint?	  
Any	  complaint	  about	  the	  way	  you	  have	  been	  dealt	  with	  during	  the	  study	  can	  be	  addressed	  by	  
Professor	  Stafford,	  Consultant	  Surgeon	  on	  01482	  465348.	  	  Alternatively	  you	  can	  contact	  the	  Patient	  
Advice	  and	  Liaison	  Service	  (PALS)	  on	  01482	  623065.	  
	  
Will	  my	  taking	  part	  in	  the	  study	  be	  kept	  confidential?	  
Yes.	  	  We	  will	  follow	  ethical	  and	  legal	  practice	  and	  all	  information	  about	  you	  will	  be	  handled	  in	  
confidence.	  	  Your	  sample	  will	  be	  identifiable	  only	  by	  a	  number	  that	  can	  only	  be	  linked	  back	  to	  
personal	  details	  via	  your	  clinical	  care	  team	  (i.e.	  Professor	  Stafford).	  	  	  
	  
What	  will	  happen	  to	  the	  samples	  I	  give?	  
The	  samples	  will	  be	  taken	  to	  the	  research	  laboratory	  at	  Castle	  Hill	  Hospital	  where	  we	  will	  investigate	  
the	  effect	  of	  drug	  treatments	  on	  them.	  Following	  completion	  of	  the	  study	  excess	  samples	  will	  remain	  
stored	  in	  liquid	  nitrogen,	  securely	  and	  anonymously	  for	  possible	  use	  in	  future	  research	  for	  a	  similar	  
project.	  	  In	  this	  instance	  further	  Research	  Ethical	  Approval	  will	  be	  sought.	  
	  
What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  
The	  results	  of	  the	  study	  maybe	  published	  in	  a	  scientific	  journal.	  	  At	  no	  time	  will	  you	  be	  identifiable	  to	  
the	  reader.	  	  No	  feedback	  will	  be	  given	  to	  you	  unless	  specifically	  requested,	  in	  which	  instance	  the	  
research	  team	  will	  be	  happy	  to	  discuss	  the	  general	  findings.	  	  	  
	  
Who	  is	  organising	  and	  funding	  the	  research?	  
The	  Head	  and	  Neck	  Cancer	  research	  team	  from	  the	  University	  of	  Hull	  will	  be	  organising	  and	  
conducting	  the	  research	  in	  the	  laboratories	  at	  Castle	  Hill	  Hospital.	  This	  research	  is	  partly	  funded	  by	  
the	  Royal	  College	  of	  Surgeons	  of	  England.	  
	  
Who	  has	  reviewed	  the	  study?	  
All	  research	  in	  the	  NHS	  is	  looked	  at	  by	  an	  independent	  group	  of	  people	  called	  a	  Research	  Ethics	  
Committee	  to	  protect	  your	  interests.	  	  This	  study	  has	  been	  reviewed	  and	  given	  favourable	  opinion	  by	  
the	  Hull	  and	  East	  Riding	  Local	  Research	  Ethics	  Committee.	  
	  
Further	  information	  
If	  you	  require	  any	  further	  general	  or	  specific	  information	  on	  the	  research,	  advice	  on	  whether	  to	  take	  
part,	  or	  if	  you	  are	  at	  all	  unhappy	  please	  contact	  Professor	  Stafford	  on	  01482	  465348.	  
Thank	  you	  for	  taking	  the	  time	  to	  read	  this	  information	  sheet.	  
	  
Consent	  
If	  you	  decide	  to	  take	  part	  in	  the	  study,	  we	  will	  provide	  you	  with	  a	  copy	  of	  the	  information	  sheet	  and	  
ask	  you	  to	  sign	  a	  study	  Consent	  Form.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
CONSENT	  FORM	  
Centre	  Number:	  	  
Study	  Number:	  	  
Patient	  Identification	  Number	  for	  this	  trial:	  
	  
The	  use	  of	  micro	  fluidic	  devices	  for	  head	  and	  neck	  cancer	  biopsies	  in	  the	  
evaluation	  of	  tumour	  biology	  and	  treatment	  response,	  correlated	  with	  patient	  
outcome	   	   	   	   	  
	  	  
1.	  I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  dated	  14.1.10	  	  
(version	  2)	  for	  the	  above	  study.	  	  I	  have	  had	  the	  opportunity	  to	  consider	  the	  information,	  ask	  
questions	  and	  have	  had	  these	  answered	  satisfactorily.	  	  
	  
2.	  I	  understand	  that	  my	  participation	  is	  voluntary	  and	  that	  I	  am	  free	  to	  withdraw	  at	  any	  time	  without	  
giving	  a	  reason,	  without	  my	  medical	  care	  or	  legal	  rights	  being	  affected.	  If	  I	  do	  withdraw,	  samples	  
already	  obtained	  may	  still	  be	  used.	  
	  
3.	  I	  understand	  that	  I	  am	  under	  no	  obligation	  to	  take	  part	  and	  that,	  if	  I	  agree	  to	  take	  part,	  I	  am	  free	  to	  
change	  my	  mind	  at	  any	  time.	  
	  
4.	  I	  understand	  that	  I	  will	  not	  benefit	  financially	  if	  this	  research	  leads	  to	  the	  development	  of	  a	  new	  
treatment	  or	  test.	  
	  
5.	  I	  give	  permission	  for	  an	  additional	  sample	  of	  tissue	  to	  be	  taken	  during	  my	  operation	  to	  be	  used	  for	  
this	  research.	  
	  
6.	  I	  agree	  that	  any	  samples	  not	  used	  in	  this	  study	  may	  be	  stored	  and	  used	  in	  future	  research	  of	  a	  
similar	  nature	  pending	  ethical	  approval.	  
	  
7.	  I	  understand	  that	  these	  samples	  will	  be	  stored	  anonymously	  and	  I	  consent	  to	  the	  information	  
derived	  from	  them	  to	  be	  analysed	  by	  computer.	  	  	  	  
	  
8.	  I	  understand	  that	  relevant	  sections	  of	  my	  medical	  notes	  and	  data	  collected	  during	  the	  study	  may	  
be	  looked	  at	  by	  individuals	  from	  the	  University	  of	  Hull,	  from	  regulatory	  authorities,	  or	  from	  the	  NHS	  
trust,	  where	  it	  is	  relevant	  to	  my	  taking	  part	  in	  this	  research.	  	  I	  give	  permission	  for	  these	  individuals	  to	  
have	  access	  to	  my	  records.	  
	  
9.	  I	  hereby	  freely	  give	  my	  consent	  to	  take	  part	  in	  this	  study.	  
	  
	  
_______________	   	   	  ________________	  	   	   _________________	  	  
Name	  of	  Volunteer	   	   	  Date	  	   	   	   	   Signature	  	  
	   	   	   	   	   	   	   	   	  
________________	  	   	   ___________________	  	  	  	  	  	  	  	  	  	  __________________	  
Name	  of	  Person	  	   	   	   Date	  	   	   	   	   Signature	  	  
taking	  consent	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Figure	  1	  Image	  of	  tumour/node	  prior	  to	  incubation	  from	  tumour	  biopsy	  edge	  at	  a)	  








	  	   	  
	  	  	  	  
	  	  
	  	  	  
	  
	  
Figure	  2	  Image	  of	  yumour/node	  at	  48	  h	  incubation	  from	  tumour	  biopsy	  edge	  at	  a)	  
x5,	  b)	  x20,	  c)	  x40	  magnification.	  Areas	  of	  cell	  viability;	  rounded	  nuclei	  and	  
maintained	  cell	  cohesion	  at	  edge	  and	  centre	  of	  tissue.	  	  Some	  areas	  degraded	  nuclei	  
(arrow).	  












Figure	  3	  Image	  of	  tumour/node	  at	  96	  h	  incubation	  from	  intermediate	  area	  of	  
tumour	  biopsy	  at	  a)	  x5,	  b)	  x20,	  c)	  x40	  magnification.	  Areas	  of	  cell	  viability	  will	  
cohesion	  maintained.	  	  Some	  nuclei	  degradation	  but	  some	  intact	  nuclei	  identifiable.	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